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Background: Endothelial dysfunction is a major factor in the development of 
atherosclerosis, thrombosis and heart disease. Evidence suggests dietary fat composition 
may modify cardiovascular risk, as well as surrogate markers of cardiovascular risk such as 
blood pressure, arterial stiffness and endothelium-dependent vasodilation. Aim: To 
investigate the impact of dietary fat composition on endothelial function and associated 
markers of vascular health. Methods: The effects of oils rich in eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) were separately investigated in a parallel-design, 
placebo-controlled randomised controlled trial (n=48, 6 weeks, 2.9 g/d), carried out in free-
living healthy young men. Following a 2 week run-in period taking placebo capsules (olive 
oil), participants underwent baseline measurements of finger capillary density, endothelial 
progenitor cell numbers (EPC), platelet-monocyte aggregate numbers (PMA), ambulatory 
blood pressure (ABP), pulse wave analysis (PWA), digital volume pulse analysis (DVP), 
and gave blood samples for plasma lipid, glucose, insulin, nitric oxide metabolites (NOx) 
and isoprostanes. The same measurements were made at the study endpoint, 6 weeks. An in 
vitro investigation of the effects of physiologically-relevant fatty acid profiles on 
microvascular endothelial cell nitric oxide and prostacyclin production was also performed. 
Results: Neither EPA nor DHA supplementation influenced EPCs, capillary density, PMA, 
ABP, PWA, DVP or plasma cholesterol, triacylglycerol, glucose, insulin, NOx or 
isoprostanes compared to placebo. However, ambulatory night-time heart rate was 
increased following EPA supplementation compared to DHA. Furthermore, both EPA and 
DHA decreased plasma non-esterified fatty acids (NEFA) compared to placebo. The in 
vitro investigations suggested that the composition of circulating NEFA may differentially 
affect endothelial function in the microvasculature. Conclusion: Dietary EPA and DHA at 
relatively high doses do not improve a number of novel markers of vascular function, 
including microvascular function and a marker of endothelial repair in young healthy men. 
EPA and DHA have differing effects on heart rate during sleep, suggesting that further 
research is required into the possible adverse effects of higher doses of individual marine 
fatty acids in at-risk individuals. Further work is required to elucidate the role of 
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Chapter 1 General introduction 
This thesis is composed of in vivo and in vitro work which explores the mechanisms 
involved in the modulation of cardiovascular disease (CVD) risk factors by dietary fatty 
acids (FA). CVD, the major cause of death worldwide, involves atherosclerosis, 
inflammation and thrombosis, in which the endothelium plays an important role. 
Endothelial dysfunction (ED) is indeed the earliest stage in the pathogenesis of 
atherosclerosis known so far. It is often encountered in insulin resistant states such as type 2 
diabetes and obesity, and has been associated with high levels of non-esterified fatty acids 
(NEFA) in plasma. Morbidity and mortality of all causes, especially CVD, have 
multifactorial causes from genetic background to environmental factors. Among the latter, 
diet is one of the most important ones. The Seven Country study was the first of its kind, 
examining the relationship between lifestyle, diet, coronary heart disease (CHD) and stroke. 
From this study arose the importance of the relationship between dietary fats and the risk of 
heart disease (Keys, et al., 1966). Amongst the different types of fats consumed, n-3 
polyunsaturated fatty acids (PUFA), especially those from fish oils, show clear health 
benefits and have become of particular importance. 
This thesis set out the hypothesis that dietary fatty acid composition modulates 
endothelial and vascular function, as well as related biological processes involved in the 
development of CVD. The following section aims at defining the current knowledge and 





1.1 Dietary fats and cardiovascular disease (CVD) risk 
1.1.1 The different types of fatty acids (FA) and their dietary 
sources 
Fatty acids (FAs) are aliphatic monocarboxylic acids that usually contain an even 
number of carbons (from 2 to 28) in their side chain. They can be classified into three 
categories depending on their degree of unsaturation (Harvey, et al., 2005, Ratnayake and 
Galli, 2009). 
Saturated FAs (SFAs) do not contain any double bond and are found universally in 
all fats. They include short chain FAs (less than 8 carbons), medium chain FAs (from 8 to 
12 carbons), long chain FAs (14-20 carbons) and very long chain FA (22 carbons and 
more). They are mainly provided by animal and especially ruminant dairy fats. Many 
vegetable oils contain as little as 10% saturated fatty acids but some tropical fats e.g. 
coconut oil, palm oil and cocoabutter are rich sources. The hydrogenation of vegetable oils 
also results in an increase in the proportion of SFA.  
Monounsaturated FAs (MUFAs) contain one double bond in their side chain and 
are universally present in most fats, from both animal and plant sources. Oleic acid (C16:1 
n-9) is the main MUFA and is found in particularly high proportions in olive oil and canola 
oil, as well as high oleic sunflower oil and safflower oil. Palmitoleic acid (C16:1 n−7), 
synthesized from palmitic acid, is present in a variety of animal, vegetable and marine oils,  
especially in liver and in fish oil. 
Polyunsaturated FAs (PUFAs) contain two or more double bonds that are 
methylene interrupted and in the cis configuration. The two main families are the n-3 and 
the n-6 PUFAs. 
n-6 PUFAs include linoleic acid (C18:2 n-6) that is found in many vegetable oils 
such as safflower, poppy seed, walnut, sunflower, olive and palm oils. It is referred to as an 
essential FA: it must be obtained from plant materials as animals and humans are not able 
to synthesize it. It is a source of arachidonic acid (AA, C20:4 n-6), which can also be 
provided in the diet by animal fats, liver, eggs and fish. γ-linolenic acid (C18:3 n-6) is an 




n-3 PUFAs include α-linolenic acid (ALA, C18:3 n-3) that is mainly found in seed 
oils, notably those of rapeseed, soybeans, walnuts and flaxseed. It is an essential FA and is 
the precursor of eicosapentaenoic (EPA, C20:5 n-3), docosapentaenoic (DPA, C22:5 n-3) 
and docosahexaenoic acid (DHA, C22:6 n-3) (Tapiero, et al., 2002). The conversion rate 
from ALA to longer n-3 PUFA is limited in humans (Burdge and Wootton, 2002, Gerster, 
1998), but EPA and DHA can be provided by fish oils such as cod liver, herring, mackerel 
or salmon oils. Long-chain (LC) n-3 PUFA refer to ALA+EPA+DPA+DHA, while very 
long chain (VLC) n-3 PUFA refer to EPA+DPA+DHA.  
EPA competes with AA through the cycloxygenase (COX) and lipoxygenase (LOX) 
pathways, leading to a set of lipid mediators that improve vasodilation and decrease 
inflammation as well as aggregation (Figure 1-1). Upon the action of aspirin, EPA and 
DHA can be converted by the COX and LOX into similar but different families of 
resolvins, E and D-series, respectively (Burdge and Calder, 2005). In addition, both EPA 
and DHA compete with AA for the cytochrome P450 enzymes, leading to the formation of 
important mediators of vasodilation (Konkel and Schunck).  
 Figure 1-1: Formation of EPA and DHA and their metabolites 
al., 1995) 
ALA, α-linolenic acid ; EPA, eicosapentaenoic acid ; DPA, docosapentaenoic acid ; DHA, 
docosahexaenoic acid ; COX, cyclooxygenase ; LOX, lipoxygenase ; CYP450, cytochrome 
P450 enzymes ; PG, prostaglandins ; TX, thromboxanes; LT: leukotrienes ; EEQ, 
epoxyeicosatetraenoic acid ; HEPE, hydroxyeicosapentaenoic acid ; EDP, 
epoxydocosapentaenoic acid ; HDoHE, hydroxydocosahexaenoic acid.
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1.1.2 Lipid metabolism and transport 
Dietary fats are mainly composed of triglycerides (TAG) containing various long 
chain FA, as well as a small proportion of short- and medium-chain FA. The latter are 
volatile and water soluble; therefore they are directly taken up by the intestine capillaries 
and released into the portal vein. In contrast, long chain FAs are highly water insoluble and 
TAG must be emulsified and hydrolysed to monoacylglycerol and free FA prior to 
absorption. This process of digestion is divided into three steps: 1) emulsification in the 
stomach, 2) lipolysis and solubilisation with bile salts in the duodenum, 3) absorption into 
the enterocyte in the ileum (Bauer, et al., 2005). 
The TAG, phospholipids (PL) and cholesterol esters (CE) - newly synthesized in the 
enterocyte – are transported into the blood stream by the lymph vessels. Since they are 
water insoluble, they must be bound to apoproteins (Apo) to form lipoprotein particles to 
circulate in the blood. Chylomicrons (large TAG rich lipoproteins) carry the esterified 
dietary derived FA from the enterocyte to peripheral tissues (muscle and adipose tissue) 
where TAG are hydrolysed through the action of lipoprotein lipase, attached to the capillary 
endothelium. The resulting non esterified FA (NEFA) and glycerol pass through the 
capillary wall where they can be used for energy or stored as TAG, while the remnants of 
chylomicrons are cleared by the liver. Unlike dietary fats, endogenous fats are combined 
with ApoB in the liver to form very low density lipoproteins (VLDL). Through the lipase 
hydrolysis, VLDL loses some of the TAG. They are progressively transformed into 
intermediate-density lipoprotein (IDL), and then low density lipoproteins (LDL), which are 
then taken up by the liver and peripheral tissues. By contrast high density lipoproteins 
(HDL) are delivered by the intestine and the liver as apoproteins (mostly ApoA-I and II) 
that are free or almost free of FA (Basso, et al., 2003, Brunham, et al., 2006). These nascent 
HDL particles subsequently recruit cholesterol and PL from the liver, as well as peripheral 
tissues. The mature HDL are returned to the liver, but can also transfer cholesterol to 
VLDL and chylomicrons (Rader and Daugherty, 2008, Ratnayake and Galli, 2009). 
More than 90 percent of FAs found in the plasma are esterified (TAG, PL, CE) and 
contained in lipoprotein particles. NEFA released from TAG stored in adipose tissue, as 
well as some of NEFA released from circulating TAG and derived from de novo 
lipogenesis in the liver, are transported in the circulation bound to albumin, before being 
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cleared by the liver (Bergman, et al., 1971, Coppack, et al., 1992, Hellerstein, 1999). The 
type of fat consumed greatly influences the composition of these lipid fractions, which can 
be used as markers of fat intake. TAG mirror the dietary intake of the few hours or the last 
day and are subject to great variations (Durrington, et al., 1977, Moore, et al., 1977, 
Vessby, et al., 1980). CE are reflective of slightly longer term intake, i.e. ~3-5 days (Zock, 
et al., 1997, Zuijdgeest-van Leeuwen, et al., 1999).  PL reflect the intake over similar 
periods to CE but appear to be more repeatable and is the fraction that is most commonly 
used, despite lower concentrations (Seppanen-Laakso, et al., 2001, Zuijdgeest-van 
Leeuwen, et al., 1999). Noteworthy, circulating cell membranes have been used to reflect 
dietary intake in nutritional interventions, including platelet, inflammatory cell and 
erythrocyte membranes. The latter have a lifespan of 120 days and their FA composition 
has been suggested to be a better marker of fat intake than plasma FA (Arab, 2003), 
especially for DHA status (Sun, et al., 2007). Because of its low turnover, adipose tissue is 
considered as the best option to represent very long-term FA intake over years (Dayton, et 
al., 1966, Hodson, et al., 2008), with an estimated half life of at least 6 months or a year 
(Beynen, et al., 1980, Katan, et al., 1997, Strawford, et al., 2004). Importantly, PUFA are 
almost exclusively exogenous and are thus better biomarkers of fat intake than those that 
can be synthesised endogenously, i.e. SFA and MUFA (Arab, 2003). 
 It should be noted that the efficiency of absorption and metabolism may vary 
depending on the TAG structure (Berry, 2009), as well as the type of FA considered. For 
example, the proportion of oleic acid in PL, but not platelet or erythrocyte PL reflected 
change in MUFA intake (Hodson, et al., 2001). There is also evidence that EPA and DHA 
from fish oils are incorporated at different rates into CE, erythrocytes and adipose tissue 
(Katan, et al., 1997).  
Nonetheless, the composition of lipid fractions represents a better index of FA 
intake that the traditional food questionnaires and has been proven to be greatly useful in 
relating FA intake to CVD risk, in both intervention and epidemiological trials. 
1.1.3 Dietary habits and CVD risk: the importance of fats 
Numerous epidemiological studies have investigated the relation between lifestyle 
and heart health over the past 100 years. Amongst them the Framingham Heart Study, 
launched in 1948 in Massachusetts (Dawber, et al., 1951), played a pioneering role in the 
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identification of CVD risk factors such as high blood pressure, high cholesterol, obesity, 
diabetes, smoking and physical inactivity (Castelli, 1984, Kannel, 1987, Kannel, et al., 
1961). The Seven Countries Study, launched 10 years later, enrolled populations of men 
ages 40-59, in eighteen areas of seven countries, with follow-up for deaths in the cohorts up 
to the present day. The Seven Country study furthered the understanding of the relationship 
between heart disease and lifestyle, particularly the composition of the diet and especially 
fat intake (Keys, et al., 1966).  
1.1.3.1 The western diet:  
It was estimated that 72% of the energy intake of our diet – as consumed in western 
countries - is composed of food that would have been scarce or unavailable in the pre-
agricultural hominin diet. This has led big differences in glycemic load, fatty acid 
composition, macronutrient composition, micronutrient density, acid-base balance, sodium-
potassium ratio, and fibre content in contemporary “Western” diets compared to the hunter-
gatherer diet that was consumed for the majority of human evolution (Cordain, et al., 2005). 
Our “western” pattern is characterized by a high intake of processed food, red meat, high-
fat dairy products, eggs, and refined grains. In terms of fats, it contains higher proportions 
of SFA and trans FA, and a higher n-6;n-3 PUFA compared to the non-western diet such as 
the Japanese diet. The Seven Country study was the first to show that high SFA and trans 
FA intake are associated with an increased platelet activity and a higher risk of 
atherosclerosis and CHD (Kromhout, et al., 1995, Lo, et al., 2001, Oomen, et al., 2001). A 
reduction in dietary SFA was later shown to improve CVD risk factors such as total and 
LDL cholesterol (Lawson, et al., 1991), and hypertension (Chisalita and Arnqvist, 2004). 
However, the relation of SFA with higher CVD risk has come under criticism (Hoenselaar, 
2012). In several randomised controlled trials, SFA was replaced by PUFA, and the ratio of 
PUFA:SFA (P:S ratio), rather than SFA per se, may responsible for the beneficial effect on 
CVD risk (Skeaff and Miller, 2009). In support of that, other studies have reported no effect 
of reduced SFA intake on CVD risk; and a recent meta-analysis of prospective 
epidemiologic studies including 347,747 subjects has shown that SFA intake had no effect 
on CHD risk (Siri-Tarino, et al., 2010). Accordingly, the replacement of 5% of total energy 
from SFA by PUFA has been estimated to reduce CHD risk by 42% and substituting SFA 
in the diet by PUFA, rather than carbohydrates, may be more beneficial with respect to 
CVD risk.  
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1.1.3.2 Mediterranean diet 
A Mediterranean diet as consumed in Italy, Spain and Greece, is a collection of 
several dietary habits and emphasizes a high intake of vegetables, legumes, fruits, nuts, 
whole grains, and olive oil, as well as a moderate intake of fish and red wine. In contrast, 
the consumption of dairy products and red meat is relatively low. Epidemiological studies 
first investigated the influence of the whole diet, rather than a single nutrient, on CVD risk. 
The beneficial aspects of the Mediterranean diet first emerged in the late 60’s from the 
Seven country study, which reported that deaths from CHD in the USA and Northern 
Europe greatly exceeded those in Southern Europe, even when controlled for age, BP, 
cholesterol, smoking, physical activity and weight (Keys, 1975, Keys, et al., 1966). This 
beneficial effect was soon attributed to the high consumption of MUFA (predominantly 
from olive oil) relative to SFA (less animal fats) (Keys, et al., 1986). From this time, 
epidemiological and intervention studies have flourished showing a beneficial effect of the 
Mediterranean diet, and particularly olive oil, on cardiovascular (CV) health, including 
lipid profiles, blood pressure, endothelial function (EF), glycemic control and insulin 
sensitivity (Alvarez Leon, et al., 2006, Esposito, et al., 2004, Gillingham, et al., 2011, 
Schwingshackl, et al., 2011, Schwingshackl, et al., 2011, Yu, et al., 1995). However, other 
components of the Mediterranean diet, including microconstituents such as phenol 
compounds, vitamin E and carotene, and n-3 PUFA from fish and nuts may also account 
for the cardioprotective effect of the Mediterranean diet. 
1.1.3.3 The Inuit diet 
While the Mediterranean diet is characterised by a complex pattern of dietary 
habits, the traditional Inuit diet consists mainly of marine animals and fish, and is therefore 
low in carbohydrates and rich in proteins and fats, particularly in n-3 PUFA. In the late 70’s 
Dyerberg and Bang were the first to highlight the cardioprotective effect of dietary long 
chain n-3 PUFA present in oily fish in the Inuit population (Dyerberg, et al., 1975). The 
authors observed a low incidence of CVD in the Inuit population living in Greenland 
compared to the residual Danish population. This favourable effect was soon associated to 
the ability of n-3 PUFA to compete with n-6 PUFA, thus showing anti-thrombotic and 
hypotriglyceridemic properties (Dyerberg and Bang, 1978, Dyerberg and Bang, 1979, 
Goodnight, et al., 1982). Over the past 30 years numerous studies – epidemiological and 
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intervention trials - have confirmed the protective effect of fish oils on CVD (Marik and 
Varon, 2009, von Schacky and Harris, 2007) such as fatal CHD (He, et al., 2004, Hu and 
Willett, 2002), atherosclerosis (von Schacky, 2000) and stroke (He, et al., 2004, Keli, et al., 
1994). The mechanisms by which fish oils improve CV health have been extensively 
investigated, showing anti-inflammatory, anti-arrhythmic, anti-aggregatory and possible 
insulin sensitising effects, as well as an improvement of vascular and EF (Calder and 
Yaqoob, 2009, Harris, et al., 2008, Johansson, et al., 2008).  
However, since the 1970’s when the cardioprotective effect of the Inuit diet was 
suggested, this population has decreased the consumption of local food, and imported 
products have increasingly featured in their diet, evolving towards a more ‘westernised’ 
diet, higher in SFA and refined carbohydrates (Deutch, et al., 2007, Sharma, 2010). This, in 
addition to a decrease in physical activity, has been postulated to explain a possible rise in 
CVD risk in this population, including hypertension and obesity (Chateau-Degat, et al., 
2010). 
1.1.3.4 Fish oils and cardiovascular health 
♦ Fish oils and CV events 
Despite fears that there may be substantial health risks to consuming oily fish such 
as salmon, comprehensive reviews and meta-analyses have clearly indicated that the 
beneficial effects of fish oils largely compensate for any risk due to the presence of heavy 
metals and organic pollutants (Mozaffarian and Rimm, 2006, Sioen, et al., 2007).  
Meta-analyses have demonstrated that reduced tissue or blood levels of LC n-3 
PUFAs, provide a better indicator of CVD risk than the n-6:n-3 ratio, especially levels of 
DHA, with an effect size of -0.77 on the occurrence of CHD events in prospective studies, 
(P < 0.01) (Harris, et al., 2007). The authors concluded that absolute amounts of n-3 PUFA, 
rather than n-6 PUFA or n-6:n-3 ratio were better predictors of CVD risk, a view supported 
by others (Hjelte and Nilsson, 2005, Horrobin, 2000, Wijendran and Hayes, 2004). Just as 
LDL is considered as a risk factor for coronary artery disease (CAD), the omega-3 index 
(erythrocyte EPA+DHA) has been proposed as a modifiable risk factor for sudden cardiac 
death (SCD), as it is determined by diet and probably also has a genetic component (Harris, 
et al., 2004, von Schacky and Harris, 2007). 
31 
 
Numerous meta-analyses have flourished in the past two decades investigating the 
effect of fish oils on the incidence of death from CVD and CV events, gathering both 
observational and intervention studies. Findings have demonstrated a significant dose-
response relationship between risk for CHD death and intake (P = 0.03), with relative risk 
reductions of 37% at an average EPA + DHA intake of 566 mg/d (Harris, et al., 2008). This 
led to dietary recommendations which targeted an intake of 400 to 500 mg/d of EPA + 
DHA in the UK and other European countries (1.1.3.5, Table 1-1), achievable by diet alone 
with the consumption of one portion of oily fish per week. In patients with a history of 
myocardial infarction, a significant reduction in the rate of sudden cardiac deaths (-40%) 
was found only when patients were treated with at least 1g EPA+DHA/d, which was 
defined by the American Heart Association and the European Society of Cardiology as a 
target intake for secondary prevention (Weber, et al., 2006) 
In a more recent review (See Figure 1-2), Mozaffarian and Wu have confirmed that 
consumption of fish or fish oil significantly reduces CHD mortality, including fatal 
myocardial infarction and sudden cardiac death, in populations with and without 
established CVD (Mozaffarian and Wu, 2011). Relationships with total CHD or nonfatal 
coronary syndromes were more modest, and the authors suggested that, at usual dietary 





Figure 1-2: meta-analyses of studies of fish or long-chain n-3 PUFA consumption and 
risk of CVD outcomes, taken from (Mozaffarian and Wu, 2011)  
prospective cohorts, PCs; randomised controlled trials, RCTs 
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♦ Fish oils and CVD risk factors 
In randomised controlled trials, most effects of fish oils on CVD risk factors are 
only obvious at intakes usually in excess of 3g/d (See Figure 1-3) and not lower intakes 
which represent the amount consumed in human diets (Mozaffarian and Rimm, 2006). 
The TAG lowering effect of FO is linearly dose-dependent up to at least 7g/d, but 
with a high variability of response, including a more important effect in individuals with 
higher baseline levels (Mozaffarian and Wu, 2011). A recent meta-analysis (58 RCT) 
concluded that each g/d of EPA+DHA reduces TAG levels by −5.9 mg/dL (95% CI : −2.5 
to −9.3 mg/dL) overall, and by 1.7mg/dL (95% CI : -3.1 to -0.2 mg/dL) among subjects 
with TAG below the median 83 mg/dL(Mozaffarian and Wu, 2011). 
The effect of fish oils on cholesterol levels is far less evident. Meta-analysis of 47 
EPA+DHA supplementation studies (average 3.25 g/d) in hyperlipidemic subjects showed 
a very slight yet significant increase in LDL (+ 0.06 mmol/L, 95% CI: 0.03 to 0.09) and 
HDL (+ 0.01 mmol/L, 95% CI: 0.00 to 0.02), without affecting total cholesterol levels 
(Eslick, et al., 2009). A more recent meta-analysis of 11 RCT (n 485) concluded that algal 
DHA (median 1.68 g/d) increased LDL by 0.23 mmol/L (95% CI: 0.16-0.30) and HDL by 
0.07 mmol/L (95% CI: 0.05-0.10) in healthy individuals (Bernstein, et al., 2012).  
Beyond cholesterol levels, a few studies have reported a beneficial impact on 
lipoprotein size. At relatively high doses (3-4g/d), EPA and DHA were shown to increase 
HDL size (Chan, et al., 2006, Rambjor, et al., 1996, Wilkinson, et al., 2005), as well as 
LDL size (Griffin, et al., 2006, Mori, et al., 2000, Wilkinson, et al., 2005). sometimes 
without a significant change in lipoprotein levels (Agren, et al., 1996, Mori, et al., 2000). 
The effect of lower doses of fish oils on cholesterol metabolism remains uncertain, further 
research is needed and there is to date no meta-analysis on the effect on particle size, which 
could allow to quantify the dose effect. While the effect on cholesterol levels is unlikely to 
explain a reduction in CVD risk, even at high doses, their effect on lipoprotein particle size 
may be more relevant to CVD risk and remains to be fully elucidated and quantified. 
Lowering blood pressure by 5 mmHg diastolic reduces the risk of stroke by an 
estimated 34% and ischaemic heart disease by 21% from any pre-treatment level, with no 
threshold (Law, et al., 2003). Recent meta-analyses indicate that EPA and DHA reduce 
both DBP and SBP, with a greater effect in hypertensive patients and those with high-
 normal blood pressure, and the 
Campbell, et al., 2012
Figure 1-3: Relative strength of effect estimated from effects of eicosapentaenoic acid 
(EPA) + docosahexaenoic acid (DHA) on each risk factor and on the corresponding 
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0.45 g/day for (SACN, 2004),. Because of the toxin content of oily fish, such as mercury, 
upper limits were set by the Food Standard Agency, according to the National Institute for 
Health and Clinical Excellence (NICE) guidelines (NICE, 2008). Men, boys and post-
menopausal women can eat up to four portions a week. Because of the risk of baby 
malformation, girls and women of child-bearing age, as well as pregnant women should eat 
one to two portions of oily fish a week. Table 1-1 summarises dietary fat recommendations 
– including EPA+DHA – in the USA, European countries and organisations. 
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Table 1-1  Overview of dietary recommendations for the intakes of total fat and fatty acids intakes for adults as set by different 
organisations, adapted from (EFSA, 2010).   
Countries / 
Organisation Total fat SFA TFA 
cis-
MUFA PUFA Cholesterol 
EPA + DHA 
(mg/d) References 
United 
Kingdom  33 E%  <10 E%  < 2 E%  12 E%  
6 E% with at least 1 E% 
LA and 0.2 E% ALA  
 




30 E%  <10 E%  < 1 E%  
 
Total PUFA: 7-10 E%, n-6 
PUFA 2.5 E%, n-3 PUFA: 
0.5 E%  
< 300 mg 
per day  250  
(DACH, 
2008) 
France  30-35 E%  <8 E%  < 2 E%  20 E%  
4 E% of which 4 % LA, 
0.8 E% ALA, 0.20 E% 
LCPUFA   




E%  < 10 E%  alap  
 
<12 E% of which at least 2 
E% LA, 1.0 E% ALA 
 
450 (GR, 2006) 
USA  20-35 E%  < 10 E%  alap  
 
5-10 E% LA, 0.6-1.2 E% 
ALA  
 
~160 (IoM, 2005) 
WHO / FAO 15-30 E%  < 10 E%  < 1 E%  
 
6-10 E%, of which 5-8 E% 
n-6 PUFA and 1-2 E% n-3 
PUFA  
< 300 mg 
per day  
400-1000 (1-2 












5-10%, of which 1 E% n-3 
fatty acids  
 
450 (NNR, 2004) 
SFA: Saturated fatty acids; TFA: Trans fatty acids; cis-MUFA: cis-monounsaturated fatty acids; PUFA: Polyunsaturated fatty acids; LA: 
Linoleic acid; ALA: alpha-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; alap = as low as possible; E%: percent 
of energy; incl., including.
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1.2 Vascular physiology and endothelial function 
1.2.1 The arterial tree and the vessel walls 
Blood flows away from the heart via arteries, which branch and narrow into 
arterioles, and continue to reduce size to become capillaries as they reach muscle or organs. 
Here the capillaries form a network throughout the tissue called capillary bed. Unlike vein 
and arteries, capillaries function is not to transport blood but allow the movement of 
substances, including gases (O2, CO2) and nutrients (glucose, amino acids) in and out of the 
capillary. After the tissue has been perfused, capillaries (containing blood enriched in CO2, 
poorer in O2 and nutrients) join and widen to become venules and then widen more to 
become veins, which return blood to the heart. 
Although blood vessels differ in size, distribution and function, they share many 
common features in terms of structure. All vessels are made of three layers (Figure 1-4), 
going from the lumen to the most external layer (Krause, 2005): 
- The tunica intima is the thinnest layer of the vessel. It is composed of a single 
layer of endothelial cells and a subendothelial connective tissue (collagenous and elastic 
fibres). 
- The tunica media, the thickest layer, is made of connective tissue and vascular 
smooth muscle cells (VSMC) which are particularly abundant in arteries and control the 
calibre of the vessel. The tunica media also contains two layers of elastic fibres, the internal 
and external elastic lamina, which support the tunica intima and adventitia, respectively. 
- The tunica adventitia is the outer layer and is made of connective tissue (mainly 




Figure 1-4 Drawing of arterial wall depicting the composition of three layers: intima, 
media, and adventitia (taken from (Sarkar, et al., 2007)). 
The aorta and other large arteries (conduit and conducting arteries) serve as a blood 
reservoir able to stretch and recoil with the pumping action of the heart; their wall is thicker 
and largely made of elastic fibres. In contrast, the small arteries and arterioles (< 300 µm), 
which are involved in the regulation of blood flow and represent the major site of 
peripheral resistance, contain less elastic fibres and more VSMC as their diameter 
diminishes (Krause, 2005). Along the arterioles, the diameter gets smaller and the vascular 
wall thinner again. In the capillaries, the vessel wall is free of VSMC and only made of one 
layer of endothelial cells supported by a basement membrane, which allow the exchange of 
nutrients between the blood and tissue (Feihl, et al., 2006). Capillaries (4-12 µm) are just 
large enough to permit red blood cells to pass in single file. Their endothelium may be 
continuous (muscle, brain: gas exchange), fenestrated (digestive tract: passage of small 
molecules such as amino acid and sugar) or discontinuous (bone marrow, liver, spleen: 
holes are large enough to allow whole cells to pass). Veins possess the same three layers as 
the arteries but contain less VSMC and connective tissue, making their wall thinner than 
the one of arteries (Wagner and Frenette, 2008). 
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1.2.1 Vascular function and blood pressure (BP) 
The macrovasculature is subject to high variations of pressure due to the pulsatile 
function of the heart while the microvasculature deals with a steady pressure and flow. 
During the contraction of the left ventricle (systole), blood pressure (BP) is mainly 
determined by the arterial stiffness of large arteries. When arteries get more rigid and less 
compliant, they lose the ability to adapt to the high pressure changes and this leads to a rise 
in systolic BP (SBP) within the vessel.  In diastole (relaxation of the heart), the elastic 
recoil of the aortic wall propels the volume of blood to the periphery and BP diminishes. 
Diastolic BP (DBP) is determined by the intensity of the pressure wave reflected from the 
periphery, and increases when vascular resistance augments, i.e. when microvascular and 
ED occur. (Feihl, et al., 2009). 
Hypertension is well-established as an independent CVD risk factor (Cacicedo, et 
al., 2004, Rizzo, et al., 2010, Staiger, et al., 2006, Symons, et al., 2009, Xiao-Yun, et al., 
2009). Historically, high DBP was considered a better predictor than SBP, and allowed 
classifications for clinical treatment accordingly (Krogmann, et al., 2011). However in the 
past 15 years a paradigm shift has occurred towards SBP being a stronger predictor of CVD 
risk (Black, 1999). It arose from the Framingham study data that DBP (largely determined 
by vascular resistance) increases with age until age 50 to 60 when it starts falling (Franklin, 
et al., 1997). In contrast SBP, as well as the pulse pressure (PP = SBP – DBP), more 
influenced by arterial stiffness, appear to increase continuously with age. Thus the 
importance of treating elevated SBP is increasingly recognised in clinical practice and SBP 
appears to be a stronger predictor of CVD in elderly (Forstermann, et al., 1995, Franklin, et 
al., 1997). In fact PP, which reflects the stiffening of the aorta and large arteries, may be an 
even better predictor (Kaplan, 2000). Arterial stiffening provides a narrower and more rigid 
reservoir wherein there is a reduced compliance in the vessel walls to the forward travelling 
pressure wave during systole. In addition, the blood travels faster in stiff arteries and the 
reflected wave returns to the central aorta in mid systole rather than diastole. As a result, 
this augments the already high SBP while removing a major support of DBP, therefore 
increasing central PP. Thus treatment of isolated hypertension with anti-hypertensive drugs 




Whether arterial stiffness and/or PP are a better target than SBP to tackle CVD 
remains uncertain. ED, which is associated with arterial compliance and implicated in the 
dysregulation of vascular tone, is also a potential target. Techniques to assess vascular 
function have flourished in order to relate these outcomes to vascular risk and investigate 
their modulation upon drug or nutritional interventions. 
1.2.2 Macrovascular function and arterial stiffness 
The two main roles of conduit and conducting arteries are to transport the blood 
from the heart to all organs and buffering the pressure oscillations generated by the 
rhythmic left ventricular ejection. With ageing and the development of CVD, the vascular 
wall becomes thicker and stiffer. This phenomenon, called arterial stiffening, leads to an 
increase in blood velocity from the heart to the periphery and a reduction in arterial 
compliance, thus altering both the conducting and ‘buffering’ functions of large arteries, 
and augmenting SBP. 
Arterial stiffening develops as a result of complex influences, both intrinsic (relative 
to the vessel wall structure and function) and ‘extrinsic’ (relative to haemodynamics and 
circulating factors such as salt, hormones or glucose). The complex mechanisms involved 
have been extensively reviewed (Zieman, et al., 2005) and entail structural changes, as well 
as the alteration of cell signalling and function. The inflammatory milieu is characterized 
by the infiltration of VSMC and the presence of macrophages and mononuclear cells, 
increased levels of metalloproteases (MMP), transforming growth factor (TGF)-β, 
intracellular adhesion molecules (ICAM) and cytokines (Lakatta, 2003), which alter the 
structure of both collagen and elastin. In addition, advanced glycation products (AGE’s), 
which accumulate with ageing and diabetes, form irreversible cross-links between 
molecules such as collagen (Verzijl, et al., 2000). The overproduction of abnormal 
collagen, alteration of elastin and VSMC hypertrophy lead to an increase in intimal-medial 
thickness, thereby reducing the compliance of large conducting arteries (Johnson, et al., 
2001, O'Leary, et al., 1999). In addition to structural changes, the alteration of smooth 
muscle tone also influences arterial stiffness. A number of locally derived factors such as 
nitric oxide, angiotensin II and endothelin-1 (produced by the endothelium), and reactive 
oxidant species (associated to ED), may alter VSMC function and contribute to arterial 
stiffening (Wilkinson and McEniery, 2004, Wykretowicz, et al., 2007). Furthermore other 
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circulating factors such as salt, glucose, insulin, neurohormones, natriuretic peptides and 
adiponectin  also contribute to the functional regulation of arterial stiffness (Wilkinson and 
McEniery, 2004, Zieman, et al., 2005).  
1.2.3 Microvascular function and vascular tone/peripheral 
resistance 
In the intact vasculature, the largest pressure drop, and thus the highest resistance to 
flow, occurs between the arterioles and bigger arteries from which they originate. The 
microcirculation, which encompasses vessels < 150 µm in diameter, is therefore extremely 
important in determining peripheral resistance. In addition, by dissipating the pressure of 
arterial blood into smaller vessels, the arterioles and capillaries ensure a tightly controlled 
intra-capillary pressure, necessary for the normal exchange of substances between the 
capillaries and the peripheral tissues, as well as the preservation of the fragile capillary wall 
(Feihl, et al., 2009). The large number of capillaries makes up the largest volume of blood 
in the body and provides a large surface area for exchange substances, pressure in them is 
very low as blood is distributed out into a greater area, and high pressure may cause 
damage to the fragile capillary wall. They have no muscle in their walls and thus cannot 
adapt their diameter to pressure changes. Instead, the blood flow in the capillaries is 
regulated by the arterioles that serve them, containing VSMC. For decades it was thought 
that capillaries were static, uniform, semipermeable pipes, all made of a single layer of 
endothelium with no other function than maintaining a passive barrier between blood and 
tissue. In fact, capillaries are dynamic structures that participate actively in water, waste, 
gas and nutrient exchange, and are capable of sensing and responding to vasoactive stimuli 
to regulate in the blood flow to the tissue, and are able to adapt their number and 
arrangement in response the nutritional state of the tissue (Baldwin, 2000, Sarelius, et al., 
2000). The regulation of VSMC contraction and vasodilation in the microvasculature, 
mainly mediated by the endothelium, may be transferred from the most distal capillaries 
towards the arterioles and subsequently to their feeding arteries (Bagher and Segal, 2011). 
Thus microvascular and EFs are crucial for the regulation of blood flow and peripheral 
resistance, and thus for the determination of DBP. 
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1.2.4 The vascular tone and the endothelium 
1.2.4.1 Vasodilatation  
The importance of the endothelium was first recognised in the 1980’s by its effect 
on vascular tone, when Furchgott and Zawadzki demonstrated that acetylcholine-induced 
vasodilation required the presence of endothelial cells and a substance released by the 
endothelium (Furchgott and Zawadzki, 1980), which was later identified as nitric oxide 
(Moncada and Higgs, 2006). Nitric oxide, together with prostacyclin discovered earlier 
(Moncada, 2006) and a hyperpolarising factor yet to be defined (Bryan, et al., 2005), are the 
three main vasodilators produced by the endothelium (Figure 1-5). 
Nitric oxide (NO) is synthesized from L-arginine via NO synthase (NOS), of which 
two types are present in the endothelium: the endothelial NOS (eNOS), constitutively 
expressed, and the inducible NOS (iNOS). eNOS is calcium-calmodulin dependent and 
produces NO under shear stress or physiological stimuli (e.g. insulin, acetylcholine or 
bradykinin) (Moncada and Higgs, 2006). In contrast, iNOS is calcium independent and 
generates large amounts of NO in response to inflammation (Moncada and Higgs, 2006). In 
physiological conditions, NO released by eNOS diffuses from endothelium to VSMC, 
where it activates the cytosolic form of guanylate cyclase, resulting in a rise of intra-
cellular cGMP. 
Prostacyclin (PGI2) is synthesized via a COX, peroxidase and PGI synthase (PGIS) 
in the endothelial cell. It binds its receptor (IP) on the VSMC and induces its relaxation of 
through a cAMP dependent mechanism (Fetalvero, et al., 2007). 
A third dilator factor has been named the endothelium-derived hyperpolarising 
factor (EDHF). Its identity and precursor remain controversial, but it is known to cause 
vasodilatation by hyperpolarising the VSMC, involving potassium channel activation, most 
often calcium-activated channels (Bryan, et al., 2005). Although the acronym suggests that 
EDHF is a unique molecule, it involves several different mechanisms. Arachidonic acid 
metabolites derived from the COX, LOX and cytochrome P450 pathways, H2O2, CO, H2S 
and various peptides can be produced by the endothelium and contribute to the EDHF 
response (Feletou and Vanhoutte, 2009). 
These three pathways lead to a decrease of intra-cellular calcium level, thus 
 phosphorylating the myosin light chains. Myosin
decreases muscle contraction.
Figure 1-5 Outline of major mechanisms for vascular smooth muscle cell relaxation 
and contraction mediated by the endothelial cell. 
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In contrast, the endothelium is also able to induce vasoconstriction by secreting or 
converting several vasoconstrictive factors. 
Thromboxane A2 (TXA2), which counters the effects of PGI2, is synthesized from 
the same pathway (COX, peroxidase and TXA2 synthase) and acts on VSMC through their 
G protein-coupled receptor TP (Norimichi, 2008). Although TXA2 may be produced by the 
endothelium, its main production site is the platelet. More importantly, other prostaglandins 
generated by endothelial cells through COX-1 and/or COX-2, such as PGH2, PGF2α, PGE2, 
and paradoxically PGI2, can all act through TP receptors and induce VSMC contraction 
(Félétou, et al., 2011). 
Endothelin-1 (ET-1) is synthesized in the endothelium by the endothelin converting 
enzyme from a biologically inactive precursor called Big ET-1. It is one of the most potent 
vasoconstrictor peptide discovered so far. It is continuously released from the EC 
(constitutive pathway), inducing intense contraction of the underlying VSMC. It can also be 
released from EC-specific storage granules in response to external stimuli (Davenport and 
Maguire, 2006).  
Angiotensin II is a hormone locally produced by angiotensin converting enzyme 
(ACE, expressed by the endothelium) from angiotensin I, converted from angiotensinogen 
by renin (Touyz and Schiffrin, 2000). 
These molecules released from the endothelium then bind their specific receptors on 
VSMC and induce a subset of phosphorylation cascades that leads to a increase of intra-
cellular calcium, thus stimulating the contraction of the cell. 
 
1.2.5 Endothelial dysfunction 
1.2.5.1 Definition of endothelial dysfunction 
The endothelium was first seen as a passive barrier between blood and tissue, which 
when disrupted would lead to platelet aggregation to the subendothelial connective tissue 
and the proliferation of VSMC involved in the pathogenesis of atherosclerosis (Matsumoto, 
et al., 2010). The thin endothelial lining is now well known to act as a paracrine, autocrine 
and endocrine-like organ exerting many important biological functions, including the 
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regulation of vascular tone, cellular adhesion, haemostasis, smooth muscle cell proliferation 
and vessel wall inflammation. Beyond its anatomical disruption, the functional status of the 
endothelium emerged as crucial in the pathogenesis of CVD. Because the endothelium 
governs such a large array of functions, it is difficult to give a single definition to ED . 
Nonetheless, ED can be defined as an imbalance between the numerous molecules 
produced by the endothelium, i.e. an enhanced pro-inflammatory, pro-thrombotic, 
vasoconstrictive activities in the detriment of anti-inflammatory, anti-thrombotic and 
vasodilatory function (Bonetti, et al., 2003, Endemann and Schiffrin, 2004). The regulation 
of vascular tone being the main function of the endothelium, the impairment of vasodilation 
is the most commonly described alteration in ED. 
A reduction of NO production by eNOS and NO availability is characteristic of ED, 
and is associated to an inflammatory and oxidant status of the endothelium. Reactive 
oxygen species (ROS) interact with NO to form peroxynitrites, which reduces NO 
availability (Koppenol, et al., 1992). Peroxynitrite contributes to the oxidation of LDL an 
important proatherogenic factor (Griendling and FitzGerald, 2003), and alter the reductase 
activity of eNOS (Milstien and Katusic, 1999), leading to more oxidative stress 
(Landmesser, et al., 2003). eNOS activity is also altered upon the action of pro-
inflammatory cytokines, such as C-reactive protein, interleukin(IL)-1, IL-6 or tumor 
necrosis factor(TNF)-α (Kofler, et al., 2005, Venugopal, et al., 2002). In contrast 
inflammatory cytokines stimulate iNOS to produce high amounts of NO (Forstermann and 
Kleinert, 1995), which in the presence of ROS will lead to the formation of more 
peroxynitrites, thus increasing again oxidative stress (Xia, et al., 1996). Asymmetric 
Dimethylarginine (ADMA) and NG-methyl-L-arginine (L-NMMA) are natural compounds 
released from cells upon protein degradation that accumulate in an inflammatory state and 
are associated with a higher incidence of CVD (Böger, et al., 2009, Kielstein and Zoccali, 
2008). As analogues of arginine (eNOS substrate), ADMA and L-NMMA act as 
competitive inhibitors of eNOS and also contribute to the reduction of NO production 
(Cardounel, et al., 2007, Kielstein, et al., 2009). Vasoconstrictive factors, including 
angiotensin II, endothelin and COX-derived prostaglandins are also associated with ED and 
further the impairment of vasodilation (Mishra, et al., 2004, Versari, et al., 2009).  
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1.2.5.2 Insulin resistance and endothelial dysfunction 
In diabetes additional mechanisms may contribute to ED due to the 
hyperinsulinaemia and lipotoxicity characteristic of insulin resistant states. In addition to its 
well known role in metabolism, insulin also exerts an important role in the vasculature. In 
physiological conditions, the main vascular action of insulin is to regulate vascular tone via 
the stimulation of the production of both NO and ET-1 (Muniyappa, et al., 2007). Insulin-
induced NO production is due to the activation of the PI3K pathway, which also mediates 
insulin-induced GLUT-4 translocation in muscle cells and adipose tissue. Through the 
stimulation of NO production, insulin-mediated vasodilation is divided into two stages, 
affecting both the micro- and macrovasculature: 1) after a few minutes, terminal arterioles 
are dilated, which increases capillary recruitment, 2) then larger vessels are relaxed, which 
increases the blood flow to the tissue. Both of those NO-dependent mechanisms in skeletal 
muscle contribute to the increase of glucose disposal (Muniyappa, et al., 2007). 
In insulin resistant state, the metabolic disorders are coupled with vascular and ED. 
Obesity is characterised by an increase in circulating NEFA levels that has been shown to 
alter the insulin-stimulated PI3K pathway, thus impairing glucose uptake. This leads to 
increased blood glucose concentrations and then to a compensatory hyperinsulinaemia that 
constitutes the early stage of type 2 diabetes development (Petersen and Shulman, 2006). 
As a consequence, hyperinsulinaemia overdrives the unaffected MAPK pathway, to the 
detriment of the PI3K pathway. In endothelium, this results in a reduction of NO 
production by eNOS associated with the increase of ET-1 production that are characteristic 
of ED (Figure 1-6) (Muniyappa and Quon, 2007). 
 Figure 1-6 Pathway selective insulin resistance in phosphatidylinosi
signaling in endothelial cell
Elevated non esterified fatty acids (NEFA) inhibit PI3K, leading to
endothelial nitric oxide synthase 
nitric oxide (NO) and glucose uptake are reduced
kinase; (MAPK) remains intact, and endothelin
leading to ED. 
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1.3.1 FA and macrovascular function 
1.3.1.1 Assessment of arterial stiffness and compliance 
Beyond the determination of pulse pressure, which represents a surrogate measure 
of arterial stiffness (Omura, et al., 2001), several techniques - both invasive and non 
invasive - have gathered great interest in the recent years to investigate the stiffness and 
compliance of the large arteries. Non invasive techniques fall into three categories: 1) 
measuring pulse wave velocity (PWV), 2) assessing the changes in diameter (or area) of an 
artery in response to distending pressure (=compliance, distensibility), and 3) analysing 
arterial pressure wave forms (Oliver and Webb, 2003). 
♦ Pulse wave velocity (PWV) 
PWV is the speed with which the pulse wave travels along a given length of artery. 
The arterial pulse wave is recorded at a proximal artery, such as the common carotid and at 
a distal artery, such as the femoral. The pulse wave travels between these two points along 
the aorta, an artery that is particularly prone to the development of arteriosclerosis and 
atherosclerosis. The distance and the time delay between these two sites allow the 
calculation of PWV in m/s. The time delay is obtained either by simultaneous 
measurement, or by independent measurements with electrocardiogram (ECG) - gating 
(Davies and Struthers, 2003).  
Carotid–femoral PWV is the gold standard for assessing central arterial stiffness 
and a useful approach to diagnose atherosclerosis. Brachial–ankle (ba) PWV has also been 
developed as a surrogate measure of carotid–femoral PWV (Yambe, et al., 2004). Pressure-
sensitive transducers (Asmar, et al., 1995), Doppler ultra-sound (Sutton-Tyrrell, et al., 
2001) or applanation tonometry (Wilkinson, et al., 1998) may be used to detect the arterial 
pulse waves. Alternatively, PWV may be measured through the aorta using the phase 
contrast-magnetic resonance imaging (PC-MRI) technique (Metafratzi, et al., 2002).  
♦ Changes in vessel diameter (or area) to distending pressure 
Arterial compliance represents the relationship between changes in volume and 
changes in pressure during diastole (Stebbins, et al., 2008). Compliance and distensibility 
are defined as the absolute and relative changes in vessel diameter for a given change in 
distending pressure, respectively. The distending pressure is measured simultaneously and 
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is mainly determined by the mean arterial pressure (MAP) (McEniery, et al., 2007). 
Changes in diameters are most frequently measured by ultrasound in a number of arteries, 
such as the carotid, brachial, radial artery or aorta (Hoeks, et al., 1990, Meinders and 
Hoeks, 2004), as well as veins (Kölegård, et al., 2009). MRI may also assess the relative 
changes in cross-sectional area of a chosen segment, using ECG-triggered spin echo or 
gradient echo sequences (Metafratzi, et al., 2002).  
♦ Arterial pressure wave form analysis 
The most frequent analysis of pulse wave form consists in recording the pulse 
waveform recorded at a peripheral (usually radial) artery by applanation tonometry. 
Because changes in the contour of the pulse due to transmission along the upper limb are 
predictable and relatively constant from individual to individual, a generalised transfer 
function can be used to derive central aortic waveform form (Chen, et al., 1997). The 
systolic pulse contour analysis (SPCA) of the central waveform obtained allows the 
assessment of central BP, as well as the central arterial stiffness estimated by the 
augmentation index (AIx). AIx is the proportion of central pulse pressure that results from 
the arterial wave reflected from the periphery, and is thought to be largely determined by 
PWV, i.e. the stiffness of large arteries (Yasmin and Brown, 1999). However, accumulating 
evidence suggest that AIx is greatly influenced by other factors, such as the left ventricular 
ejection volume, the absolute systole duration or the vascular tone, determined by the 
diameter and elasticity of small muscular arteries and arterioles (Cecelja, et al., 2009, 
Protogerou and Safar, 2007, Wilkinson, et al., 2000). 
Applanation tonometry can also be used to analyse the diastolic portion of the pulse 
wave. Diastolic pulse contour analysis (DPCA) uses a modified Windkessel model to 
assess the compliance of large and small arteries, usually referred to as C1 (proximal or 
capacitative compliance) and C2 (distal or oscillatory compliance) respectively (Nair, et al., 
2005, Rietzschel, et al., 2001). Systemic arterial compliance (SAC) may be assessed by 
combining the use of Doppler to measure volumetric blood flow and applanation tonometry 
of the right common carotid artery. Similar to SPCA, an aortic pulse pressure is derived and 
the area under the curve in the diastolic portion is used to estimate compliance of the whole 
arterial tree (Stebbins, et al., 2008). SAC is defined as: 
SAC = Ad/R(Pes-Pd) 
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where R is the total peripheral resistance (mean arterial BP / mean blood flow), Ad the area 
under the diastolic portion of the pressure waveform, Pes and Pd the the pressure at the end 
of the systolic and diastolic phase, respectively (Stebbins, et al., 2008). 
♦ Digital volume pulse 
Arterial pressure and volume wave forms may also be measured in the finger and 
closely mirror the radial wave form. Digital volume pulse (DVP) is recorded using 
plethysmography and can predict the arterial pressure pulse through a generalised transfer 
function (Millasseau, et al., 2000). Like the radial pressure pulse, the digital volume pulse 
is characterised by a forward (direct) wave and a backward (reflected) wave. The time 
delay between the two waves, and the amplitude of the reflected wave give information on 
the stiffness of large arteries (stiffness index, SI) and the vascular tone (reflection index, 
RI), respectively (Millasseau, et al., 2006). 
♦ Other techniques 
It should be noted that radial and aortic waveforms and pressures may also be 
measured invasively using fluid-filled catheters to give the indexes provided both SPCA 
(AIx) and DPCA (C2) (Segers, et al., 2001, Söderström, et al., 2002). Pressure-diameter 
relationships in the aorta have also been determined invasively with simultaneous 
measurement of arterial pressure by using a luminal pressure transducer and dimensions by 
using intravascular ultrasound (Stefanadis, et al., 2000, Stefanadis, et al., 1997). Other 
techniques such as the intima media thickness (IMT) can be used to assess the thickening of 
the carotid vascular wall, by external ultrasound or invasive ultrasound catheters to detect 
early stages of atherosclerosis or follow the evolution of plaques (Ubels, et al., 1999).  
1.3.1.2 FA and arterial stiffness 
♦ Arterial stiffness as an indicator of CVD risk 
IMT, assessing structural rather than functional changes, is a well established 
marker of atherosclerotic burden and has prognostic value (Ubels, et al., 1999). Elevated 
PWV has been associated with the presence of several CVD risk factors such as age 
(Simonson and Nakagawa, 1960, Vaitkevicius, et al., 1993), hypercholesterolemia 
(Levenson, et al., 1992, Riggio, et al., 2010) and hypertension (Dahan, et al., 1990, Safar 
and London, 1987). A recent meta-analysis showed that aortic stiffness, as measured by 
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PWV is a strong predictor of CV events and all cause mortality, independent of classic 
CVD risk factors and other potential confounders, with a better predictability for subjects 
having higher CVD risk baseline (Vlachopoulos, et al., 2010). Radial and carotid AIx have 
been positively associated to the risk of CVD such as CHD, atherosclerosis, and stroke in 
some studies (Otsuka, et al., 2010, Qureshi, et al., 2007) but not all (Krantz, et al., 2011) 
and appears a weaker predictor of CVD risk than PWV (Van Trijp, et al., 2006). Arterial 
stiffness being an additional independent risk factor for CVD, strategies aimed at lowering 
arterial stiffness, including dietary interventions may be effective in reducing CVD risk. 
Studies to investigate the effect of dietary FA on such outcome are only at their beginning. 
♦ Evidence from human studies 
The effect of dietary FA on vascular function and BP has been recently extensively 
reviewed (Hall, 2009). Chronic dietary intervention studies suggest that n-3 PUFA and to a 
lesser extent MUFA, are beneficial for BP while saturated appear detrimental (Hall, 2009). 
However the effect of MUFA and SFA on arterial stiffness specifically has been poorly 
studied, acutely or chronically.  
Acute effects: The effect of meal FA composition on post-prandial arterial stiffness 
remains uncertain. SFA (rich in stearic acid) was shown to impair stiffness index in healthy 
men in some studies (Newens, et al., 2011) but not all (Berry, et al., 2008). Recent evidence 
suggest that EPA- and DHA-enriched meals reduce arterial stiffness as measured in healthy 
males, as measured by DVP and PWA (Chong, et al., 2010, Hall, et al., 2008), but data is 
limited.  
Chronic effects: In healthy subjects, a MUFA-enriched diet provided for 4 weeks 
did not improve arterial elasticity as measured by carotid and derived aortic pulse wave 
analysis compared to an isocaloric low fat /high carbohydrate diet (energetically 
equivalent) (Ashton, et al., 2000). In overweight subjects, PWV was improved by an 8 
weeks weight loss programme with no adverse effect of SFA (Keogh, et al., 2008). In 
healthy subjects, a Mediterranean diet (8% SFA, 14% MUFA) had no differential effect on 
carotid distensibility (echo-tracking) compared to a Swedish diet (36% SFA, 12% MUFA) 
provided for 4 weeks (Ambring, et al., 2004). More recently, our group showed that 6 
months of a high SFA and high MUFA dietary intervention had no differential effect on 
stiffness index (SI), as measured by DVP, although SI was improved with a low fat diet 
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compared to the high SFA and MUFA diets (Sanders TA, 2008). While the effect of SFA 
and MUFA on arterial stiffness remains uncertain, evidence is progressively accumulating 
regarding the effect of n-3 PUFA from fish oils. A recent meta-analysis including 10 
randomised controlled trials concluded that n-3 PUFA had a beneficial effect on arterial 
stiffness and compliance, even after adjusting for BP, BMI and heart rate (Pase, et al., 
2011). However it should be noted that this study considered all populations (including 
healthy, overweight and diabetics) and two types of measurements (PWV and arterial 
compliance). More interventions are needed to confirm these results and clarify their effect 
on different populations. 
1.3.2 FA and endothelial function (EF) in humans 
1.3.2.1 Assessment of EF 
The deleterious effects of CVD risk factors (i.e. hypertension, 
hypercholesterolemia, diabetes, obesity, cigarette smoke) elicit a systemic inflammatory 
response. In blood vessel at both macro- and microvascular levels, the endothelium appears 
to be their major cellular target. Despite the multiplicity of the functions mediated by the 
endothelium, the assessment of EF in humans amounts to evaluating the degree of 
endothelium-dependent vasodilation, particularly NO-induced vasodilation. Peripheral 
arteries, including the brachial artery, respond to physical and chemical stimuli by adjusting 
vascular tone and regulating blood flow. Non invasive techniques are usually applied to the 
arm or the forearm and assess EF in the brachial artery or the resistance vessels of the upper 
arm.  
♦ Flow-mediated dilatation 
An increase in blood flow, provided by reactive hyperaemia (RH), leads to shear 
stress which stimulates endothelial NO release, inducing vasorelaxation (described earlier 
in Figure 1-5). The vasodilatory response of the brachial artery to shear stress is called flow 
mediated dilation (FMD) and is evaluated by the use of high resolution ultrasound. In this 
method, an ischemic cuff is placed either around the wrist or the upper arm and inflated for 
5 min at a pressure of 50 mmHg higher than the SBP. The brachial artery is continuously 
monitored in the baseline state (1min), during cuff inflation (5min), and postcuff release 
(5min) (Sanders, et al., 2011). The maximal diameter is detected approximately 30-90s 
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after the cuff release (Corretti, et al., 2002). Most laboratories define FMD as the 
percentage change of the brachial artery diameter from baseline (before ischemia) to the 
maximal diameter. FMD is mainly endothelium-dependent (NO dependent) and inversely 
correlated to baseline arterial diameter. It should be noted that FMD responses in humans 
are not all equally NO dependent, and may involve other vasodilators, vessel wall structural 
factors (elastin, collagen) (Green, et al., 2011). Glyceryl trinitrate (GTN, NO donor) is 
often administered sublingually to isolate NO-dependent effects (Vogel, 2001).  
♦ Gauge-strain plethysmography: Forearm blood flow measurement 
In contrast with FMD that assess changes in diameter in the brachial (conduit) 
artery, gauge-strain plethysmography evaluates the changes in blood flow in the forearm 
(resistance vessels) in response to a 5 min RH. Forearme blood flow (FBF) is measured 
using a strain gauge attached to the upper part of the left arm and connected to a 
plethysmograhy device. A congesting cuff is placed on the upper arm and inflated to 40 
mmHg for 7s in each 15s cycle to occlude venous outflow, using a rapid cuff inflator. A 
second cuff is placed on the wrist and inflated at 50 mmHg above SBP for 5 min to exclude 
the hand from the measurement. FBF is measured every 15s after the release of the 
ischaemia for 3 min. Forearm vascular resistance may be calculated as the mean BP divided 
by FBF (expressed as a mm Hg/ml/min per 100 ml of tissue of forearm volume)  (Higashi 
and Yoshizumi, 2003).  
♦ Infusion of vasoactive agents 
The intrabrachial administration of vasoactive agents such as L-NMMA (eNOS 
inhibitor), acetylcholine (eNOS activator) or sodium nitroprusside (SNP, NO donor) may 
be combined to FMD or FBF measurements in order to specify the role of NO release in 
vasodilation (Higashi and Yoshizumi, 2003, Kooijman, et al., 2008, Mosca, et al., 2009). 
Similarly, changes in coronary diameter and coronary blood flow may be measured in 
response to intracoronary agonist infusion (Reriani, et al., 2010, Tousoulis, et al., 2005). 
Alternatively, techniques such as PWA and DVP described in 1.3.1 can be used in 
combination with vasodilators such as the β-2 adrenoceptor agonist salbutamol, 
administered by inhalation or intravenously (Donald, et al., 2006).  
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♦ Circulating markers of EF 
While the techniques described above assess EF locally, the measurement of 
circulating biomarkers may allow the estimation of EF systemically. Several traditional 
biochemical markers have been measured in plasma as indicators of EF, such as NO 
metabolites (nitrites/nitrates), prostacyclin, soluble thrombomodulin, von Willebrand 
factor, or the tissue factor pathway inhibitor. In addition, novel biomarkers have emerged, 
such as ADMA, described earlier, as well as circulating progenitor cells and endothelial 
progenitor cells, representing the ability for vascular repair, as well as circulating 
endothelial cells and endothelial microparticles, representing the degree of endothelial 
damage (Li, et al., 2011). 
EPCs are a subgroup of circulating progenitor cells (CPC) that are recruited from 
the bone marrow to repair the injured vasculature (See Figure 1-7:). They have been 
associated with a reduced CVD risk (O'Dunn-Orto, et al., 2012) and may serve as markers 
of EF because they represent a greater capacity for the endothelium to repair itself. Their 
number and capacity of differentiation correlates with FMD (Miura, et al., 2009) and their 
improvement upon endurance training in subjects at high CVD risk is associated with the 
improvement of FMD and NOx levels (Steiner, et al., 2005). As a transitory state between 
bone marrow cells and endothelial cells, endothelial progenitor cells (EPCs) express 
different markers throughout their differentiation. The lack of a specific marker, in addition 
to their rarity in peripheral blood (~ 0.002% of total peripheral mononuclear cells) 
(Peichev, et al., 2000), makes EPCs a challenging population to identify by flow cytometry. 
CD133 and CD34 are early hematopoietic stem cell markers expressed on hematopoietic 
stem and progenitor cells from human bone marrow (Andrews, et al., 1989, Yin, et al., 
1997). EPC have been characterized by the co-expression of CD34, CD133 and vascular 
endothelial growth factor receptor-2 (VEGFR-2), also termed kinase insert domain receptor 
(KDR) or Flk-1 (Peichev, et al., 2000). However, while KDR is expressed all along their 
maturation, EPCs progressively lose CD133, and subsequently CD34, while they start 
expressing CD31, as expressed by mature endothelial cells (Hristov, et al., 2003). 
EPC contrast with circulating endothelial cells (CEC), which include microparticles 
(MP), and are released from the endothelium when it is injured and are characteristic of ED 
(Erdbruegger, et al., 2010). CPC express early markers of differentiation such as CD133 
55 
 
and CD34, and EPC express markers of endothelial cells such as KDR in addition to the 
early markers.  
 
Figure 1-7: Mobilization, recruitment, and differentiation of human, bone marrow-
derived angiogenic progenitor cells. (Hristov and Weber, 2004) 
Vascular and endothelial injury leads to the activation of matrix metalloproteinase-9 
(MMP-9), which promotes the transformation of membrane bound Kit-ligand to a soluble 
Kit-ligand in the bone marrow. This leads to the by detachment of early cKit+ progenitor 
cells and their movement from the stromal niche to the vascular zone of the bone marrow. 
VEGF plays an important role in EPC maturation by binding its receptor VEGFR-2 on the 
EPCs. Early EPCs (CD133+/CD34+/VEGFR-2+/CD14-) represent a small population with 
proliferative potential, capable to give rise to late endothelial outgrowth. Cells of myeloid 
origin (CD14+) may also trans-differentiate into endothelial cells and secret angiogenic 
factors, but their proliferative potential is limited. Mesenchymal CD34- progenitor cells can 
also generate endothelial cells; however, these cells showed in vivo reduced functional 




1.3.2.2 FA and EF: Evidence from human studies 
FMD is an independent predictor of CV events in chronic heart failure (Meyer, et 
al., 2005), peripheral and coronary artery disease (Brevetti, et al., 2003, Chan, et al., 2003) 
and has emerged as a potential prognostic tool (Green, et al., 2011). FMD is the most 
commonly used technique, and encounters a growing interest in dietary interventions, 
especially with fish oils. Although there is growing evidence from in vitro studies that n-3 
PUFA improve EF (Deanfield, et al., 2007, IoM, 2005), the effect remains uncertain in 
humans. Some epidemiological studies suggest that PUFA, especially n-3 PUFA are 
beneficial for EF while SFA appear detrimental (Augoustides, et al., 2007, Harris, 2008, 
Maa, et al., 2007, Mozaffarian, et al., 2005, Yli-Jama, et al., 2002). However recent data 
showed no correlation between FMD with neither phosholipid EPA and DHA nor fish 
intake in healthy subjects (Hjelte, et al., 2005).  
Numerous studies have investigated the acute effect of saturated, monounsaturated and 
n-6 PUFA on EF but findings remain conflicting (Vafeiadou, et al., 2012). Recent data suggest 
that n-3 PUFA enriched meals improve post-prandial EF in type 2 diabetics (Hilpert, et al., 
2007, West, et al., 2005) but evidence remains limited.  
Several chronic studies have reported a beneficial effect of n-3 PUFA on circulating 
markers of endothelial activation in healthy subjects, including ICAM-1, VCAM-1, E or P-
selectin (Bennett and Horrobin, 2000, Horrobin, 2000, MacDonell, et al., 2000), although 
this is not always the case (Puri, et al., 2000). Markers of endothelial activation also appear 
to be improved in patients with type 2 diabetes or dyslipidaemia while results are 
conflicting in subjects with CVD (Ueshima, et al., 2007). However, measurement of 
vasodilatory function by FMD and FBF were improved by EPA and/or DHA in several 
studies in patients with CVD (Schiano, et al., 2008), type 2 diabetes (Rizza, et al., 2009, 
Stirban, et al., 2010) or dyslipidaemia (Goodfellow, et al., 2000, Mori, et al., 2000). 
Regarding the effect of SFA and MUFA, evidence from randomised controlled trials is 
even more limited and conflictive (Hall, 2009). A randomised cross-over trial showed that a 
3-week high-SFA diet led to an impairment of EF compared with high-PUFA, -MUFA or -
carbohydrate diets (Rajendran, et al., 2007). The same study showed a decrease of P-
selectin levels with high-MUFA and -PUFA diets compared with the high-SFA diet. More 
recently, another randomised cross-over trial (4 weeks intervention) showed an 
improvement of EF upon a high-MUFA diet compared to a high SFA diet or a low fat diet 
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enriched with ALA (Strauss, et al., 2007). ED is closely related to platelet dysfunction and 
NO plays a crucial role in platelet activation, including P-selectin expression and platelet-
monocyte aggregation (Gkaliagkousi, et al., 2009). Platelet-monocyte aggregates were 
shown to be reduced by fish consumption for 4 weeks in healthy young males (Din, et al., 
2008). 
However, it should be noted that beyond the impairment of vasodilation, ED also 
involves the imbalance between other endothelium dependent processes (Cf. 1.2.5) and 
little work has been done to relate the different EF markers to one other in disease state 
(Celermajer, 2008). 
 
1.3.3 FA and microvascular function 
ED is a globalised systemic disease characterised by an impairment of vasodilation 
and constriction, and microvessel structural remodelling (arterioles and capillaries). The 
microcirculation (which encompasses a vast endothelial surface area) may not only serve as 
a target for the detrimental effects of CVD risk factors but has also been implicated in the 
initiation and/or progression of large vessel disease (Stokes and Granger, 2005, Suematsu, 
et al., 2002). Most non invasive measurement techniques described earlier to assess 
vascular function in humans, assess the vessel wall stiffness or EF in large arteries; but the 
estimation of microvascular function, systemically or locally, may also be of great interest. 
The microcirculation can be examined over large areas of skin by laser Doppler imagery, or 
more locally by laser Doppler flowmetry. Changes in the vasodilation and constriction of 
skin microvessels may be induced by RH, whole body heating or cooling, local heating or 
cooling, or by the application of vasoactive agents non invasively (iontophoresis) or using 
minimally invasive techniques such as intradermal microdialysis (Holowatz, et al., 2008). 
Skin and sublingual microcirculation are the only vascular beds that are accessible 
for clinical assessment. New techniques of videomicroscopic examinations have emerged 
and could be of great interest for diagnosis and/or research. Capillaries are only made of 
one layer of endothelium and investigating their structure and/or function can provide 
useful information on EF. Capillary rarefaction has been associated to CVD risk factors 
such as hypertension (Antonios, et al., 1999), smoking (Debbabi, et al., 2006) and obesity 
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(Sioen, et al., 2007). The cutaneous circulation has emerged as an accessible and 
representative vascular bed to look at microvascular dysfunction (Holowatz, et al., 2008), 
although its extrapolation to systemic and peripheral microvascular function remains 
controversial (Varenne, et al., 2006, Weber, 2006). Nonetheless, capillary density, i.e. the 
number of capillaries per skin area, can be easily assessed in the finger using a laser 
camera, and has shown inverse correlation with hypertension (Sioen, et al., 2007). 
Furthermore, video facilities allow real-time imaging which can provide information on the 
morphology and velocity of red blood cells (RBCV) (Awan, et al., 2010). RBCV is more 
often measured by Doppler (Bilau, et al., 2007, Sioen, et al., 2007). In addition several 
imaging techniques have been developed in order to measure RBCV at the nailfold, where 
the capillaries are horizontal. Those techniques include the frame to frame (Butti, et al., 
1975, Mugii, et al., 2009), the flying spot (Gasser and Buhler, 1992, Mahler, et al., 1987, 
Paul, 1990) or the cross-correlation (Fagrell, et al., 1977, Intaglietta and Tompkins, 1987, 
Mawson and Shore, 1998) techniques. 
Despite the development of these techniques, microvascular function has been 
poorly investigated in nutritional intervention. Some studies suggest that LC n-3 PUFA 
enriched meals may improve post-prandial microvascular reactivity through endothelium-
independent mechanisms (Armah, et al., 2008). However there is, to our knowledge, no data 
regarding the chronic effect of fats on capillary structure and function. 
1.4 Aim and objectives  
1.4.1 Aim 
The aim of this thesis is to further the understanding of the effect of different dietary 
FA on EF in humans, in vivo and in vitro. We hypothesized that the nature and proportion 
of FA differentially affects EF in vivo and in vitro. 
1.4.2 Objectives 
The objectives of our in vivo work were to investigate the differential effect of a 6-




- markers of endothelial function (EPC, NOx)  
- macrovascular function (PWA, DVP) 
- microvascular function (capillary density) 
- related markers of CVD risk (such as markers of oxidative stress, lipid profiles)  
The objective of our in vitro work was to test the effect of various FA profiles, 
characteristic of physiological NEFA profiles observed after different dietary patterns, on 






Chapter 2 The EPA and DHA trial - a randomised 
controlled dietary intervention study: Materials and 
Methods 
The EPA and DHA trial was a single-blind, randomised, parallel study designed to 
test the effects of EPA and DHA supplementation (3g/d, 6 weeks) vs placebo (olive oil) on 
EF in healthy young men. It was carried out by the author and Dr Aseel Alsaleh. Both were 
in charge of the recruiting the participants and providing them with all information at 
screening. Dr Aseel Alsaleh was responsible for the pulse wave analysis, the digital volume 
pulse, the body composition measurements and blood handling. The author was responsible 
for scheduling the participants, the ambulatory blood pressure (ABP) monitoring and 
giving the associated instructions, the microvascular measurements (capillaroscopy), 
phlebotomy and the treatment of fresh blood samples for flow cytometry analysis. The 
serum adiponectin, HOMA-IR and plasma lipid results have already been reported in the 
thesis of Dr Aseel Alsaleh (AlSaleh, 2011). 
2.1 Materials 
2.1.1 List of equipment 
- Centrifuge Jouan CR4.12 for blood handling (DJB Labcare Ltd, Buckinghamshire, 
UK) 
- Calibrated automated blood pressure monitor (Omron 705IT, Omron Healthcare 
Europe B.V.) 
- Bioelectrical impedance analysis equipment (BC-418 MA, Tanita UK Ltd, Middlesex, 
UK) 
- Digital Volume Pulse (DVP; PulseTrace PCA 2, Micro Medical Ltd) 
- Pulse Wave Analysis (PWA; SphygmoCor Px, AtCor Medical Pty Limited) 
- CapiScope Capillaroscopy System (KK Research Technology Ltd, Devon, UK) 
- FC500-Beckman Coulter flow cytometer (Beckman & Coulter Ltd, UK) 




- Eppendorff concentrator 5301 (Eppendorf UK Ltd, Cambridge, UK) 
- Agilent 6890 Gas Chromatograph (Agilent Technologies UK Ltd, Wockingham, UK) 
- Centrifuge Beckman GS-6R (Beckman & Coulter Ltd, UK) 
- Eppendorff concentrator 5301 (Eppendorf UK Ltd, Cambridge, UK) 
- GC-MS instrumentation with negative chemical ionization capability: Agilent 
Technologies 6890N network Gas Chromatograph system equipped with 7683 series 
autoinjector, PTV (Gerstel) Inlet and 5673 inert mass selective detector with chemical 
ionization module  
- D Data/Control System: Agilent Enhanced MSD Chem Station running on Windows 
XP Professional 
- Sample processing station (Argonaut Vacmaster®-20, Biotage (UK) Ltd, UK) 
- PTI-11 digital pH metre (Paper testing instruments GmbH, Austria) and pH electrode 
(Russell Ph Ltd, Auchtermuchty, UK) 
- 8-Isoprostane affinity columns (Cayman Chemical Europe cat. no. 416358, VWR 
International Ltd, UK)  
- Amicon Ultra-0.5 Centrifugal Filter Unit with Ultracel-10 membrane, 10kDa (cat.no. 
UFC501096,  Millipore Ltd., UK) 
- Partisil® absorption thin layer chromatography plates LK6D (cat.no. 4865-821, 
Whatman international Ltd, Kent, UK) 
- Venous blood collection tubes:  
o 4.5 mL EDTA lavender tubes (Becton Dickinson; cat.no. 367654, UK) 
o 4 mL fluoride/oxalate (FX) grey tubes (Becton Dickinson; cat.no. 367922, 
UK) 
o 8.5 mL gold tubes with clot activator and gel for serum separation (Becton 
Dickinson; cat.no. 367953, UK) 
o 4.5 mL citrated light blue tubes (Becton Dickinson; cat. no. 369714, UK)  
o 4 mL lithium heparin (LH) green tubes (Becton Dickinson; cat. no. 367884, 
UK)  
2.1.2 Solvents and acids 
- Methanol (HPLC grade, Fisher Scientific, UK) 
- Chloroform (BDH AnalaR, VWR International Ltd., UK), 50mg BHT/L 
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- Isopropanol (BDH AnalaR, VWR International Ltd., UK), 50mg BHT/L 
- Hexane (HPLC grade, Fisher Scientific, UK) 
- Absolute Ethanol (Sigma-Aldrich, Dorset, UK) 
- Acetone (HPLC grade, Fisher Scientific, UK) 
- Isooctane (Puriss grade Fluka-Chemika, Sigma-Aldrich, Dorset, UK) 
- Diethylether (BDH AnalaR, VWR International Ltd., UK)  
- Toluene (BDH AnalaR, VWR International Ltd., UK)  
- Formic acid (Fluka-Chemika, Sigma-Aldrich, Dorset, UK) 
- Acetyl chloride (Sigma-Aldrich, Dorset, UK) 
2.1.3 Chemicals, reagents and kits 
- Butylated hydroxytoluene (BHT, Sigma-Aldrich cat.no. B1378, Dorset, UK): 5 mM 
stock solution in ethanol 
- Sodium hydrogen carbonate (NaHCO3, BDH AnalaR, VWR International Ltd., UK) 
- Indomethacin (Sigma-Aldrich; cat.no. I7378, Dorset, UK): 2 mM in 5% w/v aqueous 
NaHCO3 
- Ethylenediaminetetraacetic acid (EDTA, BDH cat.no. 100935V, VWR International 
Ltd., UK)  
- Sodium methoxide (NaOCH3) 0.5N in anhydrous methanol (Sigma-Aldrich, cat.no. 
156256, Dorset, UK) 
- Calcium chloride (CaCl2, BDH AnalaR, VWR International Ltd., UK) 
- Potassium carbonate (K2CO3, BDH AnalaR, VWR International Ltd., UK) 6 % (w/v) 
in UltraPure water 
- Pentadecanoic acid (C15:0, internal standard for NEFA,50 mg/mL in CHCl3:MetOH 
2:1 v/v) (~99% by capillary GC, Sigma-Aldrich, cat no. P6125-5G, Dorset, UK) 
- Sodium chloride (NaCl, BDH AnalaR, VWR International Ltd., UK) 
- Potassium chloride (KCl, BDH AnalaR, VWR International Ltd., UK) 
- Magnesium sulphate, hydrated (MgSO4, 7H20, Fisons-Fisher Scientific, 
Loughborough, UK) 
- Hepes (Sigma-Aldrich cat.no. H0891, Dorset, UK) 
- iso-8-Prostaglandin F2α (iso-8-PF2α 1mg, Cayman Chemical Europe cat.no. 16350-1, 
VWR International Ltd, UK): 10µg/mL in ethanol (standard solution) 
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- iso-8-Prostaglandin F2α -17,18,19,20 – D4 (iso-8-PF2α-D4 25µg/250µl Methyl Acetate, 
Cayman Chemical Europe cat.no. 316350, VWR International Ltd, UK): 1µg/mL in 
ethanol (internal standard solution) 
- Anhydrous potassium hydroxide pellets (KOH, BDH AnalaR, VWR International Ltd., 
UK) 
- Dipotassium hydrogen ortho phosphate (K2HPO4, BDH AnalaR, VWR International 
Ltd., UK) 
- Potassium diHydrogen ortho Phosphate (KH2PO4, BDH AnalaR, VWR International 
Ltd., UK) 
- Acetic acid (BDH AnalaR, VWR International Ltd., UK) 
- Sodium Azide (NaN3, BDH AnalaR, VWR International Ltd., UK) 
- N,N-Diisopropylethylamine (DIPEA, Sigma-Aldrich, cat.no. 387649, Dorset, UK) 
- α -Bromo-2,3,4,5,6-pentafluorotoluene (PFBBr, Sigma-Aldrich, cat.no. 101052, 
Dorset, UK) 
- N,O-bis(Trimethylsilyl)-trifluoroacetamide (BSTFA, Pierce® Thermo Scientific, UK) 
- Total Nitric Oxide and Nitrite/Nitrate Assay kit (cat.no. KGE001, R&D Systems 
Europe Ltd, UK) 
2.1.4 Solutions and buffers 
- Saline 0.89% NaCl, 40mg EDTA/L 
- Phosphate buffered saline (Sigma-Aldrich, cat.no. P4417, Dorset, UK)  
- Erythrolyse red blood cell lysing buffer 10X (cat.no. BUF04B, AbD Serotec, 
Oxfordshire, UK)  
- IOTest® 3 Fixative Solution, 100 - 200 Tests, ready to use (cat.no. A07800, Beckman 
& Coulter UK Ltd, Buckinghamshire, UK)  
- Optilyse® C lysis solution, 200 tests, ready to use (cat.no. A11895, Beckman & 
Coulter UK Ltd, Buckinghamshire, UK) 
- Hepes Buffer Saline (HBS): NaCL 150 mM, KCL 5 mM, MgSO4.7H2O 1 mM, Hepes 
10 mM. 
- Isoprostane standard solution: iso-8-PF2α 10µg/mL in ethanol 
- Isoprostane internal standard solution: iso-8-PF2α-D4 1µg/mL in ethanol 
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- Affinity column buffer solution, 0.1 M PBS pH 7.4 : 13.3g K2HPO4, 3.22g KH2PO4, 
0.5g NaN3, 29.2g NaCl in 1L UltraPure water. 
- Affinity column elution solution: Ethanol 95% v/v in Ultrapure water 
- Alkalinisation solution: 15% w/v potassium hydroxide in UltraPure water 
- 1M potassium dihydrogen ortho phosphate in UltraPure water 
- DIPEA solution: 10% v/v in acetone 
- PFBBr solution: 20% v/v in acetone. 
2.1.5 Antibodies (Flow cytometry) 
- Mouse Anti-Human IgG1-FITC (cat.no. IM0639, Beckman & Coulter UK Ltd, 
Buckinghamshire, UK) 
- Mouse Anti-Human IgG1-PE (cat.no. IM0670, Beckman & Coulter UK Ltd, 
Buckinghamshire, UK) 
- Mouse Anti-Human IgG1-APC (cat.no. IM2475, Beckman & Coulter UK Ltd, 
Buckinghamshire, UK) 
- IgG1, Kappa from murine myeloma, clone MOPC31 (Sigma-Aldrich, cat.no. M9035, 
Dorset, UK) 
- Monoclonal anti-human P-Selectin/CD62P antibody, clone 9E1 (cat.no. BBA30, R&D 
Systems Europe Ltd., UK) 
- Mouse Anti-Human CD31 (PECAM-1)-FITC (cat.no. IM1431, Beckman & Coulter 
UK Ltd, Buckinghamshire, UK) 
- Mouse Anti-Human CD45-PE (cat.no. IM2078, Beckman & Coulter UK Ltd, 
Buckinghamshire, UK) 
- Mouse Anti-Human CD34-PE (cat.no. A0776, Beckman & Coulter UK Ltd, 
Buckinghamshire, UK) 
- Mouse Anti-Human CD34-FITC (cat.no. IM1870, Beckman & Coulter UK Ltd, 
Buckinghamshire, UK) 
- Monoclonal anti-human VEGF R2/KDR-APC (cat.no. FAB357A, R&D Systems 
Europe Ltd., UK) 




- Mouse Anti-Human CD14-FITC (cat.no. IM0645, Beckman & Coulter UK Ltd, 
Buckinghamshire, UK) 
- Mouse Anti-Human CD42b-PE (cat.no. IM1417, Beckman & Coulter UK Ltd, 
Buckinghamshire, UK) 
2.1.6 Supplements 
- 500mg EPA-rich oil softgel capsules (Incromega EPA500TG SR, Croda Chemicals 
Europe Ltd, Goole, UK) 
- 1000mg DHA-rich oil soft gel capsules (Incromega DHA500TG SR soft gel capsules, 
Croda Chemicals Europe Ltd, Goole, UK) 
- 1000mg olive oil soft gel capsules (Croda Chemicals Europe Ltd, Goole, UK) 
2.2 Methods and methodology development 
2.2.1 Participants 
Healthy males, non smokers, aged between 18 and 45 years old were recruited. The 
participants were excluded according to the following specified criteria: 
- Reported history of CVD (myocardial infarction, angina, venous thrombosis, stroke, 
dyslipidemia), diabetes (or fasting glucose ≥ 6.1 mmol/L), cancer, kidney, liver or bowel 
disease. 
- Presence of gastrointestinal disorder or use of drug, which is likely to alter 
gastrointestinal motility or nutrient absorption. 
- Current smokers; history of substance abuse or alcoholism (previous weekly alcohol 
intake >60 units/week); current self-reported weekly alcohol intake exceeding 28 units  
- Recent use of hypolipidaemic, antihypertensive, antiplatelet or antithrombotic 
mediations 
- Platelet count above or below the normal range or any history indicative of a congenital 
or acquired platelet or haemostatic defect. 
- Allergy or intolerance to any component of study capsules  
- Unwilling to restrict consumption of any source of fish oil for the length of the study 
- Subjects reporting consumption of >1 portion oily fish per week 
- Weight change of >3 kg in preceding 2 months; BMI <18 and >32 kg/m2 
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- Blood pressure>160/90 mmHg 
- Fasting blood cholesterol > 6.5 mmol/L; fasting triacylglycerol concentrations > 2.0 
mmol/L 
2.2.2 Recruitment methodology 
Participants were recruited through internal email circulars (0) and posters 
(Appendix II) among King’s College London students and staff, and fitness centre users in 
the London Bridge area. The methodology of recruitment is outlined in Figure 2-1. 
Volunteers expressing interest were initially sent an information sheet (Appendix III) and a 
booklet (Appendix IV) summarising the study by e-mail. Those who responded were 
initially interviewed via a questionnaire over the phone (Appendix V), to assess whether 
they were suitable for the study. Volunteers who were eligible were then invited to attend a 
screening session during which blood pressure, height and weight, percentage body fat and 
waist and hip circumference were measured. At the end of the screening visit (2.2.4), a 
small blood sample was taken for a full blood count, lipid profile, liver function tests and 
fasting glucose concentrations. Volunteers who met the inclusion criteria described in 2.2.1 





Figure 2-1: Methodology of recruitment - Outline 
2.2.3 Study design. 
A randomised single-blind parallel design was used to test the effects of 
formulations of DHA or EPA versus placebo on primary and secondary outcomes as 
outlined in Figure 2-2. 
No further action is taken 
Volunteer responds to advert by e-mail or telephone 
Volunteer is given more information verbally and 
completes screening questionnaire over the telephone 
Volunteer receives information sheet at least 3 days 
before start screening session 
No further action is taken 
Eligible 
Non eligible 
Volunteer attends screening session and information 
sheet is explained in more details. 
 If volunteer is willing to take part in the study, the 
consent form is signed. 
 Screening: height, weight, blood samples, body fat 
percentage, blood pressure, food frequency 
questionnaire 
Volunteer is accepted as a subject on the study 





 Figure 2-2: Outline of study protocol 
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EPA- and DHA-rich oils, as well as olive oil were provided in the form of 
triglycerides in soft gel capsules. Refined olive oil and DHA-rich oil were supplied as 1 g 
capsules while EPA-rich oil was supplied as 500 mg capsules. Both EPA- and DHA-rich 
oils were blended with refined BP specification olive oil, with a content of at least 65% of 
total n-3 PUFA, including a minimum of 500 mg of EPA and DHA, respectively. The 
typical content of fatty acids in EPA- and DHA-rich oil was provided by the manufacturer 
(Appendix VII, VII. A): EPA-rich oils typically contain 58.4% and DHA-rich oils 57.5%. 
Calculations were based on the FA composition described by the manufacturer, to reach a 
consumption of ~3 g/d of EPA or DHA. The participants were asked to consume 5 g of 
supplement a day, i.e. 5 capsules a day in the placebo and DHA group (1g capsules), while 
the EPA group received 10 a day (500 mg capsules). The composition of the capsules was 
later analysed by GC in our department and confirmed similar composition (Appendix VII, 
VII. B), EPA and DHA reaching ~3.1 and 2.9 g/d, respectively. Precisely, subjects in the 
EPA group typically consumed ~3098 mg EPA + 103 mg DPA + 700 mg DHA per day, 
while the DHA group consumed 2865 mg DHA + 167 mg DPA + 517 mg EPA per day 
(Table 2-1) 
 
Capsules FA content, g/100g FA intake (mg/d) 
Fatty acid DHA-rich oil EPA-rich oil DHA-rich oil EPA-rich oil 
EPA 10.3 62.0 517 3098 
DPA 3.3 2.1 167 103 
DHA 57.3 14.1 2865 705 
Table 2-1. EPA and DHA composition of EPA- and DHA- rich oils and resulting 
intake for the consumption of 5g of supplement a day. 
 
For each period, the participants were provided with the equivalent of exactly 3 
extra days in addition to the amount necessary for the run-in period (two weeks) and the 
intervention (six weeks) to ensure they had enough in case of loss or slight amendment of 
schedule. They were asked to bring the remaining capsules in the end of each period and 
capsule count was used as an indicator of compliance. 
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2.2.4 Screening visit 
Participants arrived between 8.30 am and 1 pm (staggered at 45 minute intervals). 
On arrival to the metabolic unit of KCL, the participants were briefed on what the study 
involves and were provided with a hard copy of the 'information sheet for participants' and 
booklet previously sent by e-mail (Appendix IV, Appendix V). The participants were then 
required to sign the consent form (0).  
After consent was obtained, the participants underwent a brief medical examination 
to measure blood pressure, waist and hip circumference, weight, height, and body 
composition using bioelectrical impedance (% body fat). Participants were excluded at this 
stage if any of their physical measurements did not fall within the prespecified limits 
described in 2.2.1. Standard physical measurement procedures are detailed in Appendix IX. 
All required information was documented on a standard screening record sheet (Appendix 
X). 
A fasting blood sample was taken (16.5 ml) for the analysis of fasting glucose and 
plasma lipid concentrations (total, HDL and LDL cholesterol and TAG), liver function, and 
full blood count tests. Blood for haematology was collected into EDTA containing tubes, 
for plasma glucose into FX tubes, and for serum lipids and liver function into tubes 
containing clot activator and gel for serum separation. All tubes, apart from the EDTA tube 
(whole blood), were then centrifuged at 1300 g for 15 min at 2-4ºC and samples were 
dispatched by motorcycle courier on the day of collection to an accredited clinical 
pathology laboratory at King's College Hospital for same-day analysis (Clinical Pathology 
Accreditation Ltd. (CPA) laboratory (CPA 1245); Head: Dr Roy Sherwood). Participants 
were excluded at this stage if fasting blood samples were found to have abnormal glucose 
or lipid levels, liver function or haematology. The standard blood spinning protocol is 
described in Appendix XI  
Lipids were measured via enzymatic assays and analysed on the ADVIA 2400 
automated chemistry analyser (Siemens Healthcare Diagnostics, Surrey, UK). Detailed 
protocols are described in Appendix XII, Appendix XIII and Appendix XIV. TAG were 
hydrolysed into glycerol (lipase), which was then converted into glycerol-3-phosphate. The 
latter was then oxidised (glycerol-3-phosphate oxidase) to give hydrogen peroxide (H2O2), 
which yields a coloured pigment in the presence of peroxidase. Total cholesterol esters 
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were hydrolysed (cholesterolesterase) into free cholesterols, which were in turn oxidised to 
generate H2O2 that combines with phenol and 4-aminophenazone to give a red dye. The 
HDL method was a two step procedure described in Appendix XIV. All non HDL was 
converted into H2O2 through the choleterol esterase / cholesterol oxidase system in absence 
of detergent, which protects the HDL from the enzymes. H2O2 was removed by the action 
of catalase and the procedure was repeated in the presence of detergent and sodium azide 
(catalase inhibitor). The remaining HDL produced H2O2 which reacts with 4-amino-
antipyrine to produce a blue purple compound. LDL cholesterol was calculated using the 
Friedewald formula (LDL = total cholesterol – HDL cholesterol – TAG / 2.2; in mmol/L) 
(Friedewald, et al., 1972).  
Plasma glucose was determined by the hexokinase and glucose-6-phosphate 
dehydrogenase (G6PD) method (Appendix XV) on the ADVIA 2400 automated chemistry 
analyser (Siemens Healthcare Diagnostics, Surrey, UK). Glucose was phosphorylated into 
glucose-6-phosphate, which was then oxidised into 6-phosphogluconate. The NADH+H+ 
produced by the last reaction in an increase of absorbance proportional to the glucose 
concentration in the plasma sample.  
Full blood counts were analysed by routine chemistry using the ADVIA 2120 
automated chemistry analyser (Siemens Healthcare Diagnostics, Surrey, UK). The method 
relies on four principles described in Appendix XVI  The hydrodynamic focusing is used to 
produce a single stream of cells for flow cytometry analysis. The peroxidise methods 
differentiate the populations of white cells. The ‘baso’ method consists in lysing red blood 
cells, platelets and all white cells except the basophils. The cyanide free haemoglobin 
detection is used to quantify haemoglobin released by the red blood cells after lysis. The 
nucleated red blood cells are identified by their nuclear size measured in the peroxide 
channel and their nuclear density in the ‘baso’ channel.  
Assays for liver function were carried out using the ADVIA 2400 automated 
chemistry analyser (Siemens Healthcare Diagnostics, Surrey, UK). Total protein was 
measured by the Biuret reaction (Appendix XVII), albumin by bromocresol green 
(Appendix XVIII), bilirubin by vanadate oxidation (Appendix XIX), aspartate 
aminotransferase using aspartate to glutamate conversion monitored by UV (Appendix 
XX), alkaline phosphatase using p-nitrophenol phosphate as substrate (Appendix XXI), and 
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gamma glutamyl transpeptidase using γ-glutamyl-4 nitroanilide as a substrate (Appendix 
XXII). 
Finally the participants were requested to select an 8-wk period during which they 
were able to take supplements and attend the metabolic unit for 2 x 2-hour visit after 2 and 
8 wk of intervention. A light breakfast was provided to the participants before leaving the 
screening session. 
2.2.5 The study days 
Two to 3 days prior to each study visit, participants were asked to record their blood 
pressure for 24 h. Thus, they were asked to attend the metabolic unit the week before their 
visit in order to collect the ABP monitor. This short visit lasted 20 to 30 min, during which 
the subject was shown how to use the ABP monitor and provided with a diary card where 
he had to record his activity during the 24 h BP monitoring, as well as written instructions 
(Appendix XXIII, Appendix XXIV). The subject was asked to bring back the ABP monitor 
and urine, as well as the diary card on the day of the visit. 
Prior to each visit, the participants were contacted to ask them to avoid certain 
food/drinks and activities that may affect vascular function and BP. They had to avoid 
drinking alcohol, caffeine (from midday the previous day) and taking part in any strenuous 
exercise at any time during the day preceding their visit. They were asked to fast overnight 
and instructed to avoid eating or drinking anything, except water, for 12 h before the time 
of their scheduled study visit. They were also asked to consume a low fat meal as their 
evening meal. A reminder e-mail was sent out on the morning before the study day 
summarising the instructions (Appendix XXV). 
One to two participants were scheduled between 8 am and 1 pm depending on their 
availability. On arrival, the participant was provided with water to avoid dehydration. The 
questionnaire subject record sheet (Appendix XXVI) was completed along the 2 h visit. 
The ABP monitor and diary card were collected. Seated BP and HR, as well as weight and 
body composition were then measured. The participant was then asked to rest quietly in a 
supine position for 15 min prior to the start of vascular measurements. The room 
temperature was recorded at that time (baseline: 24.17 +/- 0.50; 6 wks: 24.23 +/- 0.39). The 
programme of a typical study day is outline in Figure 2-3. 
  
Figure 2-3. Outline of a study day
BP, Blood pressure; ABP, ambulatory BP; HR, heart rate; PWA, pulse wave analysis; 
DVP, digital pulse volume analysis
♦ 
PWA and DVP analysis were performed in order to measure 
arterial stiffness and 
potential structural changes 
invasive vascular measurements 
position and are further described in 
was measured on the right arm.
Peripheral arterial tone 
forefinger pulse and pulse wave analysis (PWA) using the radial pulse, according to 
 
 
Vascular measurements (overview) 
pulse wave reflection. Capillary density was measured to assess 
in the microvasculature (finger capillaries). 
(PWA, DVP, capillaroscopy) were made
2.2.12. They were carried out 
 
was measured by digital volume pulse (DVP) using the 
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central and peripheral 
All the non-
 in the supine 
on the left arm, while BP 
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extensive recommendations (Van Bortel, et al., 2002). Supine blood pressure was measured 
concurrently. These vascular measures were made in triplicate, according to the following 
sequence: (1) a single DVP measure on the left index finger, followed by (2) a blood 
pressure measurement of the right brachial artery, and finally (3) a PWA carried out on the 
left radial artery. When the finger pulse could not be detected by DVP in the index finger, 
the probe was changed to the thumb (same hand), which may give a stronger signal. If the 
signal was still too weak (due to the low temperature of the skin), a heating blanket was 
used to warm up the subject’s hand. The temperature of the room was recorded in the end 
of the last DVP measurement and remained constant at 24.20 ˚C (±0.44). For both DVP and 
PWA analysis, the average of 3 measurements was taken, unless % COV of the 3 
recordings was >15%, in which case the average of the 2 closest was taken. The 
measurements were made by Miss Aseel Alsaleh and the data entry and analysis were 
carried out by both Aseel and the author.  
Next the subject was asked to place his left fourth finger in the finger device 
underneath the Capiscope camera. Five pictures were taken at the distal (terminal) phalanx, 
away from the nail fold, where capillaries are perpendicular to the skin and allow capillary 
density measurements. 
♦ Venepuncture and blood handling 
After the vascular measurements, the participant was advised again to drink water 
before the venepuncture. Blood was collected by the author according to the blood 
collection described in Appendix XXVI and Appendix XXVIII. The tourniquet was 
released on the 7th tube (EPC, Erythrocyte lipids) in order to ensure a steady flow for blood 
collection for prostacyclin and PMA measurement. The order of blood draw and the 





of draw Tube Outcome measured Comment 
1 8.5 mL Serum (gold) Adiponectin, CRP, Resisitin Used by Aseel Alsaleh 
2 8.5 mL Serum (gold) FLIP, Nox, ApoB100, ApoA1  
3 4 mL LH (green) Insulin  
4 4 mL FX (grey) Glucose  
5 4.5 mL citrate (light blue) Isoprostanes Pre-chilled, immediately 
transferred on ice 6 4.5 mL citrate (light blue) Isoprostanes 
7 4.5 mL EDTA (lavender) EPC*, Erythrocyte lipids Tourniquet released 
8 4.5 mL EDTA (lavender) Prostacyclin  
9 4.5 mL citrate (light blue) PMA*  
Table 2-2. Outline of blood sampling 
CRP, C-reactive protein; FLIP, full lipid profile (TAG, NEFA, total cholesterol, LDL, 
HDL); NOx, nitrates/nitrites; EPC, endothelial progenitor cells; PMA, platelet monocyte 
aggregates. 
* analysis on fresh blood. 
Tubes 3, 4 and 8 were centrifuged at 1500 g for 15 min at 4 ºC less than 10 min 
after blood sampling. Tubes 1 and 2 were allowed to stand at room temperature for 30 min 
before being centrifuged in the same conditions. Blood for 8-iso-PGF2α analysis was drawn 
into chilled citrated tubes (tubes 5 and 6) and chilled fresh indomethacin was immediately 
added (final concentration 15 µmol/L). The sample was kept on ice 30 min prior to 
centrifugation at 2400 × g; 15min.  BHT was added (final concentrations 20 µmol/L) and 
the samples stored at -80°C until analysis (detailed protocol in Appendix XXVII). Tubes 7 
and 9 were used for fresh whole blood analysis by flow cytometry. Because cold 
temperature may activate platelets, PMA tubes were kept at room temperature to be 
analysed less than 20 min after blood sampling according to the protocol described in 
2.2.13.3. EPC tubes were kept on ice and analysed within 30 min as described in 2.2.13.2. 
The 2 experiments on fresh blood were run in parallel and samples were read on a flow 
cytometer. Once whole blood was taken for PMA and EPC treatment, the EDTA and 
citrated tubes were centrifuged at 1500 g for 15 min at 4 ºC for the purpose of providing 
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spare plasma samples. Plasma and serum samples from the 9 tubes were aliquoted and 
frozen at either -40ºC or -80ºC (see Appendix XXVIII). The red cells obtained from 
centrifugation of the EPC tube (tube 7, EDTA) were kept in the fridge 3 to 5 days until they 
were treated for erythrocyte lipid analysis as described in 2.2.6. 
At the end of the 2 h visit, the participants were provided with a light meal to 
consume before leaving the metabolic unit. 
2.2.6 Erythrocyte lipids 
Erythrocyte lipids were measured in order to determine the omega-3 index 
(erythrocyte EPA+DHA) as a marker of compliance, in addition to the capsules count. 
Blood was collected in 4.5 ml EDTA tubes and centrifuged at 1300 g, 4ºC for 15 min as 
described earlier. The pellet (erythrocytes) was kept in the fridge 3 to 5 days before being 
treated according to the following protocol, adapted from Rose and Oklander, 1965 (Rose 
and Oklander, 1965). 
2.2.6.1 Lipid extraction 
Erythrocytes lipids: The buffy coat was removed, and the erythrocytes washed 
three times with 5 volumes of cold saline (0.89%)  for 10 min at 900 g, 4ºC. 0.5 ml 
erythrocytes were pipetted into large 25 ml glass-stoppered centrifuge tubes and 0.5 ml 
distilled water added. The contents were vortex-mixed to haemolyse the erythrocytes. 5.5 
ml chilled isopropanol were then added slowly, and the tube was vortexed thoroughly 
again. After 15 min storage at 4ºC, 3.5 ml chilled chloroform were added and the contents 
mixed thoroughly. At the end of another 30 min at 4ºC, the samples were centrifuged at 
1500 g for 15 min at 4ºC. The supernatant was collected and stored in glass tubes at -40ºC 
until GC analysis. 
2.2.6.2 Methyl ester preparation 
Lipid extracts were treated in 3 batches; lipid extracts from the same subjects were 
treated at the same time. 
Approximately 1 ml of each thawed lipid extract was transferred to a labelled GC 
vial and evaporated in an eppendorff concentrator at 45 ºC for ~1 h. Each extract was then 
re-dissolved in 100 µl hexane, and 50 µl NaOCH3 added to neutralise acidity. The content 
was thoroughly mixed and 1 ml hexane was added. CaCl2 was then added in order to 
77 
 
absorb any remaining water and the vials were covered and allowed to stand 1 h at RT. 
Samples were transferred to new GC vials, and evaporated for 20 min at RT. The final 
extracts were re-dissolved in 50 µl hexane and transferred to inserts in GC microvials for 
GC analysis. 
2.2.6.3 Gas chromatography (GC) conditions 
Fatty acid methyl esters were separated on an Agilent 6890 Gas Chromatograph 
(Agilent Technologies) fitted with a flame ionization detector with a 25 m BP75 capillary 
column. The injection volume was 2 µL, the temperature was 160ºC for 4 min and then rose 
to 200ºC in 10 min (gradient of 12ºC/min).  
2.2.7 Non esterified FA (NEFA) profiles 
NEFA patterns were measured in order to relate to the FA profiles used in the cell 
cultures work described in Chapter 4, representing NEFA profiles. Compared to 
erythrocyte, which give an indication of longer term FA intake over the last month, NEFA 
profiles give an index of compliance in the short term, i.e. the last few days of intervention. 
Blood was collected in 4.5 ml EDTA tubes and centrifuged at 1300 g, 4ºC for 15 min (see 
2.2.7). Plasma was aliquotted and stored at -80ºC until analysis. The NEFA were extracted 
and isolated as previously described (Burdge, et al., 2000, Folch, et al., 1957, Lepage and 
Roy, 1988, Madsen, et al., 2011). 
2.2.7.1 Lipid extraction 
0.5 mL of plasma was mixed with 0.5 mL internal standard (C15:0) and 10 mL of  
CHCl3:MeOH (2:1) + BHT 50mg/mL were added. The content was gently mixed for 15 
minutes on a roller mixer and 1.5 mL of 0.89% saline was added. Tubes were then vortexed 
and centrifuged at 1,600 g for 10 minutes at 4°C. The upper aqueous phase was discarded 
and the lower organic phase collected. The protein disk was reextracted following the same 
procedure. The two organic phases were combined and dried under nitrogen. 
2.2.7.2 Thin layer chromatography (TLC) 
The dry extract was redissolved in 50 µL CHCl3 and applied on TLC plate. Oleic 
acid was used as an external standard. The plate was placed in a tank and developing 
solution (hexane : diethylether : acetic acid, 80:20:1, v/v/v) was added. The tank was closed 
and the plate allowed to develop for approximatively 50min. Cholesterol esters migrate to 
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the solvent front, followed by TAG, NEFA, cholesterol, diacylglycerols, monoglycerols 
and phospholipids. Once the solvent reached the top of the plate, the plate was dried under 
nitrogen and sprayed with 2-7-dichlorofluorescein in 95% methanol for visualisation under 
UV light. The NEFA band was identified by comparison with the external standard band 
and scraped into a screw cap glass tube containing the methylating solution.  
2.2.7.3 Methyl ester preparation 
The extract was dissolved in 2mL toluene : methanol : acetyl chloride, 20:80:10 
(v/v) (methylating agent). Tubes were sealed and incubated overnight at 40 ºC in water 
bath. 5 mL of 6 % K2CO3 solution were added and themixtures centrifuged at centrifuged 
at 1,600 g for 10 minutes at 4°C. The upper phase was evaporated in the eppendorff 
concentrator, redissolved in 40µL hexane and transferred to insert for GC analysis. 
2.2.7.4 GC conditions 
Fatty acid methyl esters were separated on an Agilent 6890 Gas Chromatograph fitted 
with a flame ionization detector with a 25 m BP75 capillary column. The injection volume 
was 2 µL, the temperature was 160ºC for 4 min and then rose to 200ºC in 10 min (gradient 
of 12ºC/min). 
2.2.8 Lipid profiles and glycaemic control 
Blood was collected into tubes containing clot activator and gel for lipid analysis, 
FX and LH tubes for glucose and insulin analysis, respectively, as described in 2.2.5. 
Plasma and serum were frozen at -80ºC on the day of visit until analysis at KCH under the 
supervision of Dr Roy Sherwood. TAG, cholesterol, and HDL concentrations were 
measured as described in 2.2.4 and LDL cholesterol was calculated using the Friedewald 
formula. NEFA were measured using an enzymatic colorimetric method assay (NEFA-
HR(2) Assay kit, WAKO Chemicals Gmbh, Fuggerstrabe 12, D-41468 Neuss, Germany) as 
described in Appendix XXIX. Briefly NEFA is converted into Acyl-CoA by Acyl-CoA 
synthetase (ACS), which is then oxidised by Acyl-CoA oxidase (ACOD) to form 2,3-trans-
Enoyl-CoA and hydrogen peroxide. The latter yields a blue purple pigment in the presence 
of peroxidase (POD), which is proportional to the initial NEFA concentration. Glucose was 
determined by the hexokinase and G6PD method as described in 2.2.4. Insulin was 
measured by ELISA on the ADVIA Centaur® XP immune assay system (Siemens 
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Healthcare Diagnostics Ltd, Surrey, UK), as described in Appendix XXX. Insulin 
resistance was assessed by the homeostatic model assessment (HOMA-IR: Glucose mM x 
Insulin mU/L / 22.5) and the quantitative insulin sensitivity check index (QUICKI: 1 / 
(log(fasting insulin µU/mL) + log(fasting glucose mg/dL)). 
2.2.9 Nitrate and Nitrite measurements 
In vivo and in vitro, NO interacts with biological fluids to form both nitrite (NO2-) 
and nitrate (NO3-), making necessary to convert nitrate to nitrite to measure total NO. Thus, 
total NO (NOx = nitrate + nitrite) is measured in a two-step reaction: 
1- Nitrate is converted to nitrite by the nitrate reductase and its cofactor 
NADPH,H+. The resulting nitrite measured corresponds to the total NO present 
in the medium. 
2- Nitrite is complexed to a reagent for detection. Two main techniques are 
available for this step:  
- complexation with the Griess reagents (sulfanilamine and then N-(1-Naphtyl) 
ethylenediamine) that convert nitrite to a deep purple azo compound. 
- complexation with a fluorometric reagent (diaminonaphtalene: DAN) followed 
by an alkalinisation that enhances the detection. 
Here total NO was measured by a nitric oxide ELISA kit using Griess reagents for 
detection, following the manufacturer’s instructions (R&D System). Plasma sample was 
first passed through a centrifugal filter device (NMWL: 10kDa) to remove proteins which 
may affect the reading of the signal in the NO assay. It was then diluted 2 times in assay 
buffer prior to the experiment. 50 µL of each plasma sample or nitrate standards (diluted in 
assay buffer) were transferred to a 96 well plate in duplicate, to which 50 µL of assay 
buffer were added. Then 25 µL of cofactors (NADPH, H+) and 25 µL of nitrate reductase 
were added. The plate was covered, shaken and incubated 30min at 37ºC. Then 50 µL of 
each Griess reagent (I and II) were added. The plate was covered, shaken again and allowed 
to develop for 10min at RT before the absorbance was read at λ = 540 nm. 
2.2.10 Isoprostanes 
8-iso-prostaglandin-F2α (8-IsoP-F2α), a prostaglandin F2-like compound 
biosynthesized nonenzymatically by a free-radical oxygenation of arachidonic acid, was 
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measured in plasma in order to assess oxidative stress. The procedure for isoprostane 
analysis comprised the alkaline hydrolysis (saponification) of the plasma 8-isoprostanes, 
followed by a purification by immunoaffinity columns. The isoprostane salts were then 
subjected to esterification with PFBBr, followed by silylation with BSTFA (derivitisation). 
The resulting derivative was detected and quantified by GC-NCI-MS. The method of 
internal standardisation was used for quantification. 
Samples were treated in 5 batches; samples from the same subject were treated in 
the same batch. 
2.2.10.1 Alkaline Hydrolysis Protocol 
25µ1 (1ng) of internal standard working solution was added to 1.5mL-2ml of EDTA 
plasma and gently mixed. 1 mL of 15% w/v KOH was added and the resulting mixture was 
mixed and incubated for 1 hour at 60°C on a heating block. 
2.2.10.2 Purification Protocol 
Prior to the purification procedure, affinity columns were connected to the 
Vacmaster processing station and the storage solution allowed to drain out and the heating 
block was set to 60˚C. In each step, washing solutions, buffer and sample solutions were 
passed through the affinity column through gravity alone. 
The hydrolysate was allowed to cool down and neutralized with 3-4 mL of 1M 
KH2PO4. The volume of KH2PO4 was adjusted to reach a pH of 7-7.4. 2 mL of affinity 
column buffer solution were added and each mixture was gently decanted into each labeled 
column. 2ml of column buffer were added to the column in order to remove non specific 
binding, followed by 2ml of ultrapure water to wash out remaining salts. Washings were 
discarded and the 8-isoprostane were eluted by adding 2ml elution solution. The collected 2 
mL sample was evaporated to dryness in a vacuum centrifugal concentrator. In the mean 
time affinity columns were regenerated by washing with 5 mL UltraPure water followed by 
5 mL column buffer. Columns were stored in 1-2 mL column buffer solution in the upright 
position at 4°C to prevent the packing material from becoming dry. Such columns may be 
used up to five times. 
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2.2.10.3 Derivitisation Protocol 
All operations were conducted in a fume cupboard. 25µl of 10%v/v DIPEA, 
followed by 25µl of 20%v/v PFBBr were added to the dry residue and the mixture was 
gently mixed and incubated in the heating block for 10min at 60°C. The samples were 
allowed to cool down and evaporated to dryness under a nitrogen stream at room 
temperature. 50µl of BSTFA were then added, followed by 5µl of 10%v/v DIPEA and the 
mixture was gently mixed and incubated for 4 min at 60°C. The samples were allowed to 
cool down and evaporated to dryness under nitrogen. The residue was dissolved in 20µl of 
isooctane and transferred to GC insert vials for GC-MS analysis. 
Preparation of Calibration standards 
5 calibration standards were prepared. 10, 20, 200, and 400 µL of iso-8-PGF2α 
(external standard, 10µg/mL) were mixed with 20 µL (1ng) of iso-8-PGF2αD4 (internal 
standard, 1µg/mL), evaporated to dryness and derivitised as described above.  
2.2.10.4 GC- Mass spectroscopy (MS) analysis 
The operating parameters and detailed procedure is fully described in Appendix 
XXXI. Helium was used as a carrier gas and negative chemical ionization (NCI) used 
methane as a reagent gas. The initial column temperature of 80°C was held for 1.8 min and 
then programmed from 80 to 235°C at 34°C/min, then increased to 280°C at 10.3°C/min 
and maintained at 280°C for 10 min, giving a total run time of ~21 min. The F2-
isoprostanes were detected by selective ion monitoring (SIM) using m/z 569 and m/z 573 
for iso-8-PGF2α and iso-8-PGF2αD4, respectively. Peak identification was based on 
comparison of retention times with standards. 
2.2.11 Blood pressure (BP) and heart rate (HR) 
At screening, BP and HR were measured after 5 min rest in the seated position with 
an automatic upper arm blood pressure monitor (Omron 705IT). The measurements were 
done in triplicate with 3 to 5 min intervals. An additional measurement was made when one 
value varied from more than 15% from another, and the average of the 3 closest values was 
taken. On study days, BP and HR were also assessed after 15 min rest in the supine position 
at each PWA measurement (triplicate). The DVP analysis, performed in alternating order 
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with the PWA measurement, provided an additional measure of supine HR in triplicate (see 
Figure 2-3 for the progress of measurements during the study day). For BP and HR 
measured in the supine position, the average of 3 measurements was taken, unless % COV 
of the 3 recordings was >15%, in which case the average of the 2 closest was taken. The 
measurements were made by Miss Aseel Alsaleh, the data entry and analysis were carried 
out by both Aseel and the author. 
ABP was recorded 2 to 3 days before each visit day. The instrument was 
programmed to record SBP, DBP, MAP and HR every 30 min during the day (7 am-10 pm) 
and every hour at night (10 pm-7 am). Subjects were asked to engage in routine daily 
activities and write down what they were doing (walking, sitting, standing, exercising) at 
the time of each blood pressure cuff inflation, as well as the times that they were sleeping, 
on a diary card (Appendix XXIV). Data were transferred to a computer and analysed using 
the software provided by the manufacturer (A&D Instrument Ltd, Abingdon, U.K.). The 
mean of 24 h measurements, as well as mean day-time and night-time measurements were 
calculated based on the subjects’ times of sleep from the diary card. Explanations on how to 
use the monitor and fill in the diary card were given by the author; data entry and analysis 
were carried out by both Miss Aseel Alsaleh and the author. 
2.2.12 Vascular measurements  
All the non-invasive vascular measurements (PWA, DVP, capillaroscopy) were 
made in the supine position and were carried out on the left arm, while BP was measured 
on the right arm (see Figure 2-3 for the progress of vascular measurements on the study 
day). 
2.2.12.1 Radial Pulse Wave Analysis (PWA) 
SphygmoCor Pulse Wave Analysis (PWA) uses the principles of applanation 
tonometry as used in ocular tonometry (Garber, 1999) to record non invasively the 
peripheral arterial waveform from the radial pulse. It applies a convolutional algorithm and 
a generalized transfer function (characteric of the hydraulic properties of the upper limb 
vasculature) in order to obtain a derived central aortic waveform (O'Rourke, et al., 2001) 
(see chapter 1). Using a handheld probe, the radial artery was flattened (applanated) against 
a rigid underlying structure (bone). According to the Imbert-Fick law, the force per unit 
83 
 
area applied to flatten the artery equals the internal pressure of the artery. Thus, the force 
registered by the high-fidelity tonometer (strain gauge transducer, AtCor/Milar tonometer 
SPT-301B) at the tip of the probe is the true intra-arterial pressure of the radial artery. 
Applanation is appropriate if pulse waves are consistent, beat to beat, with a great 
amplitude, and if the pulse wave obtained corresponds to the one expected in an artery 
(sharp upstroke, straight rise to the first systolic peak, a definite sharp incisura, and near 
exponential pressure decay in late diastole). Measures of pressure and time obtained from 
the synthesized aortic waveform are used to assess parameters of peripheral and central 
haemodynamics (O'Rourke, et al., 2001). The computerized report on analysis of radial and 
aortic pressure waves, as obtained with Sphygmocor Px, is shown in Figure 2-4. 
The principal stiffness parameter assessed by PWA is the augmentation index, 
representing the augmentation of pressure in the systolic phase induced by the reflected 
wave, as described in Figure 2-5. The augmentation can be expressed in mmHg 
(augmentation pressure, AP or ∆P) or as a percentage called augmentation index (AIx). ∆P 
is the difference of pressure between the reflected wave P2 and the forward wave P1. AIx 
can be expressed as P1 relative to P2, or ∆P relative to pulse pressure (PP) (Mills, et al., 
2008). PWA calculates AIx from the pulse wave directly measured at the radial artery 
(peripheral AIx) and from the derived aortic pulse wave (central AIx). 
The shape of the pulse wave varies throughout the arterial tree depending on the 
stiffness of the large arteries (Figure 2-5). In the compliant and elastic arteries of healthy 
young individuals, the pulse wave velocity is reduced so that the reflected wave P2 occurs 
in diastole. Therefore P2 is inferior to P1 and the augmentation ∆P is negative. In contrast, 
with arterial stiffening, as observed in ageing, SBP is elevated and pulse wave velocity 
increases, i.e. the time to wave reflection is shortened. This means that the peak of the 
reflected wave occurs in mid systole rather than diastole, augmenting the already high SBP, 
while removing major support of DBP (Kaplan, 2000). As a result, ∆P and AIx, as well as 






Figure 2-4 Radial artery and synthesized aortic pressure waves obtained by SphygmoCor Px (AtCor Medical)   
A series of radial pressure waves, recorded over 8s (upper continuous trace) are used to synthesize a series of aortic pressure waves 
(lower continuous trace), using a generalised transfer function. Both radial and synthesized aortic waves are averaged into single waves 
(lower traces). Features of the waves including the foot, shoulder, peak, and incisura (shown in green) are identified automatically using 
differentials, flagged, and used to calculate peripheral and central haemodynamic parameters. The detailed report gives information 
relevant to ventricular/vascular interaction from both pressure and time values (lower part). The variability between the recorded wave 




Figure 2-5 Schematic representation of pulse pressure amplification, as assessed by 
applanation tonometry (Oliver and Webb, 2003)  
The augmentation pressure (∆P) is the difference between the reflected pressure wave 
(P2) and the initial systolic pressure (P1) systolic peak (forward wave). The pulse 
pressure (PP) is the difference between systolic and diastolic blood pressure. The 
augmentation index (AIx) is given as the percentage of ∆P relative to PP, or of P2 
relative to P1.  
In compliant arteries (left), the reflected pressure waves occur in diastole and ∆P is 
negative (P2<P1). With the stiffening of the arteries (right), the reflected waves arrive 
earlier, augmenting SBP in the detriment of DBP, which leads to an increasingly 





2.2.12.1 Digital Volume Pulse (DVP) analysis  
The DVP is an accurate and non invasive method used to obtain information on 
the pulse waveform in the finger, which allows the assessment of vascular tone and 
peripheral arterial stiffness (see chapter 1). DVP was recorded by measuring the 
transmission of infra-red light absorbed through the finger, which is directly 
proportional to the volume of blood in the finger pulp. The pulse waveform obtained in 
healthy individuals exhibits clearly defined two peaks (Figure 2-6). The systolic 
component results from the pressure directly transmitted from the aorta to the finger 
(direct wave). The diastolic component is formed by the pressure transmitted from the 
ventricle along the aorta to the lower body where it is reflected back along the aorta to 
the finger (reflected wave). The transit time between the two peaks (peak-to-peak time, 
PPT) is related to the stiffness of large arteries (stiffness index, SI). The amplitude of 
the reflected wave is mainly determined by the vascular tone in small arteries and 
provides the reflection index (RI) (Millasseau, et al., 2006). The DVP recorded and the 
indices calculated from the waveform are described in Figure 2-6. As observed with 
radial PWA, the shape of the wave form is altered with arterial stiffening: PPT is 
shortened, so that the second peak is attenuated and replaced by an inflection point in 
the down slope of the wave form. This inflection point is then used to calculate the 
(augmented) RI and SI (Millasseau, et al., 2006).  
It should be noted that the shapes of the radial and digital pulses are similar 
(Millasseau, et al., 2000), and both SI (measured by DVP) and the peripheral AIx 
(measured by radial PWA) are representative of the stiffness of large peripheral arteries. 
  
 Figure 2-6: Determination of the stiffness index (SI)
by contour analysis of the digital volume pulse (DVP
SI is obtained by dividing the subject height (in m) by the peak
It estimates the pulse wave velocity in large arteries and is a measure of large artery 
stiffness. 
RI is expressed as the percentage of the height of the diastolic
relative to the systolic peak (b, direct wave). It is a measure of the systemic vascular 
tone (small arteries) 




The CapiScope Image Acquisition and Analysis 
Technology) allows capturing and storing capillaroscopy images from video onto a 
Personal Computer. The laser beam can be positioned either far or next to the nail fold, 
giving images with different aspects and allowing different measurements (
Capillaries at the nail fold are parallel to the skin and the blood flow can be visualised, 
allowing the calculation of red blood cell velocity (RBCV) using the spatial correlation 
technique. Capillaries further from the nail fold are per
like dots, which allows the calculation of capillary density, i.e. the number of capillaries 
per surface unit. In our study, we positioned the laser beam on 5 different spots chosen 
arbitrarily at the medium phalanx and fa
functional capillary density as previously described 
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 Figure 2-7: Images and videos obtained by 
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2.2.13 Flow cytometry analysis 
2.2.13.1 Principle 
Flow cytometry (Figure 2-8) uses the principles of light scattering, light 
excitation, and emission of fluorochrome molecules in order to detect particles or cells 
of diameters ranging from 0.5 µm to 40 µm. Fluorochrome-labelled cells from blood or 
other biological fluids are focused in a sheath of PBS so they intercept an optimally 
focused light source (usually laser) one by one. As they intercept the light source, cells 
scatter light and fluorochromes – either intra-cellular or at the surface of the cell - are 
excited to a higher energy state. Scattered light, as well as the light emitted by the 
excited fluorochromes, are then converted to an electrical signal by optical detectors. 
Light that is scattered in the forward direction (typically up to 20° offset from the laser 
beam) is collected by a lens known as the forward scatter (FS) channel, while the light 
that is deviated at a 90° angle is detected by the side scatter (SS) channel. Signal 
collected by FSC and SSC are proportional to the size and granulosity of the particle, 
respectively. The light released by the fluorochromes has spectral properties (emission 
wavelength) that are characteristic of the fluorescent dye used. The emitted light passes 
through specific optical filters, which block certain wavelengths while transmitting 
(passing) others, before being detected by the detectors, usually photomultiplier tubes 
(PMTs). The electrical pulses generated from scattered light (FS, SS) and fluorescence 
(FL-) by the detectors are then amplified, usually through linear and log amplifiers, 
respectively. The signals obtained are processed by an analog to digital converter 
(ADC), which allows the events (each one corresponding to one cell/particle) to be 
plotted on a graphical scale. 
 Figure 2-8 Schematic overview of a flow cytometer










Calibration of the flow cytometer before running the samples is composed of 
three steps: 
1- An unstained blood sample is used to detect auto-fluorescence or 
background staining. 
2- An isotype control is needed to detect non specific binding of the antibody 
(the antibody used is the same immunoglobulin isotype as the test antibody, 
but with a specificity that is irrelevant to the sample being analysed). 
3- Colour compensation is required to correct the spectral overlap existing 
between two fluorochromes (the antibodies used are one testing antibody 
and the isotype control corresponding to the other testing antibody) 
2.2.13.2 Endothelial Progenitor Cells (EPC) 
As a transitory state between bone marrow cells and endothelial cells, EPC 
express different markers throughout their differentiation. CD133 and CD34 are early 
hematopoietic stem cell markers expressed on hematopoietic stem and progenitor cells 
from human bone marrow (Andrews, et al., 1989, Yin, et al., 1997). KDR is expressed 
all along EPC maturation and CD31 is characteristic of the mature endothelial 
phenotype, which EPC start expressing while becoming negative for CD133 (Hristov, et 
al., 2003). Various combinations of these markers (Figure 2-9) have been used to 
identify and count EPC (Nguyen, et al., 2012, Peichev, et al., 2000). In this experiment 
we used a method developed in our departments to identify two populations of EPCs, 
described as ‘early EPC’, which are KDR+/CD34+/CD133+, and ‘late EPCs’ that are 
KDR+/CD34+/CD31+. All two-markers combinations are reported, apart from 
CD31+/KDR+ cells, as it was considered that this population may not possess the 
progenitor characteristic of EPC. 
 Figure 2-9 Identification of early and late endothelial progenitor cells (EPC) 
EPC express KDR all along their maturation. Early EPC initially express bone marrow 
immature markers (CD133, CD3











♦ Sample preparation 
EDTA whole blood samples were kept on ice and analysed within 30 min of 
blood draw. From the first participant, six tubes were prepared containing the antibodies 
as listed below, volumes were defined following the manufacturer’s instructions. When 
two participants had their visit on the same day, only tubes 5 and 6 were prepared from 
the second subject: 
Tube 1, unstained sample: No antibody was added 
Tube 2, isotype control: 20µl of IgG1 Fitc,  20µl of IgG1 PE, 10µl of IgG1 APC 
Tube 3, colour compensation 1: 20µl of CD31 Fitc, 20µl of IgG1 PE 
Tube 4, colour compensation 2: 20µl of CD45 PE, 20µl of IgG1 Fitc 
Tube 5, sample: 20µl of CD31-Fitc, 20µl of CD34-PE, 10µl of KDR-APC 
Tube 6, sample: 10µl of CD133- PE, 20µl of CD34- Fitc, 10µl of KDR-APC 
100µl of whole blood were then transferred in each tube, the content was briefly 
vortex-mixed and incubated at room temperature for 20 min, sealed with parafilm and 
protected from the light. 2 mL of lysing buffer were added in each tube, the mixture was 
vortexed and incubated at RT until a clear solution appears (corresponding to the lysis 
of red cells). 25µl of fixative were then added, the content vortexed again and incubated 
for 10 min at RT. The tubes were then transferred to ice protected from the light until 
flow cytometry analysis (run on the same day). The acquisition time was 300s and the 
total events were 14227 +/- 6244 and 13516 +/- 5825 events for the first and second 
visit, respectively. 
♦ Gating Strategy 
The light transmitted in the forward direction is proportional to the volume of 
the cell, while the light scattered to the side is proportional to its granulosity. Each cell 
population in blood possesses a particular combination of size and granulosity, which 
can thus be identified according to their signal on a forward scatter (FS) vs. side scatter 
(SS) plot. An initial gate was set on mononuclear cells (gate A, Figure 2-10), which 
excludes the granulocyte population (high FS and SS). A second gate was set on a KDR 
vs. SS dot plot to include only the KDR+ events (gate N, Figure 2-10). Early and late 
EPCs were then identified on CD133 vs. CD34 and CD34 vs.CD31, in order to include 






Figure 2-10 Identification of mononuclear cells and KDR+ cells 
Mononuclear cells were gated according to their forward scatter (FS) and side scatter 
(SS) signal (Gate A). KDR+ cells were selected according to their fluorescence signal 






Figure 2-11 Identifications of ‘early’ (KDR+/CD34+/CD133+) and ‘late’ EPCs 
(KDR+/CD34+/CD31+) 
EPCs are identified according to their fluorescence signal on FL1 and FL2 (P2 region), 
after gating on mononuclear cells (A) and KDR+ cells (N) 
Early EPCs (left) are KDR+ cells that co-express CD34 (FL-1) and CD133 (FL-2) 
Late EPCs (right) are KDR+ cells that co-express CD34 (FL-2) and CD31 (FL-1) 
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2.2.13.3 Platelet Monocyte Aggregates (PMA) 
The endothelium plays a vital role in the regulation of blood flow, thrombosis 
and inflammation. Endothelium-derived anti-adhesive and anti-aggregant substances, 
including PGI2 and NO, are known to inhibit platelet activation (Deanfield, et al., 2007). 
ED or vessel wall injury lead to the activation of platelets, of which platelet-monocyte-
aggregates (PMA) are a sensitive marker (Michelson, et al., 2001), and were shown to 
inversely correlate with markers of EF in patients with stable CHD (Robinson, et al., 
2006). The measurement of PMA by flow cytometry is a method which reduces ex vivo 
platelet activation to its minimum and is believed to represent platelet activation in vivo 
(Michelson, et al., 2001). The test was adapted from Goodall et al (Goodall and 
Appleby, 2004, Li, et al., 1999). PMA were identified by the co-expression of CD14 
and CD42b (or P-selectin), specifically expressed by monocytes and activated platelets, 
respectively. 
♦ Sample preparation 
The study of PMA requires extra care in order to avoid ex vivo platelet activation 
and aggregation. Blood samples were treated within 15 min of draw at RT, and it was 
ensured that all reagents were at RT as well prior to the experiment. A blocking mouse 
immunoglobulin (MOPC31) was used to block Fc binding and non specific binding of 
monoclonal antibodies to leukocytes. In addition, a CD62P Monoclonal antibody 
blocker was used to block P-selectin binding which may encourage ex-vivo binding of 
platelets to leukocytes. 
Appropriate volumes of HBS and antibodies and then whole blood were 
transferred to each tube as described in Table 2-3: Volumes of antibodies, buffer and 

























1 50 µl - - - - - - 50 µl Blood only 
2 50 µl 5 µl 2 µl 5 µl - - - 50 µl Isotype Control 
3 50 µl 5 µl 2 µl - - 5 µl - 50 µl Isotype Control 
4 50 µl 5 µl 2 µl 5 µl - - 5 µl 50 µl Colour compensation 
5 50 µl 5 µl 2 µl - 5 µl 5 µl - 50 µl Colour compensation 
6 50 µl 5 µl 2 µl - 5 µl - 5 µl 50 µl Sample 
7 50 µl 5 µl 2 µl - 5 µl - 5 µl 50 µl Sample 
Table 2-3: Volumes of antibodies, buffer and blood required for PMA analysis by 
flow cytometry 
HBS, Hepes buffer saline; MOPC31, IgG1, Kappa from murine myeloma (clone 
MOPC31); MAb 9E1, CD62P monoclonal antibody blocker (clone 9E1) 
The 7 mixtures were incubated 30 min at RT, and 250 µl of Optilyse®C solution 
were added. Tubes were allowed to stand at RT for 15 min and 250 µl PBS were added 
to stop the red cell lysis. Samples were allowed to stand another 5 min at RT prior to the 
flow cytometry analysis. The acquisition time was 200s and the total events were 25874 
+/- 9180 and 24968 +/- 9024 events for the first and second visit, respectively. 
♦ Gating Strategy 
The monocyte population was identified by their specific expression of CD14, 
identified on the FL4 fluorescence channel. PMA were determined as events co-
expressing CD62b – specific for activated platelets, on FL2 – and CD14. The PMA 
(CD62b+/CD14+) were measured as percentage of total CD14+ (Goodall and Appleby, 





Figure 2-12 Identification of platelet monocyte aggregates (PMA) by flow 
cytometry 
Monocytes (CD14+) and platelets (CD42b) show a positive fluorescence signal on FL4 
and FL2, and appear in red and green, respectively.  
Left: Total events from peripheral blood are plotted on a forward scatter (FS) vs. side 
scatter (SS) dot plot. 
Right: PMA co-express CD14+ (FL4) and CD42b (FL2) and appear in the F2 region. 
Total events found in F1+F2 are monocytes while total platelets are identified in F2+F4. 
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2.2.1 Statistical analysis 
The capillary density and endothelial progenitor cells measurements, novel 
markers of endothelial function, were defined as primary outcomes. However, these 
variables have rarely been investigated in relation to dietary interventions when the 
present study was in the planning stages, and the author was involved in setting these 
methodologies up in the Diabetes and Nutritional Sciences Division at KCL so prior 
data was unavailable. It was decided to base the power calculation on a related outcome 
variable, platelet monocyte aggregates (PMA). ED is associated with platelet activation 
(Deanfield, et al., 2007, Gkaliagkousi, et al., 2009), systolic blood pressure is closely 
related to PMA in blood, and an increase in PMA would indicate an impairment in 
nitric oxide signalling (Gkaliagkousi, et al., 2009). Standard deviations (10%) and 
expected change was taken from a previous paper (Din, et al., 2008) showing that a 4-
wk oily fish intervention (500 g fish/wk, equivalent to 1g EPA+DHA/day) decreased 
PMA by 35%. It was calculated that a sample size of 16 in each group has an 80% 
power to detect a difference between means of 10% PMA, and a 99% power to detect 
16% changes with a significance level (alpha) of 0.05. Data were analysed by analysis 
of covariance (ANCOVA) of endpoint values, adjusted for ethnicity, age, BMI and 
baseline value. Normality of the residuals was checked for analysis and log 
transformation of the data was attempted when required. If the residuals of the log-
transformed data were still not normally distributed, non-parametrical analysis was 
performed (Kruskal-Wallis). Results were expressed as means (SD) and changes from 
baseline as differences between the means with 95% confidence intervals. When data 
were log transformed, the results were expressed as geometric means (SD) and the 
changes as ratios of the geometric means with 95% confidence intervals. In addition, 
paired t-tests were performed within each group and data were log-transformed when 
they did not follow a normal distribution as measured by the d’Agostino and Pearson 
coefficient. If data were still not normally distributed, a Wilcoxon matched-pairs test 
was performed. All statistical analysis was carried out with SPSS for Windows (version 
17.0, SPSS, Chicago, IL) on the intention-to-treat basis. When a significant difference 
was observed between or within groups, bivariate correlations were performed for the 
values at 6 weeks and for the changes from baseline, in order to see if this related to 
changes in the main VLC n-3 PUFA (together or individually: EPA, DHA, DPA, 
EPA+DHA, EPA+DHA+DPA) in erythrocytes and NEFA. The significant correlations 
obtained were re-analysed by partial correlation analysis controlling for age, BMI and 
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ethnicity. The partial coefficient r and the P value are only given for the correlations 
that remained significant after controlling for the confounding factors. GraphPad Prism 
version 5.0 was used for designing graphs and measuring the d’Agostino and Pearson 
coefficient. Outliers were identified using the box-plot method (version 17.0, SPSS, 




Chapter 3 The EPA and DHA trial: The differential 
effect of EPA and DHA on vascular and endothelial 
function 
3.1 Introduction 
Amongst the different types of fatty acids, n-3 PUFA, especially from fish oils, appear 
to be the most potent in improving cardiovascular health. Some studies suggested that 
ALA has cardioprotective effects, but evidence is not as robust as for EPA and DHA 
and there is insufficient data to encourage increasing ALA consumption (Wendland, et 
al., 2006) in order to reduce CVD risk. There is compelling evidence from 
epidemiological studies that fish oils, mainly composed of EPA and DHA, reduce the 
risk of CVD such as fatal coronary heart disease (CHD) (He, et al., 2004, Hu and 
Willett, 2002) and stroke (He, et al., 2004, Keli, et al., 1994). Several meta analyses 
have concluded that fish oils exert hypotensive, hypotriglycerideamic and anti-
thrombotic actions (Balk, et al., 2006, Eslick, et al., 2009, Geleijnse, et al., 2002, 
Hartweg, et al., 2007, Morris, et al., 1993). Recent evidence also suggest that fish oil 
consumption improves arterial stiffness (Pase, et al., 2011) and endothelial function in 
some studies (Chin, et al., 1993, De Berrazueta, et al., 2009, Goodfellow, et al., 2000, 
Khan, et al., 2003, Morgan, et al., 2006, Schiano, et al., 2008, Shah, et al., 2007, Walser, 
et al., 2006, Wright, et al., 2008), although it remains uncertain in healthy subjects 
(Hjelte, et al., 2005, Sanders, et al., 2011, Theobald, et al., 2007, Ueshima, et al., 2007). 
While there is compelling evidence from animal and in vitro studies, as well as 
epidemiological studies, that fish oils exert anti-inflammatory (Farzaneh-Far, et al., 
2009, Ferrucci, et al., 2006) and insulin sensitising (Arai, et al., 2009, Lombardo, et al., 
2007, Nigam, et al., 2009, Thorseng, et al., 2009, Yanagisawa, et al., 2010) actions, 
randomised controlled trials in humans have given mixed results  (Balk, et al., 2006, 
Hartweg, et al., 2008). The inconsistency may be due to differences in study design, 
populations, doses or duration of studies. In addition, proportions of EPA and DHA 
may greatly vary from one supplement to another and contribute to the variability of the 
results. Although there has been a growing interest in the past decade to elucidate the 
differential effect of EPA and DHA on diverse markers of CVD risk, research in this 
field is only at its beginning and the independent effects of EPA and DHA remain 
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poorly understood. The effects of EPA and DHA on markers of CVD risk were recently 
reviewed by the author of this thesis , with an emphasis on the comparison between the 
two individual FAs (Cottin, et al., 2011). While both EPA and DHA decrease 
triacylglycerol levels (Buckley, et al., 2004, Egert, et al., 2009, Grimsgaard, et al., 1997, 
Mori, et al., 2000, Nestel, et al., 2002, Olano-Martin, et al., 2010, Park and Harris, 2003, 
Woodman, et al., 2002), DHA appears to be responsible for an increase in HDL and 
LDL particle size (Kelley, et al., 2007, Liao, et al., 2010, Mori, et al., 2000, Rambjor, et 
al., 1996), although this effect has sometimes been observed with EPA (Nozaki, et al., 
1992). Evidence to date suggests that DHA is more efficient in decreasing blood 
pressure and heart rate compared to EPA (Grimsgaard, et al., 1998, Mori, et al., 1999, 
Stark and Holub, 2004, Theobald, et al., 2007). It is not yet clear whether differences 
exist between EPA and DHA in their effects on endothelial function (Engler, et al., 
2004, Mori, et al., 2000, Okumura, et al., 2002, Theobald, et al., 2007), and EPA may 
be more potent in improving arterial stiffness (Satoh, et al., 2009, Theobald, et al., 2007, 
Tomiyama, et al., 2005), although this is not supported by all studies (Nestel, et al., 
2002). The effects of EPA and/or DHA on diverse markers of CVD risk have been 
extensively reviewed (Anderson and Ma, 2009, Balligand, et al., 1995, Hall, 2009, 
Lawes, et al., 2003, Ueshima, et al., 2007) and the strength of evidence is summarised 
in Table 3-1, classified following previous recommendations from the WHO (Byers, et 
al., 2002, Tang, et al., 2008). 
Novel biomarkers and techniques have emerged in the past decade to assess 
endothelial and vascular function, which may further the understanding of the effect of 
EPA and/or DHA on CV health. Endothelial progenitor cells (EPC) were identified in 
the late 90’s as a population of bone marrow derived cells able to differentiate in vitro 
into endothelial cells (Asahara, et al., 1997). EPC present the ability to repair the injured 
endothelium (Clark, et al., 2012) and create capillary networks in areas of ischemia 
(Campbell, et al., 2012). They have been associated to CV risk and proposed as a 
potential diagnostic and prognostic tool (O'Dunn-Orto, et al., 2012, Van den Eynde, et 
al., 2012). To the authors’ knowledge, only one study has been published on the effect 
of fish oils on EPC count, repoting that a 12-week supplementation with 4 g/d fish oils 
(2.7 g/d EPA+DHA) had no effect on the number of CD133+/KDR+ cells in type 2 
diabetics (Wong, et al., 2010). Blood capillaries consist of endothelial cells and 
capillary density can be measured using capillary imaging technology (Capilloscope). It 
has been observed that capillary rarefaction occurs with the development of 
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hypertension, and that reduction of salt intake may improve capillary density (He, et al., 
2010). However nutritional interventions remain limited in this field and there is, to our 
knowledge, no data regarding the effect of dietary FA on capillary density. 
 
Table 3-1. Summary of strength of evidence for the effect of EPA and DHA on 
metabolic risk factors in humans 
 Fish Oils 
(EPA+DHA) EPA DHA 
Lipid metabolism    
TAG C ↓ C ↓ C ↓ 
Total Cholesterol P ↑ I PS ↑ 
LDL P ↑ I PS ↑ 
HDL P ↑ I PS ↑ 
LDL and HDL size P ↑ I PS ↑ 
Haemodynamics    
Blood pressure C ↓ I P ↓ 
Heart rate C ↓ I P ↓ 
Heart rate variability PS ↑ I I 
Vascular function    
Arterial stiffness P ↓ PS ↓ I 
Endothelial function P ↑ PS ↑ I 
Thrombosis/haemostasis    
Platelet activation P ↓ PS ↓ PS ↓ 
Fibrinolytic activity P = I P = 
Fibrinogen P = I P = 
Factor VII PS ↑ I PS ↑ 
Glycaemic control    
Fasting glucose P = I I 
Fasting insulin P = I I 
HbA1c P = I I 
Insulin sensitivity P = I I 
Inflammation I I I 
HbA1c, Glycated haemoglobin; ↑, increase; ↓, decrease; =, no effect; C, convincing; P, 
probable; PS, possible; I, insufficient data. 
References (Anderson and Ma, 2009, Balligand, et al., 1995, Hall, 2009, Lawes, et 




3.1.1 Aims and objectives 
Relatively few studies have made a head to head comparison of DHA with EPA. 
The understanding of this differential effect may be of great interest in populations with 
low EPA intake such as vegetarians, who may choose to supplement their dietary intake 
of LC n-3 PUFA in the form of DHA-rich algal oil. This chapter aims to investigate the 
effect of supplementation with either EPA or DHA (3g/day, 6 weeks) in healthy young 
males on endothelial and vascular function, as well as other CVD risk factors such as 
lipid profiles (TAG, cholesterol, NEFA), glycaemic control (HOMA, QUICKI), 
oxidative stress and platelet aggregation and how this relates to changes in erythrocyte 
lipid and NEFA composition. The omega-3 index (erythrocyte EPA+DHA) was used as 
a marker of compliance. Endothelial progenitor cells - novel marker of endothelial 
function - were measured by flow cytometry, and capillary density was measured by 
capillaroscopy to assess changes in microvascular function. 
3.1.2 Hypothesis 
The primary outcome variables were a change in the proportion of EPCs and an 
increase in capillary density. We tested the hypothesis that DHA would improve 
endothelial and microvascular function (increase EPC and capillary density) to a greater 
extent than EPA. Secondary outcome variables included other measures of vascular 
function, platelet function, oxidative stress and glucose metabolism. It was also 
expected that DHA but not EPA would improve blood pressure, heart rate and NOx, 
and decrease isoprostanes and platelet-monocyte aggregates, and that both EPA and 
DHA would decrease TAG levels (O'Dunn-Orto, et al., 2012), while having little or no 
effect on lipoprotein levels. No significant changes in fasting glucose or an indirect 
marker of insulin resistance (HOMA-IR) were expected as we were investigating a 
young, healthy population. 
3.1.3 Study design: Overview 
The study design (Figure 3-1) and the methods have been described in Chapter 
2. Briefly, each subject received 5g of test oil per day in gelatine coated capsules. The 
placebo treatment provided (18:1n-9+18:1n-7 3.8g, saturated fatty acids 0.7g, and 
linoleic acid 0.2g), the EPA treatment provide (3.0 EPA , 0.1g DPA, 0.7g DHA,0.1g 
SFA, 0.2gMUFA) and DHA (0.5g EPA, 0.2g DPA, 2.7g DHA, 0.2g SFA, 0.4g MUFA) 
(The full composition is described in Appendix VII). A sample size of 16 participants 
 per group gave 80% power to detect a 1 SD unit difference between groups. Statistical 
analysis was done on an intention
were done using an analysis of covariance as described in Chapte
primarily assessed by the proportion of EPA
secondarily by counting returned capsules.
Figure 3-1: Outline of study protocol 
 
 to treat basis and comparison between
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 3.2 Results 
The CONSORT chart 
study, out of 57 participants, 
completed the 8-week in
per group.  
 




and the randomized groups did not differ with the exception of plasma glucose 
concentration which was lower in the placebo group compare to the DHA group (
<0.05). Unused capsules were returned by 32/48 p
fewer than 10% and were judged as ‘good compliers’ (
 
Figure 3-2 shows the flow of participants through the 
49 were enrolled and randomized to treatment
tervention, data were available for analysis on 16 participants 
 the participants that completed the study are 
articipants, 29 of whom returned 
Table 3-2).
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(n = 16) 
DHA 
(n = 16) 
EPA 
(n = 16) 
Total 
(n = 48) 
Age, y 25.8 (7.4) 27.9 (8.0) 25.8 (7.5) 26.5 (7.5) 
BMI, kg/m2 23.6 (3.4) 23.3 (2.9) 22.9 (3.0) 23.3 (3.1) 
Waist circumference, cm 81.7 (10.2) 82.5 (10.3) 78.4 (7.4) 80.9 (9.4) 
Body fat, % 16.6 (5.5) 14.4 (4.5) 13.1 (4.4) 14.7 (4.9) 
Systolic BP, mmHg 119.5 (10.4) 124.2 (10.7) 119.5 (13.5) 121.1 (11.5) 
Diastolic BP, mmHg 66.7 (6.3) 70.9 (8.7) 67.9 (11.8) 68.5 (9.1) 
HR, bpm 59.3 (6.2) 66.0 (10.4) 65.3 (8.5) 63.4 (8.9) 
Height, m 1.76 (0.07) 1.75 (0.08) 1.79 (0.08) 1.77 (0.08) 
Weight, kg 73.0 (12.2) 72.1 (12.5) 73.5 (11.2) 72.9 (11.7) 
Plasma Glucose, mmol/L 4.9 (0.3)* 5.3 (0.4)* 5.1 (0.3) 5.1 (0.4) 
Serum total cholesterol, mmol/L 4.6 (0.6) 4.4 (0.7) 4.5 (0.7) 4.5 (0.7) 
Serum TAG†, mmol/L 0.8 (0.3) 0.8 (0.3) 0.9 (0.4) 0.8 (0.3) 
Serum HDL-cholesterol†, mmol/L 1.4 (0.4) 1 1.3 (0.31) 1.3 (0.2) 1.4 (0.3) 
Serum LDL-cholesterol, mmol/L 2.7 (0.5) 2.7 (0.6) 2.7 (0.6) 2.7 (0.6) 
Total cholesterol / HDL ratio 3.2 (0.7) 3.5 (0.8) 3.4 (0.8) 3.4 (0.8) 
Subjects returning capsules 9 10 13  
Subjects returning <10% capsules 9/9 7/10 13/13  
Values are mean ± SD. BP, blood pressure; TAG, triacylglycerol 
† geometric means; *P < 0.05 for significantly different values in the same row between 
the groups; one-way ANOVA test. 
 
Body weight and body composition remained unchanged throughout the 6 
weeks intervention (Table 3-3).  
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Table 3-3 : Metabolic parameters of the participants at baseline and after 6 weeks 
of supplementation with placebo (olive oil), EPA or DHA (3g/d). 
 
Olive Oil DHA EPA 
 
Baseline 6 weeks Baseline 6 weeks Baseline 6 
weeks 





































Values are presented as mean (SD).  
3.2.1 Erythrocyte lipids 
Table 3-4 shows the composition of individual erythrocyte lipids at run-in and 
after six weeks on placebo, DHA or EPA treatment on the intention to treat basis. The 
proportions of linoleic acid (18:2n-6), dihomogammalinolenic acid (20:3n-6), 
arachidonic acid (20:4n-6), adrenic (22:4:n-6) and docosapentaenoic acid n-6 (22:5n-3) 
were lower and those of eicosapentaenoic acid (20:5n-3) and docosapentaenoic acid n-3 
(22;5n-3) were greater following EPA vs placebo. The proportion of DHA was greater 
following DHA treatment compared with placebo. No other other significant differences 
vs placebo were noted. DHA differed compared with EPA for 20:3n-6, 20:4n-6, 





Table 3-4 Erythrocyte fatty acid composition at run-in and following placebo, DHA and EPA treatment (Intention to treat) 
Fatty acid Run-in n=47 Placebo=n=16 DHA=n=16 EPA=n=16 P value 
16:0 17.0  (2.8) 17.5  (3.1) 17.0  (3.1) 18.4  (1.7) 0.226 
16:1n-7  0.3  (0.1) 0.5  (0.5) 0.3  (0.1) 0.3  (0.1) 0.91 
18:0 15.3  (1.5) 15.3  (1.1) 15.3  (1.9) 15.7  (1.3) 0.44 
18:1 trans  0.2  (0.1) 0.2  (0.1) 0.2  (0.1) 0.2  (0.1) 0.675 
18:1n-9  14.9  (1.2) 14.8  (1.1) 15.3  (1.4) 14.6  (1.3) 0.142 
18:1n-7  1.2  (0.2) 1.3  (0.1) 1.2  (0.2) 1.2  (0.1) 0.128 
18:2n-6  12.1  (1.1) 12.2  (1.6)a 11.3  (1.3) 10.4  (1.7)b 0.003 
18:3n-3  0.2  (0.1) 0.2  (0.04) 0.2  (0.04) 0.17  (0.1) 0.144 
20:3n-6  2.2  (0.6) 2.3  (1.0)a 2.0  (0.7) 1.7  (0.4)b 0.01 
20:4n-6  17.3  (2.2) 17.1  (2.2)a 16.9  (2.9)a 15.1  (1.9)b 0.001 
20:5n-3  1.1  (0.4) 1.1  (0.4)a 1.6  (0.6)a 4.2  (1.4)b 0.001 
22:4n-6  3.6  (0.9) 3.6  (0.8) 3.4  (1.1)a 2.7  (0.9)b 0.003 
22:5n-6  0.6  (0.1) 0.6  (0.1)a 0.6  (0.1)b 0.4  (0.1)b 0.001 
22:5n-3  3.3  (0.6) 3.3  (0.6)a 3.1  (0.6)b 4.3  (0.4)b 0.001 
22:6n-3  5.74  (1.53) 6.0  (1.3)a 7.7  (2.0)b 6.3  (1.2) 0.025 
Mean values (SD)  
P value is from univariate analysis of variance of the follow-up value by treatment with baseline value, ethnicity, BMI and age as covariates 





Two outliers were identified from the omega-3 index (erythrocyte EPA+DHA) 
measurement, used as an index of compliance (Figure 3-3). The omega-3 index 
increased from 4.3% to 9.4% for one subject in the placebo group, and decreased from 
13.1% to 6.1% for another subject in the DHA group. The latter was an outlier at 
baseline for both EPA and DHA levels (2.7% and 10.4%, respectively), while EPA 
and/or DHA levels from the subject in the placebo group did not differ from the rest of 
the group at baseline and 6 weeks. Neither of these participants returned their capsules. 
Table 3-5 shows the erythrocyte lipids individually and in categories, excluding these 
participants. The omega-3 index increased by 2.7% (95% CI, +1.5, +4.0, P = 0.009) in 
the DHA group and 3.9% (95%CI, +2.7, +5.1, P < 0.001) in the EPA group. Treatment 
did not affect total SFA or total (n-3 + n-6) PUFA levels in erythrocytes. EPA but not 
DHA significantly reduced total n-6 PUFA by 5.29% (95% CI, -6.42, -4.16, P < 0.001, 
as well as individual n-6 PUFA such as LA and AA. Total n-3 were increased to a 
greater extent following EPA treatment (+4.76%, 95% CI, +3.17, +6.36, P <0.001) 
compared to DHA (+2.48%, 95%CI, +1.32, +3.65, P = 0.019). EPA levels were 
increased by EPA treatment by 3.03% (95% CI, +2.30, +3.78, P < 0.001) and to a lesser 
extent by DHA treatment (+0.59%, 95% CI, +0.29, +0.90, P = 0.006), while DHA was 
increased in the DHA group only (+2.12%; 95%CI, +1.14, +3.11, P = 0.005). EPA but 
not DHA increased DPA levels by +0.87% (95% CI, +0.43, +1.31, P < 0.001). n-6:n-3 
PUFA ratio was reduced to a greater extent with EPA (-1.52%, 95% CI, -2.04, -1.00, P 




Figure 3-3 Effect of EPA and DHA supplementation on the omega-3 index 
The bottom and top of the box represent the lower and upper quartiles, respectively, and 
the band near the middle of the box is the median. Error bars are 95% confidence 
intervals. Outliers are dots out of the error bars, representing an increase of the omega-3 
index by +5.21% in the olive oil group, and a decrease by -7.06% in the DHA group. 
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Table 3-5: Erythrocyte fatty acid composition (%) at baseline and after 6 weeks of supplementation with placebo (olive oil), EPA or DHA (3 g/d) 
after excluding 2 outliers 
Fatty acids Run-in (n = 46) Olive Oil (n = 15) DHA (n = 15) EPA (n = 16) P value 
Total SFA 32.4 (3.5) 32.34(4.0) 33.0 (3.4) 33.9 (2.7) 0.098 
    16:0 17.0 (2.5) 17.0 (3.2) 17.4 (2.1) 18.3 (1.6) 0.179 
    18:0 15.3 (1.3) 15.1 (1.1) 15.5 (1.4) 15.6 (1.3) 0.394 
Total MUFA 16.5 (1.2) 16.5 (1.0)a 16.5 (0.9)a,b 16.2 (1.4)b 0.017 
    16:1 0.3 (0.1) 0.4 (0.5) 0.3 (0.1) 0.3 (0.05) 0.987 
    18:1trans 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.1 (0.1) 0.490 
    18:1n-9 14.8 (1.2) 14.7 (1.2)a 15.1 (1.4)a,b 14.5 (1.3)b 0.048 
    18:1n-7 1.2 (0.1) 1.3 (0.1) 1.2 (0.2) 1.2 (0.1) 0.174 
Total PUFA 45.61 (3.18) 46.2 (4.5) 45.8 (3.0) 45.1 (2.2) 0.550 
Total n-6 PUFA 35.33 (2.95) 35.7 (4.7)a 33.0 (3.4)a 30.1 (3.7)b < 0.001 
    18:2n-6 12.0 (1.1) 12.2 (1.6)a 11.0 (1.0)a,b 10.3 (1.7)b < 0.001 
    20:3n-6 2.1 (0.6) 2.12 (1.1)a 1.8 (0.6)a,b 1.6 (0.4)b < 0.001 
    20:4n-6 17.0 (2.0) 17.1 (2.2)a 16.3 (2.1)a,b 15.0 (1.8)b 0.001 
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Fatty acids Run-in (n = 46) Olive Oil (n = 15) DHA (n = 15) EPA (n = 16) P value 
    22:4n-6 3.5 (0.8) 3.5 (0.9) 3.1 (0.9) 2.5 (0.9) 0.058 
    22:5n-6 0.5 (0.1) 0.6 (0.1)a 0.6 (0.1)a 0.4 (0.1)b < 0.001 
Total n-3 PUFA 10.1 (1.8) 10.3 (1.5)a 12.5 (2.3)b 14.6 (2.5)c < 0.001 
    18:3n-3 0.2 (0.1) 0.2 (0.04)a 0.2 (0.04)a,b 0.2 (0.1)b 0.042 
    20:5n-3 1.0 (0.3) 1.1 (0.4)a 1.6 (0.6)b 3.9 (1.4)c < 0.001 
    22:5n-3 3.3 (0.6) 3.2 (0.6)a 3.0 (0.5)a 4.23 (0.4)b < 0.001 
    22:6n-3 5.5 (1.4) 5.7 (1.2)a 7.6 (1.9)b 6.2 (1.2)a,b 0.007 
    ω3 Index 6.6 (1.6) 6.8 (1.4)a 9.2 (2.4)b 10.1 (2.4)b < 0.001 
    VLC n-3 PUFA 9.9 (1.8) 10.1 (1.5)a 12.3 (2.3)b 14.5 (2.5)c < 0.001 
n-6 : n-3 PUFA 3.5 (0.8) 3.5 (0.8)a 2.6 (0.8)b 2.1 (0.8)c < 0.001 
20:5n-3/20:4n-6 0.1 (0.02) 0.1 (0.03)a 0.1 (0.04)b 0.3 (0.1)c < 0.001 
22:6n-3/20:4n-6 0.3 (0.1) 0.3 (0.1)a 0.5 (0.1)b 0.4 (0.1)b 0.002 
Values are geometric means (SD), expressed in mass percentage of total erythrocyte fatty acid composition. P value is from univariate analysis of 
variance of the follow-up values by treatment with baseline values, ethnicity, BMI and age as covariates. Values in the same row with different 
superscripts are significicantly different from each other, P<0.05 using Bonferroni’s test for 3 comparisons. 
VLC n-3 PUFA, very long chain n-3 PUFA (= 20:5n-3 + 22:5n-3 + 22:6n-3) 
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3.2.2 Plasma NEFA fatty acid composition. 
Table 3-6 shows the fatty acid composition of the NEFA. In contrast to the 
erythrocyte lipids, the proportion of long-chain polyunsaturated fatty acids was much 
lower in NEFA. Both EPA and DHA decreased the proportion of palmitoleic acid 
(16:1n-7) and EPA that of oleic acid (18:1n-9) compared with placebo. EPA but not 
DHA increased NEFA EPA by +2.6% (95% CI; +1.1, +4.1, P < 0.001) while both EPA 
and DHA increased DHA levels (+1.4%; 95% CI; +0.6, +2.2; P < 0.001 and +1.1; 95% 
CI, +0.3, +1.8, P = 0.001, respectively). EPA but not DHA increased DPA levels (P = 
0.018). EPA+DHA percentage was increased by +4.9% (95% CI; +1.7, +6.3; P <0.001) 
by EPA and 1.3% (95% CI; +0.4, +2.3; P = 0.021) by DHA. EPA but not DHA 
decreased n-6:n-3 ratio. Neither EPA nor DHA influenced the proportion saturated fatty 
acids in NEFA. Changes in NEFA were more variable compared to changes in 
erythrocyte composition. In order to compare NEFA and erythrocyte FA patterns, 
Spearman’s correlations were performed between the two FA fractions for the main FA 





Table 3-6: NEFA composition (%) at baseline and after 6 weeks of supplementation with placebo (olive oil), EPA or DHA (3g/d) 
 
Run-in (n = 46) Olive Oil (n = 15) DHA (n = 15) EPA (n = 16) P value 
Total SFA 62.5 (10.7) 58.0 (9.2) 59.6 (12.3) 57.8 (13.4) 0.714 
    16:0 3.3 (0.9) 3.0 (0.7) 2.8 (1.0) 3.3 (1.0) 0.382 
    18:0 41.9 (6.4) 38.1(6.7) 39.9 (7.3) 38.5 (8.0) 0.630 
Total MUFA 15.2 (5.0) 16.6 (3.6) 16.6 (4.6) 15.8 (5.0) 0.898 
    16:1 17.9 (9.9) 23.0 (8.2)a 18.3 (9.0)b 17.1 (8.5)b 0.044 
    18:1trans 2.3 (1.0) 2.2 (0.8) 2.2 (0.9) 2.6 (1.0) 0.889 
    18:1n-9 15.1 (9.3) 20.5 (8.1)a 15.9 (8.4)a 14.3 (7.7)b 0.035 
    18:1n-7 15.5 (4.7) 16.5 (3.8) 18.1 (6.9) 20.0 (9.3) 0.134 
Total PUFA 12.2 (4.0) 13.6 (3.4) 13.5 (5.8) 13.3 (5.0) 0.971 
Total n-6 PUFA 4.8 (3.9) 7.0 (3.5) 4.6 (5.1) 5.6 (4.2) 0.655 
    18:2n-6 0.2 (0.2) 0.2 (0.2) 0.2 (0.1) 0.2 (0.1) 0.409 
    20:3n-6 0.7(0.4) 0.6 (0.2) 0.8 (0.3) 0.5 (0.4) 0.280 
    20:4n-6 1.5 (0.9) 1.4(0.4) 1.9 (1.0) 1.8 (1.2) 0.077 




Run-in (n = 46) Olive Oil (n = 15) DHA (n = 15) EPA (n = 16) P value 
    22:5n-6 0.3 (0.3) 0.2 (0.1) 0.3 (0.1) 0.3 (0.4) 0.086 
Total n-3 PUFA 3.1 (1.2) 2.8 (0.9)a 4.0 (2.6)a 6.2 (5.6)b <0.001 
    18:3n-3 1.7 (0.7) 1.5 (0.6) 1.6 (0.6) 1.8 (0.7) 0.066 
    20:5n-3 0.3 (0.1) 0.3 (0.3)a 0.5 (0.4)a 1.8 (2.9)b <0.001 
    22:5n-3 0.2 (0.2) 0.2 (0.1)a 0.2 (0.3)a 0.6 (0.7)b 0.004 
    22:6n-3 0.8 (0.3) 0.7 (0.2)a 1.5 (1.6)b 1.7 (1.8)b <0.001 
    EPA+DHA 1.1 (0.4) 1.1 (0.4)a 2.1 (2.0)b 3.4 (4.6)b <0.001 
    VLC n-3 PUFA 1.3 (0.6) 1.3 (0.4)a 2.3 (2.2)a 4.0 (5.1)b <0.001 
n-6 : n-3 PUFA 3.9 (1.6) 4.9 (2.2)a 3.3 (2.6)a,b 2.1 (1.1)b 0.001 
20:5n-3/20:4n-6 0.2 (0.2) 0.2 (0.1)a 0.3 (0.2)a 1.0 (1.1)b <0.001 
22:6n-3/20:4n-6 0.5 (0.4) 0.5 (0.2)a 0.8 (0.5)b 0.9 (0.6)b 0.011 
Values are geometric means (SD), expressed in mass percentage of total NEFA composition. P value is from univariate analysis of variance of the 
follow-up values by treatment with baseline values, ethnicity, BMI and age as covariates. Values in the same row with different superscripts are 
significantly different from each other, P<0.05 using Bonferroni’s test for 3 comparisons. 




Figure 3-4: Changes in EPA+DHA in NEFA by treatmentComparison between 




























































































Table 3-7 Pearson’s bivariate correlation for the composition in the main FA 
categories and n-3 PUFA between erythrocyte and plasma NEFA at baseline and 6 
weeks of intervention and for the changes form baseline. 
Baseline 6 weeks Changes 
r P r P r P 
SFA  0.153 0.310 -0.022 0.880 0.261 0.080 
MUFA 0.259 0.093 -0.038 0.811 0.358* 0.025 
PUFA 0.060 0.693 -0.128 0.387 -0.006 0.966 
Total n-6 PUFA 0.057 0.705 -0.035 0.815 -0.172 0.252 
Total n-3 PUFA 0.220 0.141 .404** 0.004 0.436** 0.002 
ALA 0.320* 0.034 0.052 0.733 -0.172 0.275 
EPA 0.044 0.769 0.508*** <0.001 0.527*** <0.001 
DHA 0.384** 0.008 0.349* 0.015 0.284 0.056 
DPA 0.189 0.203 0.354* 0.014 0.395** 0.006 
EPA+DHA 0.326* 0.027 0.400** 0.005 0.406** 0.005 
EPA+DHA+DPA 0.325* 0.028 0.434** 0.002 0.439** 0.002 
n-6/n-3 ratio 0.264 0.076 0.362* 0.012 0.426** 0.003 
Pearson’s correlation coefficients are presented as r . Significant P-values (P) for 





Table 3-7 shows the EPC counts – relative to total mononuclear cells - at 
baseline and follow-up, as defined by the various combinations of bone marrow and 
endothelial markers described in Chapter 2. None of these counts, including early 
(CD34+/KDR+, CD133) and late (CD34+/CD31+/KDR+) EPC populations differ 
between (ANCOVA) or within groups (Wilcoxon matched-pairs signed rank tests). The 
reproducibility of the technique was assessed by Spearman correlation analysis between 




Table 3-8: Endothelial circulating and progenitor cells at baseline and after 6 weeks of supplementation with placebo (olive oil), EPA or DHA 
(3g/d), in % of total mononuclear cells 
  
Olive oil 
n = 14 
DHA 
n = 12 
EPA 




Baseline 0.45 (0.39) 0.52 (0.33) 0.49 (0.26) 
 
6 weeks 0.44 (0.44) 0.66 (0.59) 0.55 (0.36) 
 
Change -0.01 (-0.19,0.17) 0.14 (-0.33,0.61) 0.06 (-0.15,0.26) 0.739 
 
r 0.434 0.429 0.393 
 
CD34+/ CD133+ 
Baseline 0.09 (0.10) 0.25 (0.30) 0.10 (0.13) 
 
6 weeks 0.08 (0.08) 0.31 (0.34) 0.08 (0.11) 
 
Change -0.01 (-0.08,0.06) 0.05 (-0.12,0.22) -0.02 (-0.11,0.07) 0.241 
 
r 0.452 0.750 -0.219 
 
CD34+/ KDR+ 
Baseline 0.20 (0.16) 0.26 (0.12) 0.34 (0.28) 
 
6 weeks 0.14 (0.15) 0.28 (0.29) 0.28 (0.33) 
 
Change -0.06 (-0.20,0.08) 0.02 (-0.21,0.24) -0.06 (-0.36,0.23) 0.382 
 
r 0.291 0.429 0.284 
 






n = 14 
DHA 
n = 12 
EPA 
n = 15 
P 
value 
6 weeks 0.07 (0.05) 0.26 (0.25) 0.09 (0.11) 
 
Change 0.00 (-0.05,0.05) 0.01 (-0.18,0.20) 0.02 (-0.03,0.07) 0.592 
 
r 0.263 0.500 0.492 
 
CD34+/ CD133+/ KDR+  
(Early EPC) 
Baseline 0.05 (0.05) 0.17 (0.11) 0.05 (0.06) 
 
6 weeks 0.05 (0.04) 0.21 (0.19) 0.06 (0.11) 
 
Change 0.00 (-0.04,0.03) 0.04 (-0.13,0.22) 0.01 (-0.05,0.07) 0.147 
 
r 0.814 0.071 -0.093 0.410 
CD31+/ KDR+/ CD34+  
(Late EPC) 
Baseline 0.17 (0.14) 0.22 (0.19) 0.22 (0.17) 
 
6 weeks 0.14 (0.11) 0.20 (0.21) 0.31 (0.17) 
 
Change -0.03 (-0.14,0.08) -0.02 (-0.26,0.21) 0.09 (-0.03,0.22) 0.081 
 
r 0.165 0.250 0.414 0.246 
Data are presented as means (SD) and changes from baseline are expressed as mean of the differences (CI 95%). P values are from univariate analysis 





3.2.4 Capillary density 
Table 3-8 shows the results for capillary density. The values for capillary density 
are slightly lower than literature values. There were no significant changes on treatment 
and the method generally appeared to have good reproducibility as judged the 
correlation between baseline and follow-up measures. 
Table 3-9: Capillary density (capillary count / mm2) at baseline and after 6 weeks 
of supplementation with placebo (olive oil), EPA or DHA (3g/d) 
  
Olive Oil 
(n = 15) 
DHA 
(n = 15) 
EPA 






Baseline 5.06 (0.86) 5.52 (0.71) 5.65 (1.30)  
6 weeks 5.26 (1.06) 5.53 (1.06) 5.88 (1.25)  
Change 0.20 (-0.25 ; 0.66) 0.01 (-0.72 ; 0.73) 0.24 (-0.30 ; 0.77) 0.889 




Baseline 65.02 (8.57) 69.45 (6.51) 68.85 (12.02)  
6 weeks 69.04 (9.35) 69.82 (11.76) 70.88 (11.96)  
Change 4.02 (-1.70 , 9.74) 0.37 (-6.25 , 7.00) 2.03 (-1.76 , 5.83) 0.773 
r 0.377 0.227 0.843  
Data are presented as means (SD) and changes from baseline are expressed as mean of 
the differences (CI 95%). P values are from univariate analysis of variance of the 
follow-up values by treatment with baseline values, ethnicity, BMI and age as 
covariates. Capillary density is expressed as area covered by the capillaries relative to 
the total skin area (%) or as the number of capillaries per surface unit (capillary count).  
r values are Spearman’s correlation coefficients. 
3.2.5 Vascular measurements: PWA, DVP 
The indexes of vascular function measured by PWA and DVP did not differ at 
baseline and 6 weeks of intervention between the groups (Table 3-10), or within the 
groups (Paired t-tests).   
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Table 3-10: Vascular function parameters at baseline and after 6 weeks of 
supplementation with placebo (olive oil), EPA or DHA (3g/d) 
  
Olive Oil 
(n = 13) 
DHA 
(n = 15) 
EPA 





Baseline 5.7 (0.4) 6.1 (1.6) 6.12 (0.8)  
6 weeks 5.6 (0.6) 6.1 (1.7) 5.9 (0.5)  
Change -0.0 (-0.5 , 0.4 ) -0.0 (-0.2 , 0.1 ) -0.2 (-0.6 , 0.1 ) 0.706 
Reflection 
index, % 
Baseline 65.4 (11.9) 64.6 (11.7) 68.0 (11.3)  
6 weeks 67.5 (11.8) 65.5 (14.7) 66.4 (12.8)  




Baseline 101.6 (7.3) 101.7 (8.5) 101.1 (8.7)  
6 weeks 99.4 (6.8) 101.9 (7.9) 100.2 (10.3)  




Baseline 65.5 (5.8) 65.8 (7.3) 65.1 (5.5)  
6 weeks 64.0 (5.5) 66.0 (8. 5) 65.7 (9.12)  
Change -1.4 (-4.6 , 1.8 ) 0.6 (-2.8 , 4.0) 0.6(-3. 9 , 5.0 ) 0.503 
Peripheral 
AIx, % 
Baseline 54.0 (9.0) 50.0 (15.1) 53.7 (13.2)  
6 weeks 52.7 (9.5) 48.9 (15.2) 50.2 (12.1)  
Change -2. 5 (-6.6 , 1.7 ) 0.3 (-3. 7 , 4.3 ) -3.5 (-8.5 , 1.5 ) 0.645 
Central 
AIx, % 
Baseline 112.2 (8.3) 108.4 (11.0) 110. 6 (11.3)  
6 weeks 111.0 (8.3) 105.5 (13.7) 107.7 (10.5)  
Change -2.1 (-6.9 , 2.7 ) -2.6 (-6.1 , 0.9 ) -2.9 (-8.7 , 2.8 ) 0.560 
Data are presented as means (SD) and changes from baseline are expressed as mean of 
the differences (CI 95%). P values are from univariate analysis of variance of the 
follow-up values by treatment with baseline values, ethnicity, BMI and age as 
covariates. AIx, Augmentation index (= P2/P1, where P1 and P2 are the pressure of the 
forward (systolic) and reflected (diastolic) wave, respectively.  
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3.2.6 BP and HR 
3.2.6.1 Seated and supine BP and HR 
Seated and supine SBP, DBP and HR did not differ between the groups at 
baseline and 6 weeks of intervention (Table 3-12). Paired t-tests showed no significant 
difference between end point values and baseline within each group (P values not 
shown). 
Table 3-11: Seated SBP, DBP and HR at baseline and after 6 weeks of 
supplementation with placebo (olive oil), EPA or DHA (3g/d) 
  
Olive Oil 
(n = 16) 
DHA 
(n = 16) 
EPA 





Baseline 120.8 (10.6) 121.6 (6.7) 117.8 (9.2)  
6 weeks 118.8 (10.2) 120.6 (8.6) 115.5 (12.3)  
Change -2.0 (-4.4 ; 0.4) -1.1 (-5.2 ; 3.1) -2.3 (-6.8 ; 2.2)    0.902 
DBP, 
mmHg 
Baseline 67.0 (8.7) 69.2 (6.7) 68.6 (10.1)  
6 weeks 65.6 (7.6) 68.2 (7.4) 65.9 (11.4)  
Change -1.4 (-4.1 ; 1.3) -1.1 (-4.3 ; 2.2) -2.7 (-5.7 ; 0.3) 0.875 
HR, 
bpm 
Baseline 63.4 (7.9) 66.3 (13.0) 65.9 (11.9)  
6 weeks 64.8 (10.0) 65.3 (9.6) 65.3 (12.8)  
Change 1.4 (-3.9 ; 6.8) -0.9 (-7.4 ; 5.6) -0.6 (-6.9 ; 5.7) 0.990 
Data are presented as means (SD) and changes from baseline are expressed as mean of 
the differences (CI 95%). P values are from univariate analysis of variance of the 









Table 3-12: Supine systolic, diastolic, mean arterial blood pressure (SBP, DBP, 
MAP) and supine heart rate (HR) at baseline and after 6 weeks of supplementation 
with placebo (olive oil), EPA or DHA (3g/d) 
  
Olive Oil 
(n = 16) 
DHA 
(n = 16) 
EPA 





Baseline 118.0 (9.6) 119.8 (9.2) 118.8 (10.6)  
6 weeks 116.3 (7.2) 121.5 (8.1) 119.0 (13.1)  
Change -1.7 (-6.6 ; 3.1) 1.7 (-3.0 ; 6.4) 0.2 (-7.3 ; 7.7) 0.625 
DBP, 
mmHg 
Baseline 64.3 (5.2) 64.5 (7.0) 64.2 (5.5)  
6 weeks 63.1 (5.7) 65.2 (8.4) 64.5 (8.4)  
Change -1.2 (-4.0 ; 1.6) 0.7 (-2.7 ; 4.1) 0.2 (-3.6 ; 4.1) 0.517 
MAP, 
mmHg  
Baseline 80.8 (6.1) 80.7 (7.2) 81.4 (6.3)  
6 weeks 80.8 (6.1) 80.7 (7.2) 81.4 (6.3)  
Change -1.5 (-4.7 ; 1.7) 0.6 (-3.1 ; 4.3) -0.6 (-5.4 ; 4.1) 0.751 
HR1, 
bpm 
Baseline 55.4 (5.5) 57.9 (6.3) 56.8 (7.5)  
6 weeks 56.1 (7.1) 56.3 (7.9) 56.9 (8.4)  
Change 0.7 (-1.9 ; 3.2) -1.5 (-5.4 ; 2.3) 0.1 (-4.1 ; 4.3) 0.824 
HR2, 
bpm 
Baseline 57.2 (6.2) 60.2 (7.0) 59.5 (7.5)  
6 weeks 57.6 (7.1) 58.5 (7.5) 59.4 (7.4)  
Change 0.4 (-3.6 ; 4.4) -1.7 (-6.0 ; 2.6) -0.1 (-3.6 ; 3.3) 0.816 
Data are presented as means (SD) and changes from baseline are expressed as mean of 
the differences (CI 95%). P values are from univariate analysis of variance of the 
follow-up values by treatment with baseline values, ethnicity, BMI and age as 
covariates. SBP, DBP, MAP and HR 1 were measured during the PWA assessment. HR 







3.2.6.2 Ambulatory BP and HR 
The evolutions of ambulatory BP and HR throughout the day are shown in  
Figure 3-5 and Figure 3-6. 24h and daytime SBP, DBP, MAP and HR, as well 
as night SBP and HR did not differ at baseline (Table 3-13). Night DBP and MAP at 
baseline were higher in the EPA group compared to the placebo group (P = 0.029 and P 
= 0.059, respectively, Bonferroni’s multiple comparison). There was no treatment effect 
on 24h and daytime SBP, DBP, MAP and HR, as well as night SBP, DBP and MAP 
(Table 3-13). At 6 weeks, night HR in the EPA and DHA group did not differ from the 
placebo group but was reduced by -6.5 bpm (95% CI; -12.2, -0.8) in the DHA group 
compared to the EPA group (P = 0.020) (Bonferroni multiple comparison). (Figure 3-7). 
The changes in night HR within the DHA group (-2.7 bpm; 95% CI; -0.1, -5.4) and in 
the EPA group (+3.0 bpm, 95%CI; -1.2, +7.2) did not reach significance (P = 0.057 and 
0.140, respectively, paired t-tests). There was no significant difference within groups for 

































































































































































































Figure 3-5: 24h systolic and diastolic blood pressure (BP) profiles at baseline and 
after 6 weeks of supplementation with placebo (olive oil), EPA or DHA (3g/d) 
Values are mean BP measured every half an hour during the day (7am-10pm) and every 
hour at night time (10pm-7am), error bars are SEM. Red lines represent average 




















































































































































































Figure 3-6: 24h heart rate (HR) profiles at baseline and after 6 weeks of 
supplementation with placebo (olive oil), EPA or DHA (3g/d) 
Values are mean HR measured every half an hour during the day (7am-10pm) and every 
hour at night time (10pm-7am), error bars are SEM. Red lines represent average 




Table 3-13: 24h, daytime and nighttime ambulatory SBP, DBP, MAP and HR at 





(n = 15) 
DHA 
(n = 15) 
EPA 






Baseline 117.4 (9.5) 120.5 (7.1) 121.0 (8.5)  
6 weeks 116.0 (8.0) 118.4 (7.1) 119.4 (7.0)  
Change -1.4 (-5.3 ; 2.6) -2.1 (-5.6 ; 1.5) -1.6 (-5.3 ; 2.0) 0.663 
DBP, 
mmHg 
Baseline 70.3 (10.7) 69.3 (6.9) 72.1 (4.8)  
6 weeks 67.9 (5.2) 68.0 (5.4) 70.9 (4.4)  
Change -2.4 (-8.6 ; 3.9) -1.3 (-3.2 ; 0.7) -1.1 (-3.4 ; 1.1) 0.061 
MAP, 
mmHg 
Baseline 83.9 (7.0) 86.1 (6.3) 88.0 (5.4)  
6 weeks 83.6 (5.9) 84.4 (5.5) 86.8 (4.6)  
Change -0.3 (-3.2 ; 2.6) -1.7 (-3.7 ; 0.3) -1.2 (-3.5 ; 1.1) 0.338 
HR, 
bpm 
Baseline 62.5 (6.7) 64.5 (8.5) 67.4 (9.9)  
6 weeks 63.4 (5.4) 63.2 (7.8) 67.9 (6.6)  




Baseline 122.8 (10.5) 125.2 (7.7) 124.9 (8.6)  
6 weeks 122.4 (8.7) 123.3 (6.8) 122.9 (7.7)  
Change -0.5 (-4.2 ; 3.3) -1.9 (-6.1 ; 2.2) -1.9 (-6.1 ; 2.2) 0.859 
DBP, 
mmHg 
Baseline 72.0 (6.8) 72.3 (7.8) 75.1 (5.3)  
6 weeks 72.3 (5.6) 71.3 (5.3) 73.4 (4.7)  
Change 0.3 (-2.9 ; 3.5) -1.0 (-3.7 ; 1.7) -1.8 (-4.2 ; 0.6) 0.643 
MAP, 
mmHg 
Baseline 88.7 (7.8) 89.6 (7.0) 91.3 (5.9)  
6 weeks 88.7 (6.1) 88.1 (5.2) 89.6 (5.0)  
Change 0.0 (-3.1 ; 3.1) -1.5 (-4.2 ; 1.2) -1.7 (-4.4 ; 0.9) 0.671 
HR, 
bpm 
Baseline 65.9 (7.7) 67.1 (9.0) 70.2 (10.9)  






(n = 15) 
DHA 
(n = 15) 
EPA 
(n = 14) 
P 
value 




Baseline 101.1 (8.3) 103.7 (8.0) 107.2 (10.8)  
6 weeks 102.0 (11.1) 105.1 (8.2) 107.9 (5.8)  
Change 0.9 (-3.8 ; 5.6) 1.4 (-3.7 ; 6.5) 0.7 (-4.5 ; 5.9) 0.246 
DBP, 
mmHg 
Baseline 55.4 (4.7) 58.7 (6.4) 61.1 (3.8) 
 
6 weeks 58.6 (8.6) 59.2 (5.5) 62.9 (4.6) 0.392 
Change 3.3 (-0.5 ; 7.0) 0.5 (-3.1 ; 4.1) 1.8 (-0.9 ; 4.5)  
MAP, 
mmHg 
Baseline 70.2 (5.3) 73.4 (6.1) 75.9 (5.7) 
 
6 weeks 72.5 (9.0) 74.2 (5.6) 77.6 (4.7)  
Change 2.4 (-1.5 ; 6.2) 0.8 (-2.6 ; 4.2) 1.6 (-1.4 ; 4.6) 0.551 
HR, 
bpm 
Baseline 54.8 (5.4) 56.5 (8.0) 56.9 (7.0)  
6 weeks 54.6 (5.2) 53.9 (8.8) 59.9 (6.7) 
 
Change -0.2 (-5.3 ; 4.9) -2.7 (-5.4 ; 0.1) 3.0 (-1.2 ; 7.2) 0.021 
Data are presented as means (SD) and changes from baseline are expressed as mean of 
the differences (CI 95%). P values are from univariate analysis of variance of the 
follow-up values by treatment with baseline values, ethnicity, BMI and age as 




Figure 3-7: Changes in night heart rate from baseline to 6 weeks of 
supplementation with placebo (olive oil), EPA or DHA (3g/d) 
Data are presented as means of the differences and errors bars are SD. 
P values are from Bonferroni’s multiple comparison with the placebo group (aP) and 
between the EPA and DHA group  (bP) (P values are from univariate analysis of 
variance of the follow-up values by treatment with baseline values, ethnicity, BMI and 
age as covariates). 
 
3.2.6.3 Correlations with erythrocyte and NEFA very long chain 
(VLC) n-3 PUFA 
In order to investigate whether there was any association between the changes 
observed in night heart rate and the incorporation of EPA and/or DHA in erythrocytes 
and NEFA, a partial correlation analysis was performed on the changes and on the 
endpoint values between night HR and EPA, DHA, EPA+DHA, DPA, 
EPA+DPA+DHA in erythrocytes and NEFA. There was no correlation of the changes 
but erythrocyte DPA were strongly correlated with night HR at 6 weeks (partial r = 





3.2.7 Nitrate and Nitrites (NOx) 
There was no difference in NO levels at baseline and after 6 weeks of 
intervention (Figure 3-8); and there was no difference within group (Paired t-test).  
 






























Figure 3-8: Total plasma nitrate and nitrite at baseline and 6 weeks of 
supplementation with placebo (olive oil), EPA or DHA (3g/d) 
Data are presented as means and errors bars are SEM. 
There was no difference between the groups (univariate analysis of variance of the 
follow-up values by treatment with baseline values, ethnicity, BMI and age as 






There was no difference between the groups in isoprostane levels at baseline and 
at 6 weeks of intervention. There was no within group difference (Wilcoxon matched-
pairs signed rank test) (Figure 3-9). There was no significant correlation between 
isoprostane levels and VLC n-3 PUFA, in NEFA or erythrocyte at baseline (Pearson’s 
bivariate correlation analysis). 
 





















Figure 3-9: Plasma isoprostane at baseline and 6 weeks of supplementation with 
placebo (olive oil), EPA or DHA (3g/d) 
Data are presented as means and errors bars are SEM. 
There was no difference between the groups (P  = 0.261, univariate analysis of variance 
of the follow-up values by treatment with baseline values, ethnicity, BMI and age as 





3.2.9 Platelet Monocyte Aggregates (PMA) 
Monocyte levels, platelet levels and platelet-monocyte aggregates (PMA) did 
not differ between the groups at baseline and six weeks of intervention ( 
Table 3-14). There was no change within the groups throughout the study 
(paired t-tests). There was no correlation between the PMA and erythrocyte or NEFA 
VLC n-3 PUFA, taken together or individually (Pearson’s bivariate correlation 
analysis). 
Table 3-14: Platelet monocyte aggregates (PMA) at baseline and after 6 weeks of 
supplementation with placebo (olive oil), EPA or DHA (3g/d) 






Baseline 0.58 (0.18) 0.44 (0.12) 0.59 (0.33) 
6 weeks 0.59 (0.15) 0.49 (0.13) 0.62 (0.30) 




Baseline 6.08 (1.67) 5.49 (1.43) 7.09 (2.12) 
6 weeks 6.72 (1.90) 5.95 (1.45) 7.42 (1.41) 





Baseline 9.55 (1.78) 8.21 (2.17) 7.86 (2.64) 
6 weeks 9.08 (1.45) 8.49 (2.05) 8.26 (2.69) 




Baseline 13.95 (2.72) 13.59 (4.52) 15.46 (10.31) 
6 weeks 14.18 (3.57) 14.98 (5.10) 14.67 (7.27) 
Change 0.23 (-1.62; 2.07) 1.39 (-0.72; 3.51) -0.79 (-7.06; 5.48)  0.643 
Data are presented as means (SD) and changes from baseline are expressed as mean of 
the differences (CI 95%). P values are from univariate analysis of variance of the 





3.2.10 Plasma lipid profiles 
Baseline lipid levels did not differ between groups at baseline. Neither EPA nor 
DHA affected plasma lipid concentrations at 6 weeks of intervention, including TAG, 
total cholesterol, LDL cholesterol and HDL cholesterol compared to placebo. Total 
cholesterol/HDL cholesterol and TAG/HDL cholesterol ratios also remained unchanged 
throughout the 6-week intervention with EPA or DHA compared to placebo (Table 
3-15). There was a borderline significant effect of treatment on total NEFA 
concentrations (P = 0.048). Post hoc multiple comparison test showed NEFA levels 
were reduced by 124µmol/L (95%CI; -251, +4) following EPA (P = 0.061) and by 
99µmol/L (95%CI; -226, +29) following DHA (P = 0.180) compared to placebo. 
Paired t-tests comparing baseline and 6 week plasma lipid concentrations 
showed TAG levels decreased by -27 mM in the EPA group (P = 0.005) while they 
decreased by -13 mM in the placebo group and -14 mM in the DHA group without 
reaching significance (P = 0.109 and 0.221, respectively). The variations observed in 
total cholesterol, LDL and HDL cholesterol were not significant in all groups. Total 
cholesterol / HDL ratio decreased by 0.24 (-7.2 %) in the EPA group (P = 0.013) but 
not in the placebo and DHA groups. TAG/HDL ratio was significantly reduced in the 
EPA group by 0.21 (-30.3%, P = 0.007) while it decreased by 0.14 (-20.9%) in the 
DHA group without reaching significance (P = 0.072). In the EPA group, 
apolipoprotein B levels and ApoB/LDL ratio were slightly but significantly decreased 
by -6.3 (-6.7%, P = 0.044) and -4.7 (-4.8%, P = 0.042) respectively, while they 
remained unchanged in the two other groups. Confidence intervals for the changes and 
P values for t-tests are given in Table 3-15. 
To investigate whether there was any association between the effect observed on 
TAGs and total NEFA, and the incorporation of EPA and/or DHA into the erythrocytes 
and NEFA fraction, a partial correlation analysis was performed on the changes and 
endpoint values of TAGs and total plasma NEFA, with EPA, DHA, EPA+DHA, DPA, 
EPA+DPA+DHA in erythrocytes and NEFA..Changes in TAG were inversely 
correlated with changes in the erythrocyte omega-3 index (partial r = -0.333, P = 0.029) 
and erythrocyte EPA (partial r = -0.367, P = 0.014) but not erythrocyte DHA alone (P = 
0.209). Changes in NEFA were inversely correlated to the changes in omega-3 index 
(partial r = -0.444, P = 0.003), erythrocyte DHA (partial r = -0.370, P = 0.015) and EPA 
(partial r = -0.343, P = 0.022) as well as NEFA DHA (partial r = -0.338, P = 0.023) 
(partial correlation analysis, adjusted for age, BMI and ethnicity).  
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Table 3-15: Triglyceride (TAG), total cholesterol (TC), LDL and HDL levels, TC:HDL ratio and TAG:HDL ratio at baseline and after 6 
weeks of supplementation with placebo (olive oil), DHA or EPA (3g/d). 
    Olive Oil DHA EPA Treatment effect § 
TC, mmol/L 
Baseline 4.8 (0.7) 4.5 (0.7) 4.7 (1.0) 
 
6 weeks 4.7 (0.7) 4.6 (0.9) 4.7 (0.9) 
 
Change -0.1 (-0.5 , 0.3) 0.2 (-0.2 , 0.5) 0.0 (-0.4 , 0.4)  P = 0.673 
Paired t-test NS NS NS   
TAG, mmol/L 
Baseline 0.9 (0.3) 0.9 (0.4) 1.0 (0.5) 
 
6 weeks 0.8 (0.3) 0.8 (0.3) 0.7 (0.3) 
 
Change -0.1 (-0.3 , 0.0) -0.1 (-0.3 , 0.1) -0.3 (-0.5 , -0.1)  P = 0.396 
Paired t-test NS NS P = 0.005   
HDL*, mmol/L 
Baseline 1.5 (0.4) 1.4 (0.3) 1.5 (0.3) 
 
6 weeks 1.5 (0.4) 1.4 (0.3) 1.6 (0.5) 
 
Change (ratio) 0.0 (-0.2 , 0.2) 0.06 (-0.0 , 0.2) 0.2 (-0.0 , 0.4)  P = 0.680 
Paired t-test NS NS NS   




    Olive Oil DHA EPA Treatment effect § 
6 weeks 2.8 (0.5) 2.9 (0.7) 2.8 (0.7) 
 
Change -0.1 (-0.3 , 0.2) 0.2 (-0.1 , 0.4) -0.0 (-0.3 , 0.2)  P = 0.404 
Paired t-test NS NS NS   
NEFA, mmol/L 
Baseline 0.3 (0.1) 0.4 (0.2) 0.4 (0.0) 
 
6 weeks 0.4 (0.2) 0.3 (0.1) 0.3 (0.0) 
 
Change 0.1 (-0.0 , 0.2) -0.1 (-0.2 , 0.0) -0.1 (-0.2 , 0.0) 
 P = 0.048 
Paired t-test NS NS NS   
TC:HDL, molar 
ratio 
Baseline 3.3 (0.8) 3.4 (0.8) 3.3 (0.6) 
 
6 weeks 3.2 (0.7) 3.3 (0.7) 3.1 (0.7) 
 
Change -0.1 (-0.4 , 0.1) -0.1 (-0.3 , 0.1) -0.2 (-0.4 , -0.1)  P = 0.367 
Paired t-test NS NS P = 0.013   
TAG:HDL, molar 
ratio 
Baseline 0.7 (0.4) 0.7 (0.4) 0.7 (0.4) 
 
6 weeks 0.6 (0.4) 0.5 (0.2) 0.5 (0.3) 
 
Change -0.1 (-0.2 , 0.0) -0.1 (-0.3 , 0.0) -0.2 (-0.4 , -0.1)  P = 0.442 
138 
 
    Olive Oil DHA EPA Treatment effect § 
Paired t-test NS NS P = 0.007   
ApoB, g/L 
Baseline 0.9 (0.2) 0.8 (0.3) 0.9 (0.2) 
 
6 weeks 0.8 (0.2) 0.9 (0.2) 0.9 (0.2) 
 
Change -0.1 (-0.2 , 0.1) 0.1 (-0.1 , 0.2) -0.1 (-0.1 , -0.0) P = 0.264 
Paired t-test NS NS P = 0.044   
ApoB/LDL, mass 
ratio 
Baseline 0.8 (0.1) 0.8 (0.2) 0.8 (0.1) 
 
6 weeks 0.8 (0.2) 0.8 (0.1) 0.8 (0.1) 
 
Change -0.0 (-0.1 , 0.1) 0.0 (-0.1 , 0.1) -0.0 (-0.1 , 0.0)  P = 0.632 
Paired t-test NS NS P = 0.042   
Data are presented as means (SD) and changes from baseline are differences between the means (CI 95%) at baseline and six weeks. * Data are 
geometric mean (SD) and changes are expressed as ratio of change from baseline to 6 weeks 
§ P values are from univariate analysis of variance of the follow-up values by treatment with baseline values, ethnicity, BMI and age as 
covariates.  
NS, non significant (P > 0.05)  
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3.2.11 Glycaemic control 
Treatment did not affect glucose and insulin levels, HOMA-IR or QUICKI at the end 
of the intervention (Table 3-16). Within group analysis showed no significant changes in 





Table 3-16: Plasma glucose and insulin levels, HOMA-IR and QUICKI at baseline and after 6 weeks of supplementation with placebo (olive 
oil), DHA or EPA (3g/d). 
  Olive Oil DHA EPA P-values 
Glucose, 
mM 
Baseline 5.0 (0.3) 5.3 (0.3) 5.2 (0.4) 
 
6 weeks 5.1 (0.4) 5.2 (0.5) 5.2 (0.8)  
Change 0.1 (-0.2 , 0.4) -0.0 (-0.2 , 0.2) -0.0 (-0.4 , 0.3) 0.935 
Insulin1, 
mU/L 
Baseline 5.4 (3.1) 6.4 (5.1) 5.6 (2.2)  
6 weeks 6.7 (3.6) 6.7 (5.1) 6.1 (3.7)  
Change 1.4 (-0.3 , 3.1) 0.3 (-1.3 , 1.9) 0.8 (-1.3 , 3.0) 0.826 
HOMA-
IR1 
Baseline 1.2 (0.7) 1.5 (1.2) 1.3 (0.6)  
6 weeks 1.5 (0.9) 1.6 (1.2) 1.4 (1.0)  
Change 0.4 (-0.1 , 0.8) 0.1 (-0.3 , 0.4) 0.2 (-0.3 , 0.7) 0.775 
QUICKI 
Baseline 0.38 (0.03) 0.36 (0.03) 0.37 (0.03)  
6 weeks 0.36 (0.03) 0.36 (0.03) 0.37 (0.03)  
Change -0.01 (-0.03, 0.00) -0.00 (-0.01, 0.01) -0.00 (-0.02, 0.01) 0.735 
Data are presented as means (SD) and changes from baseline are expressed as mean of the differences (CI 95%). P values at 6 weeks are from 





The EPA and DHA trial (EDT) was designed to test whether EPA and DHA 
differentially improved endothelial and microvascular function in healthy young males, 
as assessed by the novel techniques of EPC and capillary density measurements, 
respectively. Neither EPA nor DHA affected EPC or capillary density, improved 
vascular function (arterial stiffness, vascular tone) or BP, but DHA and EPA lowered 
and increased ambulatory HR at night, respectively, and night time HR was directly 
correlated with erythrocyte DPA levels at the end of the intervention. Both EPA and 
DHA tended to decrease NEFA compared to placebo. Lipoprotein profiles were 
improved in the EPA group but the changes did not differ from the placebo and DHA 
groups. Neither DHA nor EPA affected other markers of endothelial function (NOx), 
oxidative stress (isoprostanes), platelet aggregation (PMA) or the indices of glycaemic 
control.  
3.3.1 Erythrocyte lipids and NEFA profiles 
3.3.1.1 The omega-3 index 
Only two thirds of the participants (32 subjects) returned the capsules, of which 
29 were identified as good compliers. Nonetheless the omega-3 index was increased by 
~40% and ~60% in the DHA and EPA group, respectively, which suggests a good 
compliance to capsule intake. In addition to being an index of compliance, the omega-3 
index has been proposed as an independent risk factor for cardiovascular risk, especially 
death from CHD (Harris and von Schacky, 2004). Percentages of EPA and DHA in 
erythrocytes at baseline were 1.1 and 5.7%, respectively, leading to an omega-3 index 
of 6.6%, which is similar to data previously reported in healthy males (Brown, et al., 
1991, Sanders, et al., 1981, Sanders, et al., 2011) and corresponds to an intermediate 
risk of CHD according to the scale described by Harris and Von Schacky in 2004 
(Harris and von Schacky, 2004). The omega-3 index remained stable in the olive oil 
group and increased to 9.2% and 10.1% in the DHA and EPA group, respectively, rising 
above the 8% target suggested by the authors to reach protection against death from 
CHD (). Although 4 to 6 months are needed to reach a steady state for the omega-3 
index (Harris, 2010, Katan, et al., 1997), our findings confirm that the omega-3 index 
can be easily improved within a few weeks of fish oil supplementation in healthy 
subjects (Harris, 2010, Harris, et al., 2008, Larson, et al., 2008). Here we show that 
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composition. The high SFA levels in NEFA could also be due to a high endogenous 
supply (Sun, et al., 2007).  
3.3.1.3 VLC n-3 PUFA in erythrocytes and NEFA 
The changes of EPA, DPA and DHA levels in erythrocytes and NEFA 
throughout the 6 week intervention are reviewed in . Consistent with previous data, 
EPA was increased to a greater extent in the EPA group than DHA in the DHA group. 
Although the differential effect of EPA and DHA intake on erythrocyte or NEFA 
composition has been poorly investigated, there is substantial evidence that EPA is 
incorporated into erythrocyte and NEFA to a greater extent than DHA when they are 
given as a combination of both FA, either in the form of fish oils or oily fish (Cao, et al., 
2006, Conquer, et al., 2002, Hallund, et al., 2010, Katan, et al., 1997, Pedersen, et al., 
2010); and it is now well established that DHA turnover in erythrocyte membrane is 
slower than those of EPA (Brown, et al., 1991, Katan, et al., 1997). In erythrocytes, 
EPA supplementation increased EPA and DPA but not DHA, while DHA increased 
both EPA and DHA but not DPA (+ 0.6% and +2.1%, respectively), as previously 
observed in various populations and various lipid fractions, including plasma and 
platelet phospholipids (Hansen, et al., 1998, Kew, et al., 2004, Mori, et al., 2000). The 
EPA content of DHA capsules (8%, i.e. 0.4g / day) may have accounted for the EPA 
increase in the DHA group. However, the process of retroconversion from DHA to EPA 
is well documented and is more likely to explain the EPA increase (George, et al., 2007, 
Mori, et al., 2000, von Schacky and Weber, 1985). Our erythrocyte results also confirm 
that the elongation of EPA beyond DPA in humans is limited (Burdge, et al., 2002, 
Burdge and Wootton, 2002).  
In NEFA, elongation from EPA to DPA was also observed in the EPA group, 
but DHA increased EPA levels in NEFA without reaching significance, suggesting 
retroconversion is limited in the NEFA fraction. EPA supplementation increased DHA 
NEFA levels, even to a greater extent than in the DHA group. Few studies have 
reported enrichment in DHA after EPA consumption in LDL fractions (Egert, et al., 
2009), but this appears to be rare and relatively limited (Augoustides, et al., 2007, 
Gerster, 1998). The effect of supplementation of fish oils on fasting NEFA patterns has 
been poorly studied. In contrast with our findings, it was shown that EPA is 
preferentially incorporated into NEFA and DHA in TAG, a phenomenon only seen in 
non E4 carriers (Sung, et al., 2007). In addition, DHA was shown to be cleared from the 
chylomicrons at faster rate than EPA and it was suggested that DHA may be 
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preferentially cleaved by lipoprotein lipase to be transported – via NEFA - to the central 
nervous system, selectively enriched in DHA (Hansen, et al., 1998). Taken together, 
this suggests that EPA and DHA may be preferentially directed to different lipid 
fractions, which could play an important role in their differential effect on diverse CVD 







Figure 3-11: Changes in EPA, DPA and DHA in erythrocytes and NEFA upon 
EPA and DHA supplementation (3g/d, 6 weeks) 
** P < 0.01, *** P < 0.001, values are significantly different from placebo (univariate 
analysis of variance of the follow-up value by treatment with baseline value, BMI and 
age as covariates) 
3.3.2 Endothelial function: EPC and NOx 
Despite the growing interest in EPC research over the past decade, their exact 
characterisation is still debated and there is to date no standardised method for a 
reproducible enumeration that could be used in clinical settings (Resch, et al., 2011), 
and results vary greatly from one study to another (Shaffer, et al., 2006, Werner, et al., 
2005). Most studies have utilized flow cytometry and focused on the expression of the 
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stem cell markers CD133 and CD34, as well as endothelial markers KDR and CD31 
(Nguyen, et al., 2012, Snedeker, et al., 2012). Here we have defined EPC as triple 
positive events representing two states of maturation of the EPC. Both early 
(CD34+/KDR+/CD133+) and late EPC (CD34+/KDR+/CD31+), as well as 
CD34+/KDR+ populations – also previously defined as EPC population - were higher 
than what we would expect in a healthy population (Egan, et al., 2008, Nguyen, et al., 
2012, Peichev, et al., 2000, Shaffer, et al., 2006, Werner, et al., 2005). The present 
method counted stained cells in whole blood, which differs from the previously used 
Ficoll separation technique. The latter is a method of centrifugation used to isolate the 
mononuclear cells, resulting in a substantially loss of cells, which may explain this 
difference. The major limitation of this technique is the low EPC count, which restricted 
the reliability of the technique, as shown by the Pearson’s correlation coefficients 
between baseline and follow-up for each group. These technical issues, and possibly 
individual variability may have blunted any effect of fish oils on EPC levels.  
The phosphatidylinositol-3 kinase (PI3K)/protein kinase B (PKB/Akt)/eNOS 
pathway plays a pivotal role in the process of EPC mobilization from the bone marrow 
to the circulation (Everaert, et al., 2010), and n-3 PUFA have been implicated in the 
modulation of this pathway, improving insulin signalling in endothelial cells and 
vascular inflammation (Delarue, et al., 2004, Schaefer, et al., 2008). It was hypothesised 
that fish oils would improve EPC levels through the improvement of NO production 
(Li, et al., 2007, Li, et al., 2007, Xue, et al., 2006), as well as oxidative stress (An, et al., 
2009, McAnulty, et al., 2010), to which EPC are highly sensitive (Fleissner and Thum, 
2011, Tilling, et al., 2009). Very little is known regarding the impact of FA on the novel 
biomarkers of EF including EPC and circulating progenitor cells (CPC), as well as those 
of endothelial damage, such as endothelial microparticle (MP) and and circulating 
endothelial cells (CEC) (Vafeiadou, et al., 2012). Wong et al. recently reported that fish 
oil supplementation for 12 weeks (4 g/d) improved renal function without affecting 
EPC, defined as CD133+/KDR+, or FMD in type 2 diabetics (Wong, et al., 2010). n-3 
PUFA (5.4 g/d, 12 weeks) reduced platelet- and monocyte- derived MP without 
affecting endothelial MP in post-myocardial infarction patients (Turco, et al., 2008). 
Thus there is for now no evidence that EPA and DHA, taken together or individually, 
may improve EPC, MP, CEC or CPC in humans. 
NOx were consistent with data previously reported in healthy populations 
(McBrien, et al., 2012). Very few studies have examined the effect of fish oils on 
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plasma NOx, preferring the measurement of circulating markers of EF (such as E-
selectin, VCAM-1, ICAM-1), or non invasive measurements like the FMD or the 
forearm blood flow, described in Chapter 1. Worth mentioning, dietary nitrate (from 
certain vegetables such as beetroot) contributes to the circulating pool of NO. Because 
our NO assay was an add-on to the project, we did not restrict dietary nitrate prior to the 
study, which may have influenced the results. In contrast with our findings, a 12 week 
diet enriched with mackerel-derived products, providing 2.5 g of EPA+DHA per day 
has been reported to increase plasma NOx levels in elderly (De Berrazueta, et al., 2009), 
and this was associated with an improvement of forearm blood flow in response to 
reactive hyperaemia, while other markers of endothelial activation such as von 
Willebrand factor and E-selectin remained unchanged. In this case, the authors did not 
report that they controlled for or restricted nitrate dietary intake.  
In healthy subjects, there is also growing evidence that fish oils improve EF, as 
measured by non-invasive techniques, such as FMD or FBF (Chin, et al., 1993, Khan, et 
al., 2003, Shah, et al., 2007, Walser, et al., 2006). However none of the fish oil studies 
in healthy subjects have investigated the effect of fish oils on plasma NOx or EPC. In a 
design similar to ours (6 weeks, 4g/d), Mori et al. showed that DHA improved 
vasodilation in overweight mildly hyperlipidaemic subjects, as measured by FBF in 
response to acetylcholine (Ach) as well as sodium nitroprusside (SNP) or Ach+L-
NMMA, suggesting that the vasodilatory mechanisms of DHA are endothelium-
independent, while EPA had no effect (Mori, et al., 2000). In contrast, it was later 
shown that lower doses of EPA alone (1.8 g/d) provided for 12 weeks were able to 
improve FBF to ACh but not to SNP in hypertriglyceridemic subjects, suggesting EPA 
exert vasodilatory actions that are endothelium-dependent (Okumura, et al., 2002). 
More recently, corroborating our results, Egert et al. showed that there was no change 
of circulating markers of endothelial activation, including VCAM-1, ICAM1, E-selectin 
and endothelin-1 in healthy participants after 3 weeks of supplementation with either 
EPA nor DHA at 4 g/d, in a crossover design (unpublished results, see (Ueshima, et al., 
2007) for reference). The individual variability, as well as the variability in design and 
supplement composition may account for the discrepancies. Longer interventions are 
needed to determine the differential effect of EPA and DHA on EF, as well as a 
standardisation of the techniques. FMD is the gold standard technique to assess EF for 
now, but has a high inter- and intra-observer variability (Lee, et al., 2002).  
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Fish oils have been shown to improve EF as measured by non invasive 
techniques (FMD, FBF), but their effect on circulating markers of EF remains uncertain, 
and data on the separate effect of EPA and DHA are limited. The development and 
standardisation of techniques assessing circulating markers of EF, including EPC but 
also circulating endothelial cells and endothelial microparticles, (Li, Tse et al. 2011), 
may help to further our understanding of the effects of EPA and/or DHA on EF. 
3.3.3 Microvascular function (capillary density) 
The capillary network plays a major role in distributing blood flow and pressure 
to tissues and organs (groom, 1996) and its rarefaction has been associated with several 
chronic diseases such as diabetes (Campbell and Hemmelgarn, 2012) and hypertension 
(Antonios, et al., 1999). Capillary rarefaction may be primary (precedes the onset of 
hypertension) or secondary (is a consequence of high BP) (Gee, et al., 2012). It has been 
suggested that capillary rarefaction occurs in 2 phases: functional, then anatomic 
(Prewitt, et al., 1982). Capillary rarefaction appears to be primarily functional in 
hypertension and overweight individuals (Czernichow, et al., 2010, Serné, et al., 2001), 
although an impairment in structural capillary density  has also been observed in 
hypertensive (Antonios, et al., 1999, Clark, et al., 2012). Functional capillary density is 
observed at rest, while anatomic (structural) capillary density (Cheng, et al., 2008) is 
measured during the inflation of a cuff at low BP (usually 60 mmHg, 5 min), which 
induces ischaemia and recruits all capillaries present in the deeper layers of the 
epidermis to the surface (Antonios, et al., 1999, Campbell, 2012). Several drug 
interventions have aimed at improving capillary density, both functional and structural, 
especially in diabetes (Campbell and Hemmelgarn, 2012) and hypertension (Gee, et al., 
2012). To our knowledge, nutritional interventions have only investigated the effect of 
salt intake on capillary density, showing that a modest reduction of salt intake (9.7 to 
6.5g/d) for 12 weeks increased both functional and anatomic capillary density in 
subjects with untreated mildly raise BP (He, et al., 2010). In our study, functional 
capillary density, which has been associated with EF (Cheng, et al., 2008, Cheng, et al., 
2008), remained unchanged upon EPA and DHA treatment. This contrasts with the few 
studies that investigated the effect of fish oil supplementation in animals reporting a 
beneficial effect on capillary density in the ventricles of hypertensive rats (Mitasikova, 
et al., 2008), and in the cheek pouch of  hamsters, associated to an increased arteriolar 
blood flow (Conde, et al., 2007). In the latter, these beneficial effects were attributed to 
the ability of fish oils to modulate eicosanoid synthesis, Ca2+ or K+ channel activity, as 
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well as NO production, which can regulate vascular tone, thus influencing the blood 
flow in arterioles as well as capillary function and density (Conde, et al., 2007). 
The EDT study is - to our knowledge - the first study looking at the effect of fish 
oils on capillary density in humans. Long chain n-3 PUFA, especially DHA have been 
associated with reduced BP (Liu, et al., 2011), which relates to microvascular function 
and capillary density (Serne, et al., 1999). In addition microvascular function relates to 
EF and NO production (Cheng, et al., 2008, Cheng, et al., 2008, Conde, et al., 2007), 
which may be improved by fish oils (Chin, et al., 1993, Khan, et al., 2003, Shah, et al., 
2007, Walser, et al., 2006). In our study, EPA and DHA failed to affect NO production 
and EPC levels (see 3.3.1), as well as BP (see 3.3.5), which is in line with the lack of 
effect on capillary density.  
3.3.4 Arterial stiffness and peripheral resistance 
SI-DVP and RI-DVP, as well as the peripheral and central AIx, were consistent 
with data previously observed in healthy people (Evison, et al., 2006, Hall, et al., 2008, 
O'Rourke, et al., 2001) and remained unchanged upon EPA and DHA treatment. 
Conversely, a recent meta-analysis suggests that intervention with fish oils improve 
arterial stiffness (Pase, et al., 2011), however these results should be appropriately 
interpreted. Nine of the ten trials considered in this meta-analysis involved populations 
at risk, including overweight, diabetic, hypertensive, dyslipidaemic or hyperlipidaemic, 
while only one trial considered healthy young males. Importantly, the latter – whose 
data were unpublished - showed that fish oils (1.8g EPA + 1.1 g DHA / day) had no 
effect on radial-carotid PWV (See (Damsgaard, et al., 2008) for reference). Noteworthy, 
four of the ten trials investigated PWV (two at the brachial-ankle and two at the cardio-
ankle and radial-carotid sites) and six investigated as capacity compliance and systemic 
compliance, but none of them looked at carotid-femoral PWV, central haemodynamic 
indices nor any other indices of arterial stiffness measured in our study. The effect of 
fish oils on carotid-femoral PWV was recently reported by Sanders et al. who showed 
that low doses of EPA and DHA (0.45-1.8g/d) for 12 months in healthy subjects (aged 
45-70 y) had no effect (Sanders, et al., 2011). In fact, our findings are in accordance 
with the only study – to our knowledge - that investigated the impact of fish 
consumption on the augmentation index specifically. Hallund et al. recently reported 
that 8 weeks of trout consumption (150g / day), providing 2.0 and 0.9 g/d of DHA and 
EPA, respectively, had no effect on the augmentation index – as well as PWV – in 
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healthy males, compared to 150g of chicken per day (Hallund, et al., 2010). It should be 
noted that this study was not included in Pase’s meta-analysis that only looked at fish 
oil supplements, but not dietary fish intervention. Together with our findings, this 
suggests that relatively high doses of fish oils (~2-3g/d) given for less than two months 
are not able to improve central and peripheral indices of arterial stiffness/vascular tone, 
in healthy subjects. Although a difference in the rate of arterial stiffening would not be 
expected over the duration of supplementation used in the current study, these indices of 
arterial stiffness are also influenced by peripheral resistance, and could therefore be 
influenced by shorter term changes in vasodilation. The unchanged levels of NOx and 
BP corroborate the absence of effect of EPA and DHA on PWA and DVP indices in our 
study. 
3.3.5 BP and HR 
Although the hypotensive role of fish oils is well-established in subjects at 
higher CVD risk, such as elderly or hypertensive patients (Geleijnse, et al., 2002, Mori, 
2006), a lack of effect of fish oils on SBP and/or DBP is not uncommon in healthy 
people (Conquer and Holub, 1998, Damsgaard, et al., 2008, Morris, et al., 1993, 
Sanders, et al., 2006, Sanders, et al., 2011). Similarly, the HR lowering effect of fish 
oils is clear in subjects with higher baseline values (Mozaffarian, et al., 2005) but a lack 
of effect in healthy population is not unusual (Damsgaard, et al., 2008, Sanders, et al., 
2011, Walser, et al., 2006). It is therefore not surprising that EPA and DHA both failed 
to lower seated and supine HR and BP and ambulatory BP in the EDT study. Although 
we did not observe an effect on ambulatory 24h and daytime HR, night time HR was 
decreased by 3 bpm by DHA and increased by 2.7 bpm upon EPA treatment. From the 
few studies investigating the individual effect of EPA and DHA on BP and HR, it 
appears that the HR and BP lowering effects of fish oils are due to DHA rather than 
EPA (Grimsgaard, et al., 1998, Mori, et al., 1999, Theobald, et al., 2007). Interestingly, 
Grimsgaard et al. showed that while having no effect on BP, DHA (4g/d, 7 weeks) 
lowered HR in healthy males by 2.2 bpm while EPA increased it by 1.9 bpm in healthy 
males (Grimsgaard, et al., 1998), which is consistent with our findings for HR at night. 
In mildly hyperlipidaemic males, Mori et al. showed that 24h, daytime and night time 
HR increased in the EPA group by 2.0 bpm, 2.7 bpm, and 2.3 bpm, respectively, 
without reaching significance, while they were all significantly decreased by DHA 
(4g/d, 6 weeks) (Mori, et al., 1999).  
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The mechanisms by which EPA and DHA could exert opposite effects on HR 
remain unclear. Both EPA and DHA were shown to modulate potassium, sodium and 
calcium channel activities in myocardial cells, regulating myocyte electrical excitability 
and contractility (Li, et al., 2009, Xiao, et al., 1997, Xiao, et al., 2005). These effects, 
observed in a concentration-dependent manner, are thought to be mediated by the effect 
of EPA and DHA on membrane fluidity (Xiao, et al., 2005), although other 
mechanisms, such as direct binding of n-3 LCP to the channel could be involved (Kang 
and Leaf, 1996). The cardioprotective effects of fish oils are believed to be due – at least 
partially – to their incorporation in cardiac membrane cells (McLennan, 2001, 
McLennan, et al., 2011), and there is growing evidence from animal studies that DHA, 
compared to EPA, is preferentially incorporated (McLennan, 2001). Collectively, these 
findings help to explain the anti-arrythmic and HR-lowering effects observed with DHA 
but not EPA in humans (Mori, et al., 1999). In addition, incorporation of DHA into the 
membrane of cardiomyocytes influences the beta adrenergic system to a greater extent 
than EPA (Grynberg, et al., 1995), potentially an important mechanism in the 
hypotensive and anti-arrhythmic effects of DHA. DHA incorporation into the 
membrane of endothelial cells stimulates ATP release from the endothelium, increasing 
vasodilation by stimulating nitric oxide (NO) release (Hashimoto, et al., 1999). The 
induction of NO release, together with the decrease in noradrenaline levels, are likely to 
be responsible for the BP-lowering effect of DHA (Hashimoto, et al., 1999). It should 
be noted that in contrast with observations in animal cardiac membranes (McLennan, 
2001), EPA appears to be incorporated in humans to a greater extent than DHA, in 
various lipid fractions and cells (Katan, et al., 1997). Whether this is the case in human 
cardiac membranes remains uncertain as it is evidently complicated to observe in 
humans. 
Whether the changes in HR in humans are due to changes in EPA, DPA or DHA 
in the cardiac membrane remains unknown. Erythrocyte composition has been shown to 
be the most reliable lipid fraction in blood to represent cardiac membrane composition 
(Campbell, et al., 2012). Interestingly, HR was strongly correlated with DPA at the end 
of intervention, but not with other VLC n-3 PUFA. Conversely, in Grimsgaard et al.‘s 
study changes in HR were inversely correlated with changes in serum phospholipid 
DHA, and the authors observed a significant decrease in serum phospholipid DHA in 
the EPA group, where HR was increased (Grimsgaard, et al., 1998). Overall, whether 
the increase in HR sometimes observed with EPA is due to EPA itself, its conversion to 
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DPA, or DHA deprivation - as previously observed in plasma and platelet phospholipids 
upon EPA supplementation (Grimsgaard, et al., 1997, Mori, et al., 2003) - is yet to be 
elucidated. 
3.3.6 Lipid profiles 
3.3.6.1 Plasma fasting triacylglycerol and total NEFA concentrations  
Neither EPA nor DHA affected plasma TAG concentrations compared to 
placebo. While 3g of fish oils per day have shown a hypotryglyceridemic effect, 
particularly in individual with higher baseline levels (Mozaffarian and Wu, 2011), a null 
effect is not rare in normolipidaemic humans (Harris, 1996, Osterud, et al., 1995). 
However, there was a small but significant NEFA-lowering effect of EPA and DHA, 
particularly following EPA supplementation. Although the TAG lowering effect of fish 
oils is well-established, it was previously reported that only half of placebo-controlled 
trials involving normotriglyceridemic subjects showed a significant effect of fish oils on 
TAG levels, vs. 75% in hypertriglyceridemic patients (≥ 2mM) (Harris, 1996). 
Nonetheless, within-group analysis showed a significant decrease of TAG in the EPA 
group (-26.8%) but not in the DHA or placebo group. A preferential effect has been 
observed in slightly hypertriglyceridaemic subjects where 3 weeks of supplementation 
with EPA or fish oil but not DHA alone decreased TAG levels (Rambjor, et al., 1996). 
However, as the authors pointed out, the DHA group was relatively small (n = 9) 
compared to the EPA and fish oil group (n = 25 and 35, respectively) and thus 
underpowered. In addition, EPA is incorporated into various lipid fractions at a faster 
rate than DHA (Katan, et al., 1997), and three weeks of intervention may have been 
insufficient for DHA to exert its TAG lowering effect. Interestingly, seal oil (340 mg 
EPA, 230 mg DPA, 450 mg DHA) but not fish oil (210 mg EPA, 30 mg DPA, 810 mg 
DHA) reduced plasma TAG in healthy volunteers after two weeks of supplementation, 
and the authors suggested that seal oil may be more efficient in improving lipid profiles 
due to its high DPA as well as EPA content (Khan, et al., 2012).  
Changes in TAG levels were inversely correlated with EPA levels in 
erythrocytes, but not DHA, which is consistent with earlier findings showing that TAG 
changes correlated with platelet EPA but not DHA after 6 weeks of supplementation 
with fish oils (3g EPA+DHA / day) in hypertriglyceridemic men (Leigh-Firbank, et al., 
2002). Concurrent with this, previous animal and in vitro studies suggested that EPA 
was likely to be the antilipidaemic agent, due to its ability to stimulate mitochondrial 
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FA oxidation in the liver (Frøyland, et al., 1997, Madsen, et al., 1999), and to its direct 
impact on TAG synthesis, VLDL assembly and secretion (Berge, et al., 1999, 
Willumsen, et al., 1993). EPA decreased NEFA levels compared to placebo, which 
could potentially reduce FA supply for hepatic TAG synthesis. However, reduced TAG 
levels may themselves be responsible for a reduction of NEFA release from the TAG-
rich VLDL, in which case the effect observed on NEFA levels would be a consequence 
of reduced TAG rather than a cause (Harris and Bulchandani, 2006). Nonetheless, 
evidence from in vitro studies suggest that both EPA and DHA, as well as their 
derivatives, are able to regulate the expression of transcription factors in the liver, such 
as PPARs (Chambrier, et al., 2002, Itoh and Yamamoto, 2008) and SREBP-1 (Caputo, 
et al., 2010, Howell Iii, et al., 2009, Kajikawa, et al., 2009) involved in lipid 
metabolism, which may contribute to the regulation of TAG levels (Harris and 
Bulchandani, 2006). Consistent with this, supplementation with either EPA or DHA for 
at least 4 weeks have consistently shown that both EPA and DHA decrease TAG levels 
in healthy subjects (Egert, et al., 2009, Grimsgaard, et al., 1997, Olano-Martin, et al., 
2010), as well as type 2 diabetics (Woodman, et al., 2002) and dyslipidaemics (Mori, et 
al., 2000, Nestel, et al., 2002), sometimes with a more potent effect of DHA (Buckley, 
et al., 2004, Grimsgaard, et al., 1997, Mori, et al., 2000). Whether the 
hypotriglyceridaemic effect of DHA usually observed in humans is due to a direct effect 
or partially to its retroconversion to EPA remains uncertain and the differential 
mechanisms by which of EPA and DHA may alter lipid metabolism remains to be fully 
elucidated. 
3.3.6.2 Cholesterol 
The unaffected lipoprotein levels, including total cholesterol levels, LDL or 
HDL upon EPA or DHA treatment are in accordance with the majority of previous 
studies in healthy people that have reported little or no effect of fish oils or oily fish on 
HDL and LDL (Hallund, et al., 2010, Kong, et al., 2007, Maa, et al., 2007). Recent 
meta-analyses, including patients at high CVD risk, show that although fish oils show a 
consistent hypotriglyceridemic effect, they have no effect on total cholesterol and only 
slightly – but significantly – raise LDL and HDL, suggesting that fish oils are unlikely 
to exert a cardioprotective effect through a role in cholesterol metabolism (Balk, et al., 
2006, Eslick, et al., 2009). However, those analyses did not consider the total 
cholesterol/HDL ratio or the size of LDL particles, which were also reported as 
independent predictors of CV events (Mewshaw, et al., 2007, Rizzo and Berneis, 2006, 
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Ullrich, et al., 2007). Although there was no difference between groups, within group 
analysis showed a slight but significant decrease in the ApoB/LDL ratio (suggesting an 
increase in LDL size) and total cholesterol/HDL ratio in the EPA group, but not the 
DHA group. This contrasts with previous studies, generally showing an improvement in 
both LDL and HDL size upon fish oil supplementation, especially upon DHA treatment. 
In hyperlipidemic men, DHA increased LDL levels and size, as well as HDL size but 
not HDL levels, while EPA had no effect (Mori, et al., 2000). In healthy men (20-70 y 
old), within group analysis showed that DHA but not EPA increased HDL size 
(Buckley, et al., 2004), while there was no difference between groups. A beneficial 
effect on total cholesterol/HDL ratio has been observed after supplementation with fish 
oils (Harris, 2007) as well as EPA or DHA alone (Conquer and Holub, 1996, 
Grimsgaard, et al., 1997). Noteworthy, TAG/HDL ratio was significantly decreased 
within the EPA group (~ -30%, P < 0.007), while only a trend was observed in the DHA 
group (- ~21%, P = 0.072), and no change was observed with placebo. TAG/HDL ratio 
is believed to be a stronger predictor of CV events than the LDL/HDL ratio or TAG 
levels on its own (Wahamaa, et al., 2007), and our results may indicate a beneficial role 
of both EPA and DHA on lipid metabolism, despite the lack of significant effect of 
DHA on TAG levels. 
3.3.7 Oxidative stress and platelet function 
3.3.7.1 Isoprostanes 
Because of the large array of substances the endothelium secretes, numerous 
impairments are associated with endothelial dysfunction, other than the one resulting 
from the vasodilation/vasoconstriction described in chapter 1. Oxidative stress, i.e. the 
imbalance between pro- and anti-oxidant activity, plays a pivotal role in endothelial 
dysfunction and the pathogenesis of CVD (Shah, et al., 2010). Oxidative stress involves 
the accumulation or superoxide anion in the mitochondria of endothelial cells, and 
VSMC. Reactive oxygen species injure the endothelial cell and nuclei, interact with 
eNOS cofactors and NO, contributing to the alteration of vasomotion (Wong, et al., 
2010). ROS and NO are also responsible for lipid peroxidation and lead to the formation 
of oxidised LDL, which plays an important role in the development of atherogenesis 
(Steinberg, 1997). Oxidative stress may thus both precede and exacerbate endothelial 
dysfunction as well as the development of atherosclerosis. Several markers of oxidative 
stress, such as oxidised LDL or isoprostanes have emerged as valuable tools for the 
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diagnosis and prognosis of CVD (He, et al., 2010, Sotirios, 2006), and a therapeutic 
target (Sotirios, 2008).  
Plasma isoprostanes concentrations were similar to those previously reported in 
healthy subjects (Levine, et al., 2001, Upritchard, et al., 2003) and remained unchanged 
upon both EPA and DHA treatment, which is in line with the lack of effect on EF. Our 
results are also consistent with previous findings in humans, where fish oils failed to 
reduce levels of diverse markers of oxidative stress, such as malondialdehyde or 
oxidised LDL (Filaire, et al., 2010, Hanwell, et al., 2009, McAnulty, et al., 2010), as 
well as urinary F2-isoprostanes (Petersson, et al., 2010, Ulven, et al., 2011). However 
there is inconsistency as others have shown that fish oils or oily fish reduced 
isoprostane levels in diabetics (Mori, et al., 1999, Mori, et al., 2000), overweight 
hyperlipidemic (Mori, et al., 2000), post-menopausal women (Higdon, et al., 2000) or 
healthy subjects, at doses as little as 200mg/d DHA (Guillot, et al., 2009). It should be 
noted, however that these studies have measured urinary excretion of isoprostanes, 
rather than plasma concentrations. In contrast to our results, Mas et al. reported that 
both EPA and DHA (4 g/d) reduced plasma F2-isoprostanes after 6 weeks of 
intervention in overweight, dyslipidaemic men as well as in treated-hypertensive Type 2 
diabetic, patients (Mas, et al., 2010).  
In vitro studies suggest that EPA and DHA may improve oxidative stress, for 
example by regulating the uptake of oxLDL by macrophages (McLaren, et al., 2011), or 
competing with AA in the activation of NADPH oxidase (Vignais, 2002) and in the 
formation of AA derived isoprostanes. However, with their high degree of unsaturation, 
EPA and DHA are particularly prone to oxidation and may contribute to the oxidative 
stress. In support of that isoprostanes of the F-3 series can be derived from EPA, and 
have been proposed as a valuable index of oxidative stress, particularly in people with 
high intake of n-3 PUFA (Chang, et al., 2008, Song, et al., 2009), and may be of interest 
in fish oil supplementation studies. This duality may explain that there is to date no 
clear evidence that fish oils may reduce oxidative stress and lipid peroxidation in 
humans, and further research is needed to determine whether fish oils may be beneficial. 
3.3.7.2 PMA 
Previous research investigating the effect of fish oils on platelet function has 
mainly focused on platelet aggregometry - measuring ex vivo platelet activation - and 
measurements of thromboxane synthesis, and there is uncertainty regarding the 
correlation between platelet activity ex vivo and in vivo. In general, fish oils seem to 
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reduce platelet aggregation and thromboxane A2 production in response to ADP and 
collagen in healthy people (Mann, et al., 1997, Siess, et al., 1980), type 2 diabetics 
(Hartweg, et al., 2009) and in subjects with mildly raised blood pressure and cholesterol 
levels (Mori, et al., 1997). The measurement of leukocyte-platelet aggregation, 
including platelet monocyte aggregation allows the evaluation of platelet function in 
vivo. Din et al. recently showed that 500g of mackerel per week (providing 1g 
EPA+DHA / day) for 4 weeks was sufficient to reduce platelet aggregation by 35% in 
healthy men, without affecting markers of platelet activation (sP-selectin, sCD40L) 
(Din, et al., 2008).  This contrasts with the lack of effect of either EPA or DHA on PMA 
in our study. The difference may be due to the variability of technique or individual 
variability.Our population had PMA levels of ~9% at baseline, while they were reduced 
from ~24% to ~16% after the 4 weeks of fish oil supplementation in Din et al. study. 
All of these levels have been previously reported in healthy populations (Lukasik, et al., 
2011, Tapp, et al., 2011). One explanation for the current findings might be that both 
EPA and DHA together are necessary to improve platelet aggregation. However, several 
studies have shown that either EPA (Nomura, et al., 2003) (Wojenski, et al., 1991) or 
DHA (Guillot, et al., 2009, von Schacky and Weber, 1985, Woodman, et al., 2003) 
alone could improve platelet aggregation, as observed by the more traditional 
techniques of aggregometry. Interestingly, DHA, but not EPA, improved platelet 
aggregation in response to collagen and PAF in type 2 diabetics (Woodman, et al., 
2003). 
Mechanisms by which fish oils may modulate platelet function have been mostly 
attributed to the ability of EPA to compete with arachidonic acid (AA) in the COX 
pathway, leading to the formation of eicosanoids from the 3-series, less pro-thrombotic 
than the 2-series eicosanoids derived from AA (Krämer, et al., 1996, Tapiero, et al., 
2002). On the other hand, DHA may exert a greater effect on platelet membrane fluidity 
compared to EPA (Hashimoto, et al., 2006), probably because of its additional double 
bond (Hashimoto, et al., 1999). EPA and DHA may also exert their anti-thrombotic 
effect on the endothelium, by stimulating the production of EPA derived PGI3 which 
adds on to the anti-aggregatory effect of PGI2 (Hishinuma, et al., 1999), inhibiting 
platelet activating factor synthesis (Mayer, et al., 2002) or stimulating eNOS activity 
(Li, et al., 2007, Li, et al., 2007). The decrease in PAF levels, as well as the increase of 
NO, which has anti-aggregatory properties, may also contribute to the anti-thrombotic 
effects of fish oils (Serhan and Chiang, 2008). 
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Both EPA and DHA appear to reduce platelet aggregation in humans (Din, et al., 
2008), and DHA may be more potent (Woodman, et al., 2003). The reason why we did 
not observe any change in platelet monocyte aggregation remains unclear, but may 
simply be due to individual variability.  
3.3.8 Glycemia and insulin sensitivity 
As expected, six weeks of supplementation with EPA or DHA did not affect 
plasma glucose, insulin and indexes of insulin sensitivity in healthy young males. This 
is consistent with recent meta-analysis showing that fish oils had no significant effect on 
insulin, glucose and glycated hemoglobin levels (Balk, et al., 2006, Hartweg, et al., 
2008). More recently, Akinkuolie et al. were the first to publish a meta-analysis 
assessing the effect of fish oils on indexes of insulin sensitivity and included all 
populations. They concluded that fish oils had no effect on insulin sensitivity overall 
(11 trials, n 618), although subgroup analysis showed a significant improvement in the 
group where insulin sensitivity was measured by HOMA (Akinkuolie, et al., 2011). The 
authors could not investigate dose and time effect of the interventions due to the limited 
number of trials, but these factors, as well as individual variability, may contribute to 
the discrepancies observed in human interventions (Fedor and Kelley, 2009). In 
addition, lack of standardisation of the methods used to assess insulin resistance 
(Muniyappa, et al., 2008), and the differences in the FA composition of the capsules, 
may play a role in the variability of response to treatment. To date, only a few studies 
have compared the role of EPA and DHA on insulin sensitivity and glycaemic control 
and as for EPA+DHA taken together, results are inconsistent. Corroborating our 
findings, Egert et al. reported a lack of effect of both supplements (2.8-2.9 g/d, 6 weeks) 
in healthy participants on insulin levels and sensitivity (Egert, et al., 2008); however 
EPA tended to increase glucose levels. In treated hypertensive EPA or DHA (3.7-3.8 
g/d, 6 weeks) did not affect insulin levels, secretion and sensitivity but both increased 
glucose concentrations (Woodman, et al., 2002). In contrast, EPA and DHA (4 g/d, 6 
weeks) both decreased insulin levels in hyperlipidaemic subjects while EPA tended to 
increase fasting glucose (Mori, et al., 2000). Although there is inconsistency in humans, 
there is growing evidence from animal studies that both EPA and DHA exert an insulin-
sensitising effect (Fedor and Kelley, 2009) through their anti-inflammatory effect 
(Calder, 2009, Caughey, et al., 1996, Endres, et al., 1989, Meydani, et al., 1991), t 
ability to modulate adipokine production by the adipose tissue (Arai, et al., 2009), as 
well as the expression of transcription factors such as SREBP-1c, PPAR α and γ, 
158 
 
involved in glucose and lipid metabolism (Caputo, et al., 2010, Chambrier, et al., 2002, 
Howell Iii, et al., 2009, Itoh and Yamamoto, 2008, Kajikawa, et al., 2009). This 
contrasts with the discrepancy observed in humans and may suggest that more long term 
interventions (6-12 months) are required to determine whether EPA and/or DHA can 
improve adipokine levels and insulin sensitivity in humans. 
3.3.9 Conclusion and limitations 
We showed that neither EPA nor DHA improved endothelial and microvascular 
function, as assessed by NOx, EPC and functional capillary density measurements, The 
low levels of EPC in mononuclear cells limits the reliability of the method used, and 
research is still needed to standardise EPC measurement. Populations at high CVD risk, 
as well as other aspects of microvascular function, such as red blood cell velocity or 
capillary structure, may be considered in future intervention studies with fish oils. 
DHA decreased and EPA increased heart rate at night, which corroborates 
previous findings (Grimsgaard, et al., 1998, Mori, et al., 1999). The reasons for this 
difference remain uncertain and may involve changes in EPA, DHA and/or DPA in the 
cardiac membrane. Pure forms of EPA should be used with caution when 
supplementing subjects at high CVD risk, or for long periods. 
EPA and DHA showed differential incorporation into the erythrocyte and NEFA 
fractions. The dynamic of incorporation and conversion between the 3 VLC n-3 PUFA 
(EPA, DPA, DHA) may vary from one lipid fraction to another. The investigation of 
this dynamic within different lipid fractions (e.g. TAG, LDL, HDL) as well as 
circulating cells (e.g. inflammatory cells, platelets) or tissues (e.g. adipose tissue) could 
help further the understanding of the differential mechanisms by which EPA and/or 




Chapter 4 Effect of fatty acid profiles on 
endothelial function in human dermal microvascular 
endothelial cell 
4.1 Introduction 
NEFA derived from triacylglycerol-rich lipoproteins, as well as adipose tissue 
TAGs, are implicated in the pathogenesis of diabetes and metabolic syndrome (Boden, 
1997). Increased NEFA levels, as observed in the insulin resistant state, inhibit glucose 
uptake in muscle (Peterson and shulman 2002), and contribute to oxidative stress and 
inflammation (Itani 2002). Beyond NEFA levels, NEFA composition, which partially 
reflects dietary habits, may play a crucial role in the development of endothelial 
dysfunction and insulin resistance. In humans, a high proportion of SFA in NEFA is 
associated with an increased 10-year CVD risk (Skidmore, et al., 2010),  while long 
chain n-3 PUFA (especially EPA and DHA) correlate with markers of endothelial 
dysfunction (Yli-Jama, et al., 2002) and are associated to a reduced CVD risk (Rhee, et 
al., 2008, Yli-Jama, et al., 2002). 
Endothelial cells are directly exposed to circulating lipids, and endothelial 
dysfunction precedes the onset of atherosclerosis and diabetes. Several studies have 
investigated the individual role of FA on endothelial function in vitro. Both EPA and 
DHA were reported to increase eNOS activity (Li, et al., 2007, Li, et al., 2007) and 
expression (Xue, et al., 2006) and to reduce inflammation. In contrast palmitic acid 
appears to reduce eNOS activity and NO production, probably through inflammatory 
mechanisms (Kim, et al., 2005, Wang, et al., 2006). However, some studies suggest that 
EPA and DHA may have deleterious effect on endothelial function (Gousset-Dupont, et 
al., 2007) and the effect of oleic acid remains uncertain (Couloubaly, et al., 2007, Kim, 
et al., 2005). This inconsistency may be due to variability in study design, cell types, 
treatment duration, form and doses of fatty acids used. Most in vitro studies have 
investigated the individual role of fatty acids, often dissolved in DMSO. Conversely, 
NEFA circulate in blood bound to albumin, as a mixture of SFA, MUFA and PUFA 
representative of the diet. 
The microvascular network represents the largest endothelial surface, which 
makes it more vulnerable to endothelial dysfunction. The microcirculation ensures the 
delivery of nutrients, oxygen and other substances such as insulin to tissues (Campbell, 
et al., 2012) and a tightly controlled pressure, maintaining peripheral resistance (See 
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Chapter 1). Microvascular insulin resistance and dysfunction, as observed in obesity, 
diabetes or hypertension, involve the skin, skeletal muscle, cardiac muscle, retina and 
kidneys (Ko, et al., 2010, Picchi, et al., 2010) and may thus play a pivotal role in co-
morbidities of these diseases. Drug or nutritional interventions targeting an 
improvement of microvascular function could be of great importance; and the 
understanding of endothelial function at the microvascular level appears crucial, and 
would lie in the scope of the microvascular measurements described in the previous 
chapter.  
4.1.1 Aim and Objectives 
The aim of this chapter is to investigate the effect of FA profiles - typical of 
dietary patterns - on endothelial function in microvascular endothelial cells, and 
examine the modulation of their response by insulin and inflammatory conditions. The 
production of the two major vasodilators released by the endothelium, nitric oxide (NO) 
and prostacyclin (PGI2), was examined. 
4.1.2 Hypothesis 
It was hypothesised that NO production/eNOS expression would be decreased 
and increased by profiles enriched in saturated fats and n-3 PUFA, respectively. A 
secondary hypothesis was that PGI2 would be increased upon n-6 PUFA treatment, and 




4.2 Material and methods 
4.2.1 List of equipment and consumables 
- LEEC Research CO2 Incubator (cat.no. GA3N, LEEC Ltd., Nottinghamshire, UK) 
- Eppendorf centrifuge (cat.no. 5804R, Eppendorf UK Ltd., UK) 
- Synergy™ HT Multi-Mode Microplate Reader Bio-Tek® (Bio Tek, Bedfordshire, 
UK) 
- KC4.v3.4 software Bio-Tek® (Bio Tek, Bedfordshire, UK) 
- Dri-block heater (Techne cat.no. DB-2A, Thelabwarehouse Ltd., London, UK) 
- Bio-Rad® Model 200/2.0 Power Supply (Bio-Rad Laboratories Ltd., Hertfordshire,  
UK) 
- Mini-PROTEAN 3 Cell and Mini Trans-Blot® module (Bio-Rad Laboratories Ltd., 
Herts. UK) 
- V10-SDB and V20-SDB semi dry blotters (Scie-Plas Ltd., Cambridgeshire, UK) 
- Luckham rotatest R100 shaker (cat.no. 454-129, Genetic Research Instrumentation 
Ltd., Essex, UK) 
- G:Box Chemi imaging system (Syngene, Scientific Laboratory Supplies Ltd, 
Nottinghamshire, UK) 
- Genesnap image acquisition software (Syngene, Scientific Laboratory Supplies Ltd, 
Nottinghamshire, UK) 
- Agilent 6890 Gas Chromatograph (Agilent Technologies)  
- F96 MicroWell™ Plates, polystyrene clear (Nunc cat.no. 167008, Thermo Fisher 
Scientific, UK)  
- Nunc Multidishes Nunclon™∆, 24 wells (Nunc cat.no. 142475, Thermo Fisher 
Scientific, UK) 
- Sterile Acrodisc® Syringe Filters with 0.2 µm Supor® Membrane (Pall 
Corporation, VWR International Ltd., UK) 
- Chromacol glass vials and inserts for gas chromatography (Esslab Ltd., Essex, UK) 
- Short plates (cat.no. 165-3308, Bio-Rad Laboratories Ltd., Hertfordshire, UK) 
- Spacer Plates With 1.5 mm Integrated Spacers (cat.no. 165-3312, Bio-Rad 
Laboratories Ltd., Hertfordshire, UK) 
- Polyvinylidene fluoride (PVDF) transfer membranes (Immobilion®-P, cat.no. 
IPVH00010, Millipore UK Ltd, UK) 




4.2.2 List of reagents and chemicals 
4.2.2.1 Cell culture and lysis 
- Human dermal microvascular cells (HDMEC-c Endothelial Cells, cryopreserved, 
cat.no. C-12210, Promocell, UK) 
- Endothelial Cell Growth Medium MV KIT (ECGM-MV, cat.no. C-22120, 
Promocell, UK) 
- Newborn calf serum (cat.no. N4637, Sigma-Aldrich, Dorset, UK)  
- Medium 199 (cat.no. M0650, Sigma-Aldrich, Dorset, UK)  
- Fatty acid-free bovine serum albumin (FA-free BSA, cat.no. 85041C, Sigma-
Aldrich, Dorset, UK) 
- Sodium linoleate (cat.no. L8134, Sigma-Aldrich, Dorset, UK)  
- Sodium oleate (cat.no. O7501, Sigma-Aldrich, Dorset, UK) 
- Sodium arachidonate (cat.no. A8798, Sigma-Aldrich, Dorset, UK) 
- Sodium stearate (cat.no. S3381, Sigma-Aldrich, Dorset, UK) 
- Sodium palmitate (cat.no. P9767, Sigma-Aldrich, Dorset, UK) 
- Sodium cis-4,7,10,13,16,19-Docosahexaenoate (DHA, cat.no. D8768, Sigma-
Aldrich, Dorset, UK) 
- Sodium cis-5,8,11,14,17-Eicosapentaenoate (EPA, cat.no. E6627, Sigma-Aldrich, 
Dorset, UK) 
- Endothelial basal medium (EBM, MCDB 131, cat.no. U15-011, PAA Laboratories, 
Somerset, UK) 
- Endothelial cell growth supplement (ECGS, cat.no. E2759, Sigma-Aldrich, Dorset, 
UK) 
- Foetal calf serum (FCS, cat.no. F7524, Sigma-Aldrich, Dorset, UK) 
- FA-free foetal bovine serum (Equitech Bio, inc., TX, USA) 
- L-Glutamine with Penicillin/Streptomycin (L-Gln-Pen-Strep, cat.no. P11-013, PAA 
Laboratories Ltd., Somerset, UK) 
- Hydrocortisone (cat.no. H-0888, Sigma-Aldrich, Dorset, UK)  
- Trypsin EDTA (1:250) (10x) (cat.no. L11-003, PAA Laboratories, Somerset, UK) 
- Dulbecco’s Phosphate Buffered Saline (cat.no. D-1408, Sigma-Aldrich, Dorset, 
UK) 
- Gelatin from bovine skin (cat.no. G-9382, Sigma-Aldrich, Dorset, UK) 
- Tumor necrosis factor α (TNF α, cat.no. 210-TA-010, R&D Systems Europe Ltd, 
UK)  
- Insulin (Incelligent SG®, cat.no. 4502-01, Millipore UK Ltd, UK) 
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- Dulbecco’s Phosphate Buffered Saline (cat.no. D1408, Sigma-Aldrich, Dorset, UK) 
- Human dermal microvascular endothelial cells, cryopreserved, (HDMEC-c, cat.no. 
C-12210, Promocell, UK) 
- Endothelial Cell Growth Medium-MV KIT (ECGM-MV, cat.no. C-22120, 
Promocell, UK) 
- Endothelial basal medium (EBM) MCDB 131 (cat.no. U15-011, PAA Laboratories, 
Somerset, UK) 
- Endothelial cell growth supplement (ECGS, cat.no. E2759, Sigma-Aldrich, Dorset, 
UK) 
- Foetal calf serum (FCS, cat.no. F7524, Sigma-Aldrich, Dorset, UK) 
- FA-free foetal bovine serum (Equitech Bio, inc., TX, USA) 
- L-Glutamine with Penicillin/Streptomycin (L-Gln-Pen-Strep, cat.no. P11-013, PAA 
Laboratories Ltd., Somerset, UK) 
- Hydrocortisone (cat.no. H0888, Sigma-Aldrich, Dorset, UK)  
- Trypsin EDTA (1:250) (10x) (cat.no. L11-003, PAA Laboratories, Somerset, UK) 
- Gelatin from bovine skin (cat.no. G9382, Sigma-Aldrich, Dorset, UK) 
- sodium dodecyl sulphate (SDS, BDH AnalaR, VWR International Ltd., UK) 
- tris(hydroxymethyl)aminomethane (Tris base, BDH AnalaR, VWR International 
Ltd., UK) 
4.2.2.2 FA transesterification 
- Toluene (BDH AnalaR, VWR International Ltd., UK) 
- Methanol (HPLC grade, Fisher Scientific, UK) 
- Acetyl chloride (Sigma-Aldrich, Dorset, UK) 
- Potassium carbonate (K2CO3, BDH AnalaR, VWR International Ltd., UK) 6 % 
(w/v) in UltraPure water 
- Hexane (HPLC grade, Fisher Scientific, UK) 
- Pentadecanoic acid (C15:0, internal standard for NEFA,50 mg/mL in 
CHCl3:MetOH 2:1 v/v) (~99% by capillary GC, Sigma-Aldrich, cat no. P6125-5G, 
Dorset, UK) 
4.2.2.3 Western Blot 
- Ammonium persulfate (APS, cat.no. A3678, Sigma-Aldrich, Dorset, UK) 
- N,N,N',N'-tetramethylethylenediamine (TEMED, Sigma cat.no. T9281, Sigma-
Aldrich, Dorset, UK) 
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- 30% (w/v) acrylamide/methylene bisacrylamide solution (37.5:1 ratio) (Protogel®, 
cat.no. A2-0072, National Diagnostics, Geneflow Ltd, Staffordshire, UK) 
- SDS (BDH AnalaR, VWR International Ltd., UK) 
- Tris base (BDH AnalaR, VWR International Ltd., UK) 
- Bromophenol blue (BPB, cat.no. B8026, Sigma-Aldrich, Dorset, UK) 
- 2-Mercaptoethanol (cat.no. M6250, Sigma-Aldrich, Dorset, UK) 
- PageRuler™ Prestained Protein Ladder (Fermentas SM0671, Thermo Fisher 
Scientific, UK) 
- Glycine (cat.no. G8898, Sigma-Aldrich, Dorset, UK) 
- Marvel Original Dried Skimmed Milk Powder (Premier Food) 
- TWEEN® 20 (cat.no. P5927, Sigma-Aldrich, Dorset, UK) 
- Albumin from bovine serum (BSA, cat.no. A9647, Sigma-Aldrich, Dorset, UK) 
- Coomassie Brilliant Blue G (cat.no. 6104-58-1, Acros Organics Thermo Fisher 
Scientific, UK) 
- Acetic acid (BDH AnalaR, VWR International Ltd., UK) 
- Sodium Azide (NaN3, BDH AnalaR, VWR International Ltd., UK) 
- Rat α-tubulin monoclonal antibody, clone YL1/2 (Chemicon cat.no. MAB1864, 
Millipore UK Ltd, UK) 
- Rabbit eNOS polyclonal antibody (Cat.no., sc-67003 Santa Cruz Biotechnology®, 
inc., Insight Biotechnology Ltd, UK) 
- Mouse COX-2 (29) monoclonal antibody (Cat.No. sc-19999, Santa Cruz 
Biotechnology®, inc., Insight Biotechnology Ltd, UK) 
- Goat anti-rat Immunoglobulin G- Horseradish  peroxidase (IgG-HRP) (cat.no. sc-
2006, Santa Cruz Biotechnology®, inc., Insight Biotechnology Ltd, UK) 
- Goat anti-rabbit IgG-HRP (cat.no. sc-2004, Santa Cruz Biotechnology®, inc., 
Insight Biotechnology Ltd, UK) 
- Goat anti-mouse IgG-HRP (cat.no. sc-2005, Santa Cruz Biotechnology®, inc., 
Insight Biotechnology Ltd, UK) 
- Pierce® enhanced chemilumescent (ECL) Western Blotting Substrate (cat.no. 
32106, Fisher Scientific UK Ltd, UK) 
4.2.2.4 Assay kits 




- LDH Cytotoxicity assay kit (Cayman Chemical Europe, cat.no. 10008882, Axxora, 
UK) 
- Endotoxin assay kit (E-toxate®, cat.no. ET-0200, Sigma-Aldrich, Dorset, UK)  
- Nitrate/nitrite fluorometric assay kit (Cayman Chemical Europe, Cat. No. 780051, 
Axxora, UK) 
- Pierce® BCA Protein Assay Kit (Thermo Scientific, Cat. No. 23227) 
- 6-keto Prostaglandin F1α EIA Kit (Cayman Chemical Europe, Cat. No. 515211, 
Axxora, UK) 
4.2.3 Solutions and buffers 
4.2.3.1 Cell culture and lysis 
- Insulin was dissolved in HCl 10 mM at 10 mg/mL and sterile filtered (0.2 µm). 
Then it was diluted in sterile PBS at 100 µg/mL and stored at -20 ˚C. TNFα was 
diluted in sterile PBS-BSA 0.1 % at 10 µg/mL and stored at 
- SDS buffer (2% SDS, 10% Glycerol, 50mM Tris pH 6.8) 
4.2.3.2 Western blot 
♦ SDS PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) 
- Lower gel (resolving gel): Tris-SDS Buffer pH 8.8 (375mM Tris, 0.1% SDS), 10% 
acrylamide, 0.4% APS, 0.08% TEMED 
- Upper gel (stacking gel): Tris-SDS Buffer pH 6.8 (125mM Tris, 0.1% SDS), 4% 
acrylamide, 0.5% APS, 0.06% TEMED 
- Loading buffer: 0.2 % BPB/2-Mercaptoethanol (4:1, v/v) 
- Tank buffer: Tris-glycine-SDS PAGE buffer (10X) diluted in Ultra Pure water. 
(0.25M Tris, 1.92M glycine, 1% SDS) (National Diagnostics, Geneflow Ltd, 
Staffordshire, UK) 
♦ Transfer: 
- Transfer Buffer (192mM Glycine, 25mM Tris base, 20% methanol) 
♦ Protein detection 
- Washing buffer: PBS-tween 0.1% 
- Blocking solution: 5% skimmed milk, PBS-tween 0.1% 




- Gel destain solution: 5% methanol, 7% acetic acid 
- Primary antibody solutions (stored at 4°C): 
o Rat α-tubulin monoclonal antibody: 1:5000 in PBS-tween 0.1%, 
3% BSA, sodium azide 
o Rabbit eNOS polyclonal antibody: 1:1000 in PBS-tween 0.1%, 
3% BSA, sodium azide 
o Mouse COX-2 monoclonal antibody 1:100 in PBS/0.1% Tween, 
3% BSA, sodium azide 
- Horseradish  peroxidase (HRP) secondary antibody solutions (prepared on the day) 
o anti-rat antibody (for α-tubulin): 1:5000 in PBS/0.1%Tween, 3% 
skimmed milk 
o anti-rabbit (for eNOS): 1:2000 in PBS/0.1% Tween, 3% skimmed 
milk 
o anti-mouse (for COX-2):  
4.2.4 Overview 
Human dermal microvascular cells (HDMEC) were incubated with 4 different 
FA profiles, corresponding to NEFA levels typically observed in blood following 
different dietary patterns: high SFA, high MUFA, high n-3 PUFA and high n-6 PUFA. 
They were prepared at 2 different levels, 400 and 1000 µM, characteristic of healthy and 
type 2 diabetic levels, respectively. HDMEC were also incubated with a FA-free BSA 
medium (control), making 9 profiles tested in total. This was performed in the presence 
or absence of tumour necrosis factor α (TNFα) for the whole period of incubation, to 
mimic the chronic inflammation characteristic of insulin-resistant states. The cells were 
also stimulated with insulin for a shorter period to simulate the acute effect of insulin 
postprandially. NO and PGI2 production was measured in culture media for all 
conditions. In addition, eNOS and COX-2 protein expression was measured in cell 
lysates on HDMEC cultured with all profiles in absence of insulin or TNFα. 
As outlined in Figure 4-1, 3 preliminary steps were necessary in order to assess 
the effect of the 8 FA profiles on EF in HDMEC: 
1) Preparation of the FA profiles: 
FA sodium salts were combined with bovine serum albumin (BSA), in order to 
provide the endothelial cells with FA in the same form as NEFA circulate in blood. 




2) Testing of the media to apply to the cells 
Endotoxins, mainly lipopolysaccharides, may be present in BSA or FA salts and 
may affect endothelial function, including NO production and prostacyclin production 
(Lu, et al., 1996, Myers, et al., 1992, Salvemini, et al., 1989, Schildknecht, et al., 2005). 
Thus, their concentration was measured in the media prior to the experiments. In 
addition, the viability of the cells upon FA profiles application must be estimated as 
well. 
3) TNFα and insulin levels determination 
Most of in vitro studies used high levels of insulin or TNFα, generally from 100 
to 1000 times higher than physiological levels (Artwohl, et al., 2007, Eid, et al., 2007). 
Thus, different ranges of TNFα and insulin, from physiological levels to in vitro levels 
were used on a BSA (control) incubation, in order to see to what extent the treatment 
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4.2.5 BSA mixture preparation 
FA sodium salts were complexed to FA-free BSA as previously described 
(Shaw, et al., 2007). BSA was dissolved in endothelial basal medium for 30 min at 37 
ºC at 2.4 mM (control) or to reach a final concentration of 2.4 mM after combination 
with FA (profiles). Palmitate (C16:0), stearate (C18:0), oleate (C18:1(n-9)), linoleate 
(C18:2(n-6)), arachidonate (C20:4(n-6)), eicosapentaenoate (C20:5(n-3)), 
docosahexaenoate (C22:6(n-3)) were dissolved at 50 mg/mL in water 30 min at 40 ºC 
for unsaturated fats, or 70 ºC for SFA (until a clear solution is formed). They were 
immediately added to the BSA/EBM solution to reach a final ratio FA:BSA of 6 
mM:2.4mM and mixed thoroughly. Palmitate and stearate solutions needed to be 
sonicated for 30 min at 37 ºC to further dissolve particles and ensure solubilisation. The 
FA content of individual FA-BSA complexes was first measured by gas 
chromatography (GC), in order to take the yield of the FA-BSA complexation into 
account for the preparation of the final profiles (Appendix XXXIII).  
FA-BSA complexes were blown over with nitrogen to prevent oxidation and 
stored at 4 ºC overnight until final mixing. On the next day, the FA mixtures were 
combined to form four FA profiles: SFA, MUFA, n-6 PUFA and n-3 PUFA (Table 4-1). 
The remaining individual FA-BSA solutions were stored at -20ºC for endotoxin 
assessment. The final mixtures were then sterile filtered (0.2 µm), aliquoted and stored 





Table 4-1: Expected composition of the BSA-FA mixtures in molar % of total FA 
 
SFA profile MUFA profile n-6 PUFA profile n-3 PUFA profile 
  
SFA 55 35 35 35 
16:0 (PA) 37 23 23 23 
18:0 (SA) 18 12 12 12 
MUFA 30 50 35 35 
18:1 (n-9) (OA) 30 50 35 35 
PUFA 15 15 30 30 
C18:2(n-6) (LA) 12 12 25 12 
C20:4(n-6) (AA) 1 1 3 1 
C20:5(n-3) (EPA) 1 1 1 8 
C22:6(n-3) (DHA) 1 1 1 9 
Total n-6 PUFA 13 13 28 13 
Total n-3 PUFA 2 2 2 17 
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids; PA, palmitic acid; SA, stearic acid; OA, oleic acid; LA, 
linoleic acid; AA, arachidonic acid; EPA, eicospentadecanoic acid; DHA, 
docosahexaenoic acid 
The profiles were thawed on the day of experiment and applied to the cells at a 
total FA concentration of 400 and 1000 µM, corresponding to the fasting plasma levels 
found in healthy and insulin resistant states, respectively. As BSA has been shown to 
stimulate cell growth, 2 BSA controls were first prepared (BSA ‘high’ and BSA 
‘normal’), i.e. one for each level of FAs. Following initial experiments, it was decided 
to use only one BSA control: prior to each experiment, BSA control solution was added 
in the ‘normal FA’ profiles to keep the same BSA level in all mixtures. Then the eight 
profiles were diluted in EBM, Pen-Strep-Gln (2 mM-100 units/ml-0.1 mg/ml) and 
delipidised foetal calf serum 2% The average level of BSA in the eight profiles was 
used as a control. 
 4.2.6 General cell culture conditions
HDMEC were cultured in an atmosphere of 95% air and 5% CO
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4.2.7 Testing of the FA profiles 
Before applying the testing media to HDMEC, the FA profiles prepared as 
described in Chapter 2 were tested for endotoxin content, cytotoxicity and their FA 
composition was checked. 
4.2.7.1 FA composition 
FA composition of the 8 FA profiles was tested after FA-BSA complexation, 
storage at -20ºC, and combination that was necessary prior to each experiment 
(described in Chapter 2). FA-BSA complexes were transesterified as previously 
described (Lepage and Roy, 1988) for gas chromatography (GC) analysis. The mixtures 
were briefly warmed up at 37˚C to get homogenous concentrations. 100µL of each FA 
profile were mixed with 100µL of internal standard (C15:0) 1mg/mL in methanol, and 
2mL of methanol/toluene 4:1 (v/v). The tube was vortexed and chilled on ice while 
200µL acetyl chloride were added drop-wise to avoid projections of the HCl produced 
by exothermic reaction. The resultant was incubated 2h at 60˚C and then neutralized 
with 5mL K2CO3 6%. After centrifugation at 1500g, 4˚C for 10min, the supernatants 
were transferred to vials for GC analysis. 
GC conditions: The injection volume was 2 µL, the temperature was 160ºC for 4 
min and then rose to 200ºC in 10 min (gradient of 12ºC/min). 
4.2.7.2 Detection of endotoxin 
Endotoxins (ETX) may be present even in sterile media and may affect the 
activity of the endothelial cells, particularly NO or PGI2 production. Thus, the ETX 
content of each FA-BSA mixture that was used to make up the profiles was measured as 
described by the manufacturerAppendix  . ETX standard was diluted in ETX free water 
to reach a range of 0.015-0.5 EU/mL. 100 µL of either sample or standard or ETX free 
water only (negative control) + 100 µL of working solution were transferred to bijou 
tubes and incubated for 1 h at 37 ˚C, undisturbed. Then the bijou tubes were inverted 
and the formation of a hard gel was considered as a positive result. All the profiles were 
tested for qualitative analysis, and then dilutions of BSA control were used for semi 
quantitative analysis. The lowest concentration found positive in ETX standard 
corresponds to the limit of detection of the test. For examples, if the lowest 
concentration of ETX standard found positive is 0.125 EU/mL, all samples found 
negative will have an ETX level inferior 0.125 EU/mL, corresponding to 1.25 ng/mL. 
 4.2.8 Viability tests
HDMEC (P5) were seeded at 10000 ce
and incubated in a 5 % CO
overnight in EBM - FCS 2% 
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Figure 4-3: Treatment of HDMEC for viability tests
EBM, endothelial basal medium; FCS, fetal calf serum
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4.2.8.2 LDH Cytotoxicity assay 
In addition to the MTT cell proliferation assay, an LDH (lactate dehydrogenase) 
cytotoxicity assay was performed twice. The LDH test is based on the characteristic of 
both apoptotic and necrotic cells that release LDH in the culture medium. LDH then 
oxidises the lactate into pyruvate, converting NAD+ to NADH,H+ at the same time. 
NADH,H+ is then used as cofactor in the conversion of tetrazolium salts to formazan, 
catalysed by diaphorase. Unlike in MTT test, the formazan present in the medium gives 
an absorbance that is correlated to the amount of non viable cells. Cells were seeded in 
triplicate following the treatment described in Figure 4-3 and the assay was performed 
following the manufacturer’s instructions. Briefly, cells were incubated at 37 ºC in a 96 
well plate for 24 h with the media to test (120 µL/well). Then the plate was centrifuged 
5 min, 400 g. 100 µL of either supernatant or LDH standard was then transferred to a 
new plate and 100 µL of reaction mixture were added per well. The plate was shaken 30 
min at room temperature and read at 490 nm. 
4.2.9 TNFα and insulin optimisation experiments 
4.2.9.1 Preparation of reagents 
TNFα and insulin solutions - stored at -20 ˚C - were defrosted and diluted in 
sterile PBS prior to each experiment, and 5 or 3 µL of the appropriate dilution of TNFα, 
insulin or PBS only (as a control) were added the 500 or 300 µL of culture medium, 
respectively. 
As for viability tests, the concentrated FA-BSA mixtures (prepared as described 
in 4.2.5) were diluted freshly on the day in EBM-delipidised FCS 2% to reach the 
desired final concentrations. However, in order to keep the BSA levels comparable in 
all the profiles, BSA was added to the ‘normal’ FA profiles to reach the BSA levels in 
the ‘high’ profiles.  
4.2.9.2 Cell treatment 
HDMEC (P5) were seeded at 50000 cells per well in 24-well plates in EBM – 
FCS 20% and incubated in a 5 % CO2 incubator at 37 ˚C for 24h. Then the cells were 
starved overnight in EBM - FCS 2% and were incubated for another 24 h with BSA 
control (final volume: 500 µL) (Figure 4-4). TNFα was applied for the whole length of 
incubation in order to mimic chronic inflammation as observed in IR state, while insulin 
was tested for a shorter period to simulate the postprandial acute effect observed 
physiologically. Time of incubation with insulin had to be defined as well, balancing 
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between its physiological acute effect and a longer period necessary for accumulation of 
NO or PGI2 in the medium in vitro. Concentrations varied from physiological levels to 
higher levels commonly used in vitro. The concentration used for TNFα ranged from 0 
to 10 ng/mL (24h), while insulin concentrations varied from 0 to 100 ng/mL (2 and 4h) 
(see Table 4-2). Culture media were collected in the end of the 24h incubation and 
stored at -80˚C for NOx measurements, cells were lysed with sodium dodecyl sulphate 
(SDS) buffer and cell lysates were stored at -20 ˚C for protein quantification by 
bicinchoninic acid (BCA) assay. The cells were treated in triplicate and the experiment 
was repeated 3 times. 
Table 4-2: Concentrations of TNFα and insulin used in HDMEC culture in the 
presence of BSA control medium  
 
TNFα (ng/mL), 24h Insulin (ng/mL), 2h or 4h 
0.002 Physiological levels (healthy) 1 
Physiological levels (PP) 0.01 




In vitro levels 
10 
In vitro levels 1 50 
10 100 
IR, insulin resistant state; PP, postprandial state 
 Figure 4-4: Treatment of HDMEC for determination of TNF
EBM, endothelial basal medium; FCS, fetal calf serum
α and insulin levels to use 






4.2.10 Effect of FA profiles on endothelial function 
HDMEC (P5) were seeded at 50000 cells per well in 24-well plates in EBM – 
FCS 20% and incubated in a 5 % CO2 incubator at 37 ˚C for 24h. Then the cells were 
starved overnight in EBM - FCS 2% and were incubated for another 24 h with either 
BSA control, or the eight FA profiles previously described, in the presence of TNFα 
(24h) and/or insulin (2h) and/or PBS only (control). In order to increase NO 
concentration in the medium, the final volume of medium was reduced to 300 µL, and 3 
µL of TNFα (24h) and/or insulin (2h) were added to reach the final concentrations of 10 
ng/mL and 1 µg/mL, respectively. Culture media were stored at -80˚C for NO and PGI2 
analysis, cells were lysed with sodium dodecyl sulphate (SDS) buffer and cell lysates 
were stored at -20 ˚C for protein quantification by bicinchoninic acid (BCA) assay and 
Western blot analysis. The cells were treated in triplicate and the experiment was 
repeated 4 times. 
 Figure 4-5: Treatment of HDMEC for viability tests
EBM, endothelial basal medium; FCS, fetal calf serum
polyunsaturated FA; N, normal levels (400 µM); H, high levels (1000 
acid (protein measurement); 6-keto PGF11α, 6-keto prostaglandin F
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4.2.11  BCA assay for total protein quantification 
A BCA assay was performed in order to standardize NO and PGI2 
measurements, as well as eNOS and COX-2 protein expression, to the amount of 
proteins in the well, which is proportional to the amount of cells. BCA is based on the 
ability of proteins to chelate copper (Cu), leading to the reduction of Cu2+ to Cu+. The 
latter is then chelated by the BCA to form a complex that strongly absorbs at 562 nm, 
proportionally to the amount of peptidic bonds. The test was performed following the 
manufacturer’s instructions, with some modification in order to suppress the potential 
effect of SDS buffer - in which the samples are dissolved – on the absorbance. BSA 
standards were diluted in Ultrapure water. Samples were defrosted and heated 5 min at 
95 °C in a heating block. 5 µL of either sample (cell lysate) or standard (0.0625-
2mg/mL) were transferred per well, with 5 µL of either Ultrapure water or SDS buffer, 
respectively. Then 200 µL of working reagent were added in each well and the plate 
allowed to develop 30 min at 37 ºC. The absorbance was read at 562 nm. 
4.2.12   NO measurement 
The principle of nitrite/nitrate assay has been described in Chapter 2. The 
fluorometric technique, more sensitive, was chosen. Total NO was measured with a 
fluorometric assay kit following the manufacturer’s instructions (See for details). 30 µL 
of each sample (culture media) or nitrate standards (diluted in BSA control solution) 
were transferred to a 96 well plate in duplicate, to which 50 µL of assay buffer were 
added. Then 10 µL of cofactors (NADPH, H+) and 10 µL of nitrate reductase were 
added. The plate was incubated 2 h at room temperature. Then 10 µL of DAN and 20 
µL of NaOH 2.8 M were added, the plate was read at λ excitation = 360 nm, and λ 
emission = 400 nm. 
4.2.13  PGI2 measurement 
6-keto prostaglandin F1α (6-keto PGF11α), the stable product of PGI2 (highly 
unstable) was measured by an enzyme immunoassay (EIA), or enzyme linked 
immunosorbent assay (ELISA) kit, following the manufacturer’s instructions. Here is 
the general principle of the competitive method of ELISA used here: 
1- Plates are precoated with a polyclonal antibody (pAb) directed against the 
monoclonal Ab (mAb) added in 2 
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2- Free Ag (either standard or sample), labelled Ag (tracer-Ag, fixed  
concentration), and a mAb (fixed  concentration) specific for the Ag are 
incubated with pAb 
3- The plate is washed to remove all the compounds that did not specifically 
bind to the pAb. 
4- The plate is revealed with a substrate for the tracer, giving a signal of 
either absorbance or fluorescence that is proportional to the amount of 
tracer-Ag, thus inversely proportional to the bound free Ag. 
Briefly, 50 µL of BSA solution (diluent) and then 50 µL of sample or 6-keto 
PGF11α standard were transferred to the precoated 96 well plate. Then 50 µL of PGF11α 
tracer and 50 µL of PGF11α antiserum were added to each well (final volume: 200 µL), 
and the plate was incubated 18 h at 4 °C. It was then washed 5 times with PBS, revealed 
with 200 µL Ellman’s reagent (2 h on an orbital shaker, room temperature) and read at 
412 nm. 
Standards were transferred in triplicate, while samples (2 dilutions: 1/10 and 
1/100) were transferred in duplicate. 
4.2.14   eNOS and COX-2 expression: Western blotting 
Western blot consisted of the analysis of samples from cells treated with the 8 
different FA profiles and BSA control, in absence of TNFα or insulin. For each run, 
protein extracts from cell culture triplicates were loaded on 3 different gels, so that the 9 
profiles are visible on each membrane. The experiment was repeated on samples from 4 
different sets of cell cultures for eNOS expression. Another Western blot was run on 2 
sets of cultures for COX-2 expression. The general protocol is described in Appendix 
XXIV. 
4.2.14.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Proteins from cell lysates were separated on SDS-10% polyacrylamide gel in 
order to identify eNOS (~140 kDa), COX-2 (~55 kDa), as well as the house keeping 
gene α-tubulin (~70 kDa). SDS is a denaturant that gives a uniform negative charge to 
proteins which are then separated according to their molecular weight only. A 10% 
concentration of polyacrylamide was chosen in order to identify proteins of relatively 
high MW (eNOS, 140 kDa) while keeping a gel that is not too fragile.  
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The resolving and stacking gels were prepared according to the concentrations 
described in Table 4-3. After the resolving and then stacking gels were set, the comb 
was removed and the wells were rinsed with tank buffer. 30uL of cell lysates and 3µL 
2-mercaptoethanol in 0.02% BPB were loaded in each well. Samples were run in tank 
buffer (Tris/glycine/SDS) at a voltage of 150 V for approximatively 1 hour and 10 min. 
Table 4-3: Composition of resolving and stacking gels for SDS-PAGE 
 Quantity for 3 gels Final concentration 
Lower gel (resolving gel) Total = 28.8 mL  
4X Tris-SDS pH 8.8 7.2 mL 1X (375mM Tris0.1% SDS) 
30% Acrylamide 9.6 mL 10% 
Ultrapure water 12 mL  
10% APS 115 µL 0.4% 
TEMED 23 µL 0.08% 
Upper gel (stacking gel) Total = 7.92 mL  
4X Tris-SDS pH 6.8 2 mL 1X (125mM Tris0.1% SDS) 
30% Acrylamide 1.04 mL 4% 
Ultrapure water 4.88 mL  
10% APS 40 µL 0.5% 
TEMED 5 µL 0.06% 
*APS and TEMED, initiating polymerisation, were added at the very end of the 
preparations. Their volumes may be adapted for a faster polymerisation. 
4.2.14.2 Transfer of proteins 
PVDF membranes were activated in methanol for 15s and, in order to make the 
membrane more hydrophilic. Membranes, gels and filters were then equilibrated in 
transfer buffer for a few minutes and disposed as described in Figure 4-6. Proteins were 
transferred for 2h at 20V for eNOS, 1h30 for COX-2. 
 Figure 4-6: Assembly for electrophoret
PVDF: Polyvinylidene fluoride
4.2.14.3 
After transfer, gels were incubated overnight at RT in staining solution, and then 
rinsed 3 to 4 times in destain solution (until protein bands appear) in order to ch
quality of the migration. 
Membranes were incubated for 1h at RT in blocking solution, then rinsed 3 
times and washed with
incubated with eNOS or COX
as before. Next, membranes were placed in anti
for 1h at RT and then kept in 
Fluid excess was removed and the membranes placed on plastic wrap. The e
chemilumescent (ECL)
applied to the membranes for 1min. Membranes were then carefully covered with the 
plastic wrap and visualised with the SynGene software 
exposure time = 30min). Immediately after reading, membranes were rinsed and washed 
in PBS-Tween 0.1% as described earlier. They were incubated with 
for 1h at RT, rinsed and washed again, and incubated for another hour at RT with anti
rat antibody solution. Membranes were then treated with ECL reagents as described 
above and visualised with the SynGene software (Chemi Sample programme, exposure
time = 2.5 min). 
4.2.1 Statistical analysis
The term FA profile is used to define the BSA, SFA, MUFA, n
PUFA profiles. The term treatment characterises insulin and/or 
level defines the two concentrations of FA used, i.e. 400 and 1000 
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For viability tests, data were analysed by one way ANOVA to compare the 
effect of the nine media separately (BSA control, SFA N, SFA H, MUFA N, MUFA H, 
n-6 PUFA N, n-6 PUFA H, n-3 PUFA N, n-3 PUFA H), without insulin or TNFα 
treatment. 
 NO and PGI2 results were analysed by three-way ANOVA, in order to examine 
the effct of FA profiles, FA levels and treatment, and the interaction between factors. In 
this model the FA profiles were compared between them, excluding the BSA control as 
it was applied at only one concentration (no factor level). Subsequently, the FA level 
factor was excluded from the statistical model when it had no effect on NO or PGI2 
production. A two-way ANOVA was then performed (factors: FA profiles, treatment) 
and the effect of FA profiles could be compared to the BSA control. eNOS and COX-2 
expression was analysed by two-way ANOVA, with FA levels and FA profiles as 
factors, excluding the BSA control from the dependent variables. When FA levels had 
no effect, a one-way ANOVA was performed with FA profile as a unique factor in order 
to compare the FA profiles with BSA control. Bonferroni’s multiple comparison was 
used for post hoc analysis. 
Normality of the residuals was checked for analysis and log transformation of 
the data was attempted when required. If the residuals of the log-transformed data were 
still not normally distributed for the one-way ANOVA analysis, non-parametrical 
analysis was performed (Kruskal-Wallis). Non parametric tests were not required to 
substitute two- and three-way ANOVA. Results are shown as means (SEM). All 
statistical analysis was carried out with SPSS for Windows (version 17.0, SPSS, 
Chicago, IL).  
4.3 Results 
As described in 4.2.4, cell culture work was divided in 4 steps: 
1- Preparation of the FA profiles 
2- Testing the media to apply to the cells (viability and endotoxin tests) 
3- TNFα and insulin levels determination 




4.3.1 FA composition of FA profiles 
The total FA concentration measured by GC analysis for each of the 8 profiles 
showed good compliance with the expected total FA levels (400 and 1000 µM), varying 
from 96.2 to 98.2% of the expected total concentrations (results not shown). The 
composition of each profile was also shown to conform to the expected percentages, as 
shown in Table 4-4. The percentages measured in all profiles represented 98.8 % +/- 
9.3% (SD) of the expected values. n-3 PUFA levels in the SFA, MUFA and n-6 PUFA 
profiles fell below the detection limit of the GC for the ‘normal’ FA profiles (400 µM) 
but concentrations measured in the ‘high’ FA profiles (1000 µM) were consistent with 
expected 2%.  
Table 4-4: FA percentages obtained in the high SFA-, high MUFA-, high n-6 
PUFA- and high n-3 PUFA-profiles, measured by gas chromatography 
 
 Molar percentages of FA measured, expected 








FA "High" 52.8 32.4 12.7 2.1 
FA "Normal" 57.5 31.2 11.3 n.d. 
Expected 55.0 30.0 13.0 2.0 
MUFA 
FA "High" 38.9 48.5 10.8 1.8 
FA "Normal" 43.0 47.2 9.8 n.d. 
Expected 35.0 50.0 13.0 2.0 
n-6 PUFA 
FA " High " 34.1 36.7 27.1 2.0 
FA "Normal" 38.6 35.1 25.7 n.d. 
Expected 35.0 35.0 28.0 2.0 
n-3 PUFA 
FA " High " 34.1 36.7 12.6 16.7 
FA "Normal" 36.0 36.3 11.4 16.3 
Expected 35.0 35.0 13.0 17.0 
FA, fatty acids; SFA, saturated FA; MUFA, monounsaturated FA; PUFA, 
polyunsaturated FA; n.d., not detected. 
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4.3.2 Viability and endotoxin tests 
4.3.2.1 Endotoxin Assay 
♦ Qualitative measurements 
All the FA-BSA mixtures before complexation (BSA:FA 2.4 mM : 6 mM) 
showed a positive result to the endotoxin test, showing an endotoxin concentration > 
0.125 EU/mL (Table 4-5). 
Table 4-5: Results of the endotoxin test on FA-BSA mixtures 
Standard [ETX] 
EU/mL 0.5 0.25 0.125 0.063 0.031 0.016  
Results + + + - - -  
 
       
FA-BSA mixtures PA SA OA LA AA EPA DHA 
Results + + + + + + + 
ETX: endotoxin, PA: palmitic acid, SA: stearic acid, OA: oleic acid, LA: linoleic acid, 
AA: arachidonic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid. 
As the effects of endotoxin on endothelial function were showed with high 
concentration of endotoxin (from 10 ng/mL, i.e. from 100 EU/mL), a semi-quantitative 
measurement was performed, using 10 dilutions of BSA solution (control), to see if the 
real content of endotoxin was in the range of concentration that can affect endothelial 
function in vitro. 
♦ Semi-quantitative measurement (BSA control, several dilutions) 
The second test showed that the BSA control solution used in the culture (~40 
mg/mL) solution contained endotoxin at a level comprised between 2.5 and 50 EU/mL, 






Table 4-6: Results of the endotoxin (ETX) test on 10 dilutions of BSA 
Standard [ETX] 
EU/mL 0.5 0.25 0.125 0.063 0.031 0.016    
result + - - - - -    
          
Dilution of BSA 1 10 100 1000 2000 4000 8000 16000 32000 
result + + - - - - - - - 
Details for calculation: 
- The ETX standards showed a positive result at 0.5 EU/mL and  a negative 
result at 0.25 EU/mL. Thus the detection limit of the test was 0.5 EU/mL, i.e. 0.05 
ng/mL. 
- The samples showed a postive results at dilution 1/10: [ETX]1/10 > 0.25 
EU/mL, i.e. [ETX]1 > 2.5 EU/mL in the BSA control. No gel was observed for the 
dilution 1/100:  [ETX]1/100 < 0.5 EU/mL, i.e. [ETX]1 < 50 EU/mL. 
4.3.2.2 MTT test 
As FA and BSA were complexed with a same molar ratio in both high and 
normal FA profiles, they had different BSA levels and it was initially intended to use 
two BSA controls, characteristic of the two FA levels. The viability of the cells was not 
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Figure 4-7: Cytotoxicity of the FA profiles in HDMEC 
HDMEC were incubated with 24 h with either Endothelial basal medium (EBM) – 2% 
fetal calf serum (FCS, resting medium), EBM 2% delipidised FCS (DFCS), BSA only, 
or fatty acid (FA) – BSA profiles of 4 different compositions: enriched in saturated FA 
(SFA), in monounsaturated FA (MUFA), in n-6 polyunsaturated FA (PUFA) n-3 PUFA. 
These profiles were applied at either 400 (Normal, N) or 1000 µM FA (High, H). Two 
levels of BSA were used: 16.62 +/- 0.6  (N) and 41.55 +/- 1.5 (H) mg/mL. The 
experiment was repeated 6 times in triplicate. 
 
In order to rule out the effect of BSA levels may on endothelial function, BSA 
was added to all the low FA profiles to reach the same amount of BSA as the high FA 
profile. Thus, the average of BSA that was used as a unique control in all the next 
experiments was the average of BSA contained in each profile, i.e. 41.55 mg/mL, which 
is in the range of physiological serum albumin concentration in human (30-50mg/mL). 
This allowed the results to be expressed in percentage relative to the unique BSA 
control. 
 
4.3.2.3 LDH assay 
The LDH assay was performed twice in four replicates on FA profiles 
containing similar levels of BSA (from 39.8 to 42.9 mg/mL). The average of BSA 
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levels of these profiles was used as a unique control (41.55 mg/mL), which is in the 
range of physiological serum albumin concentration in human (30-50mg/mL). This 
control was used for all the next experiments and allowed the expression of the data 
relative to the BSA control. There was no significant difference in toxicity between the 
9 media tested (P = 0.926, Kruskal Wallis). However LDH activity appeared slightly 
higher in the high FA media, corresponding to a slightly higher amount of apoptotic 
and/or necrotic HDMEC (Figure 4-8). Because cell growth may slightly vary between 
wells, NO and PGI2 measurements were readjusted to the number of cells by expressing 
results as per µg protein. 
































Figure 4-8: Assessment of FA profiles cytotoxicity on HDMEC by LDH assay 
HDMEC were incubated with 24 h with either BSA only, or fatty acid (FA) – BSA 
profiles of 4 different compositions: enriched in saturated FA (SFA), in 
monounsaturated FA (MUFA), in n-6 polyunsaturated FA (PUFA) n-3 PUFA. These 
profile were applied at either 400 or 1000 µM FA, corresponding to normal (N) or high 
(H) levels, respectively. The average level of BSA was 41.55 mg/mL +/- 1.5. The 






4.3.3 Determination of TNF and insulin levels to be used 
NO concentrations were either very low or not enough to be detected, making 
the optimisation of insulin and TNF α impossible. Despite having no cytotoxic effect on 
HDMEC, the absence of lipid in the FFA-free control (BSA only) profiles (using 
delipidised FCS and delipidised BSA) may have compromised the stability and function 
of the cells, and possibly affected NO production.  
The final volume of medium was reduced to 300 µL per well in order to increase 
the NO concentration and make it detectable by the fluorometric assay. TNFα (210-TA-
010, R&D Systems) and insulin (4502-01, Millipore) concentrations were chosen 
according to the manufacturer’s instructions. 
4.3.4 Effects of FA profiles, insulin and TNFα on EF 
4.3.4.1 NO production 
♦ Three-way ANOVA (BSA control excluded) 
NO concentrations were generally very low and showed high standard 
deviations between triplicate wells and repeat experiments (n = 5). There was no 
interaction between treatment, FA profile and/or FA levels. There was no main effect of 
treatment (P = 0.595) or FA level (P = 0.209) but a borderline significant effect of FA 
profile (P = 0.045, three-way ANOVA, factors = FA profiles, FA levels, insulin/TNFα 
treatment) due to NO levels ~two fold higher upon SFA profile compared to n-3 PUFA 
profile (P = 0.032, Bonferroni’s multiple comparison). 
♦ Two-way ANOVA (BSA control included) 
Because FA level had no effect on NO production, a two-way ANOVA was 
performed with FA profile and treatment as factors. There was no interaction between 
FA profile and treatment and there was no effect of treatment. There was a borderline 
significant main effect of profile (P = 0.049) and NO was significantly higher with SFA 
than n-3 PUFA (P = 0.042, Bonferroni’s multiple comparison), differences between all 
the other profiles, including compared to the BSA control (no FA) did not reach 






Figure 4-9: Effect of different FA profiles at high (H, 1000 µM) and normal (N, 400 
µM) levels upon insulin (2h) and/or TNFα (24h) treatment on NO production in 
HDMEC 
Means are expressed as percentage of NO production adjusted for protein amount 
relative to BSA control (no FA, no insulin or TNFα). Error bars are SEM. HDMEC 
were incubated 24h in the presence of each FA profile (BSA-EBM-delipidised FCS 
2%), in the presence or absence of TNFα 10 ng/ml for 24h and/or insulin 10 µg/mL for 
the last 2h.  




4.3.4.2 PGI2 production 
♦ Three-way ANOVA (BSA control excluded) 
There was no main effect of FA level (P = 0.242) but a significant effect of FA 
profile (P < 0.001) and treatment (P < 0.001). TNFα significantly increased 6-keto 
PGF1α in all FA profiles regardless of the level applied (P < 0.01), while insulin had no 
effect. 6-keto PGF1α concentrations were increased by n-6 PUFA compared to SFA (P = 
0.001), MUFA (P = 0.011) and n-3 PUFA (P < 0.001) while they did not differ between 
MUFA and SFA profiles. n-3 PUFA showed lower levels of 6-keto PGF1α compared to 
the three other FA profiles (P < 0.001). There was no interaction between factors (three-
way ANOVA, factors = FA profiles, FA levels and insulin/TNFα treatment). 
♦ Two-way ANOVA (BSA control included) 
Because FA levels had no effect on 6-keto PGF1α concentrations, it was removed 
from the statistical model. As for the three-way ANOVA, the two way ANOVA 
analysis showed no interaction between factors and a significant effect of treatment (P < 
0.001) and FA profile (P < 0.001). The differences between treatments and between the 
FA profiles were the same as those observed with the three-way ANOVA model, with 
similar significance: PGF1α levels were significantly increased upon TNFα treatment (P 
= 0.002) but remained unchanged by insulin. 6-keto PGF1α levels were higher with n-6 
PUFA compared to SFA (P = 0.001), MUFA (P = 0.013) and n-3 PUFA (P < 0.001) and 
did not differ between SFA and MUFA. Compared to BSA control (no FA), 6-keto 
PGF1α were higher with SFA (P = 0.003), MUFA (P < 0.001) and n-6 (P < 0.001) but 
unchanged by the n-3 PUFA profile (two-way ANOVA, factors = FA profiles and 




Figure 4-10: Effect of different FA profiles at high (H, 1000 µM) and normal (N, 
400 µM) levels upon insulin (2h) and/or TNFα (24h) treatment on PGI2 production 
in HDMEC 
Means are expressed as percentage of 6-keto prostaglandin F1α (PGF1α) production 
adjusted for protein amount relative to BSA control (no FA, no insulin or TNFα). Error 
bars are SEM. The experiment was repeated 5 times. HDMEC were incubated 24h in 
the presence of each FA profile (BSA-EBM-delipidised FCS 2%), in the presence or 
absence of TNFα 10 ng/ml for 24h and/or insulin 10 µg/mL for the last 2h. 
† TNFα  increased overall PGF1α levels compared to control (P = 0.002) while insulin 
had no significant effect. There was no treatment*profile interaction. Different letters 
show significantly different PGF1α production upon the different FA profiles (P < 0.02, 
two-way ANOVA, factors = FA profiles and insulin/TNFα treatment).
 4.3.4.3 
As for NO concentrations
standard deviation between triplicate wells and repeat 
There was no effect of FA profiles or
between factors (two
level was excluded from the model, eNOS expression did not vary between the different 
profiles including the FA free BSA control (One
Figure 4-11: Effect of different FA profiles at normal (N, 400
1000µM) level on eNOS expression in HDMEC, in absence of treatment (insulin 
and/or TNFα) 
Top: Sample of Western Blot analysis of eNOS and h
expression 
Bottom: Means are expressed as percentage of eNOS expression adjusted for 
expression, relative to BSA control (no FA, no insulin or 
The Western Blot was run from 4 sets of experim
were incubated 24h in the presence of each FA profile (BSA
2%), at 400µM and 1000
eNOS expression 
, eNOS was generally very low and showed 
experiments (
 FA levels on eNOS expression, and no 
-way ANOVA, factor = FA profile, FA level
-way ANOVA, factor = FA profile).
µ
ousekeeping gene (
TNFα). Error bars are SEM.
ents in triplicate (
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µM concentration, in the absence of TNFα
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4.3.4.4 COX-2 expression 
♦ Two-way ANOVA analysis (BSA control excluded) 
When BSA control was excluded from the model, there was no effect of FA 
profile or level on COX-2 expression, and no interaction between factors (Two-way 
ANOVA; factors = FA profiles, FA levels). 
♦ One-way ANOVA (BSA control included) 
In order to compare the FA profiles with BSA control, the factor ‘FA level’ was 
excluded from the statistical model. All FA profiles reduced COX-2 expression 
compared to BSA control (no FA) (P < 0.001) (One-way ANOVA, factor = FA profiles, 






  Figure 4-12: Effect of different FA profiles at normal (400
level on COX-2 expression in HDMEC, in absence of treatment (insulin and/or 
TNFα). 
Top: Sample of Western 
expression 
Bottom: Means are expressed as percentage of COX
expression, relative to BSA control (no FA, no insulin or 
The Western Blot was run from 2 sets of experiments in triplicate (
were incubated 24h in the presence of each FA profile (BSA
2%), normal (400µM) and high (1000
insulin.  
* P < 0.001 compared 
 
µM) and high (1000
Blot analysis of COX-2 and housekeeping gene (
-2 expression adjusted for 
TNFα). Error bars are SEM.
-EBM
µM) concentration, in the absence of TNF















The primary hypothesis for this endothelial cell culture study was that NO 
production would be inhibited by a fatty acid profile enriched in SFA and increased by 
profiles enriched in n-3 PUFA. NO production was low in all profiles, yet slightly 
increased with SFA compared to n-3 PUFA, while it remained unchanged by insulin 
and TNFα, eNOS expression remained low and unchanged in all profiles. It was also 
hypothesised that PGI2 would be increased upon treatment with an n-6 PUFA-enriched 
fatty acid profile, and decreased by an n-3 PUFA rich profile. This was proven, while 
COX-2 expression remained unchanged in all FA profiles and lower than with BSA 
control. It was also expected that insulin-induced NO production would be inhibited by 
the high-SFA profile and stimulated by the n-3 PUFA profile, and that an inflammatory 
stress-induced reduction in NO was expected to be ameliorated by n-3 PUFA profiles. 
This was not observed since insulin and TNF-α did not affect NO production. 
Furthermore, the level of total FA used, either 400 or 1000 µM, as observed in healthy 
and insulin resistant state, respectively, did not affect NO and PGI2 production or eNOS 
and COX-2 expression. 
 
The BSA-FA complexation steps, as well as the freezing did not affect the FA 
concentrations in the different FA profiles tested, which correspond to the levels and 
percentages we expected, and all fall within the physiological range. SFA and MUFA 
reached ~50-55% in the SFA and MUFA profiles, respectively. Total PUFA constituted 
15% of the total FA in the SFA and MUFA, while it reached ~30% in the high PUFA 
profiles. The n-6:n-3 ratio was ~5:1 in the SFA and MUFA profiles while it reached 
14:1 in the n-6 PUFA profile, corresponding to the high n-6 PUFA intake observed in 
the western populations. These proportions enclose the physiological ranges previously 
observed in NEFA for each category (Conquer, et al., 2002, Conquer, et al., 1999, 
Conquer and Holub, 1998, Frape, et al., 2000, Newens, et al., 2011, Rhee, et al., 2008). 
In the n-3 profiles, the n-6:n-3 ratio was ~1:1.3, as it was estimated that n-6 and n-3 
PUFA were equivalent in the human diet and thus in circulating FA before the industrial 




4.4.1 Nitric oxide and eNOS expression 
NO concentrations and eNOS expression were generally very low and showed 
high standard deviations between triplicate wells and repeat experiments, suggesting 
that HDMEC have a very low basal expression, and that the NO assay was not sensitive 
enough to detect changes in NO production in this cell type. There are important 
phenotypic differences between endothelial cells from large vessels and the 
microvascular EC isolated from different tissues and organs (Kumar, et al., 1987), 
which may explain the low levels observed in our study. In contrast with most 
macrovascular EC, cardiac microvascular EC from rat were reported to have no basal 
expression of eNOS, while being able to express substantial amount of iNOS upon 
inflammatory stimulation (Balligand, et al., 1995). Ando et al. later reported lower 
eNOS expression and NO production in porcine coronary microvascular EC compared 
to aortic EC (Ando, et al., 1999). Nonetheless, previous findings suggest that HDMEC 
express eNOS and produce NO in basal conditions . Although NO or eNOS expression 
has not been measured directly in HDMEC, previous work has reported basal uptake of 
L-Arginine (eNOS substrate) as well as eNOS activity (conversion of arginine to 
citrulline) (Xiao, et al., 2001). The activity of eNOS is subject to complex regulations, 
involving phosphorylation on specific residues, binding to the calcium-calmodulin 
complex, the presence of cofactors of oxidoreduction and co- and post translational 
modifications (Sessa, 2004, Zhang, et al., 2011). The latter involve acylation – 
especially myristoylation and palmitoylation – that are essential for targeting eNOS to 
caveolae, a necessary step for eNOS activation and optimal NO release  (Liu, et al., 
1996, Shaul, et al., 1996). The caveolae is a particular type of lipid raft whose 
composition may greatly influence eNOS activity (Chikani, et al., 2004). It is likely that 
the lack of lipids in the FA-free BSA control compromised this step in the activation of 
eNOS, making the set up of TNFα and insulin concentrations impossible.   
4.4.1.1 Basal NO production and eNOS expression with different FA 
profiles 
Surprisingly, only the addition of SFA profiles appeared to slightly – yet 
significantly – increase NO production, compared to n-3 PUFA, in which NO 
production remained similar to the FA-free BSA control. As mentioned earlier, 
palmitoylation of eNOS is crucial for targeting eNOS to caveolae and its activation 
(García-Cardeña, et al., 1996, Goligorsky, et al., 2002). Therefore, the enrichment of the 
SFA profiles in palmitic acid (37%) compared to the other profiles (23%) may have 
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stimulated the palmitoylation of eNOS and explain the increase of NO production 
observed upon SFA profile, while eNOS remained unchanged. Consistent with our 
findings, previous research has reported stimulation of eNOS activity by palmitic acid 
complexed to serum albumin, and to a greater extent myristic acid  (C14:0, absent of the 
FA profiles used in our study), compared to other individual FA including stearic, oleic 
and linoleic acid, in human microvascular EC (Zhu and Smart, 2005), as well as 
EA.hy926 (macrovascular EC, immortalised) (Couloubaly, et al., 2007). This effect was 
shown to be mediated through the AMP kinase pathway, rather than the PI3K pathway 
or intra-cellular calcium increase (Zhu and Smart, 2005). 
The reason why n-3 PUFA failed to improve basal NO production, which 
remained significantly lower than with SFA, remains uncertain and does not prove our 
hypothesis. While n-3 PUFA, including EPA and DHA have been widely shown to 
stimulate NO-dependent vasorelaxation in vivo and ex vivo (Engler and Engler, 2000, 
Lawson, et al., 1991, Omura, et al., 2001), their effect on eNOS and NO production in 
EC in vitro remains controversial. Consistent with our findings, neither EPA nor DHA 
affected basal eNOS activity in EA.hy926 cells (Tardivel, et al., 2009), despite an 
increase in basal phosphorylation of eNOS (Gousset-Dupont, et al., 2007). In contrast, 
several studies have shown that either EPA or DHA stimulated basal NO production 
and eNOS activity in various other cell types, including HUVEC (Chisaki, et al., 2003, 
Li, et al., 2007, Li, et al., 2007, Okuda, et al., 1997, Omura, et al., 2001), as well as 
human coronary artery EC (Stebbins, et al., 2008) and retinal microvascular EC 
(Matesanz, et al., 2010). This beneficial effect was attributed to the enrichment of n-3 
PUFA in caveolae, which coincided with the displacement of Cav-1 from the lipid raft 
and the translocation of eNOS to the cytosol (Li, et al., 2007, Li, et al., 2007, Matesanz, 
et al., 2010). It should be noted that this was shown for incubation times of 24-48h, 
which is sufficient for EPA or DHA to be incorporated into the membrane and reach a 
constant equilibrium (Gousset-Dupont, et al., 2007). When applied for a shorter period 
(10-60 min), LC n-3 PUFA may exert their effect through different mechanisms, such 
as the stimulation of calcium inflow through the cell membrane (Chisaki, et al., 2003, 
Okuda, et al., 1997). The mechanisms may also vary depending on the dose and cell 
type used, which may contribute to the discrepancies observed and explain the lack of 
effect of n-3 PUFA in our experiments as well as others (Gousset-Dupont, et al., 2007, 
Tardivel, et al., 2009). Importantly, the studies mentioned above have investigated the 
effect of FA individually, rather than as a combined mixture as observed in circulating 
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NEFA in vivo, and sometimes refer to a control containing a different FA, such as 
arachidonic or palmitic acid (Matesanz, et al., 2010), which could interfere with eNOS 
activity and trafficking, and thus be questioned as a control. 
Notably, saturated FA, especially palmitic acid, were also reported to stimulate 
the inflammatory transcription factor the nuclear factor (NF-) κB in several types of 
human EC, in contrast to unsaturated fats such al oleic, linoleic or palmitoleic acid 
(Cacicedo, et al., 2004, Staiger, et al., 2006). NF-κB is involved in the activation of 
iNOS (Forstermann and Kleinert, 1995) and may have contributed to the increase in NO 
production observed upon SFA profiles. In contrast n-3 PUFA, especially DHA, have 
been widely shown to inhibit inflammatory processes (De Caterina, et al., 1994), and 
suppress NF-κB nuclear translocation and upstream I-κBα phosphorylation and 
degradation in human EC (Chen, et al., 2005, Wang, et al., 2011). Thus the pro- and 
anti-inflammatory actions of SFA and of n-3 PUFA, respectively, may be responsible 
for opposite effects on iNOS activity, which would explain the significant difference in 
NO production upon these two profiles, while eNOS remained unchanged.  
4.4.1.2 NO production and eNOS expression following insulin and 
TNFα treatment 
Both macro- and microvascular endothelial cells express insulin receptors 
(Jialal, et al., 1985), and the binding of insulin activates the PI3K pathway, which 
mediates the activation of eNOS as well as an anti-apoptotic effect (Hermann, et al., 
2000, Kuboki, et al., 2000). Surprisingly, insulin failed to increase NO production in 
HDMEC, even in the presence of the various FA profiles. This contrasts with previous 
research in HDMEC where insulin was able to increase tyrosine phosphorylation of the 
insulin receptor and its substrate IRS-1, leading to the activation of protein kinase B, 
proteins involved in the activation of eNOS through the PI3K pathway (Gogg, et al., 
2009). However this study showed a low expression of insulin receptors and previous 
work has shown that HDMEC were resistant to insulin at the receptor level (Johansson, 
et al., 2008), which may explain the lack of insulin on NO production in our study.  Pro-
inflammatory cytokines, including TNFα, have been widely reported to down regulate 
basal and insulin mediated eNOS expression and activity in EC (Kim, et al., 2001, Lai, 
et al., 2003, Zhang, et al., 1997), including human microvascular EC (Li, et al., 2007, 
Neumann, et al., 2004). This effect was not observed in our study, which is likely to be 
due to the low levels of NO observed in basal conditions and upon insulin treatment. 
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Interestingly, saturated fats, and particularly palmitic acid have been shown to 
impair insulin-induced eNOS activation in human and bovine aortic EC (Kim, et al., 
2005, Wang, et al., 2006), as well as human microvascular EC (Kim, et al., 2007). In 
contrast n-3 PUFA have been reported to modulate eNOS activity induced by 
vasoactive coumpounds such as insulin (Madonna, et al., 2011) or histamine (Gousset-
Dupont, et al., 2007, Tardivel, et al., 2009), and lysophosphatidylcholine (Tardivel, et 
al., 2009). Because HDMEC did not respond to insulin or TNFα, the effect of SFA and 
n-3 PUFA profiles on insulin-induced eNOS activation and NO production or 
inflammatory processes could not be observed. 
4.4.2 PGI2 and COX-2 expression 
4.4.2.1 PGI2 and FA profiles 
The increased PGI2 upon n-6 PUFA compared to the other profiles is likely to be 
due to the higher arachidonic acid (AA) levels in this profile. After its release from 
TAG, DAG or PL through phospholipase, AA is incorporated into the EC, where it is 
converted into PGI2 through the combined actions of PGH2 synthase (cyclooxygenase 1 
or 2) and prostacyclin synthase (PGIS, cytochrome P450 isomerase) (Gryglewski, 
2008). As a substrate for PGI2 production, AA dose dependently stimulates the 
formation of PGI2 by COX-2 in various cell types including HUVEC, as well as aortic 
macrovascular and microvascular EC (Egan and FitzGerald, 2006, Goldsmith, et al., 
1981, Johnson, 1980, Spector, et al., 1983). It should be noted that linoleic acid (LA) 
was present in higher proportions than AA in the n-6 PUFA profile and it could be 
hypothesized that conversion from LA to AA contributed to the increase in PGI2 
production (Salem, et al., 1999). However this process appears limited in EC 
(Grammatikos, et al., 1994, Kaduce, et al., 1982) and LA has actually been reported to 
decrease the production of PGI2, in vivo and in vitro (Batres-Cerezo, et al., 1991, Brox 
and Nordoy, 1983, Umeda, et al., 1990). Therefore, the increase of AA (3%), as well as 
the AA/LA ratio (~1:8) in the n-6 PUFA profile compared the other profiles (AA = 1% , 
AA/LA ~ 1:12), rather than an increase in total n-6 PUFA per se, is therefore more 
likely to explain the PGI2 increase observed. Surprisingly, COX-2 levels did not follow 
PGI2 production but they remained low compared to BSA control and and there were no 
significant differences between FA profiles. COX-2 expression may have been 
upregulated by AA at the beginning of the incubation, leading to the accumulation of 6-
keto PGF11α, stable metabolite of PGI2, and returned to a lower basal level by the end of 
the 24h incubation. The higher level of COX-2 expression following the BSA control 
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treatment is probably due to the delipidated environment which may have stressed the 
cells. 
 
n-3 PUFA profiles reduced PGI2 production compared to SFA and MUFA 
profiles, despite containing the same proportions of AA (1%). This suggests that while 
SFA and MUFA profiles stimulated PGI2 production, possibly due to their AA content, 
n-3 PUFA were able to compete with AA and nullify its stimulating effect on PGI2 
production. Consistent with this, previous research has shown that both EPA and DHA 
– individually - decreased PGI2 production in HUVEC (Brox and Nordoy, 1983, Oudot, 
et al., 1998) as well as bovine aortic EC (Benistant, et al., 1993). The mechanisms could 
involve the reduction of the substrate AA in cell membrane, concurrent with the 
increase of EPA content (Spector, et al., 1983), as well as a direct inhibition of COX-2 
expression and/or binding to AA. EPA is capable of counteracting AA for its 
oxygenation into its derivative bioactive products, especially PGI3, which is concurrent 
with the decrease in PGI2 (Lagarde, et al., 1993, Morita, et al., 1983). Furthermore the 
anti-inflammatory role of EPA and DHA in vitro has been well established in various 
types of EC (De Caterina and Massaro, 2005), including human microvascular cells 
(Ait-Said, et al., 2003, Chen, et al., 2005, Ibrahim, et al., 2011). Both n-3 PUFA were 
reported to down regulate COX-2 expression through the suppression of NF-kappa B in 
HUVEC (Lee, et al., 2009).  
4.5 Conclusion, limitations and future work 
The strength of our study is that we used physiological FA profiles to simulate 
NEFA composition in different dietary conditions. Previous studies used single FA 
which is not representative of a physiological FA milieu in serum and may actually 
influence cellular responses. In addition, the microvascular model used was directly 
relevant to endothelial dysfunction and the associated microvascular dysfunction 
observed in insulin resistant states. One major limitation of our study is that HDMEC 
did not respond to insulin, thus the effect of NEFA on insulin-induced eNOS could not 
be explored. Unfortunately, the set up of TNF α and insulin concentrations was not 
possible, and the two treatments were applied at supra physiological levels. The FA-free 
BSA medium used may be questioned as a control, and n-6 PUFA profiles could be 
considered as an alternative control profile, in comparison with the other profiles 
mimicking high oily fish diet, Western diet and Mediterranean diet. In contrast, most 
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studies use another FA as a control, which may affect EF in vitro. We could envisage 
shorter periods of treatment in order to see if COX-2 and/or eNOS expression, as well 
as eNOS phosphorylation, have been stimulated earlier in the incubation. 
To conclude, we have shown that a SFA-rich FA profile, representing average 
plasma NEFA compositions expected in populations consuming a “Western” style 
dietary patterns, slightly increased nitric oxide production compared to n-3 PUFA. 
Furthermore, an EPA and DHA-rich fatty acid profile, representing average NEFA 
compositions expected in populations consuming very high amounts of marine PUFA, 
such as the Inuit and other Greenland/Alaskan populations, inhibited PGI2 production 
compared to the other 3 fatty acid profiles. At 24 h, eNOS and COX expression were 
not different between fatty acid profiles, but it is unknown whether changes might have 
been observed at an earlier time point, such as 4 h. The difficulties in trying to replicate 
physiological conditions are highlighted by this experiment. However, the results do 
suggest that variations in circulating NEFA profiles may directly impact on the release 
of vasodilators by the microvascular endothelial cells, and that they are more likely to 
reflect events occurring in the endothelium in vivo than comparable studies that have 
used single fatty acids. The total concentration of NEFA does not seem to impact on 
these observations, contrasting with previous findings suggesting that elevated NEFA 
inhibit eNOS activity in EC in vitro (Kim, et al., 2005, Wang, et al., 2006). Future 
studies in this area should try to replicate the findings reported here in different types of 
endothelial cells (aortic, for example), with an emphasis on shorter term changes over 4-





Chapter 5 Final discussion and conclusions 
This thesis set out to test the hypothesis that dietary FA composition, influencing 
circulating FA pattern, affect endothelial and microvascular function in humans. On the 
one hand we compared the effects of two individual FA from fish oils, EPA and DHA, 
on novel markers of endothelial and microvascular function in humans, and related the 
outcomes measured to erythrocyte and NEFA composition. On the other hand, we 
compared the effect of four FA profiles (rich in either SFA, MUFA, n-6 PUFA, or n-3 
PUFA), representative of average NEFA profiles observed in populations characterised 
by four different dietary patterns, on EF in HDMEC in vitro. We found that neither EPA 
nor DHA, supplied for 6 weeks at ~3 g/d, affected EPC or capillary density in the finger 
in healthy young males, but capillary density was directly correlated to DHA levels in 
erythrocytes at baseline. In HDMEC, FA profiles differentially affected the production 
of the two main vasodilators, namely nitric oxide (NO) and prostacyclin (PGI2). NO 
production was low in all profiles but slightly increased by SFA compared to n-3 
PUFA; PGI2 was increased upon SFA and MUFA, and to a greater extent by n-6 PUFA 
compared to n-3 PUFA profile. 
 
The novelty of our cell culture work is that we used combinations of FA 
representing NEFA compositions following four different dietary patterns, at 
physiological concentrations. In contrast, previous in vitro research has focused on 
investigating the individual effect of FA, sometimes at supra-physiological 
concentrations. While this approach gives great insight regarding the mechanisms 
involved in the regulation of EF, the extent to which this fits in the broader 
physiological perspective is questionable. For example, eNOS, a key enzyme involved 
in EF, requires targeting to a specific lipid raft in the membrane (caveolae) and 
subsequent dislocation to the cytosol, in which saturated fats (palmitic, myristic) as well 
as n-3 PUFA play an important role (Goligorsky, et al., 2002, Li, et al., 2007, Li, et al., 
2007). Our study thus aimed at optimising the cell culture medium and see whether a 
mixture of  FA that are found in circulating blood, formulated into 4 profiles 
corresponding to specific dietary patterns, could be defined in terms of their effects on 
production of endothelial NO and PGI2. We showed that physiological FA profiles 
differently affected PGI2 production with the following order: n-6 PUFA > SFA/MUFA 
> n-3 PUFA. The higher content of arachidonic acid (AA) in n-6 PUFA profile, the anti-
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inflammatory role of n-3 PUFA (Lee, et al., 2009), as well as their competition with AA 
for COX-2 (Lagarde, et al., 1993, Morita, et al., 1983, Spector, et al., 1983), are likely 
to explain this effect. Surprisingly, SFA profiles, characteristic of the western diet, had 
the most beneficial effect on NO production, which could be due to a favourable effect 
on eNOS or iNOS activity, through palmitoylation (Goligorsky, et al., 2002) or a pro-
inflammatory action (Collins et al., 1990, MacMahon et al., 1990), respectively. 
However caution should be taken when interpreting our results as NO was 
relatively low in all profiles, which suggests that physiological FA compositions are not 
ideal for EF in vitro, despite being apparently harmless to the cell, as shown by the 
preliminary viability tests. Our experiments highlight the difficulties inherent in 
attempting to simulate physiological conditions in vitro. In order to represent a more 
natural environment, in vitro flow systems have been used to simulate shear stress on 
EC (Huang and Eniola-Adefeso, 2012, Pritchard, et al., 1995). Furthermore, insulin 
failed to stimulate NO production, which may be due to the lower expression of insulin 
receptor in this cell type compared to macrovascular cells (Gogg, et al., 2009). The 
microvasculature plays a major role in insulin resistance and represents the largest 
endothelial surface exposed to circulating lipids (Serne, et al., 1999). The investigation 
of EF and insulin sensitivity in microvascular EC is thus of great interest to further our 
understanding of systemic endothelial dysfunction and the resulting impact on diastolic 
blood pressure. The reduced responsiveness of HDMEC was thus a major limitation in 
our study, and prevented the observation of the effects of FA profiles on insulin induced 
NO production. The use of human serum taken from subjects having consumed a high 
SFA, MUFA, n-6 or n-3 PUFA meal could have a different impact on EF in HDMEC 
and other cell types and could be considered as future work.   
 
In our human study, the subcutaneous microvascular bed could be observed by 
capillaroscopy in the finger, allowing the measurement of capillary density. While 
capillary rarefaction has been associated to CVD risk factors - particularly hypertension 
- for more than a decade (Antonios, et al., 1999), intervention studies, and especially 
dietary interventions, are only at the beginning. The EPA and DHA trial was to our 
knowledge the first study that looked at the effect of dietary FA on capillary density in 
humans. We showed that neither EPA nor DHA (~3 g/d, 6 weeks) had an effect on 
capillary density in young healthy men. Because this was an exploratory outcome, it 
was not possible to calculate the sample size necessary to observe an effect. However, 
205 
 
the means and standard deviations observed in our study suggest that it was likely to 
have beenunder-powered for those outcomes. It is worth noting that animal studies have 
shown a beneficial effect of fish oils on functional capillary density in the ventricles of 
hypertensive rats (Mitasikova, et al., 2008), and in the cheek pouch of  hamsters 
(Conde, et al., 2007). In these studies, functional capillary density was defined by the 
activity of enzymatic markers of capillary network (Mitasikova, et al., 2008) or the 
number of capillaries with flowing red blood cells (Conde, et al., 2007), rather than just 
visible capillaries at rest, as assessed in the human finger. In addition to pictures, videos 
of the same area of the finger could give us more information on the dynamic structure 
of the capillary network. Capillary density may also be measured next to the nail fold 
where the small vessels are parallel to the skin (Haenggi, et al., 1995). In this area, the 
structure (tortuousness, diameter) of capillaries may be analysed, as well as the velocity 
of the red blood cells by imaging techniques (frame to frame, flying spot, cross 
correlation) (Gasser and Buhler, 1992, Mawson and Shore, 1998, Mugii, et al., 2009). 
The technique the most commonly used however is the laser Doppler imaging. In this 
technique, the laser beam is reflected by red blood cells moving perpendicular to the 
skin. The flowing cells give the laser light a Doppler shift (frequency shift) that is 
directly proportional to their velocity (Briers, 2001, Silverman, et al., 1994). Velocity 
measurements are technically demanding, require the subject to remain extremely still 
and a great expertise from the investigator. The analysis of the dynamic microvascular 
network, beyond capillary density, represents a great insight in the understanding of 
endothelial and vascular function. Techniques are expanding in this field and should be 
considered in nutritional interventions. 
Microvascular function relates to BP, as well as EF (Cheng, et al., 2008, Cheng, 
et al., 2008, Conde, et al., 2007). In line with the capillary density measurement, neither 
BP nor EF, as assessed by EPC and NOx measurements, was affected by the fish oils 
intervention. EPC were defined as CD34+/KDR+/CD133+ cells (early EPC) and 
CD34+/KDR+/CD31+ cells (late EPC). One major limitation of the EPC technique is 
the very low number of cells amongst total mononuclear cells, which limits the 
reproducibility of the counting. The lack of effect of fish oils on EPC is consistent with 
recent findings where fish oil supplementation for 12 weeks (4 g/d) failed to improve  
CD133+/KDR+ in type 2 diabetics (Wong, et al., 2010). EPC count has also been 
measured by this techniques in our department in healthy subjects (aged 45-70 y) after 
12 months with low doses of EPA+DHA (0.45-1.8 g/d) (Sanders, et al., 2011). The EPC 
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count, as defined by CD133+/KDR+ and CD34+/KDR+ remained unchanged (Maniou 
Z, 2011) while the counting of early and late EPC – co-expressing 3 markers - is still 
under analysis. Techniques to increase the EPC count such as immunomagnetic CD34+ 
cell enrichment (Distler, et al., 2009, Kuwana and Okazaki, 2012) have been developed 
and may be of use in future research in vivo. Alternatively, EPC could be isolated from 
participants after supplementation with fish oils, and cultured ex vivo, allowing the 
assessment of EPC function and colony forming units count.  
Although this was not part of our main outcomes, one effect worth mentioning is 
the opposite effect of EPA and DHA observed on night heart rate. Because this was 
only observed at night, and because our study may have been underpowered for this 
outcome, this result should be taken with caution. However, in a larger trial (n 224 
healthy men), Grimsgaard et al. reported more than 10 years ago that DHA and EPA (4 
g/d, 7 weeks) significantly decreased and increased resting HR, respectively (by ~2 
bpm) (Grimsgaard, et al., 1998). A similar increase in ambulatory HR (24h, day and 
night) was later observed after EPA treatment (4 g/d, 6 weeks) which did not reach 
significance, while it was significantly reduced by DHA (Mori, et al., 1999) This effect 
may contribute to the detrimental effect of fish oils sometimes observed, as in the 
DART-2 study, in which myocardial infarction patients had significant increased risk of 
sudden cardiac death after dietary advice to consume fish oil or oily fish (Burr, 2007). 
The effect of fish oils on HR is likely to be due to their incorporation in cardiac 
membrane. It remains uncertain whether this effect is due to changes in EPA, DPA or 
DHA in the cardiac membrane, and this is not easily observable in humans. Because HR 
is a risk factor for CVD, supplementation with EPA alone in the long term, especially in 
patients at risk such as those with angina or arrhythmia, should be considered with extra 
care pending confirmation of the current results in future studies. Accordingly, 
Mozaffarian et al recently recommended the use of a combination of both EPA and 
DHA, because of their potential complementary effect and the limited literature on the 
individual impact of each FA (Mozaffarian and Wu, 2012). Further studies on the 
separate effects of EPA and DHA could be carried out in order to determine the dose 
effect of their opposing effects on heart rate, together with ambulatory recordings of 
heart rate variability to derive parameters of sympathetic and parasympathetic 
regulation of fluctuations in heart rate during the day and night. Finally, we showed that 
the dynamic of incorporation and conversion between EPA, DHA and DPA may vary 
depending on the lipid fraction. EPA appeared to be elongated to DHA in NEFA but not 
207 
 
erythrocytes. In contrast the retroconversion from DHA to EPA seemed limited in 
NEFA compared to erythrocytes. This differential incorporation and retroconversion 
may also depend on the cell and/or organ considered, as well as individual variability. 
Examining this dynamic could help understand the differential effect of EPA and DHA 
on CVD risk factors, and for example on HR. 
 
In conclusion, numerous studies have demonstrated the cardioprotective effects 
of fish oils in humans, likely to be mediated by their hypotriglyceridaemic, hypotensive, 
anti-arrhythmic and anti-thrombotic properties depending on levels of intake. Recent 
data suggest that fish oils also improve arterial stiffness and EF (De Berrazueta, et al., 
2009, Rizza, et al., 2009), but the work reported here together with a few other 
published studies suggest that this is more likely to occur in at-risk populations 
(Sanders, et al., 2011), such as those with pre-existing vascular disease or diabetics. 
Most studies have investigated the effect of oily fish or fish oil supplements containing 
mixtures of EPA and DHA, and current UK dietary guidelines recommend the 
consumption of two portions of fish, one of which should be oily, a week to maintain 
general good health. However over the past 20 years, there has been growing evidence 
that EPA and DHA exert a heterogeneous effect on various CV outcomes, which is of 
considerable relevance for primary and secondary CV prevention. The research 
presented in this thesis corroborates this to an extent in that EPA increased night-time 
heart rate whereas DHA decreased it in young healthy men. The in vitro endothelial cell 
experiments also provide support for the theory that circulating NEFA composition may 
impact on EF.  
 
The apparent efficacy of DHA in improving a number of CVD risk factors, and 
the remaining uncertainty surrounding the actions of EPA, suggests that the production 
of n-3 PUFA oils that are a purified or enriched source of either EPA or DHA is an 
important development in the nutraceuticals industry. An increasing number of studies 
are being published on the cardioprotective effects of DHA triacylglycerol from algal 
sources, either Crypthecodinium cohnii or Schizochytrium sp. (Martek Biosciences 
Corporation, Columbia, MD, USA). Supplements, infant formula, infant foods, and 
certain other food categories fortified with algal DHA are now available to buy in many 
countries, with potential benefits for subgroups who have low intakes, such as 
vegetarians. EPA triacylglycerol-enriched oils and purified EPA ethyl ester oils are 
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available but effort is also being directed towards development of non-fish oil-derived 
EPA. As more DHA- and EPA-only products become available, partly as a result of 
concern over the sustainability of fish oil supplies and partly in response to consumer 
demand for non-fish sources, future research can be focused on establishing the most 
effective doses of DHA and EPA for improvement of CVD risk factors. This will 
inform dietary advice on the optimal intake for life-long health, and should enable a 
decision to be made on the most effective supplement dose to be taken over short 
periods to reduce risk factors such as hypertriglyceridaemia or hypertension in various 
at-risk populations. It will be important to bear in mind that not all individuals will 
respond to DHA and/or EPA in the same way, and ongoing nutrigenetic and gender 
research will be crucial in defining future advice regarding dietary and supplementary 
EPA and DHA. The role of dietary n-3 PUFA in cardiovascular health is an area of 
nutritional science/medicine that has undergone more investigation than most during the 
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Appendix I KCL RECRUITMENT EMAIL CIRCULAR 
"Circular e-mail for use for recruitment of volunteers for study ref. 
08/H0805/2, approved by Bromley Research Ethics Committee. This project 
contributes to the College's role in conducting research, and teaching research 
methods. You are under no obligation to reply to this email, however if you choose 
to, participation in this research is voluntary and you may withdraw at any time" 
 
INVESTIGATION INTO INCORPORATION OF (N−3) 
POLYUNSATURATED FATTY ACIDS, EICOSAPENTAENOIC ACID AND 
DOCOSAHEXAENOIC ACID, INTO ERYTHROCYTE MEMBRANES AND 
EFFECTS ON NOVEL MARKERS OF CARDIOVASCULAR RISK  
 
Short title: The EPA and DHA Trial 
 
We need you to help us investigate how different omega-3 fatty acids 
(eicosapentaenoic acid, abbreviated to EPA, and docosahexaenoic acid, 
abbreviated to DHA) influence circulating levels of factors in the blood that are 
related to vascular health and the elasticity of your arteries. 
 
If you are a healthy male, non-smoker and are aged between 18 and 45 
years, and not receiving any medication for blood pressure or blood cholesterol 
then you may be able to help us. 
  
By taking part in this research you will get information about your 
cardiovascular risk (computed from your age, blood fats, cholesterol level, blood 
pressure, body mass index) and haemoglobin level. 
 
All you need to do is: 
 
- Attend the Metabolic Unit in the Department of Nutrition and Dietetics (4th 
Floor Franklin-Wilkins Building, King's College London) for a screening visit; we will 
ask you questions about your medical history and dietary habits, measure your 
height, weight, percentage body fat, waist and hip circumference and blood 
pressure. We will also take a small blood sample (16.5 ml / ~3 teaspoons) to 
assess your suitability for the study. Breakfast will be provided afterwards.  
 
- Should you be suitable to take part, you would be asked to take oil 
capsules (5 per day) for 2 weeks and then attend the Metabolic Unit in the 
Department of Nutrition & Dietetics for a total of 2 occasions, 6 weeks apart, still 
consuming 5 oil capsules each day. Therefore you will be consuming 5 capsules 
per day (which either contain olive oil, fish oil rich in EPA or fish oil rich in DHA) for 
a total of 8 weeks. We shall ask you to avoid any strenuous exercise on the day 
before each of the main study visits and to avoid foods high in fat. We shall also 
ask you to fast overnight, to collect a urine sample for 24 h, and to be fitted with a 
blood pressure monitor which measures your blood pressure for 24 h.  
 
  
The following morning, we shall weigh you and estimate your body fat 
content. After resting for 15 minutes, we will measure your blood pressure and your 
pulse with external probes on your wrist and finger, and measure the small blood 
vessels in your finger using a special microscope camera. Following this we shall 
collect a small blood sample (47 ml / ~9 teaspoons) from a vein in your arm to 
measure changes in blood fats and other circulating markers of inflammation and 
blood vessel tone. Each visit will take 2-3 h and we shall take 111 ml of blood in 
total over the course of the study (including the screening visit) – this is equivalent 
to about 22 teaspoons of blood. We shall provide you with capsules to consume for 
two weeks before your first study visit (after the initial screening visit), and then you 
will be provided with more capsules to consume every day for the next 6 weeks 
until your final study visit.  
 
The risk associated with the blood collection is small, but there may be a 
small amount of bruising.  
 
You will be compensated for your time on completion of the study. 
 
The study has been approved by the Bromley National Research Ethics 
Committee  
(Reference No. 08/H0805/2) and will take place from May 2009 to 
September 2009. 
 
Thank you for your interest. 
 
For further information please contact:  
 
Sarah Cottin    sarah.cottin@kcl.ac.uk  
Aseel Al Saleh  aseel.alsaleh@kcl.ac.uk 
Or call 020 7848 4594 and ask for Sarah or Aseel. 
 
Room FWB 4.46 
Nutritional Sciences Division 
King’s College London 
Franklin Wilkins Building 












FOR NUTRITION RESEARCH 
We are running a study to look at the effects of 
omega-3 fish oil capsules on your health.  
 
These oils are of great interest as a higher dietary 
intake of them has been shown to decrease the risk of 
fatal coronary heart disease and stroke.  
 
We are looking for men: 
 
• Aged 18-45 years 
• Willing to take part in an 8-week nutrition study 
• Able to attend King’s College London, near Waterloo 
Station for 2 visits of 2h spread throughout the study 
 




You will be reimbursed for participation in the study and 
travel expenses 
 
Please contact Sarah Cottin on 0207 848 4594 
or e-mail sarah.cottin@kcl.ac.uk 
Appendix III INFORMATION SHEET FOR PARTICIPANTS 
 
REC Protocol Number   08/H0805/2 
 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
 
The EPA and DHA trial 
 
We would like to invite you to participate in this original research project.  You should only participate if 
you want to; choosing not to take part will not disadvantage you in any way. Before you decide whether 
you want to take part, it is important for you to understand why the research is being done and what your 
participation will involve. Please take time to read the following information carefully and discuss it with 
others if you wish. Ask us if there is anything that is not clear or if you would like more information.  
 
What is the purpose of this study? 
 
The omega-3 fatty acids found in oily fish are of great interest as a higher dietary intake of these omega-3 
fatty acids has been shown to decrease the risk of fatal coronary heart disease (CHD) and stroke. The 
mechanisms by which omega-3 fatty acids found in oily fish may offer protection are yet to be explained, 
and it is not known whether the different types of omega-3 fatty acids differ in their effects in the body or 
whether they act in the same way. The main types of omega-3 fatty acids found in oily fish are 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). This research project is a 
randomised controlled trial that compares capsule intakes of different mixtures of omega-3 fatty acids 
equivalent to 6 portions of oily fish each week on measurements that are related to cardiovascular 
disease risk. Study participants will be aged 18-45 years.  
 
Why have I been chosen? 
 
You have been contacted as you have expressed an interest in our research. In order to participate in this 
study you need to be able to say ‘Yes’ to the following:  
• I am male 
• I am aged between 18 and 45 years 
• I do not smoke 
• I have never had a heart attack, stroke, high blood pressure (>160/90mm Hg), liver diseases, diabetes, 
chronic gastrointestinal disorder or cancer  
• I do not have a history of excess alcohol intake or substance abuse  
• I am prepared to take 5 capsules a day for 8 weeks 
 
What will happen to me if I take part? 
 
If you would like to participate you would first need to complete a screening questionnaire with us over the 
telephone (approx. 10 mins), after which potentially eligible volunteers will be invited to attend a clinic 
  
screening appointment (approx. 45 mins) in the Metabolic Unit on 4th Floor, Corridor B, Franklin-Wilkins 
Building, Stamford Street, SE1 9NH. Volunteers will need to attend this visit after an overnight fast. 
 
The study will be explained in detail and you will be able to ask any questions you may have to ensure 
you will be giving fully informed consent. Following the signing of the consent form, your height, weight, 
waist/hip circumference and percentage body fat measurements will be recorded, and a fasting blood 
sample (approx 16.5mls/ ~3 teaspoons) will be taken to determine whether liver function, haematology, 
blood glucose and blood lipids are within normal ranges. Seated blood pressure will be measured using 
an automated sphygmomanometer (blood pressure monitor) that conforms to the recommendation of 
British Hypertension Society. Refreshments will be provided once all samples and measurements have 
been made. 
 
Eligible subjects will be asked to complete an 8-week period taking 5g oil each day in capsules (either 10 
x 500mg or 5 x 1g) whilst following dietary advice to avoid oily fish intake (e.g. salmon, herring, fresh tuna, 
mackerel, trout, or sardines) as well as fish oil/cod liver oil supplements. You can still eat as much white 
fish (e.g. cod, plaice, hake, etc), tinned tuna and shellfish as you choose. We will give you a detailed list 
of types of fish to avoid. You will be randomly allocated to 1 of 3 groups: 1 group will take olive oil 
capsules, 1 group will take fish oil capsules which contain more EPA than DHA, and the other group will 
take fish oil capsules which contain more DHA than EPA. You will have an equal chance of being 
allocated to any one of these groups.  
 
During the intervention, you will be asked to attend the Metabolic Unit at the Franklin-Wilkins Building 
twice, after 2 weeks and in the end of the intervention. The week before each visit, you will be given urine 
bottles and an ambulatory blood pressure monitor to use 2 or 3 days before your next study visit; and we 
will explain in detail how to collect your urine for 24 h and how to use the blood pressure monitor. 
 
At the end of the 2-week period you will attend the Metabolic Unit at the Franklin-Wilkins Building for your 
first study visit, bringing with you the collected urine and blood pressure monitor which you will have used 
over 24 h. We will make measurements to assess the functioning of the large and small blood vessels in 
your wrist and finger and take a blood sample (approx. 47 ml/ ~9 teaspoons. This visit lasts 2 to 3 h and 
will be repeated at the end of the intervention period. See figure 1 for an outline of these visits. To 
standardise everyone before these visits you will be asked to avoid strenuous physical activity, foods high 
in fat, caffeine or alcohol on the day before the visit. Only water will be allowed for 12 h before the 
scheduled study visit.  
 
The overall study is shown in a diagram below: 
 
 







2 weeks 6 weeks 
Total 
duration: 8 weeks 
Questionnaire 
through the 
phone (10 min) 
2-3 days prior to each visit: 
24h urine collection and blood 
  
Figure 1. Study outline. 
 
Screening visit:  
1) You should avoid eating or drinking anything, except water, for 12 h before your 
scheduled screening visit.  
2) The visit will last approximately 45 min. 
3) We will give you a copy of this information sheet, explain to you all the details of the 
study and answer any questions you have. If you are still happy to take part in the 
study, you will be asked to sign a consent form.  
4) We shall ask you questions about your medical history, your food habits through a 
Food Frequency Questionnaire and measure your weight, height, percentage body fat, 
blood pressure and waist and hip circumference.  
5) We will need to take a small blood sample (16.5 ml /~ 3 teaspoons) to check that your 
blood chemistry is normal.  
6) Then you will be provided with breakfast.  
7) The results of the screening blood test will be given to you. If any abnormal results are 
found we will inform you immediately and we will provide you with a letter for your 
GP, which we will advise you to give to your GP.  
 
Main study: 
1) Following screening, if your results comply with the study inclusion criteria you will be 
invited to attend the Metabolic Unit in the Franklin-Wilkins Building on 2 further 
occasions; each of these visits will take approximately 2-3 h each. 
2) We shall ask you to avoid eating oily fish and consuming fish oil supplements for 2 
weeks prior to the start of the study and during the study. We will provide you with 
study capsules containing a test oil and ask you to consume 5 of these capsules per day. 
We will also ask you to avoid fatty foods, drinking alcohol, and any strenuous exercise 
the day prior to each visit to the Department of Nutrition & Dietetics.  
3) We shall also ask you not to consume caffeine from midday the day before each visit 
and to avoid eating or drinking anything, except water, for 12 h before your scheduled 
study visit.  
4) 2 to 3 days prior to each of the 2 remaining visits, you will be asked to collect urine 
samples and to record your blood pressure (using the ambulatory blood pressure 
monitor) for 24 h. 
5) You will be asked to report to the Metabolic Unit in the Department of Nutrition & 
Dietetics between 08:00 h and 11:00 h, in the fasted state (i.e. without having 
consumed breakfast and without having consumed any food or drink for 12 h, 
apart from water).  Make sure you drink some water on the morning of the study 
to avoid dehydration. 
6) At each of the 2 visits (at 2 wk and 8 wk), we will then measure your blood pressure 
and the function of your large and small blood vessels. We shall make measurements of 
blood pressure using a sphygmomanometer, in which a cuff will be placed around your 
arm and will be inflated. The cuff causes a tingling sensation in your arm, but does not 
cause pain. The measurements we make to assess the function of your larger blood 
vessels are carried out using probes that are gently placed on your wrist and finger to 
determine the elasticity or tone of your arteries. The measurement of small blood vessel 
function involves you placing the top of your finger under a camera which can image 
individual capillaries (the smallest type of blood vessel) to monitor the capillary blood 
flow before and after inflation of a cuff placed around your forearm. All of these 
measurements are non-invasive and will not cause any discomfort. In the end of the 
visit, we will take a small sample of blood: 47 ml /~9 teaspoons.  
7) Finally, following these measurements you will be offered refreshments.  
  
 
After the second visit (at 2 wk), you will be provided with more oil capsules for the remainder of the study 
and you will continue to take 5 capsules per day for 6 weeks. You will be advised to avoid oily fish and to 
abstain from taking fish oil supplements or cod liver oil for the duration of the study (8 weeks in total). 
 
Will my participation be kept confidential? 
 
Any information collected about you during this research will be kept strictly confidential. Your GP will not be 
told that you are taking part in the study, unless you request us to do so. Subject confidentiality and 
anonymity will be observed throughout the study by use of subject codes in place of names, and the 
storage of subject details in a secure place. Only the investigators have access to this data. Should you 
wish to find out the results of this study you are welcome to contact Dr Wendy Hall (details below) for a 
copy of the final report once the study is finished. 
 
What will happen to my study results? 
 
We hope to publish the results of the whole study in a scientific journal. You will not be identified in any 
publication. We will be happy to discuss the overall results with you when the study is completed, and will 
let you know how you can get a copy of the published results if you wish. 
 
Who is organising and funding the study? 
 
The study is organised and funded by the Nutritional Sciences Division, Kings College London. In 
recognition of your time commitment, you will be paid an honorarium of £50 upon completion of the study.  
 
Do I have to take part? 
 
It is up to you to decide whether to take part or not. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. You can withdraw from the study at any 
time by informing one of the researchers and you are not obliged to give a reason. A decision to withdraw 
at any time, or a decision not to take part, will not affect the standard of care you receive. 
 
If you decide to take part, please let us know if you have been involved in any other study in the last year. 
 
If this study has harmed you in any way you can contact King's College London using the 
details below for further advice and information:  
Thank you for your interest. 
 
For further information, please contact: 
 
Sarah Cottin,   email: sarah.cottin@kcl.ac.uk  
or  Aseel Al Saleh,   email:  aseel.a.alsaleh@kcl.ac.uk  
 
Nutritional Sciences Division, King’s College London, Franklin Wilkins Building, 150 Stamford Street, 
London, SE1 9NH        
Chief Investigator: Dr Wendy Hall Tel. 020 7848 4197 wendy.hall@kcl.ac.uk 
Co-investigators: Prof Tom Sanders Tel. 020 7848 4273 tom.sanders@kcl.ac.uk; Dr Zoe Maniou Tel. 
020 7848 4546 zoitsa.maniou@kcl.ac.uk
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Appendix IV STUDY INFORMATION BOOKLET 
 
The EPA and DHA trial 
 
A high intake of fish oils, as observed in the Inuit population, is 
associated to a reduced risk of heart diseases and insulin resistance. 
Fish oils are composed of two types of omega-3 fatty acids: 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The 
beneficial effects of fish oils have been well established and omega 3 
supplements have flourished on the market over the past decade. 
However, it remains unclear if EPA, DHA or a combination of both are 
required to improve insulin sensitivity and cardiovascular health.  
 
  
    
This study aims at comparing the effect of EPA and DHA on different 
biological processes involved in the development of cardiovascular 
diseases, including inflammation, thrombosis and endothelial function. 
STUDY OUTLINE 
The nutritional intervention (outlined below) lasts 8 weeks during which 
you will be asked to take 5 capsules a day containing one type of fat 
(either EPA, DHA or olive oil as a placebo). You will be required to 
attend the Metabolic Unit at the Franklin-Wilkins Building, Waterloo 
Campus, of King’s College London on 3 different occasions: one 
before (screening) and 2 during the intervention. 
 
THE DAY BEFORE THE VISITS 
Prior to each of the 3 visits (screening or intervention) you should 
avoid having caffeine from midday, and also avoid doing exercise and 
drinking alcohol for 24h. You will be asked to have a low fat meal in 
the evening (instructions will be given) fast overnight (no food or drink, 
except water, from 10pm, and no breakfast on the study day). You will 
then attend the Metabolic Unit at a pre-arranged time between 8.30 
and 10.30 am. It is important that you drink water before attending.  
FIRST VISIT: SCREENING (45 min) 
The purpose of this screening session is to determine whether you are 
suitable to participate in our study. This involves measurement of your 
height, weight, waist circumference, body fat and blood pressure. It 
also involves the collection of a blood sample to determine your blood 
fats and glucose levels. We will give you more information and answer 
any question you might have regarding the study. Breakfast will be 
provided In the end of the screening session. 
2 VISITS DURING THE INTERVENTION (2-3H) 
You will be required to attend the Metabolic Unit at the Franklin-
Wilkins Building, Waterloo Campus, of King’s College London after 2 
weeks and in the end of the intervention (8 weeks). 
2 or 3 days prior to each visit, you will be asked to collect your urine 
and to record your blood pressure for 24h: A cuff will be put on your 






2 weeks 6 weeks 
Total duration: 8 weeks 
Questionnaire 
through the 
phone (10 min) 
2-3 days prior to each visit: 24h urine 
collection and blood pressure recording Stop taking 
capsules 
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left arm and inflate every half an hour during the day and every hour at 
night. 
Each visit will consist in non invasive vascular measurement (sensors 
will be placed on your finger and your wrist) and blood taking. Lunch 
will be provided in the end of each visit. 
FISH OILS RESTRICTION 
We shall ask you to avoid eating oily fish, such as salmon, trout or 
mackerel, and consuming fish oil supplements for the 8 week 
intervention period. However, you will still be allowed to eat non oily 
fish such as cod, haddock or sea bass. A more detailed list of fishes 
allowed/to avoid will be provided. 
 
STUDY DATES 
Please choose the date you will start the intervention, taking into 




Day starting taking capsules (time 0) 
 - 
2 week point 
  




WHAT YOU WILL GET BY TAKING PART 
 
 Information on your blood fats, glucose levels and full blood 
count 
 A full biochemical screening 
 Information on your body composition, physical 
measurements, vascular health and blood pressure 
 £50 for your time 
 
 
By participating in our study you will provide us with valuable 








Aseel Alsaleh aseel.alsaleh@kcl.ac.uk, 
Sarah Cottin sarah.cottin@kcl.ac.uk, 
020 7848 4594 
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Appendix V HEALTH QUESTIONNAIRE 
The EPA and DHA Trial  
 
Please complete this questionnaire and return by email to 
sarah.cottin@kcl.ac.uk or aseel.alsaleh@kcl.ac.uk,  
School of Biomedical and Health Sciences, King’s College London, 
Franklin-Wilkins Building Room 4.46A, 150 Stamford Street  
London SE1 9NN 
 
 
































Have you recently taken part in any other trial? 
 
YES / NO* 
Do you smoke? 
 
YES / NO* 
 
Do you drink alcohol? 
 
If so, how many units per /week? 
1 unit = glass of wine, shot of spirits,  
             1/2 pint of beer 
 
 
YES / NO* 
 
 
……………. Units day / week* 
 
 
Do you suffer from any allergies? 
 
If so please give details: 
                        YES / NO* 
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Do you suffer from any medical problems? 
 
If so please describe: 
 
 
YES / NO* 
 
Are you taking any medication? 
 
If so please give details: 
 
 





Do you take any dietary supplements? 
 
 
YES / NO* 
 
 
How frequently do you consume oily fish? 
(explain what oily fish are) 
 
>1 portion per wk/1 portion per 
wk/<1 portion per wk 
 
Do you have a history of any of the following? 
 












YES / NO* 
 
YES / NO* 
 
                         YES / NO* 
YES / NO* 
YES / NO* 
 
Are you receiving medication for any of the following? 
 
Raised blood cholesterol 
 
High blood pressure 
 
Immune system (anti-histamines, anti-inflammatory drugs) 
 
Do you have any special dietary requirements? 
 
Lacto-ovo vegetarian/vegan/other (specify) 
 






YES / NO* 
 
YES / NO* 
 
YES / NO* 
 
 
YES / NO* 
 
YES / NO* 
 




Appendix VI OILY FISH RESTRICTION 
 
Restriction in oily fish consumption 
 
 
You are required to avoid any source of fish oils, including supplements or oily fishes 
(left of the table below) during the 8 week intervention period 
 
 

















Jack fish  
Katla  









































Appendix VII FATTY ACID ANALYSIS (GAS CHROMATOGRAPHY) OF EPA- 
AND DHA- RICH OILS 
 
VII. A. TYPICAL FATTY ACID COMPOSITION PROVIDED BY THE 








Fatty Acid Content (%) Content (%) 
C14:0 0.5  - 
C16:0 0.9 0.7 
C16:1 0.7 0.3 
C16:2 0.7 0.5 
C16:3 0.5 0.1 
C16:4 0.5  - 
C18:0 0.4 3.7 
C18:1 3.7 6.9 
C18:2 2.1 1.6 
C18:3 n-6 0.6 0.5 
C18:3 n-3 1.1 0.2 
C18:4 n-3 5.6 0.3 
C20:0 0.5 0.6 
C20:1 0.2 2.2 
C20:2 n-6 0.8 0.5 
C20:3 n-6 0.6 0.2 
C20:4 n-6 4.1 2.8 
C20:4 n-3 3.2 0.7 
C22:0  - 0.3 
C20:5 n-3 58.4 8.3 
C22:1 1.7 0.9 
C21:5 n-3 1.6 0.5 
C24:1  - 0.6 
C22:5 n-6 0.4 4.6 
C24:0  - 0.4 
C22:5 n-3  1.5 3.1 
C24:1  - 1.3 
C22:6 n-3 8.8 57.5 
Others 0.9 0.7 
Total n-3 PUFA 67.2 65.8 
Total VLC n-3 PUFA 68.7 68.9 
Total n-6 PUFA 6.5 8.6 
Total MUFA 6.3 12.2 
Total SFA 2.3 5.7 
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Fatty Acid Content (%) Content (%) Content (%) 
16:0 10.71 0.96 0.00 
16:1 0.75 0.00 0.93 
18:0 3.42 3.51 1.82 
18:1n-9 76.62 6.27 0.78 
18:1n-7 2.06 1.23 2.51 
18:2n-6 4.69 1.16 0.66 
20:5n-3 0.00 10.34 61.97 
22:4n-6 0.00 4.25 1.80 
22:5n-6 0.00 1.27 0.00 
22:5n-3 0.00 3.34 2.06 
22:6n-3 0.00 57.31 14.10 
Total VLC n-3 PUFA 0.00 70.98 78.13 
Total n-6 PUFA 4.69 6.68 2.46 
Total MUFA 79.43 7.50 4.22 
Total SFA 14.13 4.47 1.82 
PUFA, Polyunsaturated fatty acids; VLC n-3 PUFA, very long chain n-3 PUFA 
(20:5n-3 + 22:5n-3 + 22:6n-3); MUFA, Monounsaturated fatty acids; SFA, 






Appendix VIII CONSENT FORM  
CONSENT FORM FOR PARTICIPANTS IN A NUTRITIONAL 
STUDY 
• Please complete this form after you have read the 
Information Sheet and you are satisfied that the research has 
been fully explained. 
• Title of Study: The EPA and DHA Trial 
• Research Ethics Committee Ref: 08/H0805/2 
Thank you for considering taking part in this research. The person organizing the research 
must explain the project to you before you agree to take part. 
If you have any questions arising from the Information Sheet or explanation already given to 
you, please ask the researcher before you decide whether to participate. You will be given a 
copy of this Consent Form to keep and refer to at any time. 
• I confirm that I fit into the following criteria 
 
• I understand that if I decide at any other time during the research that I no longer 
wish to participate in this project, I can notify the researchers involved and be 
withdrawn from it immediately. 
• I consent to the processing of my personal information for the purposes of this 
research study. I understand that such information will be treated as strictly 
confidential and handled in accordance with the provisions of the Data Protection 
Act 1998. 
• I agree that the research team may use my data for future research and 
understand that any such use of identifiable data would be reviewed and approved 
by a research ethics committee. Please note that in such cases, as with this 
project, confidentiality and anonymity will be maintained ant it will not be possible 





agree that the research project named above has been explained to me to my satisfaction 
and I agree to take part in the study. I have read both the notes written above and the 
Information Sheet about the project, and understand what the research study involves. 
 
Signed       Date 
 
• Investigator’s Statement: 
 
I _____________________________________________________________________ 
confirm that I have carefully explained the nature, demands and any foreseeable risks 
(where applicable) of the proposed research to the volunteer. 
 
Signed       Date 
 
  
• I am a male aged between 18 and 45 years and do not smoke 
• I do not have a history of heart disease, stroke, high blood pressure, diabetes, 
thrombosis, liver disease, chronic gastrointestinal disorders or a cancer diagnosis 
(except basal cell carcinoma)  
• I do not have a history of excess alcohol intake or substance abuse 
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Appendix IX STANDARD PHYSICAL MEASUREMENT PROCEDURES 
 
1. Height 
Ensure that subject has removed all ornamentation from his/her hair, and is barefoot. 
Using a wall mounted stadiometer, ensure that the volunteer stands upright with heels 
and shoulders against the measuring rod, knees and back straightened, and looking 
straight ahead. Lower the measuring slide onto the participants head, so that it 
compresses the participants’ hair. The measuring slide should not bend. Record the 
participants’ height at the ‘read-off’ mark. 
 
2. Waist circumference 
Waist circumference should be measured over light clothing, so that the tape measure 
can be held as closely against the body as possible. The measurement should be read 
to the nearest 0.1cm. The subject should be standing upright when the measurement is 
taken, and the measurement should be taken at the minimum circumference between 
the rib cage and the iliac crest. 
 
3. Body composition by bio-electrical impedance 
Body composition (and weight) should be assessed using a Tanita BC-418 segmental 
body composition analyzer. After turning on the power, all the required data should be 
entered. Standard settings should be used for clothes weight (1.0 kg) and body type 
(normal, not athletic). Enter the information about the participants’ gender, age and 
height, and then wait for the flashing arrow to appear next to the ‘step on’ prompt, 
before asking the subject to step onto the scales platform. Ask the participant to step 
onto the weighing platform with bare feet and to take a handgrip firmly into each hand, 
and allowing each arm to hang straight down along their sides without touching their 
body.  
 
The display will emit short beeping sounds while the body composition measurements 
are being determined. When the measurements are complete, a detailed summary of 
the results will be printed. The display will then automatically return to zero. Attach the 
print out to the screening patient record being used to manually record the other 
measurements being taken at the same screening visit. 
 
4. Blood pressure and heart rate 
Blood pressure should be taken using an Omron 705IT auto upper arm blood pressure 
monitor. When taking a blood pressure measurement, the volunteer must be calm and 
relaxed. Participants should be allowed to rest quietly at a comfortable room 
temperature for five minutes before the measurements are performed. Participants 
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should not be drinking, eating, smoking or talking at the time that the blood pressure 
will be measured. 
 
Ensure that the subject is sitting quietly with their legs uncrossed and feet flat on the 
floor. The arm that the measurement is being taken from needs to be comfortably 
supported to heart level (arm below this tends to underestimate both systolic and 
diastolic blood pressure by approximately 10 mmHg, and above the heart tends to 
overestimate). Select the appropriately sized cuff and place the bladder of the cuff 2-3 
cm above the antecubital fossa in the brachial artery (around the participants’ upper 
arm). Wrap the cuff snuggly around the arm, making sure that the cuff index line falls 
within the marked ranges. There should be space for a finger between the participants’ 
arm and the cuff. The cuff must be placed so that the participants’ artery is aligned with 
the cuff arrow marked ‘artery’. 
 
Press the start/stop button and allow the reading to take place. It takes about 40 
seconds for a measurement to be completed. If a reading is not detected, the cuff will 
automatically re-inflate. In some instances, the reading will fail yet again. This may be 
due to the fact that the cuff is not aligned correctly. It is thus important to ensure from 
the start that the cuff arrow is correctly aligned with the artery (feel for a pulse to be 
certain). 
 
Document the readings for systolic and diastolic blood pressure, as well as the heart 
rate reading. Repeat the measurements of blood pressure two more times at two - five 
minute intervals, and discard the first measurement. 
  










Is participant satisfied with 
































 Reading 1:      (S) 
                        (D) 
Reading 2:      (S) 
                        (D) 
Reading 3:      (S) 
                        (D) 
Average of reading 2 & 3:  (S)
                                              
 
 







 YES / NO  
4ml (FX), 4ml (EDTA), 8.5 ml (serum)














First visit (2 weeks) 
 


















Appendix XI BLOOD HANDLING PROTOCOL (SCREENING) 
 
 
All analysis was done at King’s College Hospital (KCH) under the supervision of Dr Roy Sherwood 
FBC; full blood counts, FLIP; full lipid count (TAG, total, HDL and LDL cholesterol), LFT; liver function 






Fluoride oxalate (grey) Ice 15 min x 1300 g 
@ 4ºC 
Separate plasma 




Freeze 1 aliquot and 
send the other fresh 
to KCH 
Same day at 
room 
temperature (1 * 4 ml C/P 368587) 
4 ml EDTA (lavender) Room 
temperature 
No None FBC Room temperature Same day at 
room 
temperature (1 * 4 ml C/P 367844) 
No anticoagulant (red) Ice 15 min x 1300 g 
@ 4ºC 
Separate into 2 x 





Freeze 1 aliquot and 
send the other fresh 
to KCH 
Same day at 
room 
temperature 




Appendix XII TRIGLYCERIDES (TRIG) 
XII. A. EXPLANATION OF THE TEST 
Triglyceride concentrations (in conjunction with serum cholesterol) are useful in 
the diagnosis and classification of the dyslipoproteinaemias (primary and secondary) 
and in the calculation of LDL cholesterol via the Friedwald formula given the total and 
HDL cholesterol. They are also used in the diagnosis and treatment of patients with 
suspected atherosclerosis, poorly controlled diabetes mellitus, nephritic syndrome, liver 
disease or obstruction and other diseases involving lipid metabolism. 
XII. B. METHOD 
Triglyceride reagents supplied by Siemens Healthcare Diagnostics Ltd, Newton 
House, Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD 
The Siemens Advia method for the measurement of triglycerides is an enzymatic 
assay. Triglycerides are converted to glycerol and free fatty acids by lipase. The 
glycerol is then converted to glycerol-3-phosphate by glycerol kinase followed by its 
conversion by glycerol-3-phosphate-oxidase to hydrogen peroxide. A coloured complex 
is formed from hydrogen peroxide, 4-aminophenazone and 4-chlorophenol under the 
catalytic influence of peroxidase. The absorbance of the complex is measured as an 
endpoint reaction at 505/694 nm. 
XII. C. TECHNICAL DATA 
• INTRA-ASSAY PRECISION 
 Level 1  Level 2  
Mean (mmol/L) 1.32 2.36 
N 20 20 
SD 0.007 0.011 
CV% 0.6 0.5 
• INTER-ASSAY PRECISION 
 Level 1  Level 2  
Mean (mmol/L) 1.32 2.36 
N 20 20 
SD 0.033 0.035 
CV% 2.5 1.5 
• SAMPLE REQUIREMENTS 
Serum or heparinised plasma may be used. Specimens may be refrigerated 
overnight or stored at room temperature in seroseparator tubes. The ADVIA 2400 uses 
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2 µL of sample in the test, although the minimum volume required in the specimen 
container is 50µL (micro sample cups) or 200µL (Vacutainers and inserts). 
• LINEARITY 
Linear to approximately 10 mmol/L. 
• SENSITIVITY 
The minimum detectable concentration of triglyceride is 0.01 mmol/L. 
• STANDARDIZATION 
The ADVIA triglyceride method measures total glycerols and is traceable to a 
reference method, which uses reference materials from the National Institute of 
Standards and Technology (NIST), via patient sample correlation. Assigned values of 
Bayer Chemistry Calibrator and Bayer Assayed Chemistry Controls are traceable to this 
standardization. 
• REFERENCE RANGE 
< 2.0 mmol/L (fasting).  
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Appendix XIII CHOLESTEROL (CHOL) 
 
XIII. A. EXPLANATION OF THE TEST 
A raised serum cholesterol has been associated for many years with an increased 
risk of atherogenic plaque formation leading to an increased likelihood of ischaemic 
heart disease, myocardial infarction and stroke (cerebrovascular accident). At a 
cholesterol concentration above 5.2 mmol/l (according to the WHO) the risk of 
atherogenesis rises in proportion to cholesterol concentration and is additive to other 
risk factors such as smoking, hypertension and family history. 
 
XIII. B. METHOD 
Cholesterol reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton 
House, Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD 
Serum cholesterol is determined using an enzymatic method. Cholesterol 
esterase completely hydrolyses cholesterol esters in serum to free cholesterol, which is 
in turn oxidised by cholesterol oxidase generating hydrogen peroxide. The hydrogen 
peroxide formed combines with 4-aminophenazone and a phenol to form a red quinone 
amine dye which is measured as an endpoint reaction at 505/694 nm. The increase in 
dye absorbance is directly proportional to the concentration of cholesterol in the sample, 
when compared to a previous calibration assay. 
 
Cholesterol esters + H2O 
 
 
Cholesterol  + fatty acid 
 
 
     H2O2   + Choleste-4-en-3-one  
+ phenol, 4-aminophenazone 
 
Red quinoneimine dye + 2 H2O   
 
XIII. C. TECHNICAL DATA 
• INTRA-ASSAY PRECISION 
 Level 1) Level 2  Level 3  





Mean (mmol/L) 3.91 5.15 5.67 
SD 0.026 0.034 0.031 
CV% 0.6 0.6 0.6 
• INTER-ASSAY PRECISION 
 Level 1  Level 2  Level 3  
N 20 20 20 
Mean (mmol/L) 3.91 5.15 5.67 
SD 0.044 0.080 0.057 
CV% 1.1 1.5 1.0 
• SAMPLE REQUIREMENTS 
Serum or heparinised plasma may be used. Specimens may be refrigerated 
overnight or stored at room temperature in seroseparator tubes. The ADVIA 2400 uses 
2 µl of sample in the test, although the minimum volume required in the specimen 
container is 50µl (micro sample cups) or 200µl (Vacutainers and inserts). 
• LINEARITY 
Linear to approx. 17 mmol/l. 
• SENSITIVITY 
The minimum detectable concentration of cholesterol is 0.01 mmol/L. 
• REFERENCE RANGE 
Quoting reference values for serum cholesterol in terms of population 
distribution is actively discouraged in favour of setting desirable targets. Current WHO 
recommendations suggest a cholesterol concentration below 5.2 mmol/L as being 
desirable to avoid coronary artery disease. 
• STANDARDIZATION 
The ADVIA cholesterol method is traceable to the CDC reference method, 
which uses reference materials from the National Institute of Standards and Technology 




Appendix XIV HIGH DENSITY LIPOPROTEIN (HDL) 
 
XIV. A. EXPLANATION OF THE TEST 
HDL (high density lipoprotein) is a lipoprotein which plays an essential role in 
cholesterol transport and metabolism, principally by transporting excess cholesterol 
from peripheral tissues to the liver. HDL cholesterol measurements enable LDL 
cholesterol to be calculated (given the total cholesterol and triglycerides), and this is the 
most important lipoprotein in the assessment of coronary artery disease. HDL itself is 
also an independent risk factor for such disease being inversely related to the risk. 
 
XIV. B. METHOD 
HDL cholesterol reagents supplied by Siemens Healthcare Diagnostics Ltd, 
Newton House, Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD. 
The Siemens Advia Direct HDL cholesterol method is a two step automated 
procedure. In the first step cholesterol esterase and cholesterol oxidase react to remove 
non-HDL cholesterol from the sample. The hydrogen peroxide produced is then 
removed by the enzyme catalase. The absence of detergent in this first reaction prevents 
HDL from reacting with the enzymes. In stage 2 detergent is added to allow HDL to 
react with the enzyme system. Sodium azide inhibits the reaction of the hydrogen 
peroxide formed with catalase. The hydrogen peroxide acts with 4-aninoantipyrine to 
produce a quinoneimine pigment measured at 596 nm.  
 
XIV. C. TECHNICAL DATA 
• INTRA-ASSAY PRECISION 
 Level 1  Level 2  Level 3  
Mean (mmol/L) 0.91 1.39 1.95 
N 20 20 20 
SD 0.010 0.019 0.029 
CV% 1.1 1.4 1.5 
• INTER-ASSAY PRECISION 
 Level 1  Level 2  Level 3  
Mean (mmol/L) 0.91 1.39 1.95 
N 20 20 20 
SD 0.020 0.029 0.049 
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CV% 2.2 2.1 2.5 
• SAMPLE REQUIREMENTS 
Serum or heparinised plasma may be used. Specimens may be refrigerated 
overnight or stored at room temperature in seroseparator tubes. The ADVIA 2400 uses 
2 µl of sample in the test, although the minimum volume required in the specimen 
container is 50µl (micro sample cups) or 200µl (Vacutainers and inserts). 
• SENSITIVITY 
The minimum detectable concentration of HDL cholesterol is 0.1 mmol/L. 
• LINEARITY 
Linear from  0.4 - 2.3 mmol/L. 
• REFERENCE RANGE 
Quoting reference values for serum HDL cholesterol in terms of population 
distribution is actively discouraged in favour of setting desirable targets. Current WHO 
recommendations suggest a cholesterol concentration above 1.0 mmol/l as being 
desirable to avoid coronary artery disease. HDL cholesterol is also used in conjunction 
with total cholesterol and triglycerides to calcualate LDL cholesterol. 
• STANDARDIZATION 
The Advia HDL method is traceable to the NCEP Designated Comparison 
Method (reference method) via patient sample correlation. Assigned values of ADVIA 
Chemistry HDL/LDL Cholesterol Calibrator and ADVIA Chemistry Lipid Controls are 
traceable to this standardization. 
  
 27
Appendix XV GLUCOSE 
 
XV. A. EXPLANATION OF THE TEST 
Glucose measurements are used in the diagnosis and management of diabetes 
mellitus and in the monitoring of patients on parenteral nutrition. Glucose is also of use 
in calculating osmolarity and in the diagnosis of diseases resulting in hypoglycaemia 
e.g. insulinoma. 
 
XV. B. METHOD 
Glucose reagent is supplied by Siemens Healthcare Diagnostics Ltd, Newton 
House, Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD. 
Glucose in the sample is phosphorylated by the transfer of phosphate from 
adenosine triphophosphate (ATP) via the action of hexokinase. Glucose-6-phosphate 
formed in this reaction is oxidised by glucose-6-phosphate dehydrogenase. This is 
accompanied by the reduction of NAD+ to NADH which results in an increase in 
absorbance at 340 nm proportional to the glucose concentration in the sample. The 
increase in absorbance is converted to glucose concentration by reference to a 
previously determined calibrator and reagent blank. 
The effect of any interfering substances is reduced by blanking each sample 
using reagent 1 (buffer and co-factors) before the addition of reagent 2 (enzymes). 
 
 
XV. A. TECHNICAL DATA 
• SAMPLE REQUIREMENTS 
The sample must be taken into a fluoride-oxalate tube as fluoride preserves 
glucose for at least 48 hours without separation. The plasma may be may be refrigerated 
overnight or stored at room temperature in seroseparator tubes. CSF and other fluids can 
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also be analysed with this method - the sample should be collected into a fluoride-
oxalate container - if not the sample should be analysed immediately.  
The ADVIA 2400 uses 3.4 µl of sample in the test, although the minimum 
volume required in the specimen container is 50µl  
• INTRA-ASSAY PRECISION 
 Level 1 Level 2 
Mean (mmol/L) 4.4 16.3 
SD 0.02 0.08 
CV (%) 0.6 0.5 
• INTER-ASSAY PRECISION 
 Level 1 Level 2 
Mean (mmol/L) 4.4 16.3 
SD 0.07 0.19 
CV (%) 1.6 1.2 
• LINEARITY 
The assay islinear up to 38.9 mmol/L 
• REFERENCE RANGE 
For fasting samples the reference range is 2.5 to 5.0 mmol/l. WHO guidelines 
state that a diagnosis of diabetes mellitus can be made on fasting plasma samples with a 
glucose concentration of 7.0 mmol/L or greater – a single result is acceptable in a 
symptomatic patient, otherwise two results are required to make the diagnosis. Other 
WHO guidelines are laid down for the diagnosis and classification of diabetes mellitus 
which are beyond the scope of this method sheet. 
CSF glucose is normally approximately 60% of the current plasma glucose. 
No reference ranges are available for other fluids 
• STANDARDIZATION 
The ADVIA glucose oxidase method is traceable to the CDC Reference Method, 
which uses reference materials from the National Institute of Standards and Technology 
(NIST), via patient sample correlation and verified with NIST Reference serum. 
Assigned values of Siemens Chemistry Calibrator, Siemens Assayed Chemistry 
Controls, and ADVIA Chemistry Urine Controls are traceable to this standardization. 
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Appendix XVI FULL BLOOD COUNT (FBC) 
 
Reagents supplied by Siemens Medical Solutions Diagnostics Limited, Bayer 
House, Strawberry Hill, Newbery, Berks. RG14 1JA 
 
XVI. A. EXPLANATION OF THE TEST 
The Siemens Advia 2120 is used to analyse the full blood count (FBC), Nucleated 
Red Blood Cell Count (NRBC) and Reticulocyte count. These are important tests 
requested by the clinician to evaluate the health of a patient. The results are used in 
conjunction with other diagnostic tests to diagnose, treat and monitor the progress of a 
patient. The Advia 2120 is a haematology analyser, which has the capacity to analyse the 
following test profiles: CBC/DIFF, CBC/DIFF/RETIC, CBC/RETIC. 
 
XVI. B. METHOD 
The Siemens Advia 2120 uses the following principles of analysis: -  
• HYDRONAMIC FOCUSING 
The sheath/rinse reagent surrounds the sample stream to produce a single stream of 
cells, which reduces co-incidence during flow cytometry analysis. 
• PEROXIDASE (PEROX) METHOD 
Uses the intracellular myeloperoxidase enzyme to distinguish between the different 
white cell types.  The cells have peroxidase enzyme substrate 4-chloro-1-napthol added in 
the presence of hydrogen peroxide, which forms a dark precipitate at endogenous sites of 
peroxidase activity in the granules of the White Blood Cell. The sample is passed through 
the flowcell and the light scatter, which determines the size of a cell and the absorption, 
which provides information on the level of staining, is measured. Neutrophils, monocytes 
and eosinophils are peroxidase positive whereas lymphocytes and basophils are peroxidase 
negative. 
• BASOPHIL/LOBULARITY (BASO) METHOD 
addition of phthalic acid and a surfactant which lyses the red cells, platelets and the 
cytoplasm of all white cells except the basophils these pass through the laser and 
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information collected from the light scatter which corresponds to the nuclear configuration 
and cell size. 
• CYANIDE FREE HAEMOGLOBIN DETECTION (HGB) 
there are 2 methods employed.  
METHOD 1: a cyanide free colourimetric method, which lyses the RBC to release 
the haemoglobin. The heme ion is oxidised to the feric state where it combines with the 
reagent to form an axial ligand monoaquomonohydroxyferri-porphyrin. Optical 
readings are taken at a wavelength of 456nm and plotted on the haemoglobin 
transmission histogram. This method is affected by background colouration e.g. 
lipaemia, haemolysis and icteric samples.  
METHOD 2: Cellular HGB is a calculated method which uses the directly 
measured parameter CHCM (Corpuscular Haemoglobin Concentration Mean) it is 
calculated using the following values CHCM x RBC x MCV /1000. This method is not 
affected by either haemolysed, lipaemic or icteric samples.  
The 2 methods should not differ by more than 1.9g/dl however if they do an 
error message is flagged. The CHCM should only be used when the haemoglobin is 
falsely increased and the MCHC is also falsely increased. Using CHCM to calculate 
Cellular HGB avoids this interference since CHCM is directly measured and is virtually 
unaffected by lipaemia. To calculate HGB, replace MCHC with CHCM as follows: 
MCHC = (HGB ¸ [RBC x MCV]) x 1000 
HGB = (MCHC x RBC x MCV) / 1000 
Cellular HGB = (CHCM x RBC x MCV) / 1000   or   (CHCM x Hct) / 100 
• NRBC COUNT 
Nucleated Red Blood Cells are identified by the nuclear size in the peroxide 
channel, and by nuclear density in the Basophil/Lobularity channel. Within the unstained 
region of the peroxidase channel the NRBC nuclei are located between the noise and 
lymphocytes and form distinct populations (1), which can be analysed to produce a count. 
Within the Basophil/Lobularity channel the NRBC nuclei are located in the 
polymorphonuclear region and can be calculated by subtracting the neutrophil and 
eosinophil counts form the total nuclei count. Therefore for every sample 4 NRBC counts 
are generated,  
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Appendix XVII TOTAL PROTEIN (TP) 
 
XVII. A. EXPLANATION OF THE TEST 
Serum proteins serve numerous functions, both physical and chemical. They 
play a general role in the maintainence of normal water distribution between tissues and 
the vascular compartment as well as acting as buffers for acid-base balance. In certain 
pathological conditions the total protein and the ratio of the individual protein fractions 
may change independently of one another. The total protein may be raised in 
dehydration, myeloma and infection. Conversely the total protein may be lowered in 
nephrotic syndrome (due to renal protein loss), malabsorption, hepatic or renal failure, 
immunoglobulin deficiency or starvation. 
 
XVII. B. METHOD 
TP reagents supplied by Siemens Healthcare Diagnostics Ltd, Newton House, 
Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD 
Biuret reagent (an alkaline solution of copper ions) reacts with the peptide bonds 
present in proteins or short polypeptides, to form a stable chromophore with an 
absorbance at 545 nm. Assuming the proportion of peptide bonds present is constant 
with respect to the weight of protein, comparison of   the increase in absorbance with a 
known calibrant enables the protein concentration of the sample to be determined. Two 
reagent additions are used, the colour reagent being in the second reagent. This enables 
a sample blank correction to be made before reagent 2 addition which reduces 
interferences (especially from lipaemia). 
 
XVII. C. TECHNICAL DATA 
• SAMPLE REQUIREMENTS 
Serum or heparinised plasma may be used. Specimens may be refrigerated 
overnight or stored at room temperature in seroseparator tubes. The ADVIA 2400 uses 
2 µL of sample in the test, although the minimum volume required in the specimen 
container is 50µL (micro sample cups) or 200µL (Vacutainers and inserts). 
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• LINEARITY 
Linear to approximately 120 g/L. 
• STANDARDIZATION 
The ADVIA triglyceride method measures total glycerols and is traceable to a 
reference method, which uses reference materials from the National Institute of 
Standards and Technology (NIST), via patient sample correlation. Assigned values of 
Bayer Chemistry Calibrator and Bayer Assayed Chemistry Controls are traceable to this 
standardization. 
• REFERENCE RANGE 
Serum: 60 - 80 g/L 
No reference ranges are available for other fluids 
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Appendix XVIII ALBUMIN (ALB) 
 
XVIII. A. EXPLANATION OF THE TEST 
Albumin is the major plasma protein. It acts as a transport protein for many 
metabolites and drugs including bilirubin, calcium, thyroxine and anticonvulsants. It 
also contributes to plasma oncotic pressure and acts as a store of circulating amino acids 
for protein synthesis by the tissues.  
Measurement of plasma albumin provides an index of liver synthetic capacity or 
dietary intake and as such is a useful prognostic indicator. Measurement of albumin 
allows interpretation of  the levels of substances which bind albumin and correction to 
extrapolate "free" levels (particularly calcium).  
Miscellaneous fluid albumin is of use in determining whether the fluid is an 
exudate (high level) or transudate (low level). 
XVIII. B. METHOD 
Albumin reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton 
House, Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD 
The Siemens Advia method for the measurement of albumin uses Bromocresol 
green (BCG) which preferentially binds serum albumin causing a shift in the absorption 
spectrum. The increase in absorbance measured at 596 nm is directly proportional to the 
albumin concentration. 
XVIII. C. TECHNICAL DATA 
• SAMPLE REQUIREMENTS 
Serum or heparinised plasma may be used. Specimens may be refrigerated 
overnight or stored at room temperature in seroseparator tubes. The ADVIA 2400 uses 
2 µl of sample in the test, although the minimum volume required in the specimen 
container is 50µl (micro sample cups) or 200µl (Vacutainers and inserts). Urinary 
albumin should be analysed by the separate immunoturbidimetric assay. 
• LINEARITY 
Linear from 10 to 60 g/l. 
• REFERENCE RANGE 
Serum 35 - 50 g/L. 
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Appendix XIX BILIRUBIN 
 
XIX. A. EXPLANATION OF THE TEST 
Bilirubin is the major breakdown product of haem metabolism, most of this 
coming from the degradation of senascent red blood cells. Plasma bilirubin is taken up 
by the hepatic circulation and conjugated to form a soluble glucuronide which is 
excreted in the bile. Normally most of the plasma bilirubin is unconjugated and 
transported bound to albumin, while some is conjugated (by the liver as described 
above) and a small proportion is thought to be covalently linked to albumin (delta 
bilirubin). 
Total bilirubin reflects either a rate of red blood cell turnover in excess of the 
rate of removal, decreased hepatic conjugative capacity or impaired biliary excretion. 
Thus, a raised total bilirubin indicates a haemolytic or hepatic disorder. 
 
XIX. B. METHOD 
Bilirubin reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton 
House, Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD 
Bilirubin reacts under acidic conditions with vanadate ions resulting in its 
oxidation to biliverdin. In the presence of detergent and a citrate buffer, both conjugated 
and unconjugated bilirubin are oxidised. The decrease in bilirubin concentration which 
results from this is measured at 451 nm, and the difference in absorbance over the 5 
minute reaction period is related to bilirubin concentration by comparison to a previous 
calibration assay. 
 
XIX. C. TECHNICAL DATA 
• SAMPLE REQUIREMENTS 
Serum, heparinised plasma or miscellaneous fluids may be used. Specimens may 
be refrigerated overnight or stored at room temperature in seroseparator tubes. The 
ADVIA 2400 uses 14 µl of sample in the test, although the minimum volume required 




Linear to 598 µmol/l. 
• REFERENCE RANGE 
The reference range for serum: 3 - 20 µmol/L 




Appendix XX ASPARTATE TRANSAMINASE (AST) 
 
XX. A. EXPLANATION OF THE TEST 
Aspartate transaminase (AST) is an intracellular (mitochondrial) enzyme present 
in most tissues, notably in the liver parenchymal cells, cardiac muscle and skeletal 
muscle. Raised levels of AST are associated with cell necrosis or increased cell leakage. 
AST is therefore markedly raised in hepatic inflammation or tissue damage and skeletal 
muscle damage and may be moderately raised in myocardial infarction. AST is thus a 
reasonably sensitive indicator of hepatitis, liver necrosis or liver transplant rejection and 
a relatively late indicator of myocardial infarction. 
 
XX. B. METHOD 
AST reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton House, 
Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD. 
The reaction is initiated by the addition of the substrate (2-oxoglutarate - 
contained in reagent 2) to the patient sample/co-enzyme (reagent 1) mixture. 
           AST 
      L-aspartate  +  2-oxoglutarate                           oxaloacetate  +  L-glutamate 
 
      malate dehydrogenase 
          oxaloacetate  +  NADH                                          malate  +   NAD+ 
The rate of NADH consumption by the 2nd (linked) reaction is monitored at 340 
nm and is directly proportional to the AST activity in the sample. Pre-incubation of the 
sample with the co-enzyme reagent removes any endogenous NADH by the conversion 
of pyruvate to lactate by lactate dehydrogenase which is added to the reagent. 
 
XX. C. TECHNICAL DATA 
• SAMPLE REQUIREMENTS 
Serum or heparinised plasma may be used. Specimens may be refrigerated 
overnight or stored at room temperature in seroseparator tubes. The ADVIA 2400 uses 
20 µl of sample in the test, although the minimum volume required in the specimen 
container is 50µl (micro sample cups) or 200µl (Vacutainers and inserts).  
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• LINEARITY 
The ADVIA 2400 performs a number of checks on the validity of the reaction 
curve to ensure linearity and to check for substrate depletion. There is also the concept 
of 'point forwarding'. This means that an assay which exceeds absorbance limits over 
the normal measuring range of the assay uses an earlier set of measuring points to 
obtain an acceptable reaction rate. The absorbance limits used are also variable 
according to the background absorbance of the sample and first reagent. This means that 
an exact linearity limit cannot be stated and that very few dilutions are necessary.  
• REFERENCE RANGE 




Appendix XXI ALKALINE PHOSPHATASE 
 
XXI. A. EXPLANATION OF THE TEST 
The enzyme alkaline phosphatase (ALP) is an indicator of bone formation and 
as such is raised in association with increased bone turnover. The production of hepatic 
ALP is increased in cholestasis by bile induction and thus a raised ALP may also act as 
a marker for cholestasis. ALP is also produced by the placenta, hence the activity is 
normally increased during pregnancy 
 
XXI. B. METHOD 
ALP reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton House, 
Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD. 
Para-nitrophenyl phosphate (PNPP) is an artificial substrate for ALP. ALP 
hydrolyses PNPP to form free phosphate and para-nitrophenol which is highly coloured 
(yellow). The reaction is monitored kinetically at 410 nm, the rate of increase in 
absorbance being directly proportional to ALP activity in the sample and expressed as 
IU/L by means of a conversion factor. 4-aminomethylpropanol (AMP) buffer maintains 
the required alkaline pH and acts as a phoshate acceptor, thus driving the reaction. 
Magnesium and zinc ions are present as ALP co-factors. 
 
XXI. C. TECHNICAL DATA 
• SAMPLE REQUIREMENTS 
Serum or heparinised plasma may be used. Specimens may be refrigerated 
overnight or stored at room temperature in seroseparator tubes. The ADVIA 2400 uses 
2 µL of sample in the test, although the minimum volume required in the specimen 
container is 50µL (micro sample cups) or 200µL (Vacutainers and inserts). 
• LINEARITY 
The ADVIA 2400 performs a number of checks on the validity of the reaction 
curve to ensure linearity and to check for substrate depletion. There is also the concept 
of 'point forwarding'. This means that an assay which exceeds absorbance limits over 
the normal measuring range of the assay uses an earlier set of measuring points to 
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obtain an acceptable reaction rate. The absorbance limits used are also variable 
according to the background absorbance of the sample and first reagent. This means that 
an exact linearity limit cannot be stated and that very few dilutions are necessary 
• REFERENCE RANGE 
The reference range for alkaline phosphatase is age-dependant according to the 
following table: 
 
Age range Reference range (IU/L) 
0 - 1 years 126 - 524 
1 - 3 years 129 - 291 
3 - 6 years 134 - 346 
6 - 9 years 156 - 386 
9 - 11 years 120 - 488 
11 - 13 years 178 - 455 
13 - 15 years 116 - 483 
15 - 18 years 58 - 237 




Appendix XXII GAMMA-GLUTAMYL TRANSFERASE (GGT) 
 
XXII. A. EXPLANATION OF THE TEST 
Gamma-glutamyl transferase (GGT) is an intracellular cytosolic enzyme present 
mainly in hepatic tissue. Plasma activity of GGT is raised by increased cell leakage (e.g. 
due to inflammation), increased cell turnover and the induction of enzyme synthesis 
which occurs via the cytochrome P450 system. Induction may be the result of 
metabolism of ethanol and certain drugs (e.g. barbiturates), and thus raised GGT 
activities may indicate long-term excessive alcohol consumption. As the level is not 
affected by changes in bone status GGT is a relatively specific and sensitive marker of 
obstructive and infiltrative hepatic disorders and is often seen raised in parallel with 
alkaline phosphatase. 
 
XXII. B. METHOD 
GGT reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton House, 
Sir William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD. 
GGT catalyses the transfer of the gamma-glutamyl residue of the artificial 
substrate gamma-glutamyl-3-carboxy-4-nitroanilide to the acceptor molecule 
glycylglycine. This liberates 4-nitroaniline which absorbs strongly at 410 nm. The 
increase in absorbance of 4-nitroaniline is directly proportional to the activity of GGT in 
the sample and expressed as IU/l by means of a conversion factor 
 
XXII. C. TECHNICAL DATA 
• SAMPLE REQUIREMENTS 
Serum or heparinised plasma may be used. Specimens may be refrigerated 
overnight or stored at room temperature in seroseparator tubes. The ADVIA 2400 uses 
10 µl of sample in the test, although the minimum volume required in the specimen 
container is 50µl (micro sample cups) or 200µl (Vacutainers and inserts). 
• LINEARITY 
The ADVIA 2400 performs a number of checks on the validity of the reaction 
curve to ensure linearity and to check for substrate depletion. There is also the concept 
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of 'point forwarding'. This means that an assay which exceeds absorbance limits over 
the normal measuring range of the assay uses an earlier set of measuring points to 
obtain an acceptable reaction rate. The absorbance limits used are also variable 
according to the background absorbance of the sample and first reagent. This means that 
an exact linearity limit cannot be stated and that very few dilutions are necessary. 
• REFERENCE RANGES 
Female: 1 - 45 IU/L 





Appendix XXIII INSTRUCTIONS FOR 24H BLOOD PRESSURE 
MONITORING 
 
24 hour Blood Pressure Monitoring - Subject Information Sheet 
 
The aim of this test is to monitor what is happening to your blood pressure over a 24 hour 
period. Please make your measurement 2 or 3 days before your visit to FWB. Please try to make 
the measurement over 25h, as the first hour when you are getting used to wearing the monitor 
does not always give us a representative reading. You will be asked to do your measurement at 
approximately the same time before each visit. 
 
We will provide you with a diary card to fill in on the day of measurements, please fill in your 




Night and day; the blood pressure cuff has two settings; a day time setting and a night time 
setting. The monitor will automatically change to night time settings at 10pm and day time 
settings at 7am. 
Frequency of cuff inflation; During the day time the cuff will inflate every 30 minutes, during 
the night time the cuff will inflate every 1 hr.  
 
During a measurement:  
To avoid incorrect results the arm must be kept still during measurements. 
If you are standing; let your arm hang loosely, whilst keeping it still. 
If you are sitting; rest your arm loosely on a table or let your arm hang loosely, whilst keeping it 
still. 
Avoid opening and closing your hand during the measurement, and do not move your fingers. 
Ensure the air tube is not kinked while the measurement is being taken. 
If you are driving when a measurement starts, continue to drive normally and do not worry 
about keeping the arm still (please make a note on the diary card if this happens), or turn the 
monitor off whilst you are driving. 
While you are asleep, place the recorder on its side so that the air tube will not kink. 
In the event of failed measurements the monitor will repeat the measurement. 
 
 
Between measurements:  
Engage in normal activities. 
Check that the yellow mark is still in position as the cuff may move during the day. 
 
 
Using the blood pressure monitor 
 
How to put the cuff on upper arm: 
Put the cuff on the upper left arm so that the position of the yellow marking of the cuff is on the 
artery; the opposite side to your elbow. 
The cuff should be wrapped on the arm tightly, but still allow a finger to slide between the cuff 
and the arm. 
 
How to turn the monitor on and off: 
To start the 24-hr measurement press and hold the black ‘AUTO ON/OFF’ button until it bleeps 
and the letter ‘A’ appears on the display.  
To turn the monitor off or pause it when you take the cuff off (during bathing or exercise) press 
and hold down the ‘AUTO ON/OFF’ button until the letter ‘A’ is no longer on the display. 
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When you want to restart it press and hold the black ‘AUTO ON/OFF’ button until it bleeps and 
the letter ‘A’ appears on the display.  
To deflate the cuff or terminate a recording press the red START/STOP button.  
If the letter ‘E’ appears on the display at any time this means that there is an error and you will 
need to contact Aseel or Sarah. If the letter ‘B’ appears on the display at any time this means 
that the batteries need replacing. 
 
If water gets into the unit, please remove the cuff and do not continue using the recorder. Turn 
off the unit and remove the batteries. 
 
Some notes on operation: 
Display  
 









A  - This is displayed when the unit is in automatic measurement mode 
B – This is displayed when battery capacity is low 







In case of any problems please call Aseel or Sarah on 020 7848 4594 or in emergency 
07789002228 or 07964919960. 
  
IF YOU EXPERIENCE ANY PAIN OR AN EXTREMELY UNPLEASANT SENSATION 
DURING MEASUREMENTS PLEASE TURN OFF THE UNIT IMMEDIATELY, USING THE 
A S 
B 
Red START/STOP button - can be used during 
a measurement to terminate a measurement and deflate 
Black AUTO ON/OFF button – this will switch 
the monitor on to automatic mode (press for 3 seconds, 
until the letter ‘A’ appears on the display) or to cancel 
automatic mode (press again for 3 seconds, until the 
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Name:      Date:   
Please fill in your activity level at the time of measurement, the time you go to bed, the time you 
get up and any unusual circumstances. 
 
Time you go to sleep…………  Time you wake up…………..... 
 
Did you take any exercise Y / N  If Yes at what time…………....  
Time Activity level (please circle) Other 
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
Time Activity level Other 
 Lying down Sitting Walking  
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 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  






Brief Instructions: Refer to the 24 hour Blood Pressure Monitoring - Subject Information 
Sheet for full instructions.  During the day time (7am – 10pm), the cuff will inflate every 30 
minutes and during the night time (10pm-7am) every 1 hr. Between measurements engage in 
normal activities, also check that the yellow mark is still in position as the cuff may move 
during the day. The arm must be kept still during measurements. To start the 24-hr measurement 
press and hold the black ‘AUTO ON/OFF’ button until it bleeps and the letter ‘A’ appears on 
the display. To turn the monitor off or pause it whilst bathing etc press and hold down the 
‘AUTO ON/OFF’ button until the letter ‘A’ is no longer on the display. To deflate the cuff or 
terminate a recording press the red START/STOP button.  
 
In case of any problems please call Aseel or Sarah on 020 7848 4594. 
 
IF YOU EXPERIENCE ANY PAIN OR AN EXTREMELY UNPLEASANT SENSATION DURING 
MEASUREMENTS PLEASE TURN OFF THE UNIT IMMEDIATELY, USING THE ON/OFF KEY 








We would like to remind you that your appointment for the EPA and DHA Trial 
is at 9 am* tomorrow morning. 
 
You will need to arrive at the metabolic unit on the 4th floor of Franklin-Wilkins 
building at the time stated above. There will be arrow signs on the 4th floor to guide 
you. Please use the phone at the end of corridor A to ring the unit on extension 4304 or 
4594 when you arrive, and we will come and get you. 
 
Please remember not to drink alcohol today and to arrive fasting, having not 
consumed any food or drink, except water, from 11pm* tonight. You should also avoid 
coffee from midday, any strenuous exercise, and consume a low fat dinner: please avoid 
any fried food, red meat or cakes, but you can have fruit, veg and starch - potato, pasta, 
rice... - as much as you like. You could also get the ready to eat low fat meals from 
Sainsbury (be good to yourself) or Tesco (healthy living) for example. We strongly 
advice that you drink water before you arrive to avoid dehydration. 
 
Please remember to bring back the blood pressure monitor and urine tanks, as 
well as the remaining capsules and the container. We will give you new ones for the 
next 6 weeks of intervention**. 
 
Thanks again for taking part in the study,  
 
We are looking forward to seeing you tomorrow, 
 
 
Sarah & Aseel 
 
 
*   Times were adapted so the subject fasts for the 12h preceding the visit. 
** Sentence was removed for the reminder of the second visit. 
 
  


















24h Blood pressure 
and diary card 
PARTICIPANT








1  /  2 /  INTERVENTION
 
Low fat meal last night (< 10 g fat)                                        
Fasted since 10 pm last night                                              
No caffeine since midday yesterday                                      YES / NO
No alcohol all day yesterday                                                  YES / NO
No exercise all day yesterday and today                               YES / N
No medications taken since the beginning of the study        YES / NO
No supplements taken since the beginning of the study       YES / NO
Compliance to oily fish consumption restriction                    YES / NO
Compliance to capsules intake 5/d      
Advise to sip water 
                                                                                              
Order of draw: 
1. 8.5 ml serum (Adpn...) 
2. 8.5 ml serum (sdLDL, Nox, IF...)
3. 4 ml LH 
4. 4 ml FX 
5. 4.5 ml Citrate (IsoP) 
6. 4.5 ml Citrate (IsoP) 
7. 4.5 ml EDTA (EPC) – RELEASE TOURNIQUET
8. 4.5 ml EDTA (PGI2) 
9. 4.5 ml Citrate (PMA) 
                                                                                             
Collected:                                                                          YES / NO
Data transferred:                                                               
Start:     … : …                                                           Finish:   … : …   
Sleep:   … : …   to   … : …    




A  /   B  /   C  /  
YES / NO 







                                 YES / NO 
YES / NO 
 
 
YES / NO 
 






To be taken at 2-5 
minute intervals 
Reading 1:      (S) Pulse: 
                        (D) 
Reading 2:      (S) Pulse: 
                        (D) 
Reading 3:      (S) Pulse: 
                        (D) 
Average of reading 2 & 3:     (S)        Pulse: 





DVP 1 2 3 Average 
HR (bpm) 
    
SI (m/s) 
    
RI (%) 
    
PPT (ms) 




PWA 1 2 3 Average 
SBP(mmHg) 
    
DBP(mmHg) 
    
MAP 
    
HR(bpm) 
    
CSp(mmHg) 
    
CDp(mmHg) 
    
Peripheral AIx 
% 
    
Central AIx % 
    
P1 (mmHg) 
    
T1 (ms) 







Appendix XXVII PREPARATION OF PLASMA SAMPLES FOR F2-
ISOPROSTANE ANALYSIS  
 
XXVII. A. SAMPLE PREPARATION 
Blood was collected into 4.5 ml citrate tubes chilled on ice beforehand. Each 
citrated blood sample (4.5 mL) was spiked with 34 µl of 2mM indomethacin solution 
and mixed several times. Blood samples were then allowed to stand on ice for 30 min 
and centrifuged at 2400 g for 15 min at 4ºC. Plasma was aspirated and transferred to 
cryovials (2 mL each). 6 µl of 5mM BHT ethanolic solution were then added to each 2 
mL aliquots before storage at -80ºC 
XXVII. B. SOLUTION PREPARATION 
Indomethacin is a 2 mM (0.716 mg/ml) working solution in 5% w/v aqueous 
NaHCO3 (sodium hydrogen carbonate) solution. 5 g NaHCO3 were dissolved in 10 mL 
distilled water (water bath). 7.16 mg indomethacin (± 0.5 mg) were added and dissolved 
again using the water bath. 
Indomethacin solution was prepared prior to blood collection and discarded after 
24h. 
 
BHT (butylated hydroxytoluene) was prepared as a 5 mM (1.102 mg/ml) stock 
solution in ethanol. 11.02 mg BHT (± 0.5 mg) were dissolved in 10 ml ethanol (or 27.55 
mg in 25 mL). 
BHT solution was stored for 2 weeks at 4oC before being discarded. 
 50
Appendix XXVIII BLOOD HANDLING PROTOCOL (STUDY DAYS)  
TUBES Order Draw ICE/ RT CENTRIFUGE 
SEPARATION ANALYTES Labels ANALYSIS STORAGE 
ul / vial vials 
4 ml fluoride 
oxalate (grey) 4 ICE 15m X 1300g 4°C 
3 1 Glucose Glc KCL– ILAB -40°C 
3 1 Spare Sp   -40°C 
8.5 ml serum  1 RT 15m X 1300g 4°C 
200 1 Adiponectin Adpn Unilever -80°C 
200 1 CRP CRP KCH -40°C 
200 1 Resistin Res Unilever -40°C 
200 1 spare Sp1   -40°C 
8.5 ml serum  2 RT 15m X 1300g 4°C 
200 1 sdLDL sdLDL   -80°C 
200 1 TAG, NEFA, cholesterol, HDL FLIP KCL - ILAB -80°C 
200 1 MMP-9 MMP9   -80°C 
500 1 NOx  NOx  KCL -80°C 
200 2 Inflammatory Markers IF   -80°C 
200 2 Spare Serum Sp2,3   -80°C 
200 1 Apolipoprotein B100 ApoB100 KCL -80°C 
200 1 Apolipoprotein A1 ApoA1   -80°C 
4 ml for 
insulin (LH) 3 ICE 15m X 1300g 4°C 
300 1 Insulin  Ins KCH -40°C 
300 1 Spare Sp   -40°C 
4.5 ml EDTA  8 ICE 15m X 1300g 4°C 
500 1 PFA PFA KCL - GLC -40°C 
600 1 prostacyclin PGI2 KCL -80°C 
200 2 spare EDTA Sp1,2   -80°C 
4.5 ml EDTA  7 ICE 
Before centrifugation ~1000   EPC EPC KCL Fresh WB 
15m X 1300g 4°C pellet   Erythrocyte lipids + spare Er Lip1,2   Fresh cells/ -40°C 
500 1 spare EDTA Sp3   -80°C 
3 *4.5 ml 
Citrate (blue) 
5 
ICE 15m X 1300g @ 21°C 1500 1 isoprostane IsoPs KCL -80°C 
6 1500 2 Spare CitSp1,2   -80°C 
9 RT Before centrifugation ~500   PMA PMA KCL Fresh WB 
15m X 1300g @ 21°C 500 1 spare CitSp3   -80°C 
  
Appendix XXIX NON ESTERIFIED FATTY ACIDS (NEFA) 
XXIX. A. EXPLANATION OF THE TEST 
Non-esterified fatty acid (NEFA) in the blood is bound to albumin and is used an 
important energy source of peripheral tissues. The amount of NEFA in serum depends on a 
balance between intake by the liver and peripheral tissues, and the release from adipose 
tissue. NEFA is decreased by physical exercise, and increased by starvation, cold, fear or 
smoking.  
NEFAs play a key role in diabetes mellitus and insulin resistance. The occurrence of 
insulin resistance, glucose intolerance, high blood pressure, obesity and lipid disorders is 
described as metabolic syndrome. An increase in NEFA plasma concentration is reported for 
insulin resistance. NEFA, therefore is a risk marker of diabetes mellitus type 2 development. 
XXIX. B. METHOD 
NEFA Assay kit is supplied by WAKO Chemicals Gmbh, Fuggerstrabe 12, D-41468 
Neuss, Germany 
NEFA in the sample is converted to acyl coenzyme A, AMP and pyrophosphoric acid 
(PPi) by the action of acyl coenzyme A synthetase (ACS), under coexistence with coenzyme 
A (CoA) and ATP. Obtained acyl coenzyme A is oxidised and yields 2,3-trans-Enoyl-CoA 
and hydrogen peroxide by the action of acyl coenzyme A oxidase (ACOD). In the presence of 
peroxidase (POD), the hydrogen peroxide formed yields a blue purple pigment by 
quantitative oxidation condensation with 3-Methyl-N-Ethyl-N-(ß-Hydroxyethyl)-Aniline 
(MEHA) and 4-amino-antipyrine (4-AA). 
Non-esterified fatty acids concentration is obtained by measuring absorbance of the 
blue purple colour. 
    ACS 
RCOOH + ATP + CoA                                  Acyl-CoA + AMP + PPi 
 
 
          ACOD 
Acyl-CoA + O2                                             2,3-trans-Enoyl-CoA + H2O2 
 
 XXIX. C. TECHNICAL DATA 
• PRECISION 
Intra-assay & inter-assay precision is not more than 1.5% 
• SAMPLE REQUIREMENTS 
Serum or EDTA plasma are recommended and they should be separated from cells 
within 3 hours of collection. Specimens may be stored at +2 to +8° for up to 2 days or at -
20°C for up to 3 months. For longer storage -80°C is recommended.  
• SENSITIVITY 
The minimum detectable concentration of NEFA is 0.01mmol/L. 
• REFERENCE RANGE 
Male:-  0.1 – 0.60 mmol/L 





 Appendix XXX INSULIN 
XXX. A. EXPLANATION OF THE TEST 
Insulin may be used, along with glucose and C-peptide levels, to help diagnose 
insulinomas and to help diagnose the cause of documented acute or chronic hypoglycemia. 
Insulin and C-peptide levels may also be used to monitor the amount of endogenous insulin 
produced by the beta cells, to check for insulin resistance, and to help determine when a type 
2 diabetic might need to start taking insulin to supplement oral medications. 
XXX. B. METHOD 
Insulin reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton House, Sir 
William Siemens Square, Frimley, Camberley, Surrey, Gu16 8QD. 
The Siemens Advia Centaur assay is a two-site sandwich immunoassay using direct 
chemiluminometric technology which uses constant amounts of two antibodies. Sample is 
incubated with two insulin-specific antibodies. The first is in the Lite reagent, is a 
monoclonal mouse anti-insulin antibody labelled with acridinium ester. The second antibody, 
in the solid phase, is a monoclonal mouse anti-insulin antibody, which is covalently coupled 
to paramagnetic particles. Insulin forms a sandwich between the two antibodies. After the 
incubation a magnetic field is applied causing the solid phase (including the sandwich) to be 
held at the site of the reaction cuvette while the liquid phase is aspirated. The cuvette is then 
washed with deionised water. Acid reagent (containing hydrogen peroxide) is then added to 
the cuvette to begin the light emission reaction with the acridinium ester. The cuvette is then 
moved to the luminometer and base reagent is added to enhance the light reaction. Light 
intensity is measured immediately and converted to relative light units. This has a direct 
proportional relationship with the insulin concentration. 
XXX. C. TECHNICAL DATA 
• INTRA-ASSAY PRECISION  
 Level 1 Level 2 Level 3 
Mean (mU/L) 14.68 45.72 124.51 
CV (%) 4.6 3.2 3.3 
• INTER-ASSAY PRECISION 
 Level 1 Level 2 Level 3 
Mean (mU/L) 14.68 45.72 124.51 
CV (%) 5.9 2.6 4.8 
 • SAMPLE REQUIREMENTS 
The specimen should be serum from a plain or gel separator vacutainer. The usual 
precautions for venipuncture should be observed.  
Serum should be placed in the freezer at -20°C until assayed. Avoid repeat freeze-
thaw cycles. 
To assay the sample in duplicate a minimum of 50 µL is required. However, the 
sample tube should contain at least a volume of 250 µL to account for the dead volume and 
dilution. 
• SENSITIVITY 
The minimum detectable concentration is 0.5 mU/L. 
• LINEARITY 
Serum concentrations up to 300 mU/L. 
• STANDARDIZATION 
The ADVIA Centaur Insulin assay standardization is traceable to World Health 
Organization (WHO) 1st IRP 66/304 Assigned values for calibrators are traceable to this 
standardization. 
 
 Appendix XXXI GC-NCI-MS PROCEDURE FOR ISOPROSTANE ANALYSIS 
 
Instrument: Agilent Technologies 6890N network Gas Chromatograph system equipped 
with 7683 series autoinjector, PTV (Gerstel) Inlet and 5673 inert mass selective detector with 
chemical ionization module 
 
Data/Control System: Agilent Enhanced MSD Chem Station running on Windows XP 
Professional 
 
XXXI. A. OPERATING PARAMETERS 
- Column Type: Supelco SPB-1701 capillary. 
- Column Dimensions: 30m length x 250µm (i.d) x 0.25µm film thickness 
- Injection Liner: Open Baffle 
- Inlet Type: Programmable Temperature Vaporization (PTV) 
- Carrier Gas: Helium (Air products GC grade) 
- Column Flow: 1.5ml/min (Constant flow mode) 
- Injection Mode: Solvent vent 
- Inlet Temperature Programme: 50C, 0.5min., then↑ 600C/min. to 300min., 2 minutes 
- Pneumatics control: Vent pressure 1.0psi, vent flow 50ml/min, vent end time 0.4 min. 
purge time 1.5min. 
- Injection Volume: 10µl total as 5x 2µl, 1s delay time 
- Oven Programme: Initial Temp.80C, 1.8min. then↑ 34 C/min. to 235C then ↑ 
10.3C/min. to 280C, 10min. 
- Interface/Source/Quad Temperatures: 280C/150C/150C 
- EM Offset: 400 above autotune 
- Solvent Delay: 12min. 
- Tune File: ncich4.u 
- Acquisition Mode: NCI SIM 
- Resolution: Low 
- Dwell time per ion: 120ms 
- Ion masses: 569, 573 corresponding to carboxylate anion (M-181) via a dissociative 
electron capture mechanism 
 
XXXI. B. PRE-START CHECKS 
Before setting up for a run ensure an adequate supply of the following : 
- Helium ( check cylinder guage) 
- Methane Reagent Gas ( check pressure gauge and replace cylinder if necessary) 
- Isooctane in autoinjector wash vials ( Top up if necessary) 
 
XXXI. C. STARTUP (FROM STANDBY STATE) 
- Depress Gas A button on flow control module to allow Methane to enter the system 
- Depress adjacent Purge button to flush out system with Methane at maximum 
- Allow system to purge for a few hours before switching off the purge (press purge 
button again) and  allowing gas to flow at 40. 
- From the PC load the method file PGF-NCI. This will automatically download the 
operating parameters to the GC-MS system. 
 - Perform a tune if necessary. 
 
XXXI. D. SETTING UP AND INITIATING A RUN 
- Load autoinjector vial rack with the sample batch (standards at front). 
- Using the Chem Station Sequence Editor create a sequence i.e a list of samples  to be 
injected in a defined order, together  with the methods under which the data is to be 
acquired and the files for data storage.                
- Click on run sequence command to execute the analysis schedule. 
 
XXXI. E. SHUTDOWN ( TO STANDBY) 
- Following completion of run, turn off reagent gas and leave system in standby state. 
 
XXXI. F. CHROMATOGRAPHIC DATA EVALUATION 
- Check chromatograms to ensure that the peaks have been correctly assigned. If 
retention times have drifted outside of the preselected retention time windows then it 
will be necessary to edit the peak table and reprocess the data. 
- If necessary adjust integration settings to improve chromatograms. 
 
XXXI. G. CALCULATIONS 
- Construct a calibration graph for each component i.e a plot of ratio of peak area of 
component of interest to that of internal standard against concentration of component 
in standard. Perform linear regression analysis to determine the best fit line for the 
calibration data. Using the corresponding area ratios for the samples interpolate 
concentration values using the equation of the regression line. 
 
  
 Appendix XXXII REVIEW PAPER 
 
The differential effects of EPA and DHA on cardiovascular risk factors. 
Cottin SC, Sanders TA, Hall WL. 
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The differential effects of EPA and DHA on cardiovascular risk factors
S. C. Cottin*, T. A. Sanders and W. L. Hall
Diabetes and Nutritional Sciences Division, School of Medicine, King’s College London, 150 Stamford Street,
London SE1 9NH, UK
Compelling evidence exists for the cardioprotective benefits resulting from consumption of
fatty acids from fish oils, EPA (20:5n-3) and DHA (22:6n-3). EPA and DHA alter membrane
fluidity, interact with transcription factors such as PPAR and sterol regulatory element binding
protein, and are substrates for enzymes including cyclooxygenase, lipoxygenase and cyto-
chrome P450. As a result, fish oils may improve cardiovascular health by altering lipid
metabolism, inducing haemodynamic changes, decreasing arrhythmias, modulating platelet
function, improving endothelial function and inhibiting inflammatory pathways. The indepen-
dent effects of EPA and DHA are poorly understood. While both EPA and DHA decrease TAG
levels, only DHA appears to increase HDL and LDL particle size. Evidence to date suggests
that DHA is more efficient in decreasing blood pressure, heart rate and platelet aggregation
compared to EPA. Fish oil consumption appears to improve arterial compliance and endothelial
function; it is not yet clear as to whether differences exist between EPA and DHA in their
vascular effects. In contrast, the beneficial effect of fish oils on inflammation and insulin
sensitivity observed in vitro and in animal studies has not been confirmed in human subjects.
Further investigation to clarify the relative effects of consuming EPA and DHA at a range of
doses would enable elaboration of current understanding regarding cardioprotective effects of
consuming oily fish and algal sources of long chain n-3 PUFA, and provide clearer evidence for
the clinical therapeutic potential of consuming either EPA or DHA-rich oils.
EPA: DHA: n-3 fatty acids: Cardiovascular risk: Vascular function
In the late 1970s, Dyerberg and Bang(1) were the first to
highlight the cardioprotective effect of dietary long chain
n-3 PUFA (n-3 LCP) present in oily fish in the Inuit
population. It is now widely accepted that habitual oily fish
and fish oil intake decreases the risk of CVD(2,3) such as
fatal CHD(4,5) and stroke(5,6). Over the past 30 years, the
mechanisms by which fish oils improve cardiovascular
health have been extensively investigated, showing anti-
inflammatory, anti-arrhythmic and anti-aggregatory effects,
as well as an improvement in endothelial function (EF).
Responding to the abundance of evidence, national and
international organisations encourage an increased fish oil
consumption(7,8). n-3 LCP from fish oils include EPA
(20:5n-3) and DHA (22:6n-3), and have been developed
commercially as dietary supplements. Recent evidence
from randomised controlled trials has produced equivocal
results(9–11). Heterogeneity of the studies in terms of
dosage, duration, population target, sample size, as well as
the relative amount of EPA and DHA used in supplements
could account for the variability of the results. Since the
appearance of purified forms of DHA on the market in the
1990s, researchers have started to investigate the differ-
ential effects of EPA and DHA on cardiovascular health.
However, the number of human studies is still limited in
this field and the independent effects of EPA and DHA on
various cardiovascular outcomes are yet to be firmly
Abbreviations: AA, arachidonic acid; a-LNA, a-linolenic acid; BP, blood pressure; COX, cyclooxygenase; CRP, C-reactive protein; CYP450, cyto-
chrome P450; EF, endothelial function; FMD, flow-mediated dilation; HMG, 3-hydroxy-3-methylglutaryl; HR, heart rate; HRV, HR variability; n-3 LCP,
long chain n-3 PUFA; LOX, lipoxygenase; LT, leukotriene; NOS, NO synthase; Rv, resolvin; SREBP, sterol regulatory element binding protein;
TX, thromboxane.
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established. Further understanding in this field is needed to
define optimal doses of EPA and/or DHA in order to target
different metabolic disorders, and to assess the relative
efficiency of algal DHA, which could be used as a source
of n-3 LCP in vegetarians.
Structure, formation and metabolism of EPA and DHA
EPA and DHA are derived from another n-3 PUFA,
a-linolenic acid (a-LNA; 18:3n-3) (Fig. 1), which is found
in common vegetable oils, such as linseed or walnut oils.
a-LNA is an essential fatty acid, i.e. it has to be provided in
the diet as human subjects are unable to synthesise it. Some
studies suggested that a-LNA has cardioprotective effects,
but evidence is not as robust as for EPA and DHA and there
are insufficient data to encourage increasing a-LNA con-
sumption(12) in order to reduce cardiovascular risk. Human
subjects can only convert a-LNA to longer-chain n-3 LCP at
a very low rate, especially DHA(13,14), and the reduced
potency or absence of effect of dietary a-LNA in improving
cardiovascular risk factors suggests that dietary intake of n-3
fatty acids in the form of oily fish or supplements is desirable
for optimal health. Cardioprotective benefits of a-LNA are
mainly attributed to competition for D6-desaturase with
linoleic acid (C18:2n-6), found in abundance in vegetable
oils, seeds and nuts, and a precursor for arachidonic acid
(AA; C20:4n-6), also directly obtained from animal sources
including meat, eggs and dairy products, leading to produc-
tion of more EPA and less AA. EPA competes with AA
through the cycloxygenase (COX) and lipoxygenase (LOX)
pathways, leading to a set of lipid mediators that improve
vasodilation and decrease inflammation, as well as aggre-
gation. Upon the action of aspirin, EPA and DHA can be
converted by the COX and LOX pathways into similar
families of resolvins, E and D series, respectively(13).
Fig. 1. Outline of the formation of EPA and DHA and their metabolites. a-LNA, a-linolenic acid;
DPA, docosapentaenoic acid; COX, cyclooxygenase; LOX, lipoxygenase; CYP450, cytochrome
P450 enzymes; TX, thromboxanes; LT, leukotriene; EEQ, epoxyeicosatetraenoic acid;
HEPE, hydroxyeicosapentaenoic acid; EDP, epoxydocosapentaenoic acid; HDoHE, hydro-
xydocosahexaenoic acid.





















In addition, both EPA and DHA compete with AA for
the cytochrome P450 (CYP450) enzymes, leading to the
formation of important mediators of vasodilation(15). These
EPA- and DHA-derived eicosanoids are likely to exert
varying effects within the cardiovascular system.
DHA possesses a longer carbon chain and one more
double bond than EPA, which is thought to be the reason
for the greater influence of DHA on membrane fluidity and
cholesterol content(16), and thus on the activity of membrane
protein or ion channels. EPA and DHA, as well as their
broad range of derivatives, may also have a differential
effect on transcription factors such as PPAR(17), NF-kB(18)
or sterol regulatory element binding protein (SREBP)(19),
with subsequent differences in lipid metabolism, insulin
sensitivity and inflammation. This review will explore the
differential effects of EPA and DHA in human subjects
and relate it to possible molecular mechanisms.
Effects of EPA and DHA on plasma lipid and
lipoprotein metabolism
Dyslipidaemia, specifically hypertriglyceridemia, hyper-
cholesterolemia and/or a low HDL cholesterol level, is a
major risk factor for development of atherosclerosis and
CVD. The cardioprotective effects of fish oils are partially
attributed to their TAG-lowering action, while their effect
on cholesterol levels appears weak or inexistent.
Effect of EPA and DHA on TAG levels
Raised fasting and postprandial TAG concentrations are now
widely recognised as markers of cardiovascular risk(20,21).
There is strong evidence from epidemiological and inter-
vention studies that EPA+DHA consumption decreases
TAG levels(22), thus improving cardiovascular health, and
this appears to be dose-dependent(23). When administered
individually for 6 weeks or more, both EPA and DHA
decrease TAG levels in normolipidaemic(24,25) and hyperli-
pidaemic subjects(26) from 15 to 30%. Interventions of £ 4
weeks are less consistent. One study showed that 3 weeks of
supplementation with EPA or fish oil, but not DHA reduced
TAG levels in healthy human subjects(27). More recently,
Buckley et al.(28) showed that 4 weeks of supplementation
with DHA significantly reduced TAG levels in normolipi-
daemic human subjects by 22%, while EPA decreased TAG
levels by 15% without reaching significance. In another 4-
week intervention in healthy human subjects, both EPA and
DHA reduced postprandial TAG without affecting fasting
TAG levels(29). However, when given for a sufficient
period, EPA and DHA seem to reduce triglyceridaemia with
no apparent differential effect (24–26,28–32) (Table 1).
Effect of EPA and DHA on lipoprotein profiles
Fish oils generally have no effect on total cholesterol but
their influence on LDL and HDL cholesterol is variable,
depending on the dose, form and population. Meta-analysis
of EPA+DHA supplementation studies showed a very
slight increase in LDL (n14009) and HDL (n15106)
cholesterol levels, but these were clinically insignificant(22).
The majority of studies investigating the effect of algal DHA
(that also contains docosapentaenoic acid, 22:5n-3) reported
a moderate but significant increase in both HDL and LDL
levels(33–37). Few studies have reported the differential effect
of purified EPA and DHA from fish oils on plasma LDL and
HDL cholesterol. Relatively high doses of DHA (2–4g/d;
6–7 weeks) increased HDL levels by 4–13% in normolipi-
daemics, whereas similar doses of EPA had no effect(24,25).
However, DHA but not EPA (3.7 and 3.8 g/d, respectively,
6 weeks) increased total LDL by 8% in hyperlipidaemic
subjects, while no significant effect was observed on total
HDL levels(26). Our recent research observed that
neither EPA nor DHA (3 g/d, 6 weeks) affected TAG, HDL










TAG levels Control Reference
Parallel Normolipidaemic human subjects EPA Spread 2.2 ﬂ (15%) None (25)
n 74 DHA 2.3 ﬂ (31%)
4 Parallel Normolipidaemic human subjects EPA EE 4.8 ﬂ (15%, NS) Olive oil (28)
n 42 DHA 4.9 ﬂ (22%)
6 Parallel Hyperlipidaemic human subjects EPA EE 3.84 ﬂ (18%) Olive oil (26)
n 56 DHA 3.68 ﬂ (20%)
7 Parallel Normolipidaemic human subjects EPA EE 3.8 ﬂ (21%) Corn oil (24)
n 224 DHA 3.6 ﬂ (26%)




n 38 DHA 3.7 ﬂ (19%)
6 Parallel T2D human subjects with treated
hypertension
EPA EE 3.84 ﬂ (15%) Olive oil (31)
n 50 DHA EE 3.68 ﬂ (19%)
7 Parallel Dyslipidaemic human subjects EPA EE 3.04 ﬂ (23%) Olive oil (32)
n 38 DHA EE 2.84 ﬂ (32%)
4 Parallel Normolipidaemic human subjects EPA EE 3.8 = Safflower oil (29)
n 33 DHA EE 3.8 =
EE, ethyl ester; NS, non-significant; T2D: type 2 diabetes; ﬂ, decrease; = , no change.





















or LDL cholesterol levels in normolipidaemic young men
(SC Cottin, TAB Sanders and WL Hall, unpublished
results).
Beyond cholesterol levels, LDL and HDL subfractions
have emerged as candidate markers of cardiovascular risk.
LDL particle size correlates negatively with TAG levels
and positively with HDL levels(38). Larger HDL (HDL-2)
carry more cholesterol and are more protective than their
counterpart (HDL-3)(39). In general, dietary fish oil
increases HDL-2 levels(40,41), sometimes without a sig-
nificant change of HDL level(42), and also decrease small
dense LDL levels(41,43). When given individually, DHA
but not EPA increased both LDL and HDL particle size in
hyperlipidaemic and healthy human subjects(26,27),
although EPA alone also increased HDL-2:HDL-3 in
hypercholesterolaemic subjects(44). High doses of DHA
alone (3 g/d, 45 d) also increased LDL particle size in
hypertriglyceridaemic men(35), whereas low doses of DHA
alone (0.7 g/d) increased LDL by 7% and LDL:apoB ratio
by 3.1% in middle-aged women and men(45), suggesting an
increase in LDL size.
Hypertriglyceridaemia is a result of overproduction
and/or decreased catabolism of TAG-rich lipoproteins,
including VLDL and chylomicrons. There is growing evi-
dence that EPA and DHA exert their TAG lowering effects
by reducing VLDL TAG release from the liver and by
increasing TAG clearance from chylomicrons and VLDL
particles(46), as well as altering VLDL concentration and
particle size(47). The potential molecular mechanisms have
been comprehensively reviewed by Harris et al.(46) and
notably involves the modulation of transcription factors
activity, including SREBP and PPAR. SREBP-1c controls
enzymes responsible for fatty acid and TAG synthesis,
while SREBP-2 modulates enzymes involved in choles-
terol synthesis. In animal and in vitro models, both EPA
and DHA were reported to down-regulate SREBP-1c
activity, and this was associated with a decrease in lipo-
genic enzymes expression(19,48,49). In addition, both EPA
and DHA are PPAR ligands and EPA and DHA stimulate
b-oxidation of fatty acids through PPARa-dependent
mechanisms in rats(50), thus contributing to the decrease
in TAG release by the liver. Lipoprotein lipase, located in
capillary endothelium, hydrolyses circulating TAG in
TAG-rich lipoprotein, generating NEFA. EPA and DHA
(4 g/d, 4 weeks) were equally as effective in accelerating
chylomicron TAG clearance by stimulating lipoprotein
lipase activity in healthy human subjects(29); possibly via
PPARg-dependent mechanisms(51).
3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase is a
key enzyme in cholesterol synthesis and is inhibited by
both EPA and DHA in hepatocytes, probably through
SREBP-2 dependent mechanisms(52,53). Although HMG-
CoA reductase inhibitors (statins) are well known for their
hypocholesterolemic effect, this has not been a consistent
outcome of fish oils consumption. However, a common
mechanism for statins and EPA/DHA may be related to
increasing LDL and HDL particle size(54–56); in fact n-3
LCP and statins may exert a synergistic beneficial effect on
lipid levels(57), and it can be postulated that EPA and DHA
modulate particle size by a mechanism analogous to that of
HMG-CoA reductase inhibitors(58).
In summary, both DHA and EPA reduce fasting plasma
TAG concentrations with no apparent differential effect,
probably by inhibiting VLDL-TAG release and increasing
TAG clearance. DHA appears to increase HDL and LDL
particle size through the regulation of cholesterol synthesis
and lipid transfer between lipoprotein.
Effects of EPA and DHA on haemodynamics
Blood pressure
Hypertension is a strong predictor of cardiovascular risk,
and there is convincing evidence that reducing blood
pressure (BP) decreases the risk of total mortality, cardio-
vascular mortality and stroke(59,60). Numerous epidemi-
ological and intervention studies have demonstrated a
hypotensive role of fish oils(61). In a meta-analysis of
thirty-one placebo-controlled trials, Morris and co-workers
showed that fish oils reduced BP with a dose-dependent
effect (systolic BP/diastolic BP: - 0.66/- 0.35mm Hg/g n-3
fatty acids), and so is of potential benefit to patients with
hypertension, atherosclerosis or hypercholesterolaemia(62).
A more recent meta-analysis of thirty-six intervention trials
confirmed the hypotensive role of fish oils on both systolic
BP and diastolic BP, especially in elderly and hypertensive
patients, although the clinical effect of doses lower than
0.5 g/d, equivalent to one portion of oily fish a week, could
not be established(63). Few human studies have investi-
gated the separate effects of EPA and DHA on BP; these
have generally been assessed by seated office measure-
ments, with no significant lowering effects in hypertensive,
dyslipidaemic and healthy human subjects(31,32,64). How-
ever, low doses of DHA alone (from algal sources) were
shown to decrease diastolic BP in healthy subjects(65).
Ambulatory BP, where monitors are worn and take read-
ings at regular intervals over 24 h, considered to be an
estimate of the true mean BP level(66), is more sensitive
than the conventional office BP in predicting cardiovas-
cular events(67,68). Mori and co-workers investigated the
effect of 6-weeks supplementation with EPA or DHA (4 g/
d) on ambulatory BP and showed that DHA but not EPA
decreased both 24 h and daytime systolic and diastolic
ambulatory BP in mildly hyperlipidaemic males(69).
Heart rate
A high heart rate (HR) has been long associated with
cardiovascular morbidity and mortality in epidemiological
studies. It is positively correlated with hypertension and has
only recently emerged as an independent cardiovascular risk
factor to be targeted to reduce cardiovascular events, espe-
cially in high-risk populations(70). A meta-analysis including
thirty randomised controlled trials showed that fish oil intake
reduces HR, especially in populations with a high-baseline
HR and when consumed for a longer intervention
period(71). This effect appears to be mediated by DHA rather
than EPA: DHA alone (2.8 g/d) decreased HR by 7% in
postmenopausal women(72), and DHA but not EPA
decreased HR by 3.5 beats per minute (bpm) and 2.2 bpm, in
hyperlipidaemic males(69) and healthy males(64), respec-
tively. In contrast, Woodman and co-workers showed no





















significant effect of neither EPA nor DHA on HR in healthy
males for similar dosage and treatment duration(31).
HR variability (HRV) is also a strong predictor of
CVD, including sudden cardiac death, arrhythmic CHD and
atrial fibrillation. Fish oils have shown anti-arrhythmic
properties in animal studies(73), and several clinical and
epidemiological studies have reported an association be-
tween an increase (improvement) of HRV and n-3 LCP
blood cell levels and/or fish oil consumption(74–76). How-
ever, fish oils fail to improve HRV in several other human
interventions. For example, n-3 LCP supplementation did
not increase HRV in haemodialysis patients(77), and failed to
increase HRV calculated from 10min recordings(78) or 24 h
Holter recordings(79) in healthy men. Nevertheless, the
authors of the latter study noted that subjects presented with
a particularly high baseline HRV, and subanalysis showed
a significant improvement of HRV for subjects with lower
baseline values(79). Inconsistency in the results of inter-
vention trials might be due to variability of design, treatment
duration, sample size or duration of HRV measurement; a
prospective observational study (n 4263) reported that fish
oil consumption, recorded over a year, correlated with an
improvement of HRV, especially in older people(80).
As previously mentioned, the incorporation of EPA and
DHA into the cell membrane influences its organisation,
fluidity and permeability, as well as the activity of trans-
membrane proteins, including receptors, enzymes and
ion channels. Both EPA and DHA were shown to modulate
K, Na and Ca channel activities in myocardial cells,
regulating myocyte electrical excitability and contrac-
tility(81–83). These effects, observed in a concentration-
dependent manner, are thought to be mediated by the effect
of EPA and DHA on membrane fluidity(83), although other
mechanisms, such as direct binding of n-3 LCP to the chan-
nel could be involved(84). Furthermore, there is growing
evidence from animal studies that DHA, compared to EPA,
is preferentially incorporated into the myocardial cell mem-
brane(73). Collectively, these findings help to explain the
anti-arrythmic and HR-lowering effects observed with DHA
but not EPA in human subjects(69). In addition, incorporation
of DHA into the membrane of cardiomyocytes influences the
beta adrenergic system to a greater extent than EPA(85),
potentially an important mechanism in the hypotensive and
anti-arrhythmic effects of DHA. DHA incorporation into the
membrane of endothelial cells stimulates ATP release from
the endothelium, increasing vasodilation by stimulating
nitric oxide (NO) release(86). The induction of NO release,
together with the decrease in noradrenaline levels, is likely to
be responsible for the BP-lowering effect of DHA(86).
DHA, but not EPA, seems to have lowering effects on
BP and HR, very probably mediated by the increased
fluidity in the membrane cardiomyocytes, potentially im-
proving channel activity and beta adrenergic signalling.
More studies are necessary to confirm this differential
effect and understand the mechanisms involved.
Effects of EPA and DHA on endothelial function
and arterial compliance
Endothelial dysfunction is a key early event in the devel-
opment of atherosclerosis and is characterised by an
imbalance between molecules produced by the endo-
thelium, impairing vasodilation, inflammatory status and
haemostasis. In human subjects, EF can be assessed by
measuring plasma markers of EF, including NO and pros-
tacyclin metabolites (the two main vasodilators) or markers
of endothelial damage and/or activation, such as soluble
thrombomodulin, von Willebrand factor or E-Selectin.
EF can also be assessed by non-invasive techniques such
as plethysmography and flow-mediated dilation (FMD) or
invasive techniques like forearm blood flow, with FMD
being more commonly used. These techniques can also
be used to measure endothelium-independent vascular
response (using NO donors, or NO synthase (NOS) inhi-
bitors) or vasoconstrictive response. Endothelium-derived
mediators influence vascular tone and structure, thus
influencing arterial stiffness and microvascular function.
Non-invasive techniques have been developed to measure
arterial stiffness/compliance in order to assess vascular
function, which include pulse wave analysis, pulse wave
velocity(87) and digital volume pulse(88).
Endothelial function
Animal studies demonstrated that EF could be modulated
by feeding EPA and DHA(89–91). An observational study
reported that plasma and erythrocyte DHA levels were
positively associated with FMD in young smokers and
young adults at greater metabolic risk(92). Recent findings
suggest that fish oil consumption can improve EF in
human subjects, particularly in those with a high risk
of CVD (Table 2). Supplementation with n-3 LCP for
periods ranging from 2 weeks up to 8 months improved
endothelium-dependent vasodilation, prevented vasocon-
striction or augmented exercise-induced blood flow at
doses ‡0.5 g/d(93–107).
The comparative effects of EPA and DHA on EF have
been seldom investigated in human subjects (Table 2).
Supplementation with EPA alone (1.8 g/d; 3 months) in-
creased endothelium-dependent forearm blood flow response
in untreated hypertriglyceridaemic males(108), whereas DHA
alone (1.2 g/d; 6 weeks) improved endothelium-dependent
FMD in hyperlipidaemic children receiving nutritional
counselling(109). Supplementation with low doses of algal
DHA did not affect salbutamol-induced changes in digital
volume pulse reflection index (a measure of endothelium-
dependent vasodilation), but more extensively validated
techniques such as FMD are required to confirm this(65).
When the vasodilatory effects of high doses of EPA and
DHA (4 g/d, 6 weeks) were compared in overweight mildly
hyperlipidaemic males, DHA, but not EPA, decreased
vasoconstrictive responses to noradrenaline and increased
vasodilatory responses to acetylcholine(97). However, DHA
(but not EPA) also increased vasodilation in response to
the co-infusion of acetylcholine and NG-monomethyl-L-
arginine citrate (an NOS inhibitor), as well as sodium
nitroprusside (a NO donor), suggesting that the vasodilatory
effects of DHA were mainly mediated through endothelium-
independent mechanisms(97). In healthy volunteers, fish oil
concentrate, but not EPA alone, increased urinary excre-
tion of NO metabolites (nitrates/nitrites), suggesting that
EPA is unlikely to be responsible for the enhancement of
EPA and DHA: separate cardiovascular effects 5
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Table 2. Effect of fish oils on endothelial function in human randomised controlled trials.
Durationj
(weeks) Design Population Dosage Measurement Effect Function assessed References
Fish oils
6 Cross-over T2D patients 2 g/d Fasting FMD = EF (fasting) (106)
n 34 Fasting RH (Doppler) = EF (fasting)
Postprandial FMD › EF (postprandial)
Postprandial RH › EF (postprandial)
12 Parallel Elderly 2.5 g/d RH (mercury strain gauge
plethysmography)
› EF (104)




12 Parallel Offsprings of T2D 2g/d FMD › EF (102)
n 50 VCAM = ED/EA
ICAM = ED/EA
E-selectin = ED/EA
12 Parallel PAD patients 2 g/d FMD › EF (103)
n 32 sTM ﬂ ED/EA
24 Parallel Lupus erythematosus
patients n 60
3 g/d FMD › EF (107)
2 Parallel Healthy subjects 1 g/d FMD › EF (98)
n 26 FMD +GTN › Endothelium
independent
vasodilation
6 Crossover Chronic heart failure
patients (>65-year-old)
3 g/d FBF +Ach › EF (105)
n 20 FBF +SNP = Endothelium
independent
vasodilation
FBF +AT-II = Vasoconstriction
FBF + L-NAME = Vasoconstriction
6 Parallel Healthy subjects 5 g/d BA diameter (post contraction) › EF (101)
n 13 BA conductance (post contraction) › EF
BA blood flow (post contraction) › EF
32 Parallel Healthy subjects 1.1–1.2 g/d Laser Doppler +Ach › EF (95)
n 173 Laser Doppler +SNP = Endothelium
independent
vasodilation
16 Parallel Hypercholesterolemic subjects 4 g/d FMD › EF (94)
n 30 FMD +GTN = Endothelium
independent
vasodilation
4 Parallel Healthy subjects 1.5–5.9 g/d FBF +NAd ﬂ Vasoconstriction (93)
n 29 +AT-II ﬂ Vasoconstriction
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Table 2 (Continued)
Durationj
(weeks) Design Population Dosage Measurement Effect Function assessed References







1.8 g/d FBF +Ach › EF (108)




6 Crossover Hyperlipidaemic children 1.2 g/d FMD › EF (109)
n 20 ADMA = ED/EA
12 Crossover Healthy subjects 0.7 g/d sTM = ED/EA (65)




6 Parallel Overweight mildly
hyperlipidaemic
subjects
4 g/d EPA FBF +NAd = Vasoconstriction (97)
FBF +Ach = EF
FBF +Ach + L-NMMA = Endothelium
independent
vasodilation
FBF +SNP = Endothelium
independent
vasodilation
DHA FBF +NAd ﬂ Vasoconstriction
n 56 FBF +Ach › EF
FBF +Ach + L-NMMA › Endothelium
independent
vasodilation
FBF +SNP › Endothelium
independent
vasodilation
T2D, type 2 diabetes; PAD, peripheral arterial disease; CAD, coronary artery disease; FMD, flow-mediated dilation; RH, reactive hyperaemia; BA, brachial artery; EF, endothelial function; ED/EA, endothelial
dysfunction/endothelial damage; NOx, nitrates/nitrites; vWF, von Willebrand factor; VCAM, vascular cell adhesion molecule; ICAM, intercellular adhesion molecule; sTM, soluble thrombomodulin; FBF, forearm blood
flow; Ach, acetylcholine; SNP, sodium nitroprusside (NO donor); L-NAME, nitro-L-arginine-methyl ester (NOS inhibitor); GTN, glyceryl trinitrate (NO donor); AT-II, angiotensin II; NAd, noradrenaline (norepinephrine);
ADMA, asymmetrical dimethylarginine; L-NMMA, NG-monomethyl-L-arginine.







































NO production(110). In summary, there are too few data to
conclude whether EPA and DHA have differing effects on
endothelium-dependent vasodilation, but early indications
are that DHA might be more effective in improving EF.
Arterial compliance
Little is known about the influence of dietary n-3 LCP
on arterial stiffness, although it has been observed that
Japanese populations with higher intakes of n-3 LCP have
reduced arterial stiffness(111), and the results of two ran-
domised controlled trials indicate a beneficial effect(112,113).
Even less is known about the individual effects of either
EPA or DHA. Three-month supplementation with low
doses of DHA (0.7 g/d) in healthy subjects had no effect on
indices of arterial stiffness using digital volume pulse,
suggesting that either larger doses are necessary for mea-
surable changes to occur during that time period, that fish
oil is more effective in subjects at greater cardiovascular
risk (our group also found no effects of 3 g/d EPA or DHA
for 6 weeks in young healthy males (SC Cottin, TAB
Sanders and WL Hall, unpublished results)) or lastly, that
EPA rather than DHA is the active constituent of fish oil in
relation to arterial stiffness(65). In support of this, EPA
supplementation (1.8 g/d; 3 months) improved pulse wave
velocity and cardio-ankle vascular index in obese Japanese
subjects, the latter measure being a novel index of arterial
stiffness that is less influenced by BP than pulse wave
velocity(114). The same dose of EPA consumed for 12
months by hyperlipidaemic patients also prevented the
increase of pulse wave velocity due to ageing, even after
adjustment for gender, age and BP change(115). However,
not all evidence supports the theory that EPA is the sole
active constituent of fish oil in relation to arterial stiffness;
the only trial to compare the individual effects of EPA and
DHA showed that 7 weeks supplementation with EPA
increased systemic arterial compliance in dyslipidaemics
by 36% and DHA increased it by 27%, with no significant
differences in the size of the effect between the two
groups(32).
Microvascular dysfunction, as observed in hypertensive
and insulin-resistant states, is characterised by capillary
rarefaction in skin and muscle(116,117). Fish oil supple-
mentation increased capillary density in ventricles(118) and
skin (cheek pouch)(119) in hypertensive rats and hamsters,
respectively, suggesting there might be beneficial effects
on human microvasculature. Videomicroscopic techniques
(capillaroscopy) have been developed and used in human
subjects in order to look at microcirculation in the skin and
oral mucosa (tongue), which are readily accessible for
microscopic measurements (see comprehensive review(120)).
Capillaries appear either parallel (loops) or perpendicular
(dot or comma shaped) to the skin, and can be analysed in
terms of shape (tortuousness and diameter) and number
(density). Capillaroscopy also gives the possibility to
assess the velocity of the erythrocytes by video or laser
Doppler. However, to date, the effect of fish oil on this
outcome has not been investigated. In our recent trial,
neither EPA nor DHA changed finger capillary density
(Capiscope; KK Technologies) in healthy young men (SC
Cottin, TAB Sanders and WL Hall, unpublished results),
but further research is needed in sub-populations with
impaired microvascular function to ascertain whether fish
oils or individual n-3 LCP have protective effects.
The expression of endothelial NOS is vital to EF and
therefore a major factor in atherogenesis. Cell membranes
are organised in microdomains, called lipid rafts, that co-
localise transmembrane proteins involved in intracellular
signalling pathways. When incorporated into the mem-
brane, EPA and DHA can alter this organisation, thus
modulating signalling in various types of cells(121). In
endothelial cells, both EPA and DHA were shown to alter
the organisation of caveolae, a particular subset of lipid
rafts, and displace endothelial NOS from caveolae, a
necessary step in the activation of endothelial NOS(122,123).
This could potentially lead to an increase in NO release by
the endothelium and explain the putative beneficial effects
of EPA and DHA on vasodilation observed to date
(Table 2). EPA and DHA probably also influence the pro-
duction of the two other main vasodilators produced by
the endothelium: prostacyclin and endothelium-dependent
hyperpolarising factor. EPA, as a direct substrate for COX,
may be converted to 3-series prostacyclin, analogue to the
2-series prostacyclin derived from AA. Both EPA and
DHA increased 3-series prostacyclin production by endo-
thelial cells to the same extent without affecting 2-series
prostacyclin levels, suggesting a retroconversion from
DHA to EPA(124). In addition, EPA was shown to increase
acetylcholine-induced endothelium-dependent hyperpolar-
ising factor-mediated vasodilation in diabetic rats(125).
Endothelium-independent vasodilatory effects are mediated
by the modulation of Ca2 + signalling in smooth muscle
cells, but the mechanisms, especially with respect to the
type of Ca channels involved, remain uncertain(126–129).
AA, EPA and DHA are also substrates for the CYP450
enzymes that act as monooxygenases, catalysing hydro-
xylation, epoxidation or allylic oxidation. CYP450-
dependent derivatives include epoxyeicosatrienoic acids and
hydroxyeicosatetraenoic acids, potentially important factors
in the regulation of vasodilation and vasoconstriction, and
modulate renal, vascular and cardiac function. CYP450
enzymes are highly regioselective and stereospecific, and
several isoforms prefer n-3 LCP as substrates rather than n-6
LCP. Investigation into the physiological roles of CYP450-
dependent EPA and DHA metabolites is at an early stage,
but recent data suggest that CYP450-dependent mediators
derived from EPA and DHA contribute to the vasodilatory
and cardioprotective effects of fish oils(130). Interestingly,
different CYP450 isoforms have a different affinity, regios-
electivity and stereospecificity for EPA and DHA (see
comprehensive review(15)), leading to various sets of med-
iators that will exert varying effects on the vasculature.
In addition, EPA and DHA modulate EF through
anti-inflammatory effects. When endothelial cells undergo
inflammatory activation, they increase the expression of
adhesion molecules, allowing the migration of leucocytes
through the endothelium, an important process in the
pathophysiology of atherosclerosis(131). General patterns
that emerge from in vitro experimental literature indicate
that DHA has a greater effect than EPA in reducing
endothelial inflammation. DHA tends to inhibit markers of
EF, such as inflammatory cell adhesion molecules and





















monocyte chemoattractant protein-1 gene and protein
expression, and the adhesion of leucocytes to the endo-
thelium, whereas EPA either up-regulated gene expression
of monocyte chemoattractant protein-1 or was a weaker
inhibitor of cell adhesion molecules than DHA(132–137).
The effect of DHA on vascular cell adhesion molecule-1 is
likely to be mediated by the inhibition of the mobilisation
of the nuclear transcription factor, NF-kB(136), which
regulates the expression of numerous cytokines and other
adhesion molecules.
Fish oils generally improve EF and arterial compliance
in subjects at high cardiovascular risk. However, the
effects of fish oils in healthy human subjects and
the mechanisms (endothelium dependent and independent)
by which EPA and/or DHA improve vascular function are
yet to be fully established.
Effects of EPA and DHA on inflammation
Inflammation is an important process in the development
of CVD; and chronic inflammation, characterised by
elevated plasma levels of inflammatory markers, is com-
monly found in subjects at high cardiovascular risk,
including type 2 diabetics and patients with CHD.
Epidemiological studies strongly suggest that fish oils
have anti-inflammatory properties, and levels of n-3 LCP
in plasma, as well as in erythrocyte membrane, negatively
correlate with plasma pro-inflammatory markers, including
C-reactive protein (CRP) and IL-6(138,139). Another hypo-
thesis for the cardioprotective effects of fish oil supple-
mentation is the inhibition of cytokine production,
as measured directly in plasma or ex vivo, and studies
have been published that support and challenge the hypo-
thesis that n-3 LCP inhibit cytokine and CRP produc-
tion(102,103,140–150). In their recent meta-analysis including
twenty-one trials, Balk et al.(151) concluded that the effect
of n-3 LCP, including EPA and DHA, on CRP levels in
human subjects was unconvincing. In human subjects, only
one study investigated the differential role of EPA and
DHA (4 g/d; 6 weeks), reporting that plasma CRP, IL-6
and TNF-a remained unchanged in hypertensive type 2
diabetics(152). When investigated separately, DHA (3 g/d,
3 months) reduced CRP at 6 weeks and IL-6 at 12 weeks
of intervention in hypertriglyceridaemic subjects(153),
while EPA (1.8 g/d, 8 weeks) decreased CRP levels in
obese subjects(114). Lower doses of DHA, representative
of levels of intake obtained from dietary sources, failed
to affect plasma CRP levels in healthy subjects(65).
Complete understanding of this topic requires intervention
studies on the anti-inflammatory effects of long-term
combined EPA and DHA intakes at low doses (<1.5 g/d),
relevant to dietary guidelines for optimal health, and also
shorter-term higher doses EPA and DHA (1.5–5 g/d),
potentially important in developing therapies for at-risk
patients.
Related to the observations for cytokines, an increasing
dietary intake of n-3 LCP also modifies the eicosanoid
profile in blood, reducing production of AA-derived med-
iators by inflammatory cells, such as leukotriene (LT) B4
and PGE2 and increasing EPA-derived mediators such as
LTB5 and PGE3 (see review
(154) for further information).
As indicated earlier, EPA and DHA supplementation
lowers the cell membrane n-6:n-3 ratio. This reduces AA
availability for the production of lipid mediators through
the COX and LOX pathways, including 4-series LT,
2-series PG and thromboxane (TX), while increasing the
production of 5-series LT, and 3-series PG and TX(154).
3-series EPA-derived eicosanoids, are thought to be less
potent than AA-derived eicosanoids, thus contributing to
the anti-inflammatory, but also the anti-aggregatory and
vasodilatory effects of fish oils(154) previously described.
As mentioned earlier, EPA, unlike DHA, is a direct sub-
strate for COX and LOX for the synthesis of LT, PG and
TX, which might explain why it reduces LTB4 and PGD2
production in macrophages to a greater extent than
DHA(155). The slight but significant effect of DHA might
be due to its partial reconversion to EPA(156).
In addition, both EPA and DHA undergo a series of
reactions involving COX-2 in the presence of aspirin and
5-LOX(2), leading to a novel class of lipid mediators,
known as E-series resolvins (Rv) from EPA and D-series
Rv and neuroprotectin D1 from DHA, which are involved
in the resolution of inflammation. Although EPA-
and DHA-derived compounds possess strong similarities,
they exert different actions that could account for the
differential effect of EPA and DHA on various processes
in cardiovascular health and disease. For example, both
RvE1 and RvD1 reduced the expression of vascular cell
adhesion molecule-1, IL-8, macrophage inflammatory
protein-1b and TNF-a by endothelial cells and reduced
leucocyte transmigration through the endothelium(157).
However, the DHA-derived compound RvD1, but not the
EPA-derived RvE1, decreased PGE2 production in endo-
thelial cells(157).
In summary, fish oils decrease inflammation, although
efficacy in human studies depends on dose, population and
inflammation marker chosen. Individually, DHA, and to a
lesser extent EPA, have anti-inflammatory properties
in vitro but there is insufficient information to determine
whether one is more potent than the other.
Effects of EPA and DHA on thrombosis
and haemostasis
While noting the cardioprotective effects of n-3 LCP from
fish oils, Bang and Dyerberg reported that very high oily
fish consumption was associated with lengthened bleeding
time(1). The anti-thrombotic action of fish oils in both
healthy human subjects and people at high cardiovascular
risk have been extensively investigated during the ensuing
decades. Several intervention studies later confirmed the
effect on bleeding time in healthy, hyperlipidaemic and
patients with heart disease at generally relatively high
doses of fish oils(158,159), while lower doses (<2 g/d) seem
to have no significant effect(160,161). A recent meta-analysis
including twenty-four trials in type 2 diabetics (1533 sub-
jects) concluded that fish oils reduced platelet aggregation
to ADP and to collagen by 22 and 21%, respectively(162).
In general, fish oils seem to reduce platelet aggregation
and TX A2 production in response to ADP and collagen
in healthy people(163,164) and in subjects with mildly
raised BP and cholesterol levels(165). However, platelet





















aggregation is usually measured in the laboratory in
response to various stimuli and there is uncertainty
regarding the correlation between platelet activity ex vivo
and in vivo. The effect of fish oils on in vivo platelet
aggregation in healthy young males was recently investi-
gated by Din and co-workers measuring platelet monocyte
aggregates by flow cytometry; low doses of fish oils (1 g/d;
4 weeks) reduced platelet monocyte aggregate, while
markers of platelet activation (soluble P-selectin, soluble
CD40L) remained unchanged(166).
Anti-thrombotic properties of fish oils were initially
attributed to EPA due to its competition with AA in the
COX and LOX pathways. Accordingly, 1.8 g EPA given
daily to hyperlipidaemic diabetics for 4 weeks was shown
to reduce platelet- and monocyte-derived particles, as well
as the expression of CD62P, CD63 and PAC-1, all markers
of platelet activation(167). Interestingly, EPA but not DHA
was also able to reduce mean platelet volume, a simple
marker of platelet activation in healthy subjects(168). Four-
week supplementation with 3.6 g EPA alone, daily, was
also shown to decrease platelet aggregation and TX pro-
duction in response to collagen in healthy males(169).
However, in agreement with animal studies(170–172), human
studies suggest that DHA is a more potent anti-aggregatory
agent than EPA at high doses(173,174). More recently, 8-
week supplementation with DHA alone were shown to
reduce platelet aggregation to collagen in healthy males for
doses as low as 0.4 g/d(175).
Due to great variability in terms of design, dose of fish
oils and population type, there is inconsistency regarding the
effect of fish oils on haemostatic factors in human sub-
jects(151,176). However, studies generally show no significant
effect of n-3 LCP on haemostatic factors levels or activities
in healthy subjects(177–179), with similar findings for algal
DHA(180). In type 2 diabetics, fish oil supplementation
decreased fibrinogen levels by 10%(162), and increased fac-
tor VII by 25%(181), based on meta-analysis of three trials
(159 participants) and two trials (116 participants), respec-
tively. More studies are needed to clarify the independent
effects of EPA and DHA on haemostatic factors.
Dietary EPA and DHA are readily incorporated into
platelet membrane, leading to the formation of eicosanoids
from the 3-series, less pro-thrombotic than the 2-series
eicosanoids derived from AA (Fig. 2). This, in addition to
the effect on platelet membrane fluidity, is likely to influ-
ence haemostatic and thrombotic processes. Competition
of EPA with AA in the COX pathway (Fig. 2) reduces
TXA2 production, leading to the formation of TXA3, a less
Fig. 2. Outline of the pathways of eicosanoid and lipid mediators synthesis from arachidonic acid (AA), EPA and DHA.
Through cyclooxygenases (COX) and lipoxygenases (LOX), AA is converted into a set of lipid mediators including
2-series PG and thromboxanes (TX), 4-series leukotrienes (LT) and lipoxins. Competing with AA for COX and LOX
enzymes, EPA is converted to 5-series LT, 3-series PG and TX, which are overall less inflammatory than the
AA-derived eicosanoids. In the presence of aspirin, both EPA and DHA are substrates for COX-2, eventually leading to
the formation of E- and D-series resolvins, respectively, involved in the resolution of inflammation. In addition, DHA may
undergo lipoxygenation (through 5-LOX) and other reactions, producing the anti-inflammatory mediator neuroprotectin
D1. HETE, hydroxyeicosatetraenoic; HPEPE, hydroperoxy-EPA; HPDHA, hydroperoxy-DHA.





















potent vasoconstrictor and pro-aggregatory mediator.
Accordingly, both EPA and DHA decrease AA-induced
TXA2 production by platelets, while only EPA increases
TXA3 production, showing that EPA, but not DHA is a
direct substrate for the COX/TX synthase complex(182).
Anti-thrombotic effects of EPA and DHA might also be
endothelium dependent. 3-series prostacyclin is synthe-
sised from EPA by endothelial cells, which adds on to
the anti-aggregatory effect of 2-series prostacyclin(124).
In addition, both EPA and DHA inhibit platelet-
activating factor synthesis(183) and stimulate endothelial
NOS activity(122,123) in endothelial cells. The decrease in
platelet-activating factor levels, as well as the increase of
NO, which has anti-aggregatory properties, may also con-
tribute to the anti-thrombotic effects of fish oils.
Fish oils seem to exert their anti-thrombotic action in
human subjects by influencing platelet activation and
aggregation rather than haemostatic factors levels and/or
activity. DHA is more potent than EPA in reducing platelet
aggregation in animals, and possibly in human subjects,
possibly as a result of its greater effect on membrane
fluidity(170). In contrast to DHA, EPA is a direct substrate
of COX for the synthesis of anti-inflammatory and anti-
aggregatory mediators, a key factor in the inhibition
of platelet activation. Further investigation is needed to
specify the individual role of EPA and DHA in platelet
function in human subjects, especially in vivo.
Insulin sensitivity and glycaemic control
Insulin resistance is characteristic of type 2 diabetes and
is associated with several disorders involved in the de-
velopment of CVD, including chronic inflammation, dys-
lipidaemia, hypertension and endothelial dysfunction.
Plasma and erythrocyte n-3 LCP, n-3:n-6, and espe-
cially EPA:AA ratios correlate positively with insulin
sensitivity in healthy subjects and type 2 diabetics(184–186).
There is also growing evidence from animal studies that fish
oil intake increases insulin sensitivity and adiponectin levels
in insulin resistant rats and mice(187,188). In contrast, inter-
vention studies generally show little or no effect of fish oils
on insulin sensitivity and glycaemic control in human
subjects. Balk’s meta-analysis considered healthy subjects,
type 2 diabetics, hypertensives, dyslipidaemics or patients
with CVD and concluded that fish oils induced no change
in glycated Hb (HbA1c, eighteen trials, 578 participants)
and a slight but non-significant increase in fasting blood
sugar (seventeen trials, 1427 participants)(151). This was
more recently confirmed in a meta-analysis including 1075
type 2 diabetics, where the authors showed no effect of
EPA and DHA on HbA1c, fasting glucose, fasting insulin
or body weight(189).
There is growing evidence from animal and in vitro
studies that both EPA and DHA, taken individually,
exert an insulin-sensitising action(187,190–193). However, the
relative effect of EPA and DHA on insulin sensitivity
in human subjects has been poorly investigated. EPA
alone decreased insulin reactivity and increased adipo-
nectin levels in obese Japanese, without affecting leptin
levels(114). In type 2 diabetics, EPA had no effect on
adiponectin levels but an additive positive effect when
combined with statin treatment(194). To date, only three
studies investigated the independent effects of EPA and
DHA on insulin sensitivity in human subjects. In hyper-
lipidaemic subjects, both EPA and DHA (6 weeks, 4 g/d)
decreased fasting insulin levels, and fasting glucose tended
to increase in the EPA group, remaining unchanged fol-
lowing DHA supplementation(26). In treated hypertensive
type 2 diabetics, neither EPA nor DHA influenced insulin
levels, secretion or sensitivity, but both increased fasting
glucose(31). More recently, Egert and co-workers confirmed
that neither EPA nor DHA had an effect on HbA1c, insulin
level or sensitivity in healthy subjects, although EPA
showed a minor increase in glucose levels while DHA had
no effect(195).
Conclusion
Numerous studies have proven the cardioprotective effects
of fish oils in human subjects, showing their hypo-
triglyceridaemic, hypotensive, anti-arrhythmic and anti-
thrombotic properties. Recent data suggest that fish oils
also improve arterial stiffness and EF, and increase HDL
and LDL particle size. Most studies have investigated the
effect of oily fish or fish oil supplements containing mix-
tures of EPA and DHA, and current UK dietary guidelines
recommend the consumption of one portion of oily fish a
week to maintain general good health. However, over the
past 20 years, there has been growing evidence that EPA
and DHA exert a heterogeneous effect on various cardio-
vascular outcomes, which is of considerable relevance for
primary and secondary cardiovascular prevention. While
both EPA and DHA are able to reduce TAG levels, DHA
appears responsible for the BP and HR-lowering effect of
fish oils. DHA also seems to be beneficial for EF and pla-
telet function, although an active role for EPA has not been
ruled out. Although fish oils show anti-inflammatory and
insulin-sensitising properties in vitro and in animal studies,
human studies are often conflicting and efficacy remains
uncertain; accordingly, neither EPA nor DHA alone
showed an effect on inflammation or insulin sensitivity in
human subjects, despite indications for potency in vitro.
The apparent efficacy of DHA in improving a number of
cardiovascular risk factors, and the remaining uncertainty
surrounding the actions of EPA, suggest that there is a
need for n-3 LCP oils that are a purified or enriched source
of either EPA or DHA. An increasing number of studies
are being published on the cardioprotective effects of DHA
TAG from algal sources, either Crypthecodinium cohnii
or Schizochytrium sp. (Martek Biosciences Corporation,
Columbia, MD, USA). Supplements, infant formula, infant
foods and certain other food categories (dairy, bakery, eggs
and non-alcoholic beverages) fortified with algal DHA are
now available to buy in many countries. The potential
benefits of algal DHA supplements for subgroups that have
low intakes, such as vegetarians, should be a high priority
for investigation. EPA TAG-enriched oils and purified
EPA ethyl ester oils are available but currently a large
amount of effort is being directed by industry towards
the development of non-fish oil-derived EPA. As more





















DHA- and EPA-only products become available, partly as
a result of concern over the sustainability of fish oil sup-
plies and partly in response to consumer demand for non-
fish sources, future research can be focused on establishing
the most effective doses of DHA and EPA for improve-
ment of cardiovascular risk factors. This will inform
dietary advice on the optimal intake for life-long health,
and should enable a decision to be made on the most
effective supplement dose to be taken over short periods
to reduce risk factors such as hypertriglyceridaemia or
hypertension in various at-risk populations. It will be
important to bear in mind that not all individuals will
respond to DHA and/or EPA in the same way, and ongoing
nutrigenetic and gender research will be crucial in defining
future advice regarding dietary and supplementary EPA
and DHA. The role of dietary n-3 LCP in cardiovascular
health is an area of nutritional science/medicine that has
undergone more investigation than most during the past 30
or more years, yet the gaps in our understanding of this
field remain substantial.
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 Appendix XXXIII CALCULATION OF FA YIELD OBTAINED AFTER BSA-FA COMPLEXATION 
 
Sodium salts C16:0 C18:0 C18:1(n-9) C18:2(n-6) C20:4(n-6) C20:5(n-3) C22:6(n-3) 
PA SA OA LA AA EPA DHA 
MW FA salt (g/mol) 278.41 306.50 304.45 302.44 326.00 324.40 350.50 
MW Na (g/mol) 22.99 22.99 22.99 22.99 22.99 22.99 22.99 
MW FA (g/mol) 255.42 283.51 281.46 279.45 303.01 301.41 327.51 
Expected [FA] g/L 1.53 1.70 1.69 1.68 1.82 1.81 1.97 
Expected [FA] mM 6.00 6.00 6.00 6.00 6.00 6.00 6.00 
Area peak Standard 1 305.00 535.39 423.00 560.96 549.16 416.00 418.00 
Area peak FA 1 494.00 739.94 520.00 638.28 746.18 502.00 556.00 
Observed [FA] g/L 1 1.62 1.38 1.23 1.14 1.36 1.21 1.33 
Observed [FA] mM 1 6.34 4.87 4.37 4.07 4.48 4.00 4.06 
Yield (%) 1 105.69 81.25 72.79 67.86 74.74 66.73 67.69 
Area peak FA 2 457.00 774.45 500.00 683.31 798.50 481.00 522.00 
Observed [FA] g/L 2 1.09 1.39 1.16 1.16 1.41 1.10 1.24 
Area peak Standard 2 421.00 558.16 432.00 589.70 566.29 436.00 421.00 
Observed [FA] mM 2 4.25 4.89 4.11 4.15 4.65 3.66 3.79 
Yield (%) 2 70.83 81.57 68.54 69.11 77.56 61.00 63.10 
Average yield (%) 88.26 81.41 70.66 68.49 76.15 63.86 65.39 
MW, molecular weight; FA, fatty acids;, palmitic acid; SA, stearic acid; OA, oleic acid; LA, linoleic acid; AA, arachidonic acid; EPA, 
eicospentadecanoic acid; DHA, docosahexaenoic acid 
 Appendix XXXIV WESTERN BLOTTING FOR ENOS AND COX-2 
 
XXXIV. A. SDS-PAGE 
• GEL PREPARATION 
 LOWER GEL 
Reagent 10% (x1gel) 10% (x2gels) 10% (x3gels) Final con. 
4xTris-SDS pH 
8.8 (mL) 




3.2 6.4 9.6 13, 12, 10 or 8%, 
respectively 
dd H2O (mL) 4 8 12  
10% APS *(uL) 35 70 105 0.04% 
TEMED *(uL) 7.5 15 22.5 0.08% 
* Toxic- use in hood  
 
If necessary clean glass plates with water and wipe dry.   
Wipe each plate with methanol (to precipate any protein residues) 
Place smaller plate on top of larger plate and place in plate holder (with green clips) with the 
small plate at the front and ensure that the bottom is flat by placing the whole assembly on 
bare bench. Fasten clips. 
Put plate holder in casting stand and fill plate cavities with MilliQ water to check if any 
leakage. 
Whilst water is still inside the glass plates, make up lower and upper gel, minus APS and 
TEMED (see tables above). Invert gently to mix. 
Check plates for water leakage. Pour off water, tip casting stand slightly to one side and insert 
filter paper between plates to remove excess water. 
Insert comb into plate cavity and mark plate 1cm from bottom of comb. Remove comb. 
Pipette APS and then TEMED into lower gel mixture and invert to mix. 
Pipette gel mixture into each plate cavity with a plastic Pasteur until it reaches approx 2 mm 
above marked line (gel will shrink).  Take up some of the remaining gel into the pipette (to 
subsequently check that the gel has set). 
Slowly add ~0.5-0.6 mL water-saturated butanol into each plate cavity (to exclude air 
bubbles and create and sharp top edge). 
Leave for 30-45 minutes until set (use gel in pipette to check this). 
Make 4 mL wash solution: 1:4 dilution of Tris-SDS buffer (diluted with water). 
Once the gel has set, pour off butanol (into sink). 
Tip casting stand slightly to one side and carefully insert filter paper to remove excess 
butanol. 
Place casting stand flat and pipette in washing solution (2mL each) (diluted Tris-SDS buffer). 
Remove excess washing solution as above. 
  
  UPPER GEL 
Reagent Amount Final Conc. 
4xTris-SDS pH 6.8 (mL) 2 1x (375mM Tris0.1% SDS) 
30% Acrylamide (mL) 1.04 4% 
dd H2O (mL) 4.88  
10% APS *(uL) 40 (70!) 0.05% 
TEMED *(uL) 5 (15!) 0.06% 
* Toxic- use in hood 
 
Make upper gel in 30 mL universal according to the volumes specified in BioRad Table: 
Tris-SDS, water and acrylamide (order of addition not important). 
Add APS and TEMED according to Table above (higher volumes set more quickly) 
Using a plastic Pasteur pipette fill plate cavities to top with upper gel mixture. 
Carefully remove air bubbles with the pipette. 
Insert the comb at an angle and push down.  The gel solution will spill over down the side of 
the plate.  Take up some of the remaining gel into the pipette (to subsequently check that the 
gel has set). 
• SDS-PAGE 
Make up a 20% stock solution of 2-mercaptoethanol in 0.02% bromophenol blue (80 µL BPB 
+ 20 µL 2ME into a 1.5 mL Eppendorf tube – remainder can be frozen and defrosted once). 
Pipette 30µl of protein samples into new Eppendorfs (max volume that can be loaded) 
Add 3µL 2ME/BPB. 
Heat sample tubes for 3 min at 95oC in heat block (add tubes individually, place metal block 
on top and remove individually in same order as inserted) 
Make up the tank buffer: dilute 10x Tris/glycine/SDS 1: with water – add buffer to the water 
not the other way round (to avoid excessive bubbling). 
Once the upper gel is set, remove plates from casting stand by releasing the top clip and place 
in the electrode assembly clamp with the combs facing inward.  Push plates down into 
assembly clamp and clamp shut.  Pour tank buffer into the middle of the assembly to check 
leaking. 
Use a gentle rocking motion to dislodge the combs and then pull each one straight up to 
remove. 
Attach a yellow tip to the end of a plastic Pasteur pipette and gently wash each well out by 
pipetting up and down twice to remove unpolymerised gel. 
Use gel loading tip to load 10 µL protein ladder into lane 2 (‘Rainbow marker recombinant.  
Load samples into wells – use wells 3-14).  If a positive control is used, and there are no 
spare lanes, load the control in lane 1 or 15. 
Fill the tank with buffer and use a plastic Pasteur pipette to remove excess bubbles 
Plug leads into power pack (red to red and black to black) 
Set voltage to 150 V and check there is current. Leave for approx 1 hour and 10 min.  If short 
of time, voltage can be set to 180 V for 50 minutes. 
After the running time has elapsed check that the BPB has reached the bottom of the gel.  
Switch off the power pack and disconnect the leads.  Pour off the buffer and take assembly 
back to the bench. 
 
 XXXIV. B. WESTERN BLOT  
• TRANSFER 
Cut four 5x8 cm pieces of filter paper and two 5x8 cm pieces of PVDF membrane. 
Soak the membranes in absolute methanol. After that pour back the methanol.  
Carefully remove each plate taking note of which is which (hold onto plates in case they fall). 
Remove the outer plates and cut out the upper gel then score along the sides of the gel to free 
it from the inner plate (keep gel wet to prevent tearing).  Cut lower corner on marker side of 
each gel.  Place gels in transfer buffer to equilibrate for a few minutes. 
Place a piece of filter paper onto the plate electrode of the transfer kit, pour on some transfer 
buffer. 
Cut one corner of the membrane and place the membrane on the filter paper.   
Scoop up a gel and place on the membrane so the corners match. 
Pour on more transfer buffer and cover the membrane (membrane 1) with a second piece of 
filter paper. 
Repeat steps 5-8 for remaining pieces of filter paper and membrane 2. 
Using a roller, roll out any air bubbles working outwards from the middle of each stack and 
taking care not to dislodge the gel. 
Pour on more transfer buffer and clip cover of transfer kit into place. Add a weight on the kit. 
Connect the leads (red to red and black to black) and set the voltage on the power pack to 20 
V.  Check that there is current. 
Whilst the transfer is taking place make up 5% skimmed milk powder in PBS/0.1% Tween (1 
g milk powder in 20 mL PBS/Tween). 
Following transfer (2h for eNOS), remove the membranes from the transfer kit and place 
each in a plastic box containing the skimmed milk/PBS/Tween solution.  Label the boxes 1 
and 2. (membranes may be briefly rinsed in PBS/0.1%  Tween prior to refrigerating). 
Block on a shaker at 1-2 rpm for 1 hour.   
Place gels in a container of stain (membrane 2 on top of membrane 1) and place on shaker at 
~1 rps overnight. 
• PROTEIN DETECTION 
 GELS 
Pour the stain solution from gel back into original bottle and add destain to the gel.   
Place on a shaker at 1-2 rpm and periodically change the destain solution (3-4 times, timing 
not crucial) until protein bands are detectable on the gel. 
Check to see if the lanes appear to have run straight or if there are any anomalies. 
The gel may be preserved by wetting it with PBS/0.1% Tween and sealing in a plastic bag. 
 MEMBRANES 
Pour off the milk solution and rapidly rinse the membranes twice in PBS/0.1% Tween.  
Pour on enough TBS/0.1% Tween to cover each membrane and then place the containers on a 
shaker for 15 min at ~1 rpm to wash, then wash 3 x 5 min. 
Meanwhile, make up 20 mL primary antibody: 
Anti eNOS (Rabbit): diluted 1:1000 with PBS/0.1% Tween containing 3% BSA and a few 
granules of sodium azide to inhibit bacterial growth.  This working solution may be 
refrigerated and reused approximately 10 times. 
Anti α-tubulin (Rat): diluted 1:5000 with PBS/0.1% Tween containing 3% BSA and a few 
granules of sodium azide to inhibit bacterial growth. This working solution may be 
refrigerated and reused approximately 10 times. 
 Divide the antibody solution equally between two small plastic boxes that are just over 5x8 
cm in size. 
Remove membrane 1 from its box with flat forceps and carefully remove excess liquid by 
gently dragging the membrane over the rim of the box.  Blot off remaining excess from the 
bottom edge of the membrane onto a blue paper towel. 
Transfer membranes 1 and 2 to a small plastic boxes marked ‘1’ and ‘2’, respectively, 
containing 10 mL primary antibody. 
Place boxes on a shaker at ~1 rpm for 1 hour at RT (or overnight at 4°C). 
Remove each membrane from its box with flat forceps and carefully remove excess antibody 
by gently dragging the membrane over the rim of the box.  The antibody solution should be 
poured back into its container and stored at 4oC.  The boxes should be washed with MilliQ 
water and dried. 
Place membranes in larger boxes and cover with TBS/0.1% Tween, rinse rapidly three times 
in TBS/0.1% Tween and wash for 1 x 15 min and then 3 x 5 min replacing the TBS/0.1% 
Tween prior to each wash. 
Make up 20 mL secondary antibody: 
Anti Rabbit (eNOS): 10ul diluted 1:2000 with PBS/0.1% Tween containing 3% skimmed 
milk powder (0.6g).  This working solution is discarded after use. 
Anti Rat (α-tubulin): 4ul (1:5000) in PBS/0.1%Tween 3% skimmed milk (0.6g) is used for 
step 12. 
Divide the antibody solution equally between the two small boxes. 
Place boxes on a shaker at ~1 rpm for 1 hour. 
Pour off the secondary antibody and wash membranes as in step 9. 
Lay a piece of blue towel on the bench.  Cut two pieces of Saran wrap the first approx 20x15 
cm and the second approx 40x15cm and place onto the blue towel. 
Pipette 1 mL ECL detection reagent one and the same volume of reagent 2 into a 7 mL 
bijoux. Invert to mix. 
Turn on computer and machine (open SynGene). Select Chemi Sample. 
Remove each membrane from their boxes using flat forceps and dab off excess fluid onto a 
blue towel.  Place membrane 1 onto the smaller piece of Saran wrap and membrane 2 below 
it (cut corner to the bottom right). 
Pipette 1mL ECL reagent mix onto membrane one, start timer and 30 sec later pipette 1mL 
reagent onto membrane 2. 
When 1 min has elapsed, pick up membrane one, dab off excess reagent and place it onto 
upper half of the second piece of Saran wrap.  After a further 30 seconds, repeat for 
membrane 2 and place below membrane 1. 
 Fold the Saran wrap over the membranes and carefully smooth out any air bubbles.  Trim off 
excess Saran wrap leaving a ~2 cm border around the membranes and put in the machine. 
Reduce focus (eye) to ~43 and increase magnification so that membranes fill in the screen 
(~29). Take one picture with the door open (press the green button, then red) 
Close the door and select parameters for reading (camera+files icon): 
- eNOS: Number of images = 6; Exposure time = 5 min  30min in total 
- Α-tubulin: Number of images = 5; Exposure time = 30 s  2.5 min in total 
- COX2: 
Immediately after reading, put the membranes back in PBS-Tween for storage or too proceed 
to new incubation (repeat steps 2-22) 
Once the membranes have been probed for α-tubulin, they may be wetted with PBS/0.1% 
Tween and wrapped in Saran wrap for long-term storage at 4oC. 
